<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004183.pub2" GROUP_ID="LIVER" ID="647502081413551983" MERGED_FROM="" MODIFIED="2008-05-26 10:11:30 +0200" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-05-26 09:06:36 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.11 beta" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2008-05-26 09:06:36 +0100" MODIFIED_BY="dimitrinka nikolova">
<TITLE>Antioxidant supplements for preventing gastrointestinal cancers</TITLE>
<CONTACT>
<PERSON ID="906FC17F82E26AA2010A531404C98F59" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Goran</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bjelakovic</LAST_NAME>
<SUFFIX>MD Dr.Med.Sci</SUFFIX>
<POSITION/>
<EMAIL_1>goranb@junis.ni.ac.yu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+381 641 192 823</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Copenhagen Trial Unit, Centre for Clinical Intervention Research</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital, Rigshospitalet, Department 3344</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7113</PHONE_1>
<PHONE_2/>
<FAX_1>+45 35345 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-05-26 09:06:36 +0100" MODIFIED_BY="dimitrinka nikolova">
<PERSON ID="906FC17F82E26AA2010A531404C98F59" MODIFIED="2008-05-26 09:06:13 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Goran</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bjelakovic</LAST_NAME>
<SUFFIX>MD Dr.Med.Sci</SUFFIX>
<POSITION/>
<EMAIL_1>goranb@junis.ni.ac.yu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+381 641 192 823</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Copenhagen Trial Unit, Centre for Clinical Intervention Research,</DEPARTMENT>
<ORGANISATION>Department 3344, Rigshospitalet, Copenhagen University Hospital,</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7113</PHONE_1>
<PHONE_2/>
<FAX_1>+45 35345 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6511" MODIFIED="2008-05-26 09:06:28 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Dimitrinka</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nikolova</LAST_NAME>
<SUFFIX>M.A.</SUFFIX>
<POSITION>Managing Editor, Review Group Co-ordinator</POSITION>
<EMAIL_1>dnikolov@ctu.rh.dk</EMAIL_1>
<EMAIL_2/>
<URL>http://inet.uni2.dk/~ctucph/chbg</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research,</ORGANISATION>
<ADDRESS_1>Department 3344, Rigshospitalet, Copenhagen University Hospital,</ADDRESS_1>
<ADDRESS_2>Blegdamsvej 9</ADDRESS_2>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7169</PHONE_1>
<PHONE_2/>
<FAX_1>+45 3545 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="CB3CA0A782E26AA201BA4B54804A2B4B" MODIFIED="2008-05-26 09:06:33 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rosa G</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Simonetti</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>rosasimo@libero.it</EMAIL_1>
<EMAIL_2>r_simonetti@virgilio.it</EMAIL_2>
<URL/>
<MOBILE_PHONE>+39 335 8369 575</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Divisione di Medicina</DEPARTMENT>
<ORGANISATION>Ospedale V.Cervello</ORGANISATION>
<ADDRESS_1>Via Trabucco 180</ADDRESS_1>
<ADDRESS_2/>
<CITY>Palermo</CITY>
<ZIP>I-90146</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+ 39 91 6882821</PHONE_1>
<PHONE_2/>
<FAX_1>+39 91 6885111</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6439" MODIFIED="2008-05-26 09:06:36 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Christian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>M.D, Dr. Med. Sci.</SUFFIX>
<POSITION>Head of Department</POSITION>
<EMAIL_1>cgluud@ctu.rh.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research,</ORGANISATION>
<ADDRESS_1>Department 3344, Rigshospitalet, Copenhagen University Hospital,</ADDRESS_1>
<ADDRESS_2>Blegdamsvej 9</ADDRESS_2>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+ 45 3545 7175</PHONE_1>
<PHONE_2/>
<FAX_1>+ 45 3545 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-05-23 14:18:42 +0100" MODIFIED_BY="Goran Bjelakovic" NOTES="&lt;p&gt;Minor update: 25/02/08&lt;/p&gt;&lt;p&gt;New studies sought but none found: 01/10/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 30/09/07&lt;/p&gt;&lt;p&gt;Conclusions changed: 19/10/07&lt;/p&gt;" NOTES_MODIFIED="2008-05-23 14:18:42 +0100" NOTES_MODIFIED_BY="Goran Bjelakovic">
<UP_TO_DATE>
<DATE DAY="12" MONTH="11" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="10" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="9" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-26 08:56:21 +0100" MODIFIED_BY="dimitrinka nikolova" NOTES="&lt;p&gt;The present systematic review is an update of the systematic review 'Antioxidant supplements for preventing of gastrointestinal cancers' published in the Cochrane Library, Issue 4, 2004. &lt;br&gt;&lt;br&gt;Six new trials were identified (SUVIMAX 2004; Li 2004; HOPE TOO 2005; SIT 2006; Plummer 2007; WACS 2007). The results of three previously included trials have been updated with results from a longer follow-up (ATBC 2003; CARET 2004; WHS 2005). One trial (NIT2 1993) has been reclassified from high- to low-bias risk trial after obtaining additional information from the authors.&lt;br&gt;&lt;br&gt;The conclusions, based now on the results of 20 randomised clinical trials with 211,818 participants, remain unchanged.&lt;/p&gt;" NOTES_MODIFIED="2008-05-26 08:56:21 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="17" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-26 08:55:28 +0100" MODIFIED_BY="dimitrinka nikolova">
<DATE DAY="30" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>Six new trials were added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-05-26 08:56:21 +0100" MODIFIED_BY="dimitrinka nikolova">
<DATE DAY="30" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>Conclusions did not change.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-04-17 10:41:48 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Knowledge and Research Centre for Alternative Medicine (ViFAB)</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-26 08:48:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUMMARY>
<TITLE>Antioxidant supplements cannot be recommended for gastrointestinal cancer prevention</TITLE>
<SUMMARY_BODY>
<P>Our body cannot synthesize all compounds that are essential for health. Therefore such compounds must be taken through diet. Oxidative stress may cause cell damage that is implicated in chronic diseases like cancer. Gastrointestinal cancers are among the most common cancers worldwide. The poor prognosis of patients diagnosed with gastrointestinal cancers made primary prevention a potentially attractive approach. The evidence on whether antioxidant supplements are effective in decreasing gastrointestinal cancers is contradictory.</P>
<P>In this review prevention with antioxidant supplements of oesophageal, gastric, small intestinal, colorectal, pancreatic, liver, and biliary tract cancers is assessed. The review includes 20 randomised clinical trials. In total, 211,818 participants were randomised to antioxidant supplements (beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) versus placebo. Trial quality was exceptionally good.</P>
<P>Based on properly designed and conducted randomised clinical trials, convincing evidence that beta-carotene, vitamin A, vitamin C, and vitamin E or their combinations may prevent gastrointestinal cancers is not found. A total of 2057 of 95084 participants (2.2%) randomised to antioxidant supplements and 1548 of 78935 participants (2.0%) randomised to placebo developed gastrointestinal cancers. These antioxidant supplements even seem to increase mortality. A total of 17114 of 122,501 participants (14.0%) randomised to antioxidant supplements and 8799 of 78693 participants (11.2%) randomised to placebo died. Selenium alone may have preventive effects on gastrointestinal cancers. This finding, however, is based on trials with flaws in their design and needs confirmation in properly conducted randomised clinical trials. <B>
<BR/>
</B>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-26 08:48:19 +0100" MODIFIED_BY="dimitrinka nikolova">
<ABS_BACKGROUND>
<P>Oxidative stress may cause gastrointestinal cancers. The evidence on whether antioxidant supplements are effective in preventing gastrointestinal cancers is contradictory.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the beneficial and harmful effects of antioxidant supplements in preventing gastrointestinal cancers.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We identified trials through the trials registers of the four Cochrane Review Groups on gastrointestinal diseases, <I>The Cochrane Central Register of Controlled Trials</I> in <I>The Cochrane Library</I> (Issue 2, 2007), <I>MEDLINE</I>, <I>EMBASE</I>, <I>LILACS</I>, <I>SCI-EXPANDED, and The Chinese Biomedical Database</I> from inception to October 2007. We scanned reference lists and contacted pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing antioxidant supplements to placebo/no intervention examining occurrence of gastrointestinal cancers.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors (GB and DN) independently selected trials for inclusion and extracted data. Outcome measures were gastrointestinal cancers, overall mortality, and adverse effects. Outcomes were reported as relative risks (RR) with 95% confidence interval (CI) based on random-effects and fixed-effect model meta-analysis. Meta-regression assessed the effect of covariates across the trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-26 08:48:19 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We identified 20 randomised trials (211,818 participants), assessing beta-carotene (12 trials), vitamin A (4 trials), vitamin C (8 trials), vitamin E (10 trials), and selenium (9 trials). Trials quality was generally high. Heterogeneity was low to moderate. Antioxidant supplements were without significant effects on gastrointestinal cancers (RR 0.94, 95% CI 0.83 to 1.06). However, there was significant heterogeneity (I<SUP>2</SUP> = 54.0%, P = 0.003). The heterogeneity may have been explained by bias risk (low-bias risk trials RR 1.04, 95% CI 0.96 to 1.13 compared to high-bias risk trials RR 0.59, 95% CI 0.43 to 0.80; test of interaction P &lt; 0.0005), and type of antioxidant supplement (beta-carotene potentially increasing and selenium potentially decreasing cancer risk). The antioxidant supplements had no significant effects on mortality in a random-effects model meta-analysis (RR 1.02, 95% CI 0.97 to 1.07, I<SUP>2</SUP> = 53.5%), but significantly increased mortality in a fixed-effect model meta-analysis (RR 1.04, 95% CI 1.02 to 1.07). Beta-carotene in combination with vitamin A (RR 1.16, 95% CI 1.09 to 1.23) and vitamin E (RR 1.06, 95% CI 1.02 to 1.11) significantly increased mortality. Increased yellowing of the skin and belching were non-serious adverse effects of beta-carotene. In five trials (four with high risk of bias), selenium seemed to show significant beneficial effect on gastrointestinal cancer occurrence (RR 0.59, 95% CI 0.46 to 0.75, I<SUP>2</SUP> = 0%).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>We could not find convincing evidence that antioxidant supplements prevent gastrointestinal cancers. On the contrary, antioxidant supplements seem to increase overall mortality. The potential cancer preventive effect of selenium should be tested in adequately conducted randomised trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-26 08:48:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<BACKGROUND>
<P>Our body cannot synthesize all compounds that are essential for health. Therefore they must be taken through diet. Oxidative stress may cause cell damage that is implicated in chronic diseases like cancer (<LINK REF="REF-Sies-1985" TYPE="REFERENCE">Sies 1985</LINK>; <LINK REF="REF-Ames-1995" TYPE="REFERENCE">Ames 1995</LINK>). Antioxidants are compounds that can protect against oxidative stress (<LINK REF="REF-Diplock-1994" TYPE="REFERENCE">Diplock 1994</LINK>; <LINK REF="REF-Poppel-1997" TYPE="REFERENCE">Poppel 1997</LINK>; <LINK REF="REF-Papas-1999" TYPE="REFERENCE">Papas 1999</LINK>; <LINK REF="REF-Tamimi-2002" TYPE="REFERENCE">Tamimi 2002</LINK>; <LINK REF="REF-Willcox-2004" TYPE="REFERENCE">Willcox 2004</LINK>). Laboratory and epidemiologic studies suggest a role of antioxidants in cancer prevention (<LINK REF="REF-Schrauzer-1977" TYPE="REFERENCE">Schrauzer 1977</LINK>; <LINK REF="REF-Peto-1981" TYPE="REFERENCE">Peto 1981</LINK>). The possibility to improve health and prevent diseases by ameliorating excessive oxidative stress has attracted the attention of researchers in the last decades (<LINK REF="REF-Willcox-2004" TYPE="REFERENCE">Willcox 2004</LINK>). Even though a healthy diet provides a sufficient amount of antioxidants, there are a number of people who regularly take antioxidant supplements (<LINK REF="REF-Balluz-2000" TYPE="REFERENCE">Balluz 2000</LINK>; <LINK REF="REF-Millen-2004" TYPE="REFERENCE">Millen 2004</LINK>; <LINK REF="REF-Radimer-2004" TYPE="REFERENCE">Radimer 2004</LINK>; <LINK REF="REF-Lichtenstein-2005" TYPE="REFERENCE">Lichtenstein 2005</LINK>; <LINK REF="REF-Nichter-2006" TYPE="REFERENCE">Nichter 2006</LINK>). </P>
<P>
<B>Gastrointestinal cancers</B>
<BR/>Gastrointestinal cancers are among the most common cancers and the leading cause of cancer death worldwide (<LINK REF="REF-Ferlay-2004" TYPE="REFERENCE">Ferlay 2004</LINK>). The poor prognosis of patients diagnosed with gastrointestinal cancers made chemoprevention an attractive approach. It is, therefore, understandable that antioxidant prevention of gastrointestinal cancers has drawn much attention (<LINK REF="REF-Garcea-2003" TYPE="REFERENCE">Garcea 2003</LINK>; <LINK REF="REF-Sharma-2004" TYPE="REFERENCE">Sharma 2004</LINK>; <LINK REF="REF-Grau-2006" TYPE="REFERENCE">Grau 2006</LINK>).</P>
<P>Oesophageal cancer is characterized by low likelihood of cure (<LINK REF="REF-Enzinger-2003" TYPE="REFERENCE">Enzinger 2003</LINK>). Prevention is complicated by the fact that the two major histologic types, ie, squamous-cell carcinoma and adenocarcinoma, differ substantially (<LINK REF="REF-Fitzgerald-2006" TYPE="REFERENCE">Fitzgerald 2006</LINK>; <LINK REF="REF-Holmes-2007" TYPE="REFERENCE">Holmes 2007</LINK>). The role of oxidative stress in the aetiology of two histological types of oesophageal cancer is unclear (<LINK REF="REF-Tzonou-1996" TYPE="REFERENCE">Tzonou 1996</LINK>; <LINK REF="STD-Terry-2000" TYPE="STUDY">Terry 2000</LINK>; <LINK REF="STD-Mayne-2001" TYPE="STUDY">Mayne 2001</LINK>). Antioxidants were discussed as protective agents in studies of oesophageal squamous-cell carcinoma as well as Barrett's oesophagus, a precancerous condition for oesophageal adenocarcinoma (<LINK REF="REF-Cheng-1996" TYPE="REFERENCE">Cheng 1996</LINK>; <LINK REF="STD-Terry-2000" TYPE="STUDY">Terry 2000</LINK>; <LINK REF="REF-Sihvo-2002" TYPE="REFERENCE">Sihvo 2002</LINK>; <LINK REF="REF-Mehta-2005" TYPE="REFERENCE">Mehta 2005</LINK>; <LINK REF="REF-Stoner-2007" TYPE="REFERENCE">Stoner 2007</LINK>).</P>
<P>Gastric cancer is the fourth most common cancer and second leading cause of cancer death in the world (<LINK REF="REF-Ferlay-2004" TYPE="REFERENCE">Ferlay 2004</LINK>). <I>Helicobacter pylori</I> is the important aetiological agent of gastric cancer (<LINK REF="REF-Sugiyama-2004" TYPE="REFERENCE">Sugiyama 2004</LINK>). Eradication of <I>Helicobacter pylori</I> and chemoprevention with antioxidants emerged as alternative strategies in reducing the incidence and mortality of gastric cancer (<LINK REF="REF-Leung-2006" TYPE="REFERENCE">Leung 2006</LINK>; <LINK REF="STD-SIT-2006" TYPE="STUDY">SIT 2006</LINK>; <LINK REF="STD-Plummer-2007" TYPE="STUDY">Plummer 2007</LINK>). </P>
<P>Small intestinal cancers are rare (<LINK REF="REF-Neugut-1998" TYPE="REFERENCE">Neugut 1998</LINK>), and prevention with antioxidant supplements has, according to our knowledge, not been extensively tested.</P>
<P>Colorectal cancer is the third most common cancer worldwide (<LINK REF="REF-Ferlay-2004" TYPE="REFERENCE">Ferlay 2004</LINK>). It develops in multiple steps (<LINK REF="REF-Potter-1999" TYPE="REFERENCE">Potter 1999</LINK>). Most colorectal cancers arise from adenomas, as a result of a series of molecular changes that transform normal colonic epithelial cells into colorectal cancer (<LINK REF="REF-Janne-2000" TYPE="REFERENCE">Janne 2000</LINK>; <LINK REF="REF-Lynch-2002" TYPE="REFERENCE">Lynch 2002</LINK>). The transition from normal mucosa to carcinoma offer opportunities for prevention (<LINK REF="REF-Gwyn-2002" TYPE="REFERENCE">Gwyn 2002</LINK>). Observational studies postulate that diet may be associated with colorectal cancer. A diet rich in antioxidants is claimed to be able to lower the risk of colorectal cancer (<LINK REF="REF-Boyle-1985" TYPE="REFERENCE">Boyle 1985</LINK>; <LINK REF="STD-Bostick-1993" TYPE="STUDY">Bostick 1993</LINK>; <LINK REF="REF-Kune-2006" TYPE="REFERENCE">Kune 2006</LINK>). Antioxidants were the first agents evaluated in prevention of colorectal cancer (<LINK REF="REF-Grau-2006" TYPE="REFERENCE">Grau 2006</LINK>). However, antioxidant supplements have no significant effect on primary or secondary prevention of colorectal adenoma (<LINK REF="REF-Bjelakovic-2006" TYPE="REFERENCE">Bjelakovic 2006</LINK>).</P>
<P>Pancreatic cancer has a poor prognosis. Possible aetiologic factors for pancreatic cancer include chronic pancreatitis, smoking, diabetes, and other medical conditions (<LINK REF="REF-Lowenfels-2006" TYPE="REFERENCE">Lowenfels 2006</LINK>). Chronic inflammation, resulting in chronic phagocytic activity, one of the major endogenous sources of free radicals, is associated with cancer of several organs (<LINK REF="REF-Collins-1987" TYPE="REFERENCE">Collins 1987</LINK>; <LINK REF="REF-Shimoda-1994" TYPE="REFERENCE">Shimoda 1994</LINK>; <LINK REF="REF-Holzinger-1999" TYPE="REFERENCE">Holzinger 1999</LINK>). Experimental and observational studies have shown that antioxidants might be effective in the prevention of pancreatic cancer (<LINK REF="REF-Doucas-2006" TYPE="REFERENCE">Doucas 2006</LINK>). </P>
<P>Hepatocellular carcinoma incidence has increased over the last decades. Cirrhosis and aflatoxins are the main risk factors for its development (<LINK REF="REF-Yates-2007" TYPE="REFERENCE">Yates 2007</LINK>). Viral or chemical damage to the liver results in oxidative damage that may inhibit apoptosis and promote hepatocarcinogenesis (<LINK REF="REF-Patel-1998" TYPE="REFERENCE">Patel 1998</LINK>; <LINK REF="REF-Tabor-1999" TYPE="REFERENCE">Tabor 1999</LINK>; <LINK REF="REF-MacDonald-2001" TYPE="REFERENCE">MacDonald 2001</LINK>; <LINK REF="REF-Sasaki-2006" TYPE="REFERENCE">Sasaki 2006</LINK>). The liver is well endowed with antioxidant mechanisms to combat oxidative stress, including micronutrients, such as vitamin E and vitamin C, and some enzymes that metabolise reactive metabolites and reactive oxygen species (<LINK REF="REF-Kaplowitz-2000" TYPE="REFERENCE">Kaplowitz 2000</LINK>). Whether additional antioxidant supplements could be beneficial is not clear.</P>
<P>The role of antioxidant supplements in preventing biliary tract cancers is not sufficiently investigated. There are only a few experimental studies dealing with this question (<LINK REF="REF-Takeda-2002" TYPE="REFERENCE">Takeda 2002</LINK>). </P>
<P>
<B>Antioxidant supplements</B>
<BR/>Vitamin A is essential for growth. Since cancer involves disturbances in normal tissue growth and differentiation, it was one of the first vitamins to be evaluated with respect to carcinogenesis. Later studies indicated that protective effects were only observed for dietary vitamin A from plant sources (beta-carotene) (<LINK REF="REF-Peto-1981" TYPE="REFERENCE">Peto 1981</LINK>; <LINK REF="REF-Ziegler-1989" TYPE="REFERENCE">Ziegler 1989</LINK>). Vitamin C has antioxidative properties with possible cancer preventive potential (<LINK REF="REF-Hanck-1988" TYPE="REFERENCE">Hanck 1988</LINK>). Vitamin E acts as a free radical scavenger to prevent lipid peroxidation of polyunsaturated fatty acids and block nitrosamine formation (<LINK REF="REF-Oshima-1982" TYPE="REFERENCE">Oshima 1982</LINK>; <LINK REF="REF-Poppel-1997" TYPE="REFERENCE">Poppel 1997</LINK>). Vitamin E supplementation can increase production of humoral antibodies and may have antitumour proliferation capacities, possibly by modulating gene expression (<LINK REF="REF-Knekt-1994" TYPE="REFERENCE">Knekt 1994</LINK>). Selenium, a trace element, is also important for antioxidant defences of the body as an integral component of metalloprotein enzymes. It is a component of selenoproteins, which have important enzymatic functions (<LINK REF="REF-Hughes-2000" TYPE="REFERENCE">Hughes 2000</LINK>; <LINK REF="REF-Rayman-2000" TYPE="REFERENCE">Rayman 2000</LINK>). There is an inverse relationship between selenium intake and cancer mortality (<LINK REF="REF-Schrauzer-1977" TYPE="REFERENCE">Schrauzer 1977</LINK>). In the USA, cancer mortality rates are significantly higher in low selenium regions (<LINK REF="REF-Clark-1991" TYPE="REFERENCE">Clark 1991</LINK>). </P>
<P>The evidence on whether antioxidant supplements are effective in decreasing gastrointestinal cancers is contradictory (<LINK REF="REF-Nomura-1987" TYPE="REFERENCE">Nomura 1987</LINK>; <LINK REF="REF-Dawsey-1994" TYPE="REFERENCE">Dawsey 1994</LINK>; <LINK REF="STD-Yu-1997" TYPE="STUDY">Yu 1997</LINK>). We conducted a systematic Cochrane review on the issue published in 2004 and were unable to demonstrate convincing beneficial effects of antioxidant supplements (beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) on gastrointestinal cancers (<LINK REF="REF-Bjelakovic-2004a" TYPE="REFERENCE">Bjelakovic 2004a</LINK>; <LINK REF="REF-Bjelakovic-2004b" TYPE="REFERENCE">Bjelakovic 2004b</LINK>). Our results even suggested that these supplements, with the possible exception of selenium, may increase mortality (<LINK REF="REF-Bjelakovic-2004a" TYPE="REFERENCE">Bjelakovic 2004a</LINK>; <LINK REF="REF-Bjelakovic-2004b" TYPE="REFERENCE">Bjelakovic 2004b</LINK>). This present review is an update of the former review.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the beneficial and harmful effects of antioxidant supplements in preventing gastrointestinal cancers (oesophageal, gastric, small intestine, colorectal, pancreatic, liver, and biliary tract cancers).</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-05-26 08:48:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<SELECTION_CRITERIA MODIFIED="2008-05-26 08:48:25 +0100" MODIFIED_BY="dimitrinka nikolova">
<CRIT_STUDIES>
<P>We included all randomised trials, irrespective of blinding, publication status, publication year, or language.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adult participants (age 18 years or over) who were: <BR/>
</P>
<UL>
<LI>participants from the general population irrespective of age, sex, or ethnic origin; or</LI>
<LI>participants at high risk of developing gastrointestinal cancers (with premalignant conditions, or living in areas with high incidence of gastrointestinal cancers); or</LI>
<LI>participants coming from other patient groups, primarily with non-gastrointestinal diseases.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-05-26 08:48:25 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We considered for inclusion trials that compared antioxidant supplements (ie, beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) at any dose, duration, and route of administration versus placebo or no intervention.</P>
<P>The antioxidants could have been administered:<BR/>
</P>
<UL>
<LI>singly; or</LI>
<LI>in any combination among themselves; or</LI>
<LI>in combination with other vitamins; or</LI>
<LI>in combination with trace elements without antioxidant function.</LI>
</UL>
<P>Concomitant interventions were allowed if used equally in both intervention arms of the trial.</P>
<P>Studies concerning antioxidant supplements in prevention of other organ system disease (cardiovascular, respiratory, urinary tract, etc.) were considered if data on the occurrence of gastrointestinal cancers during the trial could be obtained.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Our primary outcome measures were:<BR/>(1) Number of patients developing gastrointestinal cancers. <BR/>We determined whether supplementation with antioxidants, administered separately or in combination, influenced the incidences of any of the gastrointestinal cancers (oesophageal, gastric, small intestinal, colorectal, pancreatic, liver, and biliary tract cancers) and all gastrointestinal cancers combined. <BR/>(2) Overall mortality.</P>
<P>Our secondary outcome measures were:<BR/>(3) Any adverse effects as reported in the trials. Incidence and types of adverse effects connected with the active intervention.<BR/>(4) Quality-of-life measures. <BR/>(5) Health economics.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The trials search co-ordinators of The Cochrane Colorectal Cancer Group, The Cochrane Hepato-Biliary Group, The Cochrane Inflammatory Bowel Disease Group, and The Cochrane Upper Gastrointestinal and Pancreatic Diseases Group provided us with searches of their respective trials registers on antioxidant supplements and prevention of oesophageal, gastric, small intestinal, colorectal, pancreatic, liver, and biliary tract cancers. We also conducted electronic searches in <I>the Cochrane Central Register of Controlled Trials</I> (<I>CENTRA</I>L) in <I>The Cochrane Library</I> (Issue 2, 2007), <I>MEDLINE</I> (1966 to October 2007), <I>EMBASE</I> (Excerpta Medica Database) (1985 to October 2007), <I>LILACS</I> (1982 to October 2007), the <I>Science Citation Index Expanded</I> (<I>SCI-EXPANDED</I>) (1945 to October 2007) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). All search strategies are given in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. In addition, we obtained a search result in <I>the Chinese Biomedical Database</I> (1978 to October 2007).</P>
<P>We scanned reference lists from review articles retrieved from the searches above in order to identify additional trials.</P>
<P>We contacted DSM, Roche, Bristol-Meyers Squibb, BASF AIS, Hoechst, Bayer, Aventis, Takeda, and Lederle Laboratories, manufacturers of antioxidant supplements, to ask for unpublished randomised trials. Of these, Roche suggested some published trials, which we knew of. No other information was received.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-26 08:48:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>
<B>Inclusion criteria application<BR/>
</B>We retrieved the identified material for assessment. GB and DN independently applied the inclusion criteria to all potential studies. We performed this without blinding. No discrepancy occurred in the trial selection.</P>
<P>
<B>Data extraction<BR/>
<I>Participant characteristics, diagnosis, and interventions</I>
<BR/>
</B>We recorded the following data from the individual randomised trials: first author; country of origin; country income category (low, middle, high) (<LINK REF="REF-World-Bank-2006" TYPE="REFERENCE">World Bank 2006</LINK>); number of participants; characteristics of participants: age range (mean or median) and sex ratio; participation rate; dropout rate; trial design (parallel or factorial); type of antioxidant; dose; duration of supplementation; duration of follow-up (ie, duration of intervention plus post-intervention follow-up); co-interventions; and the occurrence of gastrointestinal cancers (oesophageal, gastric, small intestinal, colorectal, pancreatic, liver, and biliary tract cancers).</P>
<P>
<I>
<B>Trial characteristics<BR/>
</B>
</I>We recorded the date, location, sponsor of the trial (known or unknown and type of sponsor) as well as publication status.</P>
<P>
<B>Assessment of methodological quality<BR/>
</B>We assessed the methodological quality defined as the confidence that the design and report restrict bias in the intervention comparison based on the randomisation, blinding, and follow-up (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>). The following definitions were used:<BR/>
<B>
<BR/>
<I>Generation of the allocation sequence</I>
<BR/>
</B>
</P>
<UL>
<LI>Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice was considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.</LI>
<LI>Inadequate, if a system involving dates, names, or admittance numbers were used for the allocation of patients.</LI>
</UL>
<P>
<B>
<BR/>
<I>Allocation concealment </I>
<BR/>
</B>
</P>
<UL>
<LI>Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.</LI>
<LI>Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
<P>
<I>
<B>Blinding (or masking)</B>
</I>
<B>
<BR/>
</B>
</P>
<UL>
<LI>Adequate, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.</LI>
<LI>Unclear, if the trial was described as double blind, but the method of blinding was not described.</LI>
<LI>Not performed, if the trial was not double blind.</LI>
</UL>
<P>
<I>
<B>Follow-up</B>
</I>
<B>
<BR/>
</B>
</P>
<UL>
<LI>Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.</LI>
<LI>Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.</LI>
<LI>Inadequate, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>Trials with adequate generation of the allocation sequence, adequate allocation concealment, adequate blinding, and adequate follow-up were considered low-bias risk trials (high methodological quality) (<LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Gluud-2006a" TYPE="REFERENCE">Gluud 2006a</LINK>). Trials with one or more unclear or inadequate quality components were classified as high-bias risk trials (low methodological quality) (<LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Gluud-2006a" TYPE="REFERENCE">Gluud 2006a</LINK>).</P>
<P>We also reported on whether the investigators had performed a sample-size calculation and used intention-to-treat analysis (<LINK REF="REF-Gluud-2001" TYPE="REFERENCE">Gluud 2001</LINK>).</P>
<P>We used the classification of quality for sensitivity analyses and not as exclusion criteria.</P>
<P>
<B>Statistical analyses </B>
<BR/>We performed the meta-analyses according to the recommendations of <I>The Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). For the statistical analyses, we used RevMan Analyses (<LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>), STATA 8.2 (STATA Corp, College Station, Tex), Sigma Stat 3.0 (SPSS Inc, Chicago, Ill), and Stats-Direct (StatsDirect Ltd, Altrincham, England).</P>
<P>We analysed the data with both random-effects (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and fixed-effect (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>) models meta-analyses. We present the results of the random-effects model analysis if the two models concur regarding statistical significance (P &lt; 0.05). If not, we present both analyses. Results are presented as the relative risk (RR) with 95% confidence intervals (CI). We assessed heterogeneity with I<SUP>2</SUP>, which describes the percentage of total variation across studies due to heterogeneity rather than chance (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). I<SUP>2</SUP> can be calculated as I<SUP>2</SUP> = 100% × (Q-df)/Q (Q = Cochran's heterogeneity statistics, df = degrees of freedom). I<SUP>2</SUP> ranged between 0% (ie, no observed heterogeneity) and 100% (maximal heterogeneity) (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). We used the STATA metareg command (<LINK REF="REF-Sharp-1998" TYPE="REFERENCE">Sharp 1998</LINK>) for the random-effects meta-regression analyses to assess potential covariates predicting intertrial heterogeneity, ie, the covariates that are statistically associated with estimated intervention effects. The included covariates were type and dose of supplement, duration of supplementation, bias risk (low or high), and primary or secondary prevention. Trials with participants coming from the general population, areas with high incidence of gastrointestinal cancers, and other patient groups with non-gastrointestinal diseases were considered primary prevention trials. Trials in participants with premalignant conditions of the gastrointestinal tract were considered secondary prevention trials. We performed univariate and multivariate analyses including all covariates.</P>
<P>All our analyses followed the intention-to-treat principle. We accounted all of the participants for each trial and performed the analyses irrespective of how the original trialists had analysed the data. Participants lost to follow-up were considered survivors. For trials with a factorial design, we based our results on 'at-margins' analysis, comparing all groups that received antioxidant supplements with groups that did not receive antioxidant supplements (<LINK REF="REF-McAlister-2003" TYPE="REFERENCE">McAlister 2003</LINK>). To determine the effect of a single antioxidant we performed 'inside the table' analysis (<LINK REF="REF-McAlister-2003" TYPE="REFERENCE">McAlister 2003</LINK>) in which we compared the single antioxidant arm with the placebo/no intervention arm. In the trials with parallel group design with more than two arms and additional therapy, we compared only the arms supplemented with antioxidants with the placebo arm (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>).</P>
<P>Comparison of intervention effects was conducted with test of interaction (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>).</P>
<P>We performed adjusted rank correlation (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>) and regression asymmetry test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) for detection of bias. A P &lt; 0.10 was considered significant.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-05-24 16:39:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Search results</B>
<BR/>We identified a total of 1096 references through the four gastrointestinal disease Cochrane Groups (n = 90), <I>the Cochrane Central Register of Controlled Trials </I>in<I> The Cochrane Library</I> (n = 221), <I>MEDLINE</I> (n = 224), <I>EMBASE</I> (n = 269), <I>LILACS</I> (n = 75), <I>Science Citation Index Expanded (SCI-expanded)</I> (n = 96), the <I>Chinese Biomedical Database</I> (n = 36), and reading references (n = 85). We excluded 411 duplicates and 374 clearly irrelevant references through reading abstracts. Accordingly, 311 references were retrived for further assessment. Of these, we excluded 58 references because they did not fulfill our inclusion criteria. Reasons for exclusion are listed in the table 'Characteristics of excluded studies'. In total, 253 references describing 24 randomised trials fulfilled our inclusion criteria. Among these references, 11 references described 4 ongoing trials. These trials are listed under 'Characteristics of ongoing studies'. The remaining 242 references, describing 20 trials, fulfilled our inclusion criteria and provided data for the analyses. Details of the trials are shown in the table 'Characteristics of included studies'.</P>
<P>
<B>Trial design</B>
<BR/>Nine trials used factorial designs (one trial 'half replicate of two-by-two-by-two-by-two', 4 trials 'two-by-two-by-two', and 4 trials 'two-by-two') and 11 trials used the two- or more-armed parallel group trial designs. One 'two-by-two-by-two' factorial trial proceeded as a 'two-by-two' factorial trial. Two of the 'two-by-two' factorial trials proceeded as two-armed trials (<LINK REF="REF-Pocock-1991" TYPE="REFERENCE">Pocock 1991</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>
<B>Participants</B>
<BR/>A total of 211,818 participants were randomised in the 20 trials. The number of participants in each trial ranged from 216 to 39876. We were not able to extract relevant data on the sex of the participants from two trials. The percentage of men was 58% of the trials reporting sex. The age varied from 18 to 84 years with a mean age of 56.5 years.</P>
<P>There were five trials with 122,411 participants from the general population (<LINK REF="STD-PHS-1996" TYPE="STUDY">PHS 1996</LINK>; <LINK REF="STD-ATBC-2003" TYPE="STUDY">ATBC 2003</LINK>: <LINK REF="STD-CARET-2004" TYPE="STUDY">CARET 2004</LINK>; <LINK REF="STD-SUVIMAX-2004" TYPE="STUDY">SUVIMAX 2004</LINK>; <LINK REF="STD-WHS-2005" TYPE="STUDY">WHS 2005</LINK>), four trials (<LINK REF="STD-Munoz-1985" TYPE="STUDY">Munoz 1985</LINK>; <LINK REF="STD-Yu-1991" TYPE="STUDY">Yu 1991</LINK>; <LINK REF="STD-NIT1-1993" TYPE="STUDY">NIT1 1993</LINK>; <LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK>) with 37701 healthy participants living in areas at higher risk of developing gastrointestinal cancers, and four trials (<LINK REF="STD-NPCT-1996" TYPE="STUDY">NPCT 1996</LINK>: <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>; <LINK REF="STD-HOPE-TOO-2005" TYPE="STUDY">HOPE TOO 2005</LINK>: <LINK REF="STD-WACS-2007" TYPE="STUDY">WACS 2007</LINK>) with 39560 participants with non-gastrointestinal diseases; all were considered as primary prevention trials. There were seven trials (<LINK REF="STD-NIT2-1993" TYPE="STUDY">NIT2 1993</LINK>; <LINK REF="STD-Yu-1997" TYPE="STUDY">Yu 1997</LINK>; <LINK REF="STD-Correa-2000" TYPE="STUDY">Correa 2000</LINK>; <LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Zhu-2003" TYPE="STUDY">Zhu 2003</LINK>; <LINK REF="STD-SIT-2006" TYPE="STUDY">SIT 2006</LINK>: <LINK REF="STD-Plummer-2007" TYPE="STUDY">Plummer 2007</LINK>) with 12102 participants with premalignant conditions of the gastrointestinal tract; these were considered as secondary prevention trials.</P>
<P>
<B>Experimental interventions</B>
<BR/>The route of antioxidant administration was oral for all the trials. Antioxidants were administered either alone, or in combination with other antioxidants, or with or without other vitamins, minerals or other interventions (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The types, doses, dose regimens, and duration of supplementation with antioxidants were as follows: beta-carotene 6 mg to 30 mg (12 trials), vitamin A 1500 µg to 15000 µg (4 trials), vitamin C 120 to 2000 mg (8 trials), vitamin E 30 to 600 mg (10 trials), daily or on alternate days for 1.1 to 12 years; selenium 50 to 228 µg (9 trials), daily for two to four years (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). In one trial antioxidant supplements (vitamin A, riboflavin, and zinc) were given once weekly (<LINK REF="STD-Munoz-1985" TYPE="STUDY">Munoz 1985</LINK>). One trial administered beta-carotene 30 mg daily for the first year and 30 mg two times a week for the second (<LINK REF="STD-Zhu-2003" TYPE="STUDY">Zhu 2003</LINK>). One trial administered selenium 100 µg on alternate days for one month of each year during two years (<LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK>).</P>
<P>Beta-carotene, vitamin C, vitamin E, or selenium were administered as a single antioxidant supplement (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Beta-carotene, vitamin A, vitamin C, vitamin E, and selenium formed different combinations of antioxidant supplements only or were administered together with non-antioxidant supplements (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The administered combinations consisting only of antioxidant supplements were: beta-carotene and vitamin A; beta-carotene and vitamin C; beta-carotene and vitamin E; beta-carotene, vitamin C, and vitamin E; vitamin C, vitamin E, and selenium; beta-carotene, vitamin C, and vitamin E, and selenium (see 'Characteristics of included studies' and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>Six trials added non-antioxidant vitamins, ie, vitamin B<SUB>12</SUB> and folic acid (<LINK REF="STD-Zhu-2003" TYPE="STUDY">Zhu 2003</LINK>), vitamin B<SUB>6</SUB>, vitamin B<SUB>12</SUB>, and folic acid (<LINK REF="STD-WACS-2007" TYPE="STUDY">WACS 2007</LINK>), or non-antioxidant vitamins and minerals (<LINK REF="STD-Munoz-1985" TYPE="STUDY">Munoz 1985</LINK>; <LINK REF="STD-NIT1-1993" TYPE="STUDY">NIT1 1993</LINK>; <LINK REF="STD-NIT2-1993" TYPE="STUDY">NIT2 1993</LINK>; <LINK REF="STD-SUVIMAX-2004" TYPE="STUDY">SUVIMAX 2004</LINK>) to the experimental arms (see 'Characteristics of included studies' and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>
<B>Control interventions<BR/>
</B>All trials used placebo capsules or tablets as control intervention.</P>
<P>
<B>Concomitant interventions</B>
<BR/>The factorial designs of the trials permitted other interventions to be administered to some of the participants in the antioxidant experimental arms and in the control arms. Four trials primarily connected with the occurrence of cancers and cardiovascular diseases tested additional therapies: aspirin 100 mg to 325 mg, given daily or on alternate days (<LINK REF="STD-PHS-1996" TYPE="STUDY">PHS 1996</LINK>; <LINK REF="STD-WHS-2005" TYPE="STUDY">WHS 2005</LINK>); simvastatin (cholesterol lowering therapy) 40 mg (<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>); or ramipril 10 mg (angiotensin-converting enzyme inhibitor) (<LINK REF="STD-HOPE-TOO-2005" TYPE="STUDY">HOPE TOO 2005</LINK>). Two trials assessed anti-<I>Helicobacter pylori</I> interventions (<LINK REF="STD-Correa-2000" TYPE="STUDY">Correa 2000</LINK>; <LINK REF="STD-SIT-2006" TYPE="STUDY">SIT 2006</LINK>), two trials aged garlic extract 200 mg (<LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK>; <LINK REF="STD-SIT-2006" TYPE="STUDY">SIT 2006</LINK>), and one trial vitamin B<SUB>6</SUB> 50 mg, vitamin B<SUB>12</SUB> 1 mg, and folic acid 2.5 mg (<LINK REF="STD-WACS-2007" TYPE="STUDY">WACS 2007</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>
<B>Outcome measures</B>
<BR/>All 20 trials examined gastrointestinal cancers. We were able to extract relevant data on the incidence of gastrointestinal cancers from 18 trials. We were not able to extract data on the incidence of gastrointestinal cancers for each arm separately from one trial (<LINK REF="STD-NIT1-1993" TYPE="STUDY">NIT1 1993</LINK>), and the authors did not respond to our requests for further information. The data from <LINK REF="STD-WACS-2007" TYPE="STUDY">WACS 2007</LINK> are not yet available.</P>
<P>Only 14 of the trials (70%) could provide data on overall mortality.<BR/>
<B>
<BR/>Sponsorship</B>
<BR/>Pharmaceutical companies were the provider or sponsor of antioxidant supplements in 17 trials. This information was not available in three trials (<LINK REF="STD-Yu-1991" TYPE="STUDY">Yu 1991</LINK>; <LINK REF="STD-Yu-1997" TYPE="STUDY">Yu 1997</LINK>; <LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>). Roche was the sponsor or provider in 8 out of 17 trials (47%).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-23 15:47:28 +0100" MODIFIED_BY="[Empty name]">
<P>For an overview of the methodological quality of the included trials see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<P>
<B>Gastrointestinal cancers<BR/>
</B>Twelve trials out of the 18 (66.7%) providing data on gastrointestinal cancers reported adequate generation of the allocation sequence, 13 trials (72.3%) reported adequate allocation concealment, 18 trials (100%) used placebo and hence had presumed adequate blinding, and 16 trials (88.9%) reported adequate follow-up. Twelve trials (66.7%) reported sample-size calculations. Twelve trials (66.7%) based their analyses on the intention-to-treat principle.</P>
<P>There were 12 trials (66.7%) of low-bias risk (high methodological quality) with adequate generation of the allocation sequence, allocation concealment, blinding, as well as follow-up.</P>
<P>
<B>Overall mortality</B>
<BR/>Among the 14 trials providing data on mortality, thirteen (92.9%) were of low-bias risk (high methodological quality) with adequate generation of the allocation sequence, allocation concealment, blinding, as well as follow-up. The 14<SUP>th</SUP> trial had inadequate follow-up (<LINK REF="STD-NIT1-1993" TYPE="STUDY">NIT1 1993</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-24 16:41:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Gastrointestinal cancers<BR/>
</B>Antioxidant supplements had no significant influence on gastrointestinal cancer occurrence (RR 0.94, 95% CI 0.83 to 1.06, I<SUP>2</SUP> = 54.0%). Approximately 2.2% of the participants in the antioxidant group compared with 2.0% in the placebo group developed gastrointestinal cancers at the end of follow-up.</P>
<P>
<I>
<B>Funnel plot asymmetry</B>
</I>
<BR/>We analysed the antioxidant effect on gastrointestinal cancers for funnel plot asymmetry (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). From inspection of the figure, one may suspect bias. The asymmetry was statistically significant (P = 0.009) by Egger's test and (P = 0.096) by Begg's test.</P>
<P>
<I>
<B>Meta-regression analysis</B>
</I>
<BR/>Univariate meta-regression analyses revealed that the following covariates were significantly associated with estimated intervention effect on the occurrence of the gastrointestinal cancers: dose of beta-carotene (RR 1.01, 95% CI 1.002 to 1.02; P = 0.012) and dose of selenium (RR 0.997, 95% CI 0.995 to 0.998, P &lt; 0.0001). None of the other covariates (dose of vitamin A; dose of vitamin C; dose of vitamin E; bias risk of the trials; duration of supplementation; and primary or secondary prevention) were significantly associated with estimated intervention effect on gastrointestinal cancers.</P>
<P>In multivariate meta-regression analysis including all covariates, dose of selenium was associated with a significantly lower estimated intervention effect on the gastrointestinal cancers (RR 0.996, 95% CI 0.994 to 0.999; P = 0.007). None of the other covariates was significantly associated with the estimated intervention effect on the gastrointestinal cancers.</P>
<P>
<I>
<B>Methodological quality and antioxidant effect on gastrointestinal cancer occurrence</B>
</I>
<BR/>The trials with low risk of bias (n = 12) did not show a significant effect of antioxidant supplements on gastrointestinal cancers (RR 1.04, 95% CI 0.96 to 1.13, I<SUP>2</SUP> = 19.6%). In the trials with high risk of bias (n = 6) antioxidant supplements significantly decreased gastrointestinal cancers (RR 0.59, 95% CI 0.43 to 0.80, I<SUP>2</SUP> = 18.1%). The difference between the estimates obtained by trials with adequate and unclear or inadequate methodology was statistically significant by test of interaction (z = -3.53, P &lt; 0.0005).</P>
<P>
<I>Generation of the allocation sequence </I>
<BR/>In the trials with adequate generation of the allocation sequence, antioxidant supplements did not significantly influence gastrointestinal cancers (RR 1.05, 95% CI 0.98 to 1.13, I<SUP>2</SUP> = 0%). In the trials with unclear or inadequate generation of the allocation sequence, antioxidant supplements showed a significant beneficial effect on gastrointestinal cancers (RR 0.59, 95% CI 0.43 to 0.80, I<SUP>2 </SUP>= 18.1%). The difference between the estimates obtained by trials with adequate and unclear or inadequate generation of the allocation sequence was statistically significant by test of interaction (z = -3.55, P &lt; 0.0005).</P>
<P>
<I>Allocation concealment</I>
<BR/>In the trials with adequate allocation concealment, antioxidant supplements did not significantly influence gastrointestinal cancers (RR 1.05, 95% CI 0.98 to 1.13, I<SUP>2</SUP> = 0%). In the trials with unclear or inadequate allocation concealment, antioxidant supplements showed a significant beneficial effect on gastrointestinal cancers (RR 0.57, 95% CI 0.41 to 0.78, I<SUP>2</SUP> = 19.6%). The difference between the estimates obtained by trials with adequate and unclear or inadequate allocation concealment was statistically significant by test of interaction (z = -3.64, P &lt; 0.0003).</P>
<P>
<I>Blinding</I>
<BR/>Blinding was assumed adequate in all the 18 trials due to the use of placebo.</P>
<P>
<I>Follow-up</I>
<BR/>In the trials with adequate follow-up, antioxidant supplements did not significantly influence gastrointestinal cancers (RR 0.98, 95% CI 0.87 to 1.10, I<SUP>2</SUP> = 49.8%). In the trials with unclear follow-up, antioxidant supplements showed no significant effect on gastrointestinal cancers (RR 0.72, 95% CI 0.51 to 1.02, I<SUP>2</SUP> = 0%). The difference between the estimates obtained by trials with adequate and unclear or inadequate follow-up was not statistically significant by test of interaction (z = -1.65, P = 0.0989).</P>
<P>
<I>
<B>Type of antioxidant supplement</B>
</I>
<BR/>Beta-carotene (RR 1.04, 95% CI 0.80 to 1.35) or vitamin E (RR 1.11, 95% CI 0.93 to 1.34) given singly did not significantly influence gastrointestinal cancers. Different combinations of antioxidants, that is, beta-carotene and vitamin A; beta-carotene and vitamin C; beta-carotene and vitamin E; vitamin A, riboflavin, and zinc; beta-carotene, vitamin C, and vitamin E; vitamin C, vitamin E, and selenium; beta-carotene, vitamin C, vitamin E, and selenium, or combinations of 26 vitamins/minerals did not significantly influence gastrointestinal cancers (RR 1.10, 95% CI 0.91 to 1.32; RR 2.90, 95% CI 0.12 to 70.52; RR 1.18, 95% CI 0.98 to 1.41; RR 1.33, 95% CI 0.30 to 5.91; RR 0.96, 95% CI 0.80 to 1.16; RR 1.01, 95% CI 0.60 to 1.68; RR 0.83, 95% CI 0.53 to 1.32; RR 1.05, 95% CI 0.88 to 1.25; respectively). Selenium given singly significantly decreased gastrointestinal cancers (RR 0.59, 95% CI 0.46 to 0.75, I<SUP>2 </SUP>= 0%). Selenium combined did not significantly influence gastrointestinal cancers (RR 1.02, 95% CI 0.87 to 1.19, I<SUP>2</SUP> = 0%). Selenium given singly or combined significantly decreased gastrointestinal cancers (RR 0.86, 95% CI 0.75 to 0.98, I<SUP>2</SUP> = 60.8%). Five out of the nine trials assessing selenium had high-bias risk. The effect of selenium given singly or combined in 4 low-bias risk trials was not significant (RR 0.89, 95% CI 0.68 to 1.18, I<SUP>2</SUP> = 45.0%). For an overview of the effect of the different antioxidant supplements on different gastrointestinal cancers see (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>
<I>
<B>Occurrence of oesophageal cancer</B>
</I>
<BR/>Antioxidant supplements did not significantly influence oesophageal cancer (RR 1.06, 95% CI 0.89 to 1.28, I<SUP>2</SUP> = 0%). Approximately 0.36% of the participants in the antioxidant group compared to 0.38% in the placebo group developed oesophageal cancer at the end of follow-up. Antioxidants administered singly, ie, beta-carotene (RR 0.75, 95% CI 0.25 to 2.30); vitamin E (RR 1.46, 95% CI 0.72 to 2.96); selenium (RR 0.40, 95% CI 0.08 to 2.07), or in certain combinations as beta-carotene and vitamin A (RR 1.43, 95% CI 0.90 to 2.29); beta-carotene and vitamin E (RR 1.23, 95% CI 0.59 to 2.56); vitamin A, riboflavin, and zinc (RR 1.33, 95% CI 0.30 to 5.91); beta-carotene, vitamin C, and vitamin E (RR 1.19, 95% CI 0.71 to 2.01); beta-carotene, vitamin C, vitamin E and selenium (RR 1.01, 95% CI 0.14 to 7.16), or combination of 26 vitamins/minerals (RR 0.96, 95% CI 0.76 to 1.22) versus placebo for a period of 1.1 to 10.1 years, with a follow-up up to 14.1 years, did not significantly influence oesophageal cancer.</P>
<P>
<I>
<B>Occurrence of gastric cancer</B>
</I>
<BR/>Antioxidant supplements did not significantly influence gastric cancer (RR 1.14, 95% CI 0.97 to 1.33, I<SUP>2</SUP> = 0%). Approximately 0.51% of the participants in the antioxidant group compared to 0.38% in the placebo group developed gastric cancer at the end of follow-up. Antioxidants administered singly, ie, beta-carotene (RR 1.12, 95% CI 0.79 to 1.59); vitamin E (RR 1.30, 95% CI 0.90 to 1.88); selenium (RR 0.76, 95% CI 0.44 to 1.31), or in certain combinations as beta-carotene and vitamin A (RR 0.89, 95% CI 0.46 to 1.73); beta-carotene and vitamin C (RR 2.90, 95% CI 0.12 to 70.52); beta-carotene and vitamin E (RR 1.40, 95% CI 0.98 to 2.01); beta-carotene, vitamin C, and vitamin E (RR 1.25, 95% CI 0.78 to 2.00); vitamin C, vitamin E, and selenium (RR 1.01, 95% CI 0.60 to 1.68); beta-carotene, vitamin C, vitamin E, and selenium (RR 1.01, 95% CI 0.14 to 7.16), or combination of 26 vitamins/minerals (RR 1.19, 95% CI 0.89 to 1.58) versus placebo for a period of 2.1 to 12 years and follow-up up to 14.1 years did not significantly influence gastric cancer.</P>
<P>
<I>
<B>Occurrence of small intestine cancer</B>
</I>
<BR/>Only one trial had results about small intestine cancer (<LINK REF="STD-WHS-2005" TYPE="STUDY">WHS 2005</LINK>). Antioxidant supplements did not significantly influence small intestine cancer (RR 4.00, 95% CI 0.45 to 35.79).</P>
<P>
<I>
<B>Occurrence of colorectal cancer</B>
</I>
<BR/>Antioxidant supplements did not significantly influence colorectal cancer (RR 0.97, 95% CI 0.86 to 1.09, I<SUP>2</SUP> = 19.7%). Approximately 1.07% of the participants in the antioxidant group compared to 1.09% in the placebo group developed colorectal cancer at the end of follow-up. Antioxidants administered singly, ie, beta-carotene (RR 1,09 95%CI 0.79 to 1.51); vitamin E (RR 1.10, 95% CI 0.87 to 1.39); selenium (RR 0.48, 95% CI 0.22 to 1.05); or in combinations as beta-carotene and vitamin A (RR 0.97, 95% CI 0.76 to 1.25); beta-carotene and vitamin E (RR 1.20, 95% CI 0.89 to 1.63); beta-carotene, vitamin C, and vitamin E (RR 0.84, 95% CI 0.65 to 1.07); beta-carotene, vitamin C, vitamin E, and selenium (RR 0.88 95% CI 0.49 to 1.58) versus placebo for a period of 2.1 to 12 years and follow-up up to 14.1 years did not significantly influence colorectal cancer.</P>
<P>
<I>
<B>Occurrence of pancreatic cancer</B>
</I>
<BR/>Antioxidant supplements did not significantly influence pancreatic cancer (RR 1.16, 95% CI 0.90 to 1.50, I<SUP>2</SUP> = 31.4%). Approximately 0.37% of the participants in the antioxidant group compared to 0.25% in the placebo group developed pancreatic cancer at the end of follow-up. Antioxidants administered singly, ie, beta-carotene (RR 1.02, 95% CI 0.54 to 1.90); vitamin E (RR 0.97, 95% CI 0.67 to 1.39); or in combinations as beta-carotene and vitamin A (RR 1.33, 95% CI 0.84 to 2.09); beta-carotene and vitamin E (RR 0.93, 95% CI 0.65 to 1.35); beta-carotene, vitamin C, and vitamin E (RR 1.00, 95% CI 0.57 to 1.76); beta-carotene, vitamin C, vitamin E, and selenium (RR 0.67, 95% CI 0.19 to 2.38) versus placebo for a period of 2.1 to 12 years and follow-up up to 14.1 years did not significantly influence pancreatic cancer.</P>
<P>
<I>
<B>Occurrence of hepatocellular carcinoma</B>
</I>
<BR/>Antioxidant supplements did not significantly influence hepatocellular carcinoma (RR 0.80, 95% CI 0.56 to 1.14, I<SUP>2</SUP> = 38.5%). This effect was significantly beneficial in a fixed-effect model (RR 0.76, 95% CI 0.60 to 0.96). Approximately 0.20% of the participants in the antioxidant group compared to 0.24% in the placebo group developed hepatocellular carcinoma at the end of follow-up. Beta-carotene administered singly (RR 1.92 95% CI 0.96 to 3.85), and vitamin E administered singly (RR 1.33, 95% CI 0.63 to 2.82) versus placebo for a period of 2 to 10.1 years and follow-up up to 14.1 years did not significantly influence hepatocellular carcinoma. Antioxidants in combinations as beta-carotene and vitamin A (RR 1.35, 95% CI 0.51 to 3.54), beta-carotene and vitamin E (RR 1.25, 95% CI 0.59 to 2.67), beta-carotene, vitamin C, and vitamin E (RR 1.40, 95% CI 0.44 to 4.41), or beta-carotene, vitamin C, vitamin E, and selenium (RR 1.01, 95% CI 0.06 to 16.12) did not significantly influence hepatocellular carcinoma. Selenium administered singly versus placebo for two to four years significantly decreased hepatocellular carcinoma (RR 0.56, 95% CI 0.42 to 0.76, I<SUP>2</SUP> = 0%). All four trials assessing selenium singly had high-bias risk.</P>
<P>
<I>
<B>Occurrence of biliary tract cancer</B>
</I>
<BR/>Antioxidant supplements did not significantly influence biliary tract cancers (RR 0.61, 95% CI 0.21 to 1.78, I<SUP>2</SUP> = 0%. Approximately 0.019% of the participants in the antioxidant group compared to 0.034% in the placebo group developed biliary tract cancers at the end of follow-up. Antioxidants administered in combination as beta-carotene, vitamin C, vitamin E, and selenium had no significant influence on biliary tract cancers (RR 0.20, 95% CI 0.01 to 4.20).</P>
<P>
<B>Overall mortality</B>
<BR/>Antioxidant supplements had no significant effect on mortality in a random-effects model meta-analysis (RR 1.02, 95% CI 0.97 to 1.07, I<SUP>2 </SUP>= 54.9%). Antioxidant supplements significantly increased mortality in the fixed-effect model meta-analysis (RR 1.04, 95% CI 1.02 to 1.07). A total of 17114 of 122,501 participants (14.0%) that were randomised to antioxidant supplements and 8799 of 78693 participants (11.2%) randomised to placebo died. To explore the reason for the difference between the two models, we excluded the trials administering selenium. After their exclusion, mortality was significantly higher in the antioxidant group with both the random-effects (RR 1.06, 95% CI 1.01 to 1.10, I<SUP>2</SUP> = 43.3%) and fixed-effect model meta-analyses (RR 1.06, 95% CI 1.03 to 1.09).</P>
<P>
<I>
<B>Funnel plot asymmetry<BR/>
</B>
</I>We analysed the antioxidant effect on mortality for funnel plot asymmetry (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The asymmetry was not statistically significant (P = 0.13) by Egger's test and (P = 0.15) by Begg's test.</P>
<P>
<I>
<B>Meta-regression analysis</B>
</I>
<BR/>Univariate meta-regression analyses revealed that the following covariates were significantly associated with estimated intervention effect on mortality: dose of beta-carotene (RR 1.007, 95% CI 1.002 to 1.012; P = 0.003), dose of vitamin A (RR 1.000006, 95% CI 1.000001 to 1.000011, P = 0.009), and dose of selenium (RR 0.998, 95% CI 0.997 to 0.999, P = 0.002). None of the other covariates, ie, dose of vitamin C; dose of vitamin E; bias risk of the trials; duration of supplementation; and primary or secondary prevention, were significantly associated with estimated intervention effect on mortality.</P>
<P>In multivariate meta-regression analysis including all covariates, dose of selenium was associated with the estimated intervention effect on mortality (RR 0.998, 95% CI 0.997 to 1.000, P = 0.043). None of the other covariates was significantly associated with the estimated intervention effect on mortality.</P>
<P>
<I>
<B>Methodological quality and antioxidant effect on overall mortality</B>
</I>
<BR/>The effect of antioxidant supplements on mortality in trials with low risk of bias (high methodological quality) was not statistically significant in a random-effects model meta-analysis (RR 1.03, 95% CI 0.98 to 1.08, I<SUP>2</SUP> = 53.5%). Antioxidant supplements significantly increased mortality in a fixed-effect model meta-analysis (RR 1.05, 95% CI 1.02 to 1.07). In the one trial with high risk of bias (<LINK REF="STD-NIT1-1993" TYPE="STUDY">NIT1 1993</LINK>) antioxidant supplements did not significantly influence mortality (RR 0.94, 95% CI 0.84 to 1.06). The difference between the estimate of antioxidant effect in low-bias and high-bias risk trials was not significant by test of interaction (z = -1.42, P = 0.156).</P>
<P>
<I>
<B>Type of antioxidant supplement</B>
</I>
<BR/>Antioxidants given singly, ie, beta-carotene (RR 1.05, 95% CI 0.99 to 1.11), vitamin C (RR 0.97, 95% CI 0.77 to 1.23); vitamin E (RR 1.02, 95% CI 0.98 to 1.06); and selenium (RR 0.84, 95% CI 0.67 to 1.07) did not significantly influence mortality. Beta-carotene used singly significantly increased mortality in a fixed-effect model meta-analysis (RR 1.06, 95% CI 1.02 to 1.10). Mortality in participants supplemented with beta-carotene and vitamin A (RR 1.16, 95% CI 1.09 to 1.23), or beta-carotene and vitamin E (RR 1.06, 95% CI 1.02 to 1.11) was significantly higher than in the placebo group. Antioxidants given in certain combinations, ie, beta-carotene and vitamin C (RR 2.79, 95% CI 0.57 to 13.68); beta-carotene, vitamin C, and vitamin E (RR 1.04, 95% CI 0.97 to 1.11); vitamin C, vitamin E, and selenium (RR 0.82, 95% CI 0.62 to 1.08); beta-carotene, vitamin C, vitamin E, and selenium (RR 0.78, 95% CI 0.58 to 1.05), or combination of 26 vitamins/minerals (RR 0.94, 95% CI 0.85 to 1.05) versus placebo did not significantly influence mortality.</P>
<P>
<B>Non-serious adverse effects</B>
<BR/>Several adverse effects were recorded in the antioxidant group. Persistent yellowing of the skin and belching were significantly increased in participants supplemented with beta-carotene (RR 29.14, 95% CI 21.60 to 39.32; RR 2.22, 95% CI 1.80 to 2.74; respectively). Transient yellowing of the skin (RR 1.85, 95% CI 0.74 to 4.67) and gastrointestinal upset (RR 1.03, 95% CI 1.00 to 1.06) were not significantly influenced. Haemorrhagic stroke was not significantly influenced by vitamin E (RR 1.01, 95% CI 0.82 to 1.23, I<SUP>2</SUP> = 0%). Gastrointestinal upset in participants supplemented with selenium was not significantly different when compared to placebo (RR 1.51, 95% CI 0.78 to 2.95). Increased yellowing of the urine and the feeling of being hot and dry in participants taking a combination of 13 vitamins and 13 minerals was also not significantly different between the antioxidant and the placebo group.</P>
<P>
<B>Quality of life and cost-effectiveness</B>
<BR/>We did not find any data on quality of life in the randomised trials included in this review. We found cost-effectiveness analyses in one trial (<LINK REF="STD-PHS-1996" TYPE="STUDY">PHS 1996</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-23 18:12:52 +0100" MODIFIED_BY="[Empty name]">
<P>Compared to our previous review (<LINK REF="REF-Bjelakovic-2004a" TYPE="REFERENCE">Bjelakovic 2004a</LINK>), the number of included trials in the present review is expanded with six new trials (42.9%) adding 41293 participants (24.2%). Moreover, we have obtained updated results of longer follow-up from three large-scale randomised trials (<LINK REF="STD-ATBC-2003" TYPE="STUDY">ATBC 2003</LINK>; <LINK REF="STD-CARET-2004" TYPE="STUDY">CARET 2004</LINK>; <LINK REF="STD-WHS-2005" TYPE="STUDY">WHS 2005</LINK>). Our results remain largely the same. Antioxidant supplements, ie, beta-carotene, vitamin A, vitamin C, and vitamin E given singly or in combinations, do not seem to prevent gastrointestinal cancers. Beta-carotene and vitamin A may increase the cancer risk. The studied antioxidants, other than selenium, also seem to increase overall mortality. Thus, the present results support our findings from 47 low-bias risk trials showing increased mortality in participants undergoing primary or secondary prevention with similar antioxidant supplements (<LINK REF="REF-Bjelakovic-2007" TYPE="REFERENCE">Bjelakovic 2007</LINK>). Selenium might potentially reduce gastrointestinal cancers and mortality, but these observations run the risk of bias due to the low methodological quality of most of the assessed trials. Only one of the trials investigating selenium given as a single antioxidant had low-bias risk (<LINK REF="STD-NPCT-1996" TYPE="STUDY">NPCT 1996</LINK>). Although several hypotheses have been explored, the mechanisms involved in the possible cancer preventive role of selenium are largely unknown (<LINK REF="REF-Rayman-2005" TYPE="REFERENCE">Rayman 2005</LINK>; <LINK REF="REF-Papp-2007" TYPE="REFERENCE">Papp 2007</LINK>). Recently, a randomised trial has shown that selenium may carry health risks, eg, increasing the risk of diabetes mellitus (<LINK REF="REF-Stranges-2007" TYPE="REFERENCE">Stranges 2007</LINK>). Before therapeutic or preventive actions are considered, results of ongoing high-quality randomised trials with selenium are needed (<LINK REF="STD-APPOSE-2001" TYPE="STUDY">APPOSE 2001</LINK>; <LINK REF="STD-SELECT-2003" TYPE="STUDY">SELECT 2003</LINK>; <LINK REF="STD-HGPIN-2006" TYPE="STUDY">HGPIN 2006</LINK>).</P>
<P>Our review shows that beta-carotene possesses significantly harmful effects on gastrointestinal cancers and seems to increase mortality when applied singly or in combination with vitamin A or vitamin E. A recent study suggests that beta-carotene may act as a co-carcinogen (<LINK REF="REF-Paolini-2003" TYPE="REFERENCE">Paolini 2003</LINK>). In another review that we have performed, we have also demonstrated that beta-carotene seems to increase mortality (<LINK REF="REF-Bjelakovic-2007" TYPE="REFERENCE">Bjelakovic 2007</LINK>). We were unable to identify trials assessing vitamin A alone in the prevention of gastrointestinal cancers. The combination of beta-carotene and vitamin A was assessed in a high-quality, large-scale randomised trial having lung cancer prevention as the primary outcome (<LINK REF="STD-CARET-2004" TYPE="STUDY">CARET 2004</LINK>). Gastrointestinal cancer occurrence and overall mortality were significantly higher in the vitamin A supplemented group. Recent research in this field suggest that vitamin A might have pro-oxidant abilities, which could lead to carcinogenesis (<LINK REF="REF-Murata-2000" TYPE="REFERENCE">Murata 2000</LINK>) and may even increase mortality (<LINK REF="REF-Bjelakovic-2007" TYPE="REFERENCE">Bjelakovic 2007</LINK>). This finding was corroborated in the present systematic review. The trials in which vitamin C was applied alone or in different combinations with beta-carotene, vitamin A, vitamin E, and selenium found no significant effect on gastrointestinal cancers, or on overall mortality. Vitamin E did not significantly influence gastric, pancreatic, and colorectal cancer or overall mortality. According to recent meta-analyses, vitamin E seems to increase overall mortality (<LINK REF="REF-Miller-2005" TYPE="REFERENCE">Miller 2005</LINK>; <LINK REF="REF-Bjelakovic-2007" TYPE="REFERENCE">Bjelakovic 2007</LINK>). Therefore, preventive use of vitamin E cannot be recommended.</P>
<P>The bias risk of the trials had a significant impact on our results. The low-bias risk trials either showed significant harmful effects or no significant effects of antioxidant supplements on the primary outcome measures. On the contrary, trials with high-bias risk found either no significant effects or significant beneficial effects. These observations are in accordance with several studies linking high-bias risk with significant overestimation of beneficial effects (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>; <LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>; <LINK REF="REF-Gluud-2006a" TYPE="REFERENCE">Gluud 2006a</LINK>; <LINK REF="REF-Gluud-2006b" TYPE="REFERENCE">Gluud 2006b</LINK>) and underreporting of adverse effects (<LINK REF="REF-D_x0027_Amico-2003" TYPE="REFERENCE">D'Amico 2003</LINK>). Our meta-regression analysis failed to identify bias risk as associated with risk of cancer, but we observed that trials with high risk of bias found a decreased risk of cancer.</P>
<P>We can only speculate what caused the significantly higher mortality among the participants supplemented with antioxidants. Based on our present results as well as the results of previous randomised trials and meta-analysis it is likely that both cardiovascular diseases (<LINK REF="STD-ATBC-2003" TYPE="STUDY">ATBC 2003</LINK>; <LINK REF="REF-Vivekananthan-2003" TYPE="REFERENCE">Vivekananthan 2003</LINK>) and cancers (<LINK REF="STD-ATBC-2003" TYPE="STUDY">ATBC 2003</LINK>; <LINK REF="STD-CARET-2004" TYPE="STUDY">CARET 2004</LINK>) have led to increased mortality. We observed a non-significant tendency towards increased occurrence of gastrointestinal cancers in the supplemented group of low-bias risk trials (RR 1.04, 95% CI 0.96 to 1.13). Observational studies have shown possible detrimental effects of antioxidant supplements on cardiovascular mortality (<LINK REF="REF-Lee-2004" TYPE="REFERENCE">Lee 2004</LINK>), prostate cancer (<LINK REF="REF-Lawson-2007" TYPE="REFERENCE">Lawson 2007</LINK>), and lung cancer (<LINK REF="REF-Slatore-2007" TYPE="REFERENCE">Slatore 2007</LINK>). Cardiovascular diseases and cancers of the lung and gastrointestinal tract are the leading causes of death worldwide (<LINK REF="REF-Ferlay-2004" TYPE="REFERENCE">Ferlay 2004</LINK>; <LINK REF="REF-Lopez-2006" TYPE="REFERENCE">Lopez 2006</LINK>; <LINK REF="REF-Mathers-2006" TYPE="REFERENCE">Mathers 2006</LINK>). Reactive oxygen species in moderate concentrations are essential mediators of reactions by which unwanted cells are deleted from the body. Schulz et al found that the inhibition of reactive oxygen species formation in cells decreases the life span of nematodes (<LINK REF="REF-Schulz-2007" TYPE="REFERENCE">Schulz 2007</LINK>). Excessive suppression of free radicals may have unwanted consequences to our health (<LINK REF="REF-Salganik-2001" TYPE="REFERENCE">Salganik 2001</LINK>).</P>
<P>There are still many gaps in our knowledge of the mechanisms of bioavailability, biotransformation, and action of antioxidant supplements (<LINK REF="REF-Haenen-2002" TYPE="REFERENCE">Haenen 2002</LINK>). Antioxidant supplements in pills are factory processed, biochemically unbalanced, and apparently unsafe compared to their naturally occurring counterparts (<LINK REF="REF-Herbert-1997" TYPE="REFERENCE">Herbert 1997</LINK>; <LINK REF="REF-Seifried-2003" TYPE="REFERENCE">Seifried 2003</LINK>). Antioxidant supplements also possess pro-oxidant effects (<LINK REF="REF-Podmore-1998" TYPE="REFERENCE">Podmore 1998</LINK>; <LINK REF="REF-Paolini-1999" TYPE="REFERENCE">Paolini 1999</LINK>; <LINK REF="REF-Murata-2000" TYPE="REFERENCE">Murata 2000</LINK>; <LINK REF="REF-Lee-2003" TYPE="REFERENCE">Lee 2003</LINK>; <LINK REF="REF-Duarte-2005" TYPE="REFERENCE">Duarte 2005</LINK>). A balanced diet typically contains safe levels of antioxidant vitamins and trace elements (<LINK REF="REF-Camire-1999" TYPE="REFERENCE">Camire 1999</LINK>). Some of the trials included in our review investigated the effects of antioxidant supplements administered at doses significantly higher than those found in a balanced diet. Some trials used dosages well above the recommended tolerable upper intake levels (<LINK REF="REF-Anonymous-2000a" TYPE="REFERENCE">Anonymous 2000a</LINK>; <LINK REF="REF-Anonymous-2000b" TYPE="REFERENCE">Anonymous 2000b</LINK>). The majority of the trials were conducted in middle- and high-income countries among populations with already sufficient levels of antioxidant vitamins and trace elements. This might be a cause for the lack of protective effects and for the increase in mortality of antioxidant supplements.</P>
<P>For many years scientists have been concerned about possible harm caused by antioxidants (<LINK REF="REF-Herbert-1994" TYPE="REFERENCE">Herbert 1994</LINK>; <LINK REF="REF-Schwartz-1996" TYPE="REFERENCE">Schwartz 1996</LINK>). However, large expectations and unconfined belief in the cancer preventive potential of the antioxidants have overwhelmed these concerns. The available data on adverse effects of antioxidant supplements are still limited (<LINK REF="REF-Mulholland-2007" TYPE="REFERENCE">Mulholland 2007</LINK>) and often underreported (<LINK REF="REF-Woo-2007" TYPE="REFERENCE">Woo 2007</LINK>). Less than 1% of all adverse effects associated with antioxidant supplements are notified (<LINK REF="REF-Woo-2007" TYPE="REFERENCE">Woo 2007</LINK>). Consumers presume antioxidant supplements to be safe and use them without physicians' supervision (<LINK REF="REF-Webb-2007" TYPE="REFERENCE">Webb 2007</LINK>). We find that it is high time that antioxidant supplements are moved from the free 'over the counter' market to the prescription regulatory market.</P>
<P>Certain potential limitations of this review warrant consideration. We are dealing with a group of trials, which by the nature of their topic, that is, preventive efforts over a number of years, may have inherent mistakes. We found a number of inconsistencies among the different reports of the individual trials. We tried in all cases to obtain clarification from the authors. However, this was not always possible. Diagnostic criteria and timing of screening differed among the trials or were not always well defined. We have compared the intervention effects of antioxidants of different types and their influence on different gastrointestinal cancers with different aetiology, biology, and epidemiology. Moreover, the examined populations varied. The effects of supplements were assessed in the general population, participants with premalignant conditions of gastrointestinal tract, and participants coming from other patient groups, primarily with non-gastrointestinal diseases. The variable risk to develop cancer can influence the results. These populations mostly came from countries without overt deficiencies of specific supplements. Accordingly, we are unable to assess the influence of antioxidant supplements on gastrointestinal cancer occurrence in populations with specific needs. In general, the risk of individual cancer was below 1%. This may make it difficult to detect any effects - beneficial or harmful.</P>
<P>The reporting of the occurrence of gastrointestinal cancers and overall mortality in the randomised trials was not always sufficient and consistent. Regarding gastrointestinal cancers, all included trials gave results. However, from one trial (<LINK REF="STD-NIT1-1993" TYPE="STUDY">NIT1 1993</LINK>) we were unable to extract data for each arm separately. Data are awaited from another trial (<LINK REF="STD-WACS-2007" TYPE="STUDY">WACS 2007</LINK>). Of 20 trials included in our systematic review, only 14 (70%) reported overall mortality. We tried to obtain additional information from the authors but without success. Therefore, outcome reporting bias could influence the result of our meta-analysis. Outcome reporting bias is defined as selective reporting of some results in trial publications and represent a threat to validity of meta-analysis (<LINK REF="REF-Chan-2004a" TYPE="REFERENCE">Chan 2004a</LINK>; <LINK REF="REF-Chan-2004b" TYPE="REFERENCE">Chan 2004b</LINK>; <LINK REF="REF-Chan-2005" TYPE="REFERENCE">Chan 2005</LINK>; <LINK REF="REF-Williamson-2005" TYPE="REFERENCE">Williamson 2005</LINK>; <LINK REF="REF-Furukawa-2007" TYPE="REFERENCE">Furukawa 2007</LINK>). We are well aware of the difficulties in collecting data on outcomes in clinical trials focusing on safety and efficacy evaluations. The worst result of outcome reporting bias and suppression of some significant or non-significant findings could be the use of harmful interventions. Most of the included trials lacked detailed information on disease-specific causes of mortality as well as separate reporting of cancers according to sex.</P>
<P>The choice of statistical model for performing meta-analysis is important. The fixed-effect model meta-analysis assumes that the true intervention effect is the same in every randomised trial, ie, the effect is fixed across trials. The random-effects model assumes that the effects being estimated based on the different randomised trials differ, but follow some general distribution. When there is no heterogeneity (I<SUP>2</SUP> = 0%), then fixed- and random-effects models meta-analyses tend to give the same result. If heterogeneity increases, the estimated intervention effect and the corresponding 95% confidence interval will differ in the two models. The trials in the present review had clinical heterogeneity. This argues in favour of the random-effects model. The standard random-effects model used in RevMan Analysis is the DerSimonian and Laird method, which models the known differences between trials by incorporating a variance parameter tau to account for across-trial variation (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). Adoption of the random-effects model in meta-analysis permits inferences to a broader population of studies than the fixed-effect model does namely because it includes the parameter tau in the model. The use of the random-effects model may come at a price. If there is between-trial heterogeneity, then the weight of the large trials (usually providing more realistic estimates of intervention effects) is reduced. At the same time, the weight of small trials (usually providing more unrealistic estimates of intervention effects due to 'bias' (systematic errors) and 'chance' (random errors)) increases. Therefore, we also analysed our meta-analyses with the fixed-effect model.</P>
<P>We only examined certain antioxidant supplements that had been tested in randomised trials. Our results should not be translated to the potential effects of fruits and vegetables, which are rich not only in antioxidants but also in a number of other substances. In spite of intensive research, it is still not clear exactly which specific dietary constituents of fruits and vegetables might have anticarcinogenic properties. The results of randomised clinical trials on cancer prevention with high intake of fruits and vegetables are inconsistent and vary by cancer type and affected organ (<LINK REF="REF-Neuhouser-2003" TYPE="REFERENCE">Neuhouser 2003</LINK>; <LINK REF="REF-Nouraie-2005" TYPE="REFERENCE">Nouraie 2005</LINK>). Recently published results of a randomised trial found non-significant effect of high fruit and vegetable diet on colorectal adenoma recurrence (<LINK REF="REF-Lanza-2007" TYPE="REFERENCE">Lanza 2007</LINK>). Results of epidemiologic studies differ significantly too, reporting beneficial or null effects (<LINK REF="REF-Larsson-2006" TYPE="REFERENCE">Larsson 2006</LINK>; <LINK REF="REF-Freedman-2007" TYPE="REFERENCE">Freedman 2007</LINK>; <LINK REF="REF-Koushik-2007" TYPE="REFERENCE">Koushik 2007</LINK>; <LINK REF="REF-Kubo-2007" TYPE="REFERENCE">Kubo 2007</LINK>; <LINK REF="REF-Takachi-2007" TYPE="REFERENCE">Takachi 2007</LINK>).</P>
<P>Our results are in accordance with the results of other recently published meta-analyses and systematic reviews (<LINK REF="REF-Caraballoso-2003" TYPE="REFERENCE">Caraballoso 2003</LINK>; <LINK REF="REF-Vivekananthan-2003" TYPE="REFERENCE">Vivekananthan 2003</LINK>; <LINK REF="REF-Bjelakovic-2004a" TYPE="REFERENCE">Bjelakovic 2004a</LINK>; <LINK REF="REF-Bjelakovic-2004b" TYPE="REFERENCE">Bjelakovic 2004b</LINK>; <LINK REF="REF-Miller-2005" TYPE="REFERENCE">Miller 2005</LINK>; <LINK REF="REF-Bjelakovic-2006" TYPE="REFERENCE">Bjelakovic 2006</LINK>; <LINK REF="REF-Bjelakovic-2007" TYPE="REFERENCE">Bjelakovic 2007</LINK>), as well as recommendations of the United States Preventive Services Task Force and British Nutrition Foundation for the use of vitamin supplementation (<LINK REF="REF-McKevith-2003" TYPE="REFERENCE">McKevith 2003</LINK>; <LINK REF="REF-Morris-2003" TYPE="REFERENCE">Morris 2003</LINK>; <LINK REF="REF-USPSTF-2003" TYPE="REFERENCE">USPSTF 2003</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no convincing evidence that the studied antioxidant supplements have beneficial effect on the occurrence of gastrointestinal cancers or on overall mortality. Beta-carotene, vitamin A, vitamin C, and/or vitamin E seem to increase overall mortality. Therefore, we cannot recommend the use of these antioxidant supplements as a preventive measure.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Selenium may potentially possess beneficial effects on gastrointestinal cancers. The potential anticarcinogenic effects of selenium have to be elucidated. Randomised clinical trials with selenium are ongoing and further trials may be needed.</P>
<P>The significant association between unclear or inadequate methodological quality and overestimation of intervention effects has again focused on the need for more objective assessment of preventive and therapeutic interventions.</P>
<P>National and international laws and regulations should require that anything sold to the public claiming health benefits is subjected to adequate assessment of benefits and harms before market release. We suggest that antioxidant supplements should be regulated as drugs.</P>
<P>Researches wishing to examine the influence of antioxidant supplements on gastrointestinal cancers or other diseases should adopt the CONSORT statement while performing and reporting randomised clinical trials (CONSORT - Consolidated Standards of Reporting Trials: www.consort-statement.org).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We extend our gratitude to all participants in the randomised clinical trials. We thank Ronald L. Koretz, Contact Editor of The CHBG for very helpful comments on the review. We thank Mike Clarke, The Director of The UK Cochrane Centre; David Forman, The Co-ordinating Editor of The Cochrane Upper Gastrointestinal and Pancreatic Diseases Group; John McDonald, The Co-ordinating Editor of The Cochrane Inflammatory Bowel Disease Group, and Peer Wille-Jørgensen, The Co-ordinating Editor of The Cochrane Colorectal Cancer Group for their expert comments during preparation of the protocol. We thank Yan Gong and Bodil Als-Nielsen for useful advice and comments, Yan Gong and Wendong Chen for translation of Chinese articles, and Maoling Wei, The Chinese Cochrane Centre, for performing searches on the Chinese Database and providing us with some articles. We are grateful to Jarmo Virtamo, Nea Malila, Julie Buring, Nancy Cook, Pelayo Correa, John A Baron, Howard Sesso, Serge Hercberg, Mark Thornquist, Matt Barnett, Gary Goodman, I-Min Lee, Martyn Plummer and Mitchell H. Gail for the information on the trials they were involved in.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Goran Bjelakovic conceived the idea for and drafted the protocol and the review. Dimitrinka Nikolova developed the search strategy and revised the protocol and the review. Rosa Simonetti revised the protocol and the review. Christian Gluud provided input during the protocol stage as Contact Editor and joined the team of authors during the preparation of the review providing strategy for data analyses, data interpretation, and revisions of the review. All co-reviewers contributed to the data extraction, data verification, and update of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>The Protocol for this Review was published with a title 'Antioxidats for preventing gastrointestinal cancers'.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-24 17:01:30 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-ATBC-2003" NAME="ATBC 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al</AU>
<TI>Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1995</YR>
<VL>62</VL>
<NO>6 Suppl</NO>
<PG>1427s-30s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7495243"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, et al</AU>
<TI>Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>21</NO>
<PG>1560-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8901854"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albanes D, Malila N, Taylor PR, Huttunen JK, Virtamo J, Edwards BK, et al</AU>
<TI>Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland)</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>3</NO>
<PG>197-205</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10782653"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumberg J</AU>
<TI>The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland</TI>
<SO>Nutrition Reviews</SO>
<YR>1994</YR>
<VL>52</VL>
<NO>7</NO>
<PG>242-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8090376"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freedman DM, Tangrea JA, Virtamo J, Albanes D</AU>
<TI>The effect of beta-carotene supplementation on serum vitamin D metabolite concentrations</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>12</NO>
<PG>1115-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10613346"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartman TJ, Dorgan JF, Woodson K, Virtamo J, Tangrea JA, Heinonen OP, et al</AU>
<TI>Effects of long-term alpha-tocopherol supplementation on serum hormones in older men</TI>
<SO>Prostate</SO>
<YR>2001</YR>
<VL>46</VL>
<NO>1</NO>
<PG>33-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11170129"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leppala JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, et al</AU>
<TI>Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers</TI>
<SO>Arteriosclerosis Thrombosis and Vascular Biology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>1</NO>
<PG>230-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10634823"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liede KE, Haukka JK, Saxen LM, Heinonen OP</AU>
<TI>Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid</TI>
<SO>Annals of Medicine</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>6</NO>
<PG>542-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9920356"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malila N, Taylor PR, Virtanen MJ, Korhonen P, Huttunen JK, Albanes D, et al</AU>
<TI>Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland)</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>7</NO>
<PG>617-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12296509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malila N, Virtamo J, Virtanen M, Albanes D, Tangrea J, Huttunen J</AU>
<TI>The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>6</NO>
<PG>489-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10385137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malila N, Virtamo J, Virtanen M, Pietinen P, Albanes D, Teppo L</AU>
<TI>Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>7</NO>
<PG>615-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12080400"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michaud DS, Pietinen P, Taylor PR, Virtanen M, Virtamo J, Albanes D</AU>
<TI>Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>9</NO>
<PG>960-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12434284"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rautalahti MT, Virtamo JR, Taylor PR, Heinonen OP, Albanes D, Haukka JK, et al</AU>
<TI>The effects of supplementation with alpha-tocopherol and beta-carotene on the incidence and mortality of carcinoma of the pancreas in a randomized, controlled trial</TI>
<SO>Cancer</SO>
<YR>1999</YR>
<VL>86</VL>
<NO>1</NO>
<PG>37-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10391561"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, et al</AU>
<TI>Helicobacter pylori seropositivity as a risk factor for pancreatic cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2001</YR>
<VL>93</VL>
<NO>12</NO>
<PG>937-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11416115"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teikari JM, Laatikainen L, Rapola JM, Virtamo J, Haukka J, Liesto K, et al</AU>
<TI>Retinal vascular changes following supplementation with alpha-tocopherol or beta-carotene</TI>
<SO>Acta Ophthalmologica Scandinavica</SO>
<YR>1998</YR>
<VL>76</VL>
<NO>1</NO>
<PG>68-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9541437"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teikari JM, Laatikainen L, Virtamo J, Haukka J, Rautalahti M, Liesto K, et al</AU>
<TI>Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy</TI>
<SO>Acta Ophthalmologica Scandinavica</SO>
<YR>1998</YR>
<VL>76</VL>
<NO>2</NO>
<PG>224-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9591958"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teikari JM, Rautalahti M, Haukka J, Jarvinen P, Hartman AM, Virtamo J, et al</AU>
<TI>Incidence of cataract operations in Finnish male smokers unaffected by alpha tocopherol or beta carotene supplements</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>7</NO>
<PG>468-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9799882"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The ATBC Cancer Prevention Study Group</AU>
<TI>The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance</TI>
<SO>Annals of Epidemiology</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8205268"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The ATBC Cancer Prevention Study Group</AU>
<TI>The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>15</NO>
<PG>1029-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8127329"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tornwall ME, Virtamo J, Haukka JK, Albanes D, Huttunen JK</AU>
<TI>Alpha-tocopherol (vitamin E) and beta-carotene supplementation does not affect the risk for large abdominal aortic aneurysm in a controlled trial</TI>
<SO>Atherosclerosis</SO>
<YR>2001</YR>
<VL>157</VL>
<NO>1</NO>
<PG>167-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11427217"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tornwall ME, Virtamo J, Haukka JK, Aro A, Albanes D, Huttunen JK</AU>
<TI>The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial</TI>
<SO>Atherosclerosis</SO>
<YR>1999</YR>
<VL>147</VL>
<NO>1</NO>
<PG>193-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10525141"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Albanes D, Huttunen JK</AU>
<TI>Postintervention effect of alpha tocopherol and beta carotene on different strokes: a 6-year follow-up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study</TI>
<SO>Stroke</SO>
<YR>2004</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1908-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15205487"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, et al</AU>
<TI>Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>9</NO>
<PG>950-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11063155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varis K, Taylor PR, Sipponen P, Samloff IM, Heinonen OP, Albanes D, et al</AU>
<TI>Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. The Helsinki Gastritis Study Group</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>3</NO>
<PG>294-300</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9548624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Virtamo J, Edwards BK, Virtanen M, Taylor PR, Malila N, Albanes D, et al</AU>
<TI>Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland)</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>10</NO>
<PG>933-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11142528"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ, et al</AU>
<TI>Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>4</NO>
<PG>476-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12876090"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woodson K, Tangrea JA, Barrett MJ, Virtamo J, Taylor PR, Albanes D</AU>
<TI>Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>20</NO>
<PG>1738-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10528024"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CARET-2004" NAME="CARET 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfano CM, Klesges RC, Murray DM, Bowen DJ, McTiernan A, Vander Weg MW, et al</AU>
<TI>Physical activity in relation to all-site and lung cancer incidence and mortality in current and former smokers</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>12</NO>
<PG>2233-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15598785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aliyu OA, Cullen MR, Barnett MJ, Balmes JR, Cartmel B, Redlich CA, et al</AU>
<TI>Evidence for excess colorectal cancer incidence among asbestos-exposed men in the beta-carotene and retinol efficacy trial</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>9</NO>
<PG>868-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16177148"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnhart S, Keogh J, Cullen MR, Brodkin C, Liu D, Goodman G, et al</AU>
<TI>The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts</TI>
<SO>American Journal of Industrial Medicine</SO>
<YR>1997</YR>
<VL>32</VL>
<NO>6</NO>
<PG>573-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9358912"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowen DJ, Thornquist M, Anderson K, Barnett M, Powell C, Goodman G, et al</AU>
<TI>Stopping the active intervention: CARET</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>1</NO>
<PG>39-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12559641"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodkin CA, McCullough J, Stover B, Balmes J, Hammar S, Omenn GS, et al</AU>
<TI>Lobe of origin and histologic type of lung cancer associated with asbestos exposure in the Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>American Journal of Industrial Medicine</SO>
<YR>1997</YR>
<VL>32</VL>
<NO>6</NO>
<PG>582-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9358913"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cartmel B, Dziura J, Cullen MR, Vegso S, Omenn GS, Goodman GE, et al</AU>
<TI>Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>10</NO>
<PG>1173-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16015255"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Challem JJ</AU>
<TI>Re: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>4</NO>
<PG>325-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9048840"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chuwers P, Barnhart S, Blanc P, Brodkin CA, Cullen M, Kelly T, et al</AU>
<TI>The protective effect of beta-carotene and retinol on ventilatory function in an asbestos-exposed cohort</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<NO>3</NO>
<PG>1066-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9116988"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cullen MR, Barnett MJ, Balmes JR, Cartmel B, Redlich CA, Brodkin CA, et al</AU>
<TI>Predictors of lung cancer among asbestos-exposed men in the beta-carotene and retinol efficacy trial</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2005</YR>
<VL>161</VL>
<NO>3</NO>
<PG>160-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15671258"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman GE, Omenn GS, Thornquist MD, Lund B, Metch B, Gylys-Colwell I</AU>
<TI>The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with cigarette smokers</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1993</YR>
<VL>2</VL>
<NO>4</NO>
<PG>389-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8348063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman GE, Omenn GS</AU>
<TI>Carotene and retinol efficacy trial: lung cancer chemoprevention trial in heavy cigarette smokers and asbestos-exposed workers. CARET Coinvestigators and Staff</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>1992</YR>
<VL>320</VL>
<PG>137-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1442278"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman GE, Schaffer S, Omenn GS, Chen C, King I</AU>
<TI>The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>6</NO>
<PG>518-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12814997"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman GE, Thornquist M, Kestin M, Metch B, Anderson G, Omenn GS</AU>
<TI>The association between participant characteristics and serum concentrations of beta-carotene, retinol, retinyl palmitate, and alpha-tocopherol among participants in the Carotene and Retinol Efficacy Trial (CARET) for prevention of lung cancer</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>10</NO>
<PG>815-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8896893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL Jr, Omenn GS, et al</AU>
<TI>The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2004</YR>
<VL>96</VL>
<NO>23</NO>
<PG>1743-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15572756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman GE, Valanis B, Meyskens FL Jr, Williams JH Jr, Metch BJ, Thornquist MD, et al</AU>
<TI>Strategies for recruitment to a population-based lung cancer prevention trial: the CARET experience with heavy smokers. Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>5</NO>
<PG>405-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9610790"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>King IB, Kristal AR, Schaffer S, Thornquist M, Goodman GE</AU>
<TI>Serum trans-fatty acids are associated with risk of prostate cancer in Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>4</NO>
<PG>988-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15824175"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leo MA, Lieber CS</AU>
<TI>Re: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>22</NO>
<PG>1722-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9390543"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neuhouser ML, Patterson RE, Thornquist MD, Omenn GS, King IB, Goodman GE</AU>
<TI>Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the Beta-Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>4</NO>
<PG>350-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12692110"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neuhouser ML, Patterson RE, Thornquist MD, Omenn GS, King IB, Goodman GE</AU>
<TI>Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the Beta-Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>4</NO>
<PG>350-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12692110"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman G, Grizzle J, Thornquist M, Rosenstock L, Barnhart S, et al</AU>
<TI>CARET, the Beta-Carotene and Retinol Efficacy Trial to prevent lung cancer in asbestos-exposed workers and in smokers</TI>
<SO>Anticancer Drugs</SO>
<YR>1991</YR>
<VL>2</VL>
<NO>1</NO>
<PG>79-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1958856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman G, Grizzle J, Thornquist M, Rosenstock L, Barnhart S, et al</AU>
<TI>Recruitment for the Beta-Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in smokers and asbestos-exposed workers</TI>
<SO>Western Journal of Medicine</SO>
<YR>1992</YR>
<VL>156</VL>
<NO>5</NO>
<PG>540-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1595284"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman G, Thornquist M, Barnhart S, Balmes J, Cherniack M, et al</AU>
<TI>Chemoprevention of lung cancer: the Beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers</TI>
<SO>IARC Scientific Publications</SO>
<YR>1996</YR>
<VL>136</VL>
<PG>67-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8791118"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, et al</AU>
<TI>The Beta-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers</TI>
<SO>Cancer Research</SO>
<YR>1994</YR>
<VL>54</VL>
<NO>7 Suppl</NO>
<PG>2038s-43s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8137335"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman GE, Thornquist M, Brunzell JD</AU>
<TI>Long-term vitamin A does not produce clinically significant hypertriglyceridemia: results from CARET, the Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>8</NO>
<PG>711-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7881345"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al</AU>
<TI>Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>18</NO>
<PG>1150-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8602180"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A</AU>
<TI>Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>21</NO>
<PG>1550-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8901853"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS, Goodman GE, Thornquist MD, Rosenstock L, Barnhart S, Gylys-Colwell I, et al</AU>
<TI>The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with asbestos-exposed workers</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1993</YR>
<VL>2</VL>
<NO>4</NO>
<PG>381-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8602180"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omenn GS</AU>
<TI>CARET, the Beta-Carotene and Retinol Efficacy Trial to prevent lung cancer in high-risk populations</TI>
<SO>Public Health Reviews</SO>
<YR>1991</YR>
<VL>19</VL>
<NO>1-4</NO>
<PG>205-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1844268"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redlich CA, Chung JS, Cullen MR, Blaner WS, Van-Bennekum AM, Berglund L</AU>
<TI>Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Beta-Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>Atherosclerosis</SO>
<YR>1999</YR>
<VL>143</VL>
<NO>2</NO>
<PG>427-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10217373"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smigel K</AU>
<TI>Beta carotene fails to prevent cancer in two major studies; CARET intervention stopped</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>3-4</NO>
<PG>145</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8632485"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sondik EJ</AU>
<TI>CARET study: women included</TI>
<SO>Science</SO>
<YR>1991</YR>
<VL>254</VL>
<NO>5030</NO>
<PG>360</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1925587"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornquist MD, Edelstein C, Goodman GE, Omenn GS</AU>
<TI>Streamlining IRB review in multisite trials through single-study IRB cooperative agreements: experience of the Beta-Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>1</NO>
<PG>80-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11852169"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornquist MD, Omenn GS, Goodman GE, Grizzle JE, Rosenstock L, et al</AU>
<TI>Statistical design and monitoring of the Beta-Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1993</YR>
<VL>14</VL>
<NO>4</NO>
<PG>308-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8365195"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornquist MD, Patrick DL, Omenn GS</AU>
<TI>Participation and adherence among older men and women recruited to the Beta-Carotene and Retinol Efficacy Trial (CARET)</TI>
<SO>Gerontologist</SO>
<YR>1991</YR>
<VL>31</VL>
<NO>5</NO>
<PG>593-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1778482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornquist MD, Urban N, Tseng A, Edelstein C, Lund B, Omenn GS</AU>
<TI>Research cost analyses to aid in decision making in the conduct of a large prevention trial, CARET. Beta-Carotene and Retinol Efficacy Trial</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1993</YR>
<VL>14</VL>
<NO>4</NO>
<PG>325-39</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8365196"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valanis B, Blank J, Glass A</AU>
<TI>Mailing strategies and costs of recruiting heavy smokers in CARET, a large chemoprevention trial</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>1</NO>
<PG>25-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9492967"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Correa-2000" NAME="Correa 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al</AU>
<TI>Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>23</NO>
<PG>1881-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20560859"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al</AU>
<TI>Re: chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2001</YR>
<VL>93</VL>
<NO>7</NO>
<PG>559-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gail MH, Brown LM, You WC</AU>
<TI>Re: chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2001</YR>
<VL>93</VL>
<NO>7</NO>
<PG>559-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11287457"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al</AU>
<TI>Long term follow up of patients treated for Helicobacter pylori infection</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>11</NO>
<PG>1536-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15985559"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz B, Garay J, Correa P, Fontham ET, Bravo JC, Bravo LE, et al</AU>
<TI>Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>12</NO>
<PG>3281-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11774937"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HOPE-TOO-2005" NAME="HOPE TOO 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, HOPE/HOPE-TOO Study Investigators</AU>
<TI>Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>9</NO>
<PG>1339-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16129815"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerstein HC</AU>
<TI>Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE</TI>
<SO>Diabetes/Metabolism Research and Reviews</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>suppl 3</NO>
<PG>s82-s5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12324991"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heart Outcomes Prevention Evaluation Study Investigators</AU>
<TI>Effects of ramipril on cardiovascular and microvascular outcomes in patients with diabetis mellitus: results of the HOPE study and MIRCO-HOPE substudy</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9200</NO>
<PG>253-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10675071"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heart Outcomes Prevention Evaluation Study Investigators</AU>
<TI>The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>2</NO>
<PG>127-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamy A, Yusuf S, Pogue J, Gafni A, Heart Outcomes Prevention Evaluation Investigators</AU>
<TI>Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>7</NO>
<PG>960-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12600907"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al</AU>
<TI>Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>11</NO>
<PG>1338-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15769967"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E, Mathew J, Pogue J, Johnstone D, Danisa K, Bosch J, et al</AU>
<TI>Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients</TI>
<SO>European Journal of Cardiovascular Prevention and Rehabilitation</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>6</NO>
<PG>420-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14671464"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, et al</AU>
<TI>Effect of long-term therapy with ramipril in high-risk women</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>4</NO>
<PG>693-702</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12204499"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, et al</AU>
<TI>Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1919-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12401733"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S</AU>
<TI>Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>8</NO>
<PG>629-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11304102"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, et al</AU>
<TI>Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>5</NO>
<PG>936-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14582037"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, et al</AU>
<TI>Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>3</NO>
<PG>641-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12595499"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, et al</AU>
<TI>Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>4</NO>
<PG>1375-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15086477"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann JF, Yi QL, Sleight P, Dagenais GR, Gerstein HC, Lonn EM, et al</AU>
<TI>Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study</TI>
<SO>Clinical Nephrology</SO>
<YR>2005</YR>
<VL>63</VL>
<NO>8</NO>
<PG>181-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15786818"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McQueen MJ, Lonn E, Gerstein HC, Bosch J, Yusuf S</AU>
<TI>The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences</TI>
<SO>Scandinavian Journal of Clinical and Laboratory Investigation</SO>
<YR>2005</YR>
<VL>Suppl 240</VL>
<PG>143-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16112972"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al</AU>
<TI>Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease</TI>
<SO>European Heart Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14683738"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharpe N</AU>
<TI>The HOPE TIPS: The HOPE Study Translated into Practices</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>3</NO>
<PG>197-201</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16142597"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, et al</AU>
<TI>Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>110</VL>
<NO>11</NO>
<PG>1413-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15353497"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P</AU>
<TI>Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>3</NO>
<PG>154-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al</AU>
<TI>Ramipril and the development of diabetes</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>15</NO>
<PG>1882-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11597291"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G</AU>
<TI>Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>3</NO>
<PG>145-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10639539"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HPS-2002" NAME="HPS 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armitage J, Collins R</AU>
<TI>Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF Heart Protection Study and other major trials</TI>
<SO>Heart</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>4</NO>
<PG>357-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10995396"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bates CJ</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1781-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480450"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown MJ</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1782</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480451"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Armitage J, Parish S, Sleight P, Peto R</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1783-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480453"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Peto R, Armitage J</AU>
<TI>The MRC/BHF Heart Protection Study: preliminary results</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11831837"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durrington PN</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1781</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480449"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farmer JA</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial</TI>
<SO>Current Atherosclerosis Reports</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>93-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12573191"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience</TI>
<SO>European Heart Journal</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>10</NO>
<PG>725-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10329064"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kris-Etherton PM</AU>
<TI>MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial</TI>
<SO>Current Atherosclerosis Reports</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>6</NO>
<PG>411-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12361485"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kulbertus H, Scheen AJ</AU>
<TI>Clinical study of the month. The MRC/BHF Heart Protection Study</TI>
<TO>L'etude clinique du mois. La MRC/BHF Heart Protection Study</TO>
<SO>Revue Medicale de Liege</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>9</NO>
<PG>613-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12440352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumana CR, Cheung BM, Lauder IJ</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>ACP Journal Club</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>2</NO>
<PG>A15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12614142"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>MRC/BHF Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9326</NO>
<PG>23-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12114037"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC/BHF Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience</TI>
<SO>European Heart Jornal</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>10</NO>
<PG>725-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10329064"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC/BHF Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9326</NO>
<PG>7-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12114036"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robins SJ, Despres JP</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1780</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480447"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan CJ, Buckley BM</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1780-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Violi F, Micheletta F, Iuliano L</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1782-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480452"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wald N, Law M</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9347</NO>
<PG>1781</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12480448"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" NAME="Li 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li W, Zhu Y, Yan X, Zhang Q, Li X, Ni Z, et al</AU>
<TI>The prevention of primary liver cancer by selenium in high risk populations</TI>
<SO>(Zhonghua Yu Fang Yi Xue Za Zhi) Chinese Journal of Preventive Medicine</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>6</NO>
<PG>336-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11860943"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li WG</AU>
<TI>Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer</TI>
<SO>(Zhonghua Yu Fang Yi Xue Za Zhi) Chinese Journal of Preventive Medicine</SO>
<YR>1992</YR>
<VL>26</VL>
<NO>5</NO>
<PG>268-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1298601"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" NAME="Li 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li H, Li HQ, Wang Y, Xu HX, Fan WT, Wang ML, et al</AU>
<TI>An intervention study to prevent gastric cancer by micro-selenium and large dose of allitridum</TI>
<SO>Chinese Medical Journal</SO>
<YR>2004</YR>
<VL>117</VL>
<NO>8</NO>
<PG>1155-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15361287"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munoz-1985" NAME="Munoz 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munoz N, Wahrendorf J, Bang LJ, Crespi M, Thurnham DI, Day NE, et al</AU>
<TI>No effect of riboflavine, retinol, and zinc on prevalence of precancerous lesions of oesophagus. Randomised double-blind intervention study in high-risk population of China</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>8447</NO>
<PG>111-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85266610"/>
<IDENTIFIER TYPE="OTHER" VALUE="00039020"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIT1-1993" NAME="NIT1 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al</AU>
<TI>Nutrition Intervention Trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1993</YR>
<VL>85</VL>
<NO>18</NO>
<PG>1483-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8360931"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blot WJ, Li JY, Taylor PR, Guo W, Dawsey SM, Li B</AU>
<TI>The Linxian trials: mortality rates by vitamin-mineral intervention group</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1995</YR>
<VL>62</VL>
<NO>6 Suppl</NO>
<PG>1424s-6s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7495242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blot WJ, Li JY</AU>
<TI>Some considerations in the design of a Nutritional Intervention Trial in Linxian, People's Republic of China</TI>
<SO>National Cancer Institute Monographs</SO>
<YR>1984</YR>
<VL>69</VL>
<PG>29-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3914622"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li B, Taylor PR, Li JY, Dawsey SM, Wang W, Tangrea JA, et al</AU>
<TI>Linxian Nutrition Intervention Trials. Design, methods, participant characteristics, and compliance</TI>
<SO>Annals of Epidemiology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>6</NO>
<PG>577-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7921303"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li JY</AU>
<TI>Vitamins and minerals in cancer: The Nutrition Intervention Trials in Linxian, China</TI>
<SO>Medecine Biologie Environnement</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>2</NO>
<PG>187-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, et al</AU>
<TI>Prospective study of serum selenium levels and incident esophageal and gastric cancers</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>21</NO>
<PG>1753-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11058618"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, Guo W, et al</AU>
<TI>Prevention of esophageal cancer: the Nutrition Intervention Trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group</TI>
<SO>Cancer Research</SO>
<YR>1994</YR>
<VL>54</VL>
<NO>7 Suppl</NO>
<PG>2029s-31s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8137333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, Blot WJ, et al</AU>
<TI>Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>2</NO>
<PG>161-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8049638"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIT2-1993" NAME="NIT2 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li JY, Li B, Blot WJ, Taylor PR</AU>
<TI>Preliminary report on the results of nutrition prevention trials of cancer and other common diseases among residents in Linxian, China</TI>
<SO>(Zhonghua Zhong Liu Za Zhi) Chinese Journal of Oncology</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>3</NO>
<PG>165-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8261860"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, et al</AU>
<TI>Nutrition Intervention Trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1993</YR>
<VL>85</VL>
<NO>18</NO>
<PG>1492-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8360932"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mark SD, Liu SF, Li JY, Gail MH, Shen Q, Dawsey SM, et al</AU>
<TI>The effect of vitamin and mineral supplementation on esophageal cytology: results from the Linxian Dysplasia Trial</TI>
<SO>International Journal of Cancer</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>2</NO>
<PG>162-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8157352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor PR, Wang GQ, Dawsey SM, Guo W, Mark SD, Li JY, et al</AU>
<TI>Effect of nutrition intervention on intermediate endpoints in esophageal and gastric carcinogenesis</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1995</YR>
<VL>62</VL>
<NO>6 Suppl</NO>
<PG>1420s-3s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7495241"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NPCT-1996" NAME="NPCT 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al</AU>
<TI>Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial</TI>
<SO>Journal of American Medical Association</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>24</NO>
<PG>1957-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8971064"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, et al</AU>
<TI>Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial</TI>
<SO>British Journal of Urology</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>5</NO>
<PG>730-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9634050"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combs GF Jr, Clark LC, Turnbull BW</AU>
<TI>Reduction of cancer mortality and incidence by selenium supplementation</TI>
<SO>Medizinische Klinik</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>Suppl 3</NO>
<PG>42-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9342915"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combs GF Jr</AU>
<TI>Impact of selenium and cancer-prevention findings on the nutrition-health paradigm</TI>
<SO>Nutrition and Cancer</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>1</NO>
<PG>6-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11799925"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combs GF, Clark LC, Turnbull BW</AU>
<TI>Reduction of cancer risk with an oral supplement of selenium</TI>
<SO>Biomedical and Environmental Sciences</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>2-3</NO>
<PG>227-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9315315"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs Jr GF, Slate EH, Fischbach LA</AU>
<TI>Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>7</NO>
<PG>630-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, et al</AU>
<TI>Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells</TI>
<SO>Carcinogenesis</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1195-202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9214603"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR</AU>
<TI>Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>11</NO>
<PG>1285-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12433704"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PHS-1996" NAME="PHS 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albert CM, Gaziano JM, Willett WC, Manson JE</AU>
<TI>Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<NO>12</NO>
<PG>1382-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12076237"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreotti F, Burzotta F, De-Stefano V, Maseri A, Iacoviello L</AU>
<TI>The G20210A prothrombin mutation and the Physicians' Health Study</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>101</VL>
<NO>21</NO>
<PG>E207-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10831536"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger K, Kase CS, Buring JE</AU>
<TI>Interobserver agreement in the classification of stroke in the Physicians' Health Study</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>2</NO>
<PG>238-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8571416"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buring JE, Hebert P, Romero J, Kittross A, Cook N, Manson J, et al</AU>
<TI>Migraine and subsequent risk of stroke in the Physicians' Health Study</TI>
<SO>Archives of Neurology</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>2</NO>
<PG>129-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7848119"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buring JE, Hennekens CH</AU>
<TI>Cost and efficiency in clinical trials: the U.S. Physicians' Health Study</TI>
<SO>Statistics in Medicine</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>1-2</NO>
<PG>29-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2345836"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL</AU>
<TI>Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2001</YR>
<VL>74</VL>
<NO>4</NO>
<PG>549-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11566656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christen WG, Glynn RJ, Ajani UA, Schaumberg DA, Manson JE, Buring JE, et al</AU>
<TI>Baseline self-reported cataract and subsequent mortality in Physicians' Health Study I</TI>
<SO>Ophthalmic Epidemiology</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>2</NO>
<PG>115-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10934462"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christen WG, Glynn RJ, Seddon JM, Manson JE, Buring JE, Hennekens CH</AU>
<TI>Confirmation of self-reported cataract in the Physicians' Health Study</TI>
<SO>Ophthalmic Epidemiology</SO>
<YR>1994</YR>
<VL>1</VL>
<NO>2</NO>
<PG>85-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8790615"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH</AU>
<TI>Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States)</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>7</NO>
<PG>617-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10977106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH</AU>
<TI>A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the Physician's Health Study</TI>
<SO>Archives of Dermatology</SO>
<YR>2000</YR>
<VL>136</VL>
<NO>2</NO>
<PG>179-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10677093"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, et al</AU>
<TI>Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>1</NO>
<PG>96-105</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10636266"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al</AU>
<TI>Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>18</NO>
<PG>1145-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8602179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hennekens CH, Buring JE</AU>
<TI>Methodologic considerations in the design and conduct of randomized trials: the U.S. Physicians' Health Study</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>4 Suppl</NO>
<PG>142S-50S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2605963"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hennekens CH, Eberlein K</AU>
<TI>A randomized trial of aspirin and beta-carotene among U.S. physicians</TI>
<SO>Preventive Medicine</SO>
<YR>1985</YR>
<VL>14</VL>
<NO>2</NO>
<PG>165-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3900975"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonas S</AU>
<TI>The Physician's Health Study. A neurologist's concern</TI>
<SO>Archives of Neurology</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>12</NO>
<PG>1352-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2252454"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH</AU>
<TI>Estimating the effect of the run-in on the power of the Physicians' Health Study</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>10</NO>
<PG>1585-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1947514"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee IM, Manson JE, Ajani U, Paffenbarger RS Jr, Hennekens CH, Buring JE</AU>
<TI>Physical activity and risk of colon cancer: the Physicians' Health Study (United States)</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>4</NO>
<PG>568-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9242472"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu S, Lee IM, Ajani U, Cole SR, Buring JE, Manson JE</AU>
<TI>Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: the Physicians' Health Study</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>1</NO>
<PG>130-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11171873"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lotufo PA, Chae CU, Ajani UA, Hennekens CH, Manson JE</AU>
<TI>Male pattern baldness and coronary heart disease: the Physicians' Health Study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>2</NO>
<PG>165-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10647754"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lotufo PA, Lee IM, Ajani UA, Hennekens CH, Manson JE</AU>
<TI>Cigarette smoking and risk of prostate cancer in the Physicians' Health Study (United States)</TI>
<SO>International Journal of Cancer</SO>
<YR>2000</YR>
<VL>87</VL>
<NO>1</NO>
<PG>141-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10861465"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma J, HennekensCH, Ridker PM, Stampfer MJ</AU>
<TI>A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>5</NO>
<PG>1347-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10193737"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH</AU>
<TI>Fish consumption and cardiovascular disease in the physicians' health study: a prospective study</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1995</YR>
<VL>142</VL>
<NO>2</NO>
<PG>166-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7598116"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perera FP, Mooney L A, Stampfer M, Phillips DH, Bell DA, Rundle A, et al</AU>
<TI>Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study</TI>
<SO>Carcinogenesis</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>10</NO>
<PG>1641-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12376472"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Physicians' Health Study Research Group</AU>
<TI>Peliminary report: findings from the aspirin component of the ongoing Physicians Health Study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<NO>4</NO>
<PG>262-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Satterfield S, Greco PJ, Goldhaber SZ, Stampfer MJ, Swartz SL, Stein EA, et al</AU>
<TI>Biochemical markers of compliance in the Physicians' Health Study</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>1990</YR>
<VL>6</VL>
<NO>5</NO>
<PG>290-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2268456"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sesso HD, Gaziano JM, VanDenburgh M, Hennekens CH, Glynn RJ, Buring JE</AU>
<TI>Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>6</NO>
<PG>686-702</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12505246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steering Committee of the Physicians' Health Study Research Group</AU>
<TI>Final report on the aspirin component of the ongoing Physicians' Health Study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>321</VL>
<NO>3</NO>
<PG>129-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2664509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sturmer T, Glynn RJ, Lee IM, Christen WG, Hennekens CH</AU>
<TI>Lifetime cigarette smoking and colorectal cancer incidence in the Physicians' Health Study I</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>14</NO>
<PG>1178-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10904092"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, et al</AU>
<TI>Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the Physicians Health Study</TI>
<SO>Cancer Research</SO>
<YR>2001</YR>
<VL>61</VL>
<NO>18</NO>
<PG>6708-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11559540"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vieth R</AU>
<TI>Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>76</VL>
<NO>2</NO>
<PG>490-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12145029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plummer-2007" NAME="Plummer 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munoz N, Kato I, Peraza S, Lopez G, Carrillo E, Ramirez H, et al</AU>
<TI>Prevalence of precancerous lesions of the stomach in Venezuela</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>1</NO>
<PG>41-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8770465"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munoz N, Vivas J, Buiatti E, Kato I, Oliver W</AU>
<TI>Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data</TI>
<SO>IARC Scientific Publications</SO>
<YR>1996</YR>
<VL>139</VL>
<PG>125-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8923024"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Plummer M, Vivas J, Lopez G, Bravo JC, Peraza S, Carillo E, et al</AU>
<TI>Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<NO>2</NO>
<PG>137-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17227997"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Sanjose S, Munoz N, Sobala G, Vivas J, Peraza S, Cano E, et al</AU>
<TI>Antioxidants, Helicobacter pylori and stomach cancer in Venezuela</TI>
<SO>European Journal of Cancer Prevention</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8664811"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SIT-2006" NAME="SIT 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;12(5):575-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gail MH, Pfeiffer RM, Brown LM, Zhang L, Ma JL, Pan KF, et al</AU>
<TI>Garlic, vitamin, and antibiotic treatment for Helicobacter pylori: a randomized factorial controlled trial</TI>
<SO>Helicobacter</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>5</NO>
<PG>575-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17760729"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gail MH, You WC, Chang YS, Zhang L, Blot WJ, Brown LM, et al</AU>
<TI>Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>4</NO>
<PG>352-69</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9683311"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gail MH, You WC</AU>
<TI>A factorial trial including garlic supplements assesses effect in reducing precancerous gastric lesions</TI>
<SO>Journal of Nutrition</SO>
<YR>2006</YR>
<VL>136</VL>
<NO>3 Suppl</NO>
<PG>813S-5S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16484571"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al</AU>
<TI>Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>14</NO>
<PG>974-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16849680"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>You WC, Chang YS, Heinrich J, Ma JL, Liu WD, Zhang L, et al</AU>
<TI>An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity</TI>
<SO>European Journal of Cancer Prevention</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>3</NO>
<PG>257-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11432713"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Gail MH, Wang YQ, Brown LM, Pan KF, Ma JL, et al</AU>
<TI>A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>4</NO>
<PG>912-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17023720"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SUVIMAX-2004" NAME="SUVIMAX 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Astorg P, Arnault N, Czernichow S, Noisette N, Galan P, Hercberg S</AU>
<TI>Dietary intakes and food sources of n-6 and n-3 PUFA in French adult men and women</TI>
<SO>Lipids</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>6</NO>
<PG>527-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15554151"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barrere X, Valeix P, Preziosi P, Bensimon M, Pelletier B, Galan P, et al</AU>
<TI>Determinants of thyroid volume in healthy French adults participating in the SU.VI.MAX cohort</TI>
<SO>Clinical Endocrinology</SO>
<YR>2000</YR>
<VL>52</VL>
<NO>3</NO>
<PG>273-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10718824"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellisle F, Altenburg de Assis MA, Fieux B, Preziosi P, Galan P, Guy-Grand B, et al</AU>
<TI>Use of 'light' foods and drinks in French adults: biological, anthropometric and nutritional correlates</TI>
<SO>Journal of Human Nutrition and Dietetics</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>3</NO>
<PG>191-206</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11424511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertrais S, Galan P, Renault N, Zarebska M, Preziosi P, Hercberg S</AU>
<TI>Consumption of soup and nutritional intake in French adults: consequences for nutritional status</TI>
<SO>Journal of Human Nutrition and Dietetics</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>2</NO>
<PG>121-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11330261"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertrais S, Polo Luque ML, Preziosi P, Fieux B, Torra De Flot M, Galan P, et al</AU>
<TI>Contribution of ready-to-eat cereals to nutrition intakes in French adults and relations with corpulence</TI>
<SO>Annals of Nutrition &amp; Metabolism</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>5-6</NO>
<PG>249-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11146332"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertrais S, Preziosi P, Mennen L, Galan P, Hercberg S, Oppert JM</AU>
<TI>Sociodemographic and geographic correlates of meeting current recommendations for physical activity in middle-aged French adults: the Supplementation en Vitamines et Mineraux Antioxydants (SUVIMAX) Study</TI>
<SO>American Journal of Public Health</SO>
<YR>2004</YR>
<VL>94</VL>
<NO>9</NO>
<PG>1560-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15333315"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boini S, Briancon S, Guillemin F, Galan P, Hercberg S</AU>
<TI>Impact of cancer occurrence on health-related quality of life: a longitudinal pre-post assessment</TI>
<SO>Health and Quality of Life Outcomes</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>1</NO>
<PG>4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14715085"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruckert E, Czernichow S, Bertrais S, Paillard F, Tichet J, Galan P, et al</AU>
<TI>Blood lipid and lipoprotein levels: relationships with educational level and region of residence in the French SU.VI.MAX study</TI>
<SO>Preventive Medicine</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>6</NO>
<PG>803-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15850882"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cailhol J, Czernichow S, Mennen L, Boutron-Ruault MC, Zarebska M, Franchisseur C, et al</AU>
<TI>Participation and medical follow-up in screening of colorectal cancer in France within the SU.VI.MAX study</TI>
<TO>Dépistage du cancer colorectal par test Hémoccult : taux de participation et prise en charge médicale des sujets à test positif au sein de l'étude SU.VI.MAX</TO>
<SO>Revue d'Epidémiologie et de Santé Publique</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>3</NO>
<PG>321-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12122348"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chango A, Potier De Courcy G, Boisson F, Guilland JC, Barbe F</AU>
<TI>5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohort</TI>
<SO>The British Journal of Nutrition</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>6</NO>
<PG>891-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11177206"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czernichow S, Bertrais S, Oppert JM, Galan P, Blacher J, Ducimetiere P, et al</AU>
<TI>Body composition and fat repartition in relation to structure and function of large arteries in middle-aged adults (the SU.VI.MAX study)</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>7</NO>
<PG>826-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15917850"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czernichow S, Bertrais S, Preziosi P, Galan P, Hercberg S, Oppert JM, et al</AU>
<TI>Indicators of abdominal adiposity in middle-aged participants of the SU.VI.MAX study: relationships with educational level, smoking status and physical inactivity</TI>
<SO>Diabetes &amp; Metabolism</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>2</NO>
<PG>153-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15223987"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czernichow S, Mennen L, Bertrais S, Preziosi P, Hercberg S, Oppert JM</AU>
<TI>Relationships between changes in weight and changes in cardiovascular risk factors in middle-aged French subjects: effect of dieting</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>8</NO>
<PG>1138-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12119581"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derumeaux H, Valeix P, Castetbon K, Bensimon M, Boutron-Ruault MC, Arnaud J, et al</AU>
<TI>Association of selenium with thyroid volume and echostructure in 35- to 60-year-old French adults</TI>
<SO>European Journal of Endocrinology</SO>
<YR>2003</YR>
<VL>148</VL>
<NO>3</NO>
<PG>309-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12611611"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duport N, Preziosi P, Boutron-Ruault MC, Bertrais S, Galan P, Favier A, et al</AU>
<TI>Consequences of iron depletion on health in menstruating women</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>9</NO>
<PG>1169-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12947438"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Arnaud MJ, Czernichow S, Delabroise AM, Preziosi P, Bertrais S, et al</AU>
<TI>Contribution of mineral waters to dietary calcium and magnesium intake in a French adult population</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2002</YR>
<VL>102</VL>
<NO>11</NO>
<PG>1658-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12449291"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Briancon S, Favier A, Bertrais S, Preziosi P, Faure H, et al</AU>
<TI>Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels?</TI>
<SO>British Journal of Nutrition</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>1</NO>
<PG>125-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12484233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Favier A, Preziosi P, Bertrais S, Arnault N, Hercberg S</AU>
<TI>The bank of biological material in the SU.VI.MAX study</TI>
<TO>La biothèque dans l'étude SU.VI.MAX</TO>
<SO>Revue d'Epidemiologie et de Sante Publique</SO>
<YR>2003</YR>
<VL>51</VL>
<NO>1 Pt 2</NO>
<PG>147- 50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12684572"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Preziosi P, Durlach V, Valeix P, Ribas L, Bouzid D, et al</AU>
<TI>Dietary magnesium intake in a French adult population</TI>
<SO>Magnesium Research</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>4</NO>
<PG>321-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9513928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Renault N, Aissa M, Adad HA, Rahim B, Potier de Courcy G, et al</AU>
<TI>Relationship between soup consumption, folate, beta-carotene, and vitamin C status in a French adult population</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>2003</YR>
<VL>73</VL>
<NO>5</NO>
<PG>315-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14639794"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Viteri FE, Bertrais S, Czernichow S, Faure H, Arnaud J, et al</AU>
<TI>Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>10</NO>
<PG>1181-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16034362"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, Fieux B, et al</AU>
<TI>Determining factors in the iron status of adult women in the SU.VI.MAX study. SUpplementation en VItamines et Mineraux AntioXydants</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>6</NO>
<PG>383-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9683388"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gauthier-Chelle K, Mennen L, Arnault N, Rigalleau V, Hercberg S, Gin H</AU>
<TI>Comparison of the diet of self-declared diabetics with non-diabetic patients in the SU.VI.MAX study: did the diabetics modify their nutritional behavior?</TI>
<SO>Diabetes &amp; Metabolism</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>6</NO>
<PG>535-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15671923"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guinot C, Latreille J, Malvy D, Preziosi P, Galan P, Hercberg S, et al</AU>
<TI>Use of multiple correspondence analysis and cluster analysis to study dietary behaviour: food consumption questionnaire in the SU.VI.MAX. cohort</TI>
<SO>European Journal of Epidemiology</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>6</NO>
<PG>505-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11949721"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guinot C, Malvy DJ, Latreille J, Ezzedine K, Galan P, Tenenhaus M, et al</AU>
<TI>Sun-reactive skin type in 4912 French adults participating in the SU.VI.MAX</TI>
<SO>Photochemistry and Photobiology</SO>
<YR>2005</YR>
<VL>81</VL>
<NO>4</NO>
<PG>934-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15850423"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S, Bertrais S, Czernichow S, Noisette N, Galan P, Jaouen A, et al</AU>
<TI>Alterations of the lipid profile after 7.5 years of low-dose antioxidant supplementation in the SU.VI.MAX Study</TI>
<SO>Lipids</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>4</NO>
<PG>335-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16032784"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al</AU>
<TI>The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<NO>21</NO>
<PG>2335-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15557412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S, Galan P, Preziosi P, Malvy M, Briancon S, Ait HM, et al</AU>
<TI>The SU.VI.MAX trial on antioxidants</TI>
<SO>IARC Scientific Publications</SO>
<YR>2002</YR>
<VL>156</VL>
<PG>451-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12484233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S, Galan P, Preziosi P, Roussel AM, Arnaud J, Richard MJ, et al</AU>
<TI>Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. SUpplementation en VItamines et Mineraux AntioXydants Study</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>1998</YR>
<VL>68</VL>
<NO>1</NO>
<PG>3-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9503043"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S, Hebel P, Preziosi P, Briancon S, Favier A, Galan P, et al</AU>
<TI>Motivations of volunteers for participation in an interventional study in the field of nutritional prevention: results of a pilot study of the SU.VI.MAX project</TI>
<SO>Revue d'Epidemiologie et de Sante Publique</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>2</NO>
<PG>139-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7732200"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D, et al</AU>
<TI>A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study-design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>4</NO>
<PG>336-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9683310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S, Preziosi P, Galan P, Faure H, Arnaud J, Duport N, et al</AU>
<TI>"The SU.VI.MAX Study": a primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers. SUpplementation on VItamines et Mineraux AntioXydants</TI>
<SO>Food and Chemical Toxicology</SO>
<YR>1999</YR>
<VL>37</VL>
<NO>9-10</NO>
<PG>925-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10541446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hercberg S</AU>
<TI>Antioxidant micronutrients and chronic degenerative pathology: the role of complementary nutritional doses</TI>
<SO>Bulletin et Memoires de l'Academie Royale de Medecine de Belgique</SO>
<YR>1997</YR>
<VL>152</VL>
<NO>10-11</NO>
<PG>379-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9627441"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lairon D, Bertrais S, Vincent S, Arnault N, Galan P, Boutron MC, et al</AU>
<TI>Dietary fibre intake and clinical indices in the French Supplementation en Vitamines et Mineraux AntioXydants (SU.VI.MAX) adult cohort</TI>
<SO>The Proceedings of the Nutrition Society</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>1</NO>
<PG>11-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12740051"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leclere J</AU>
<TI>Multinodular goiters</TI>
<SO>La Revue du Praticien</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>2</NO>
<PG>167-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15825997"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukasiewicz E, Mennen LI, Bertrais S, Arnault N, Preziosi P, Galan P, et al</AU>
<TI>Alcohol intake in relation to body mass index and waist-to-hip ratio: the importance of type of alcoholic beverage</TI>
<SO>Public Health Nutrition</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>3</NO>
<PG>315-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15918929"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malkin JE, Morand P, Malvy D, Ly TD, Chanzy B, de Labareyre C, et al</AU>
<TI>Seroprevalence of HSV-1 and HSV-2 infection in the general French population</TI>
<SO>Sexually Transmitted Infections</SO>
<YR>2002</YR>
<VL>78</VL>
<NO>3</NO>
<PG>201-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12238654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malvy DJ, Favier A, Faure H, Preziosi P, Galan P, Arnaud J, et al</AU>
<TI>Effect of two years' supplementation with natural antioxidants on vitamin and trace element status biomarkers: preliminary data of the SU.VI.MAX study</TI>
<SO>Cancer Detection and Prevention</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>5</NO>
<PG>479-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11718454"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malvy J, Guinot C, Preziosi P, Vaillant L, Tenenhaus M, Galan P, et al</AU>
<TI>Epidemiologic determinants of skin photoaging: baseline data of the SU.VI.MAX. cohort</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1 pt 1</NO>
<PG>47-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10607319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mennen LI, Bertrais S, Galan P, Arnault N, Potier de Couray G, Hercberg S</AU>
<TI>The use of computerised 24 h dietary recalls in the French SU.VI.MAX Study: number of recalls required</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>7</NO>
<PG>659-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12080407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mennen LI, Sapinho D, de Bree A, Arnault N, Bertrais S, Galan P, et al</AU>
<TI>Consumption of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently healthy French women</TI>
<SO>The Journal of Nutrition</SO>
<YR>2004</YR>
<VL>134</VL>
<NO>4</NO>
<PG>923-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15051848"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, et al</AU>
<TI>Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial</TI>
<SO>International Journal of Cancer</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>2</NO>
<PG>182-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15800922"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohammed-Cherif S, Briancon S, Potier de Courcy G, Preziosi P, Fieux B, Zarebska M, et al</AU>
<TI>Factors determining the use of hormone replacement therapy in recent naturally postmenopausal women participating in the French SU.VI.MAX cohort</TI>
<SO>European Journal of Epidemiology</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>5</NO>
<PG>477-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10997836"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preziosi P, Czernichow S, Gehanno P, Hercberg S</AU>
<TI>Workplace air-conditioning and health services attendance among French middle-aged women: a prospective cohort study</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2004</YR>
<VL>33</VL>
<NO>5</NO>
<PG>1120-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15319412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rouillier P, Boutron-Ruault MC, Bertrais S, Arnault N, Daudin JJ, Bacro JN, et al</AU>
<TI>Alcohol and atherosclerotic vascular disease risk factors in French men: relationships are linear, J-shaped, and U-shaped</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>1</NO>
<PG>84-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15654296"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rouillier P, Boutron-Ruault MC, Bertrais S, Arnault N, Daudin JJ, Bacro JN, et al</AU>
<TI>Drinking patterns in French adult men - a cluster analysis of alcoholic beverages and relationship with lifestyle</TI>
<SO>European Journal of Nutrition</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>2</NO>
<PG>69-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15083313"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valeix P, Dos Santos C, Castetbon K, Bertrais S, Cousty C, Hercberg S</AU>
<TI>Thyroid hormone levels and thyroid dysfunction of French adults participating in the SU.VI.MAX study</TI>
<TO>Statut thyroïdien et fréquences des dysthyroïdies chez les adultes inclus dans l&#8217;étude SU.VI.MAX en 1994-1995</TO>
<SO>Annales d'Endocrinologie</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>6</NO>
<PG>477-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15731735"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valeix P, Zarebska M, Bensimon M, Cousty C, Bertrais S, Galan P, et al</AU>
<TI>Ultrasonic assessment of thyroid nodules, and iodine status of French adults participating in the SU.VI.MAX study</TI>
<TO>Nodules thyroïdiens à l'échographie et statut en iode des adultes volontaires de l'étude SU.VI.MAX</TO>
<SO>Annales d'Endocrinologie</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>6</NO>
<PG>499-506</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11845024"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vazquez Martinez C, Galan P, Preziosi P, Ribas L, Serra LL, Hercberg S</AU>
<TI>The SUVIMAX (France) study: the role of antioxidants in the prevention of cancer and cardiovascular disorders</TI>
<SO>Revista Espanola de Salud Publica</SO>
<YR>1998</YR>
<VL>72</VL>
<NO>3</NO>
<PG>173-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9810825"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vercherin P, Gutknecht C, Guillemin F, Ecochard R, Mennen LI, Mercier M</AU>
<TI>Missing data mechanisms of the questionnaire SF-36's items in the SU.VI.MAX study</TI>
<TO>Non-réponses aux questionnaires de qualité de vie SF-36 dans un échantillon de l'étude SU.VI.MAX</TO>
<SO>Revue d'Epidémiologie et de Santé Publique</SO>
<YR>2003</YR>
<VL>51</VL>
<NO>5</NO>
<PG>513-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14657798"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vuillemin A, Boini S, Bertrais S, Tessier S, Oppert JM, Hercberg S, et al</AU>
<TI>Leisure time physical activity and health-related quality of life</TI>
<SO>Preventive Medicine</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>2</NO>
<PG>562-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15917053"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vuillemin A, Oppert JM, Guillemin F, Essermeant L, Fontvieille AM, Galan P, et al</AU>
<TI>Self-administered questionnaire compared with interview to assess past-year physical activity</TI>
<SO>Medicine and Science in Sports and Exercise</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>6</NO>
<PG>1119-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10862539"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zureik M, Galan P, Bertrais S, Mennen L, Czernichow S, Blacher J, et al</AU>
<TI>Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries</TI>
<SO>Arteriosclerosis, Thrombosis, and Vascular Biology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1485-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15217803"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WACS-2007" NAME="WACS 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bassuk SS, Albert CM, Cook NR, Zaharris E, MacFadyen JG, Danielson E, et al</AU>
<TI>The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants</TI>
<SO>Journal of Women's Health</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>1</NO>
<PG>99-117</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15006283"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al</AU>
<TI>A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2007</YR>
<VL>167</VL>
<NO>15</NO>
<PG>1610-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17698683"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manson JE, Gaziano JM, Spelsberg A, Ridker PM, Cook NR, Buring JE, et al</AU>
<TI>A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>4</NO>
<PG>261-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8520707"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason PJ, Manson JE, Sesso HD, Albert CM, Chown MJ, Cook NR, et al</AU>
<TI>Blood pressure and risk of secondary cardiovascular events in women: the Women's Antioxidant Cardiovascular Study (WACS)</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>109</VL>
<NO>13</NO>
<PG>1623-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15023883"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHS-2005" NAME="WHS 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buring JE, Hennekens CH</AU>
<TI>The Women's Health Study: rationale and background</TI>
<SO>The Journal of Myocardial Ischemia</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>3</NO>
<PG>30-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buring JE, Hennekens CH</AU>
<TI>The Women's Health Study: summary of study design</TI>
<SO>The Journal of Myocardial Ischemia</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>3</NO>
<PG>27-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al</AU>
<TI>Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>1</NO>
<PG>47-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15998890"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlson EW, Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH</AU>
<TI>Comparison of self-reported diagnosis of connective tissue disease with medical records in female health professionals: the Women's Health Cohort Study</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>150</VL>
<NO>6</NO>
<PG>652-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10490005"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al</AU>
<TI>Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>1</NO>
<PG>56-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15998891"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH</AU>
<TI>Randomised beta-carotene supplementation and incidence of cancer and cardiovascular disease in women: the Women's Health Study</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1999</YR>
<VL>91</VL>
<PG>2102-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11875728"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee IM, Cook NR, Manson JE, Buring JE</AU>
<TI>Randomized beta-carotene supplementation and incidence of cancer and cardiovascular disease in women: is the association modified by baseline plasma level</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>5</NO>
<PG>698-701</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11875728"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu S, Manson JE, Lee IM, Cole SR, Hennekens CH, Willett WC, et al</AU>
<TI>Fruit and vegetable intake and risk of cardiovascular disease: the Women's Health Study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>72</VL>
<NO>4</NO>
<PG>922-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11010932"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE</AU>
<TI>Baseline characteristics of participants in the Women's Health Study</TI>
<SO>Journal of Women's Health and Gender Based Medicine</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>1</NO>
<PG>19-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10718501"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al</AU>
<TI>A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>13</NO>
<PG>1293-304</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15753114"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1991" NAME="Yu 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu SY, Zhu YJ, Li WG, Huang QS, Huang CZ, Zhang QN, et al</AU>
<TI>A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China</TI>
<SO>Biological Trace Element Research</SO>
<YR>1991</YR>
<VL>29</VL>
<NO>3</NO>
<PG>289-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1726411"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1997" NAME="Yu 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu SY, Zhu YJ, Li WG</AU>
<TI>Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong</TI>
<SO>Biological Trace Element Research</SO>
<YR>1997</YR>
<VL>56</VL>
<PG>117-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97297046"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2003" NAME="Zhu 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhu S, Mason J, Shi Y, Hu Y, Li R, Wahg M, et al</AU>
<TI>The effect of folic acid on the development of stomach and other gastrointestinal cancers</TI>
<SO>Chinese Medical Journal</SO>
<YR>2003</YR>
<VL>116</VL>
<NO>1</NO>
<PG>15-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12667380"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Document Type: Article&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Zhu S, Mason J, Shi Y, Hu Y, Li R, Wang M, et al</AU>
<TI>The interventional effect of folic acid on the development of gastric and other gastrointestinal cancers -Clinical trial and follow-up for seven years</TI>
<SO>Chinese Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>2</NO>
<PG>73-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bespalov-2004" NAME="Bespalov 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berspalov VG, Shcherbakov AM, Kalinovskii VP, Novik VI, Chepik OF, Aleksandrov VA, et al</AU>
<TI>Study of the antioxidant drug "Karinat" in patients with chronic atrophic gastritis</TI>
<TO>Izucenie antioksidatnogo preparata "Karinat" kak sredstva dla lecenih boljnih s hroniceskim atroficeskim gastritom</TO>
<SO>Voprosii Onkologii</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>1</NO>
<PG>81-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15088527"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bostick-1993" NAME="Bostick 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bostick RM, Potter JD, McKenzie DR, Sellers TA, Kushi LH, Steinmetz KA, et al</AU>
<TI>Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women's Health Study</TI>
<SO>Cancer Research</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>18</NO>
<PG>4230-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8364919"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bukin-1996" NAME="Bukin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bukin YV, Poddubniy BK, Kuvshinov YP, Draudin-Krylenko VA, Shabanov MA</AU>
<TI>The effects of certain vitamins and natural anti-oxidants on ornithine decarboxylase activity and on atrophic and premalignant changes in the human gastric mucosa</TI>
<SO>Digestive Endoscopy</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>3</NO>
<PG>184-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996267562"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bussey-1982" NAME="Bussey 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bussey HJ, DeCosse JJ, Deschner EE, Eyers AA, Lesser ML, Morson BC, et al</AU>
<TI>A randomized trial of ascorbic acid in polyposis coli</TI>
<SO>Cancer</SO>
<YR>1982</YR>
<VL>50</VL>
<NO>7</NO>
<PG>1434-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7049351"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chuang-2002" NAME="Chuang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chuang CH, Sheu BS, Huang AH, Yang HB, Wu JJ</AU>
<TI>Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection</TI>
<SO>Helicobacter</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>5</NO>
<PG>310-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12390211"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Stefani-1999" NAME="De Stefani 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Stefani E, Ronco A, Mendilaharsu M, Deneo-Pellegrini H</AU>
<TI>Diet and risk of cancer of the upper aerodigestive tract-II. Nutrients</TI>
<SO>Oral Oncology</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>1</NO>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Stefani-1999a" NAME="De Stefani 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Stefani E, Deneo-Pellegrini H, Mendilaharsu M, Ronco A</AU>
<TI>Diet and risk of cancer of the upper aerodigestive tract-I. Foods</TI>
<SO>Oral Oncology</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>1</NO>
<PG>17-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10211305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Stefani-2000" NAME="De Stefani 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Stefani E, Brennan P, Boffetta P, Ronco AL, Mendilaharsu M, Deneo-Pellegrini H</AU>
<TI>Vegetables, fruits, related dietary antioxidants, and risk of squamous cell carcinoma of the esophagus: a case-control study in Uruguay</TI>
<SO>Nutrition and Cancer</SO>
<YR>2000</YR>
<VL>38</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeCosse-1975" NAME="DeCosse 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cosse JJ, Adams MB, Kuzma JF, Lo Gerfo P, Condon RE</AU>
<TI>Effect of ascorbic acid on rectal polyps of patients with familial polyposis</TI>
<SO>Wisconsin Medical Journal</SO>
<YR>1976</YR>
<VL>75</VL>
<NO>1</NO>
<PG>S8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1246900"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>DeCosse JJ, Adams MB, Kuzma JF, LoGerfo P, Condon RE</AU>
<TI>Effect of ascorbic acid on rectal polyps of patients with familial polyposis</TI>
<SO>Surgery</SO>
<YR>1975</YR>
<VL>78</VL>
<NO>5</NO>
<PG>608-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1188603"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeCosse-1989" NAME="DeCosse 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>DeCosse JJ, Miller HH, Lesser ML</AU>
<TI>Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1989</YR>
<VL>81</VL>
<NO>17</NO>
<PG>1290-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ECP_x002d_IM-1994" NAME="ECP-IM 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reed PI, Johnston BJ</AU>
<TI>Primary prevention of gastric cancer - The ECP-IM intervention study</TI>
<SO>Acta Endoscopica</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>1</NO>
<PG>45-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reed PI</AU>
<TI>The ECP-IM intervention study</TI>
<SO>European Journal of Cancer Prevention</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>Suppl 2</NO>
<PG>99-104</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7735056"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EUROSCAN-2000" NAME="EUROSCAN 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Zandwijk N, Dalesio O, Pastorino U, de-Vries N, van Tinteren H</AU>
<TI>EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>12</NO>
<PG>977-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10861309"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frank-1995" NAME="Frank 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frank E</AU>
<TI>The Women Physicians' Health Study: background, objectives, and methods</TI>
<SO>Journal of the American Medical Women's Association</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>2</NO>
<PG>64-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7722210"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1990" NAME="Greenberg 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, et al</AU>
<TI>A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>323</VL>
<NO>12</NO>
<PG>789-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2202901"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishikawa-1995" NAME="Ishikawa 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishikawa H, Akedo I, Suzuki T, Otani T, Sobue T</AU>
<TI>Interventional trial for colorectal cancer prevention in Osaka: an introduction to the protocol</TI>
<SO>Japanese Journal of Cancer Research</SO>
<YR>1995</YR>
<VL>86</VL>
<NO>8</NO>
<PG>707-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7559090"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-2001" NAME="Jacobs 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs EJ, Connell CJ, Patel AV, Chao A, Rodriguez C, Seymour J, et al</AU>
<TI>Vitamin C and vitamin E supplement use and colorectal cancer mortality in a large American Cancer Society cohort</TI>
<SO>Cancer Epidemiology Biomarkers and Prevention</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>1</NO>
<PG>17-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11205484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-1999" NAME="Jansen 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansen MC, Bueno de Mesquita HB, Buzina R, Fidanza F, Menotti A, Blackburn H, et al</AU>
<TI>Dietary fiber and plant foods in relation to colorectal cancer mortality: the Seven Countries Study</TI>
<SO>International Journal of Cancer</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>2</NO>
<PG>174-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10188715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ji-1995" NAME="Ji 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ji BT, Chow WH, Gridley G, Mclaughlin JK, Dai Q, Wacholder S, et al</AU>
<TI>Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai China</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1995</YR>
<VL>4</VL>
<NO>8</NO>
<PG>885-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8634662"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirk-2006" NAME="Kirk 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirk GR, White JS, McKie L, Stevenson M, Young I, Clements WD, et al</AU>
<TI>Combined antioxidant therapy reduces pain and improves quality of life in chronic pancreatitis</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>4</NO>
<PG>499-503</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16627214"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krishnaswamy-1993" NAME="Krishnaswamy 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krishnaswamy K, Prasad MPR, Krishna TP, Pasricha S</AU>
<TI>A case-control study of selenium in cancer</TI>
<SO>Indian Journal of Medical Research</SO>
<YR>1993</YR>
<VL>98</VL>
<PG>124-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Vecchia-2002" NAME="La Vecchia 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Vecchia C</AU>
<TI>Tomatoes, lycopene intake, and digestive tract and female hormone-related neoplasms</TI>
<SO>Experimental Biology and Medicine</SO>
<YR>2002</YR>
<VL>227</VL>
<NO>10</NO>
<PG>860-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacroix-1987" NAME="Lacroix 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacroix A, Bhat PV, Karabatsos A, Couture P, Latreille J, Beaulieu R, et al</AU>
<TI>Plasma levels of retinol in cancer patients supplemented with retinol</TI>
<SO>Oncology</SO>
<YR>1987</YR>
<VL>44</VL>
<NO>2</NO>
<PG>108-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3554082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanza-1996" NAME="Lanza 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanza E, Schatzkin A, Ballard-Barbash R, Corle D, Clifford C, Paskett E, et al</AU>
<TI>The polyp prevention trial II: dietary intervention program and participant baseline dietary characteristics</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>5</NO>
<PG>385-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9162305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanza-2001" NAME="Lanza 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanza E, Schatzkin A, Daston C, Corle D, Freedman L, Ballard-Barbash R, et al</AU>
<TI>Implementation of a 4-Y, high-fiber, high-fruit-and-vegetable, low-fat dietary intervention: results of dietary changes in the Polyp Prevention Trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2001</YR>
<VL>74</VL>
<NO>3</NO>
<PG>387-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-2000" NAME="Levi 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi F, Pasche C, Lucchini F, La Vecchia C</AU>
<TI>Selected micronutrients and colorectal cancer: case-control study from the Canton of Vaud, Switzerland</TI>
<SO>European Journal of Cancer</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>16</NO>
<PG>2115-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11044650"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Limburg-2005" NAME="Limburg 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, et al</AU>
<TI>Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>3</NO>
<PG>863-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16143126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macrae-1999" NAME="Macrae 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macrae F</AU>
<TI>Wheat bran fiber and development of adenomatous polyps: evidence from randomized, controlled clinical trials</TI>
<SO>American Journal of Medicine</SO>
<YR>1999</YR>
<VL>106</VL>
<NO>1 A</NO>
<PG>38S-42S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marotta-2003" NAME="Marotta 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marotta F, Barretto R, Tajiri H, Bertuccelli J, Safran P, Bobadilla J, et al</AU>
<TI>Atrophic/metaplastic changes of gastric mucosa: a preliminary interventional trial comparing different antioxidant supplements</TI>
<SO>International Congress Series</SO>
<YR>2003</YR>
<VL>1255</VL>
<PG>291-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marotta-2004" NAME="Marotta 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marotta F, Barreto R, Tajiri H, Bertuccelli J, Safran P, Yoshida C, et al</AU>
<TI>The aging/precancerous gastric mucosa: a pilot nutraceutical trial</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2004</YR>
<VL>1019</VL>
<PG>195-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15247013"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayne-2001" NAME="Mayne 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan Tl, et al</AU>
<TI>Nutrient intake and risk of subtypes of esophageal and gastric cancer</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>10</NO>
<PG>1055-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11588131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moriwaki-2002" NAME="Moriwaki 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moriwaki H</AU>
<TI>Prevention of liver cancer: current strategies and future perspectives</TI>
<SO>International Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11942046"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muto-1996" NAME="Muto 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al</AU>
<TI>Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>24</NO>
<PG>1561-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8628336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newsome-2000" NAME="Newsome 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newsome PN, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, et al</AU>
<TI>Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>10</NO>
<PG>1295-301</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11012474"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nomura-1987a" NAME="Nomura 1987a" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nomura A, Heilbrun LK, Morris JS, Stemmermann GN</AU>
<TI>Serum selenium and the risk of cancer, by specific sites: case-control analysis of prospective data</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1987</YR>
<VL>79</VL>
<NO>1</NO>
<PG>103-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3474437"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-1993" NAME="Pan 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan WH, Wang CY, Huang SM, Yeh SY, Lin WG, Lin DI, et al</AU>
<TI>Vitamin A, Vitamin E or beta-carotene status and hepatitis B-related hepatocellular carcinoma</TI>
<SO>Annals of Epidemiology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>3</NO>
<PG>217-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8275192"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Podmore-1998a" NAME="Podmore 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, et al</AU>
<TI>Vitamin C exhibits pro-oxidant properties</TI>
<SO>Nature</SO>
<YR>1998</YR>
<VL>392</VL>
<NO>6676</NO>
<PG>559</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9560150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qu-2007" NAME="Qu 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qu CX, Kamangar F, Fan JH, Yu B, Sun XD, Taylor PR, et al</AU>
<TI>Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<NO>16</NO>
<PG>1240-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17686823"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocchi-1997" NAME="Rocchi 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocchi E, Seium Y, Camellini L, Casalgrandi G, Borghi A, D'Alimonte P, et al</AU>
<TI>Hepatic tocopherol content in primary hepatocellular carcinoma and liver metastases</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9214453"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russo-1997" NAME="Russo 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS</AU>
<TI>Plasma selenium levels and the risk of colorectal adenomas</TI>
<SO>Nutrition and Cancer</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>2</NO>
<PG>125-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9290116"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sasazuki-2003" NAME="Sasazuki 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim MK, Sasaki S, Sasazuki S, Okubo S, Hayashi M, Tsugane S</AU>
<TI>Lack of long-term effect of vitamin C supplementation on blood pressure</TI>
<SO>Hypertension</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>6</NO>
<PG>797-803</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12468560"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim MK, Sasazuki S, Sasaki S, Okubo S, Hayashi M, Tsugane S</AU>
<TI>Effect of five-year supplementation of vitamin C on serum vitamin C concentration and consumption of vegetables and fruits in middle-aged Japanese: a randomized controlled trial</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>3</NO>
<PG>208-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12805247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sasaki S, Tsubono Y, Okubo S, Hayashi M, Kakizoe T, Tsugane S</AU>
<TI>Effects of three-month oral supplementation of beta-carotene and vitamin C on serum concentrations of carotenoids and vitamins in middle-aged subjects: a pilot study for a randomized controlled trial to prevent gastric cancer in high-risk Japanese population</TI>
<SO>Japanese Journal of Cancer Research</SO>
<YR>2000</YR>
<VL>91</VL>
<NO>5</NO>
<PG>464-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10835489"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sasazuki S, Sasaki S, Tsubono Y, Okubo S, Hayashi M, Kakizoe T, et al</AU>
<TI>The effect of 5-year vitamin C supplementation on serum pepsinogen level and Helicobacter pylori infection</TI>
<SO>Cancer Science</SO>
<YR>2003</YR>
<VL>94</VL>
<NO>4</NO>
<PG>378-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12824908"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsubono Y, Okubo S, Hayashi M, Kakizoe T, Tsugane S</AU>
<TI>A randomized controlled trial for chemoprevention of gastric cancer in high-risk Japanese population; study design, feasibility and protocol modification</TI>
<SO>Japanese Journal of Cancer Research</SO>
<YR>1997</YR>
<VL>88</VL>
<NO>4</NO>
<PG>344-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9197524"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsugane S, Tsubono Y, Okubo S, Hayashi M, Kakizoe T</AU>
<TI>A pilot study for a randomized controlled trial to prevent gastric cancer in high-risk Japanese population: study design and feasibility evaluation</TI>
<SO>Japanese Journal of Cancer Research</SO>
<YR>1996</YR>
<VL>87</VL>
<NO>7</NO>
<PG>676-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8698614"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schatzkin-1996" NAME="Schatzkin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schatzkin A, Lanza E, Freedman LS, Tangrea J, Cooper MR, Marshall JR, et al</AU>
<TI>The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>5</NO>
<PG>375-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9162304"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simone-2002" NAME="Simone 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simone F, Pappalardo G, Maiani G, Guadalaxara A, Bugianesi R, Conte AM, et al</AU>
<TI>Accumulation and interactions of beta-carotene and alpha-tocopherol in patients with adenomatous polyps</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>6</NO>
<PG>546-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12032655"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siriwardena-2007" NAME="Siriwardena 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siriwardena AK, Mason JM, Balachandra S, Bagul A, Galloway S, Formela L, et al</AU>
<TI>Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis</TI>
<SO>Gut</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>10</NO>
<PG>1439-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17356040"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takshashi-2003" NAME="Takshashi 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takashashi Y, Sasaki S, Takahashi M, Okubo S, Hayashi M, Tsugane S</AU>
<TI>A population-based dietary intervention trial in a high-risk area for stomach cancer and stroke: changes in intakes and related biomarkers</TI>
<SO>Preventive Medicine</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>5</NO>
<PG>432-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14572428"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terry-2000" NAME="Terry 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terry P, Lagergren J, Ye WM, Nyren O, Wolk A</AU>
<TI>Antioxidants and cancers of the esophagus and gastric cardia</TI>
<SO>International Journal of Cancer</SO>
<YR>2000</YR>
<VL>87</VL>
<NO>5</NO>
<PG>750-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10925371"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisburger-1991" NAME="Weisburger 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisburger JH</AU>
<TI>Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1991</YR>
<VL>53</VL>
<NO>1</NO>
<PG>S226-S237</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1985392"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whelan-1999" NAME="Whelan 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whelan RL, Horvath KD, Gleason NR, Forde KA, Treat MD, Teitelbaum SL, et al</AU>
<TI>Vitamin and calcium supplement use is associated with decreased adenoma recurrence in patients with a previous history of neoplasia</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>2</NO>
<PG>212-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10211498"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2000" NAME="Yang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang CS</AU>
<TI>Vitamin nutrition and gastroesophageal cancer</TI>
<SO>Journal of Nutrition</SO>
<YR>2000</YR>
<VL>130</VL>
<NO>2</NO>
<PG>338S-9S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10721901"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1995" NAME="Yu 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu MW, Hsieh HH, Pan WH, Yang CS, Chen CJ</AU>
<TI>Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma</TI>
<SO>Cancer Research</SO>
<YR>1995</YR>
<VL>55</VL>
<NO>6</NO>
<PG>1301-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7882326"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1999" NAME="Yu 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu M W, Horng IS, Hsu KH, Chiang YC, Liaw Y F, Chen CJ</AU>
<TI>Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>150</VL>
<NO>4</NO>
<PG>367-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99381616"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-1995" NAME="Zheng 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng W, Sellers TA, Doyle TJ, Kushi LH, Potter JD, Folsom AR</AU>
<TI>Retinol, antioxidant vitamins, and cancers of the upper digestive tract in a prospective cohort study of postmenopausal women</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1995</YR>
<VL>142</VL>
<NO>9</NO>
<PG>955-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7572976"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-APPOSE-2001" NAME="APPOSE 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costello AJ</AU>
<TI>A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues</TI>
<SO>Urology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>4</NO>
<PG>182-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11295622"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HGPIN-2006" NAME="HGPIN 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, et al</AU>
<TI>Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>8</NO>
<PG>1479-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16896036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PHS-II-2000" NAME="PHS II 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christen WG, Gaziano JM, Hennekens CH</AU>
<TI>Design of Physicians' Health Study II a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials</TI>
<SO>Annals of Epidemiology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>2</NO>
<PG>125-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10691066"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SELECT-2003" NAME="SELECT 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, et al</AU>
<TI>Molecular epidemiologic studies within the Selenium and vitamin E Cancer Prevention Trial (SELECT)</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>7</NO>
<PG>627-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11552710"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, et al</AU>
<TI>The Selenium and vitamin E Cancer Prevention Trial</TI>
<SO>World Journal of Urology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12756490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al</AU>
<TI>SELECT: the Selenium and vitamin E Cancer Prevention Trial</TI>
<SO>Urologic Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12684129"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al</AU>
<TI>SELECT: the Selenium and vitamin E Cancer Prevention Trial: rationale and design</TI>
<SO>Prostate Cancer and Prostatic Diseases</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>3</NO>
<PG>145-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12497090"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al</AU>
<TI>SELECT: the next prostate cancer prevention trial. Selenum and vitamin E Cancer Prevention Trial</TI>
<SO>The Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>4</NO>
<PG>1311-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11547064"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein EA</AU>
<TI>Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and vitamin E Cancer Prevention Trial</TI>
<SO>Recent Results in Cancer Research</SO>
<YR>2003</YR>
<VL>163</VL>
<PG>212-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12903856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein EA</AU>
<TI>Selenium and vitamin E Cancer Prevention Trial</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2004</YR>
<VL>1031</VL>
<PG>234-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15753149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, et al</AU>
<TI>Designing the Selenium and vitamin E Cancer Prevention Trial (SELECT)</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2005</YR>
<VL>97</VL>
<NO>2</NO>
<PG>94-102</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15657339"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-24 17:01:30 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-24 17:01:30 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-2003" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Interaction revisited: the difference between two estimates</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12543843"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ames-1995" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Ames 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ames BN, Gold LS, Willett WC</AU>
<TI>The causes and prevention of cancer</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America Sci USA</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>12</NO>
<PG>5258-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2000a" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 2000a" TYPE="OTHER">
<TI>Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</TI>
<SO>National Academy Press, Washington DC</SO>
<YR>2000</YR>
<PG>1-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2000b" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 2000b" TYPE="OTHER">
<TI>Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of DRIs, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Institute of Medicine. Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids</TI>
<SO>National Academy Press, Washington, DC</SO>
<YR>2000</YR>
<PG>1-529</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balluz-2000" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Balluz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Balluz LS, Kieszak SM, Philen RM, Mulinare J</AU>
<TI>Vitamin and mineral supplement use in the United States. Results from the third National Health and Nutrition Examination Survey</TI>
<SO>Archives of Family Medicine</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>258-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumdar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1088-101</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7786990"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bjelakovic-2006" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bjelakovic 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bjelakovic G, Nagorni A, Nikolova D, Simonetti RG, Bjelakovic M, Gluud C</AU>
<TI>Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>2</NO>
<PG>281-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16842454"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bjelakovic-2007" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bjelakovic 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bjelakovic G, Nikolova D, Gluud LL, Simoneti RG, Gluud C</AU>
<TI>Mortality in randomized trials on antioxidant supplements for primary and secondary prevention. Systematic review and meta-analysis</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>8</NO>
<PG>842-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17327526"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boyle-1985" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Boyle 1985" TYPE="JOURNAL_ARTICLE">
<AU>Boyle P, Zaridze DG, Smans M</AU>
<TI>Descriptive epidemiology of colorectal cancer</TI>
<SO>International Journal of Cancer</SO>
<YR>1985</YR>
<VL>36</VL>
<NO>1</NO>
<PG>9-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2991145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Camire-1999" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Camire 1999" TYPE="JOURNAL_ARTICLE">
<AU>Camire ME, Kantor MA</AU>
<TI>Dietary supplements: nutritional and legal considerations</TI>
<SO>Food Technology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>7</NO>
<PG>87-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caraballoso-2003" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Caraballoso 2003" TYPE="OTHER">
<AU>Caraballoso M, Sacristan M, Serra C, Bonfill X</AU>
<TI>Drugs for preventing lung cancer in healthy people</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003, Issue 2. Art. No.: CD002141. DOI: 10.1002/14651858.CD002141</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004a" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15161896"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004b" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Krleza-Jeric' K, Schmid I, Altman DG</AU>
<TI>Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2004</YR>
<VL>171</VL>
<NO>7</NO>
<PG>735-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15451835"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-2005" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Altman DG</AU>
<TI>Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors</TI>
<SO>BMJ (Clinical Research Ed)</SO>
<YR>2005</YR>
<VL>330</VL>
<NO>7494</NO>
<PG>753</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15681569"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cheng-1996" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cheng K, Day N</AU>
<TI>Nutrition and esophageal cancer</TI>
<SO>Cancer Causes and Control</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8850433"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clark-1991" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Clark 1991" TYPE="JOURNAL_ARTICLE">
<AU>Clark LC, Cantor KP, Allaway WH</AU>
<TI>Selenium in forage crops and cancer mortality in U.S. counties</TI>
<SO>Archives of Environmental Health</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>1</NO>
<PG>37-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992931"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-1987" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Collins 1987" TYPE="JOURNAL_ARTICLE">
<AU>Collins RH, Feldman M, Fordtran JS</AU>
<TI>Colon cancer, dysplasia and surveillance in patients with ulcerative colitis. A critical review</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>316</VL>
<PG>1654-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3295551"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-2003" MODIFIED="2008-05-24 16:59:19 +0100" MODIFIED_BY="[Empty name]" NAME="D'Amico 2003" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico G, Pietrosi G, Tarantino I, Pagliaro L</AU>
<TI>Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>5</NO>
<PG>1277-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12730868"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dawsey-1994" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Dawsey 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dawsey SM, Wang GQ, Taylor PR, Li JY, Blot WJ, Li B, et al</AU>
<TI>Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the Dysplasia Trial in Linxian, China</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>2</NO>
<PG>167-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8049639"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3616287"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3802833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Diplock-1994" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Diplock 1994" TYPE="JOURNAL_ARTICLE">
<AU>Diplock AT</AU>
<TI>Antioxidants and disease prevention</TI>
<SO>Molecular Aspects of Medicine</SO>
<YR>1994</YR>
<VL>15</VL>
<PG>293-376</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95147668"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Doucas-2006" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Doucas 2006" TYPE="JOURNAL_ARTICLE">
<AU>Doucas H, Garcea G, Neal CP, Manson MM, Berry DP</AU>
<TI>Chemoprevention of pancreatic cancer: a review of the molecular pathways involved, and evidence for the potential for chemoprevention</TI>
<SO>Pancreatology</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>5</NO>
<PG>429-39</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16847380"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duarte-2005" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Duarte 2005" TYPE="JOURNAL_ARTICLE">
<AU>Duarte TL, Lunec J</AU>
<TI>Review: When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C</TI>
<SO>Free Radical Research</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>7</NO>
<PG>671-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16036346"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997456606"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-2003" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Juni P, Bartlett C, Holenstein F, Sterne J</AU>
<TI>How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study</TI>
<SO>Health Technolology Assessment</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>1-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12583822"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Enzinger-2003" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Enzinger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Enzinger PC, Mayer RJ</AU>
<TI>Esophageal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>23</NO>
<PG>2241-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14657432"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2004" MODIFIED="2008-05-24 16:59:19 +0100" MODIFIED_BY="[Empty name]" NAME="Ferlay 2004" TYPE="OTHER">
<AU>Ferlay J, Bray F, Pisani P, Parkin DM</AU>
<TI>GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide</TI>
<SO>IARC CancerBase No 5, version 2.0</SO>
<YR>2004</YR>
<PB>IARC Press, Lyon, France</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-2006" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Fitzgerald 2006" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald RC</AU>
<TI>Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma</TI>
<SO>Gut</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>12</NO>
<PG>1810-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17124160"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freedman-2007" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Freedman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Freedman ND, Park Y, Subar AF, Hollenbeck AR, Leitzmann MF, Schatzkin A, et al</AU>
<TI>Fruit and vegetable intake and esophageal cancer in a large prospective cohort study</TI>
<SO>International Journal of Cancer</SO>
<YR>2007</YR>
<VL>121</VL>
<NO>12</NO>
<PG>2753-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17691111"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2007" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2007" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH</AU>
<TI>Association between unreported outcomes and effect size estimates in Cochrane meta-analyses</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>5</NO>
<PG>468-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17284696"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garcea-2003" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Garcea 2003" TYPE="JOURNAL_ARTICLE">
<AU>Garcea G, Dennison AR, Steward WP, Berry DP</AU>
<TI>Chemoprevention of gastrointestinal malignancies</TI>
<SO>ANZ Journal of Surgery</SO>
<YR>2003</YR>
<VL>73</VL>
<PG>680-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12956781"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2001" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2001" TYPE="BOOK_SECTION">
<AU>Gluud C</AU>
<TI>Alcoholic hepatitis: no glucocorticosteroids?</TI>
<SO>Steatohepatitis (NASH and ASH) - Falk Symposium 121</SO>
<YR>2001</YR>
<PG>322-42</PG>
<ED>Leuschner U, James OFW, Dancygier H</ED>
<PB>Kluwer Academic Publisher</PB>
<CY>Lancaster</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2006a" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Gluud LL</AU>
<TI>Bias in clinical intervention research</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>6</NO>
<PG>493-501</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16443796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2006b" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Gluud C</AU>
<TI>The culture of designing hepato-biliary randomised trials</TI>
<SO>Journal of Hepatology</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>3</NO>
<PG>607-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16434120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grau-2006" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Grau 2006" TYPE="JOURNAL_ARTICLE">
<AU>Grau MV, Rees JR, Baron JA</AU>
<TI>Chemoprevention in gastrointestinal cancers: current status</TI>
<SO>Basic &amp; Clinical Pharmacology &amp; Toxicology</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>3</NO>
<PG>281-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16611203"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gwyn-2002" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Gwyn 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gwyn K, Sinicrope FA</AU>
<TI>Chemoprevention of colorectal cancer</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>1</NO>
<PG>13-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11808936"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haenen-2002" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Haenen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Haenen GR, Bast A</AU>
<TI>The use of vitamin supplements in self-medication</TI>
<SO>Therapie</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>2</NO>
<PG>119-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12185958"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hanck-1988" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Hanck 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hanck AB</AU>
<TI>Vitamin C and cancer</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1988</YR>
<VL>259</VL>
<PG>307-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="88203700"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herbert-1994" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Herbert 1994" TYPE="JOURNAL_ARTICLE">
<AU>Herbert V</AU>
<TI>The antioxidant supplement myth</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>60</VL>
<NO>2</NO>
<PG>157-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8030591"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herbert-1997" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Herbert 1997" TYPE="JOURNAL_ARTICLE">
<AU>Herbert V</AU>
<TI>The value of antioxidant supplements vs their natural counterparts</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1997</YR>
<VL>97</VL>
<NO>4</NO>
<PG>375-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9120187"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12111919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>In: The Cochrane Library, Issue 4, 2006. Chichester, UK</SO>
<YR>2006</YR>
<PB>John Wiley &amp; sons, Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmes-2007" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Holmes 2007" TYPE="JOURNAL_ARTICLE">
<AU>Holmes RS, Vaughan TL, Holmes RS, Vaughan TL</AU>
<TI>Epidemiology and pathogenesis of esophageal cancer</TI>
<SO>Seminars in Radiation Oncology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>1</NO>
<PG>2-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17185192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holzinger-1999" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Holzinger 1999" TYPE="JOURNAL_ARTICLE">
<AU>Holzinger F, Z'graggen K, Büchler MW</AU>
<TI>Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma</TI>
<SO>Annals of Oncology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Suppl 4</NO>
<PG>S122-S6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10436802"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2000" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Hughes 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hughes D</AU>
<TI>Dietary antioxidants and human immune function</TI>
<SO>Nutrition Bulletin</SO>
<YR>2000</YR>
<VL>25</VL>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janne-2000" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Janne 2000" TYPE="JOURNAL_ARTICLE">
<AU>Janne PA, Mayer RJ</AU>
<TI>Chemoprevention of colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<PG>1960-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10874065"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: assessing the quality of controlled clinical trials</TI>
<SO>BMJ (Clinical Research Ed)</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11440947"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaplowitz-2000" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Kaplowitz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kaplowitz N</AU>
<TI>Cell death at the millennium. Implications for liver diseases</TI>
<SO>Clinics in Liver Disease</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>1</NO>
<PG>1-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11232179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11730399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Knekt-1994" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Knekt 1994" TYPE="BOOK_SECTION">
<AU>Knekt P</AU>
<TI>Vitamin E and cancer prevention</TI>
<SO>Natural Antioxidants in Human Health and Disease</SO>
<YR>1994</YR>
<PG>199-239</PG>
<ED>Balz Frei</ED>
<PB>Academic Press, Inc.</PB>
<CY>San Diego</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koushik-2007" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Koushik 2007" TYPE="JOURNAL_ARTICLE">
<AU>Koushik A, Hunter DJ, Spiegelman D, Beeson WL, van den Brandt PA, Buring JE, et al</AU>
<TI>Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<NO>19</NO>
<PG>1471-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17895473"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kubo-2007" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Kubo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kubo A, Corley DA</AU>
<TI>Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2007</YR>
<VL>102</VL>
<NO>10</NO>
<PG>2323-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17581269"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kune-2006" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Kune 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kune G, Watson L</AU>
<TI>Colorectal cancer protective effects and the dietary micronutrients folate, methionine, vitamins B6, B12, C, E, selenium, and lycopene</TI>
<SO>Nutrition and Cancer</SO>
<YR>2006</YR>
<VL>56</VL>
<NO>1</NO>
<PG>11-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17176213"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lanza-2007" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Lanza 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lanza E, Yu B, Murphy G, Albert PS, Caan B, Marshall JR, et al</AU>
<TI>The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>9</NO>
<PG>1745-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17855692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Larsson-2006" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Larsson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Larsson SC, Håkansson N, Näslund I, Bergkvist L, Wolk A</AU>
<TI>Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>10</NO>
<PG>1998-2001</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17855692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lawson-2007" MODIFIED="2008-05-24 16:59:19 +0100" MODIFIED_BY="[Empty name]" NAME="Lawson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, et al</AU>
<TI>Multivitamin use and risk of prostate cancer in the National Institutes of Health &#8211; AARP diet and health study</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<NO>10</NO>
<PG>754-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17505071"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-2003" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lee BM, Park KK</AU>
<TI>Beneficial and adverse effects of chemopreventive agents</TI>
<SO>Mutation Research</SO>
<YR>2003</YR>
<VL>523-4</VL>
<PG>265-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12628524"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-2004" MODIFIED="2008-05-24 16:59:19 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR Jr</AU>
<TI>Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>80</VL>
<NO>5</NO>
<PG>1194-200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15531665"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leung-2006" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Leung 2006" TYPE="JOURNAL_ARTICLE">
<AU>Leung WK, Sung JJ, Leung WK, Sung JJ</AU>
<TI>Chemoprevention of gastric cancer</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>8</NO>
<PG>867-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16825903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lichtenstein-2005" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Lichtenstein 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lichtenstein AH, Russell RM</AU>
<TI>Essential nutrients: food or supplements? Where should the emphasis be</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>3</NO>
<PG>351-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16030280"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lopez-2006" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Lopez 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ</AU>
<TI>Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9524</NO>
<PG>1747-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16731270"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lowenfels-2006" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Lowenfels 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lowenfels AB, Maisonneuve P</AU>
<TI>Epidemiology and risk factors for pancreatic cancer</TI>
<SO>Best Practice &amp; Research Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>2</NO>
<PG>197-209</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16549324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lynch-2002" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Lynch 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lunch JP, Hoops TC</AU>
<TI>The genetic pathogenesis of colorectal cancer</TI>
<SO>Hematology/oncology Clinics of North America</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>4</NO>
<PG>775-810</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12418049"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MacDonald-2001" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="MacDonald 2001" TYPE="JOURNAL_ARTICLE">
<AU>MacDonald GA</AU>
<TI>Pathogenesis of hepatocellular carcinoma</TI>
<SO>Clinics in Liver Disease</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>1</NO>
<PG>69-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11218920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mathers-2006" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Mathers 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mathers CD, Loncar D</AU>
<TI>Projections of global mortality and burden of disease from 2002 to 2030</TI>
<SO>PLoS Medicine</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>11</NO>
<PG>e442</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17132052"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McAlister-2003" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="McAlister 2003" TYPE="JOURNAL_ARTICLE">
<AU>McAlister FA, Straus SE, Sackett DL, Altman DG</AU>
<TI>Analysis and reporting of factorial trials. A systematic review</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>289</VL>
<NO>19</NO>
<PG>2545-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12759326"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McKevith-2003" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="McKevith 2003" TYPE="JOURNAL_ARTICLE">
<AU>McKevith B, Kelly C, Stanner S, Hughes J, Buttriss J</AU>
<TI>The Food Standards Agency's antioxidants in food programme-a summary</TI>
<SO>Journal of Human Nutrition and Dietetics</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>4</NO>
<PG>257-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12859707"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mehta-2005" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Mehta 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mehta S, Johnson IT, Rhodes M</AU>
<TI>Systematic review: the chemoprevention of oesophageal adenocarcinoma</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>9</NO>
<PG>759-68</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16225483"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Millen-2004" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Millen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Millen AE, Dodd KW, Subar AF</AU>
<TI>Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>6</NO>
<PG>942-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15175592"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2005" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2005" TYPE="JOURNAL_ARTICLE">
<AU>Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E</AU>
<TI>Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2005</YR>
<VL>142</VL>
<NO>1</NO>
<PG>37-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15537682"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9746022"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morris-2003" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Morris 2003" TYPE="JOURNAL_ARTICLE">
<AU>Morris CD, Carson S</AU>
<TI>Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>1</NO>
<PG>56-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12834320"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mulholland-2007" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Mulholland 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mulholland CA, Benford DJ</AU>
<TI>What is known about the safety of multivitamin-multimineral supplements for the generally healthy population? Theoretical basis for harm</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2007</YR>
<VL>85</VL>
<NO>1</NO>
<PG>318S-322S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17209218"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Murata-2000" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Murata 2000" TYPE="JOURNAL_ARTICLE">
<AU>Murata M, Kawanishi S</AU>
<TI>Oxidative DNA damage by vitamin A and its derivative via superoxide generation</TI>
<SO>The Journal of Biological Chemistry</SO>
<YR>2000</YR>
<VL>275</VL>
<NO>3</NO>
<PG>2003-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10636903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neugut-1998" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Neugut 1998" TYPE="JOURNAL_ARTICLE">
<AU>Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N</AU>
<TI>The epidemiology of cancer of the small bowel</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>3</NO>
<PG>243-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9521441"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neuhouser-2003" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Neuhouser 2003" TYPE="JOURNAL_ARTICLE">
<AU>Neuhouser ML, Patterson RE, Thornquist MD, Omenn GS, King IB, Goodman GE</AU>
<TI>Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET)</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>4</NO>
<PG>350-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12692110"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nichter-2006" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Nichter 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nichter M, Thompson JJ</AU>
<TI>For my wellness, not just my illness: North Americans' use of dietary supplements</TI>
<SO>Culture, Medicine and Psychiatry</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>2</NO>
<PG>175-222</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16841188"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nomura-1987" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Nomura 1987" TYPE="JOURNAL_ARTICLE">
<AU>Nomura A, Heilbrun LK, Morris JS, Stemmermann GN</AU>
<TI>Serum selenium and the risk of cancer, by specific sites: case-control analysis of prospective data</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1987</YR>
<VL>79</VL>
<NO>1</NO>
<PG>103-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3474437"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nouraie-2005" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Nouraie 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nouraie M, Pietinen P, Kamangar F, Dawsey SM, Abnet CC, Albanes D, et al</AU>
<TI>Fruits, vegetables, and antioxidants and risk of gastric cancer among male smokers</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>9</NO>
<PG>2087-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16172214"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oshima-1982" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Oshima 1982" TYPE="JOURNAL_ARTICLE">
<AU>Oshima H, Berezial J</AU>
<TI>Monitoring N-nitrosamino acids excreted in the urine and feces of rats as an index of endogenous nitrozation</TI>
<SO>Carcinogenesis</SO>
<YR>1982</YR>
<VL>3</VL>
<NO>1</NO>
<PG>115-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6175434"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paolini-1999" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Paolini 1999" TYPE="JOURNAL_ARTICLE">
<AU>Paolini M, Pozzetti L, Pedulli GF, Marchesi E, Cantelli-Forti G</AU>
<TI>The nature of prooxidant activity of vitamin C</TI>
<SO>Life Sciences</SO>
<YR>1999</YR>
<VL>64</VL>
<NO>23</NO>
<PG>PL 273-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10372660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paolini-2003" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Paolini 2003" TYPE="JOURNAL_ARTICLE">
<AU>Paolini M, Abdel-Rahman SZ, Sapone A, Pedulli GF, Perocco P, Cantelli-Forti G, et al</AU>
<TI>Beta-carotene: a cancer chemopreventive agent or a co-carcinogen?</TI>
<SO>Mutation Research</SO>
<YR>2003</YR>
<VL>543</VL>
<NO>3</NO>
<PG>195-200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12787812"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Papas-1999" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Papas 1999" TYPE="BOOK">
<AU>Papas A</AU>
<SO>Antioxidant Status, Diet, Nutrition and Health</SO>
<YR>1999</YR>
<PB>Boca Raton FL: CRC: Press</PB>
<CY>London, New York, Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papp-2007" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Papp 2007" TYPE="JOURNAL_ARTICLE">
<AU>Papp LV, Lu J, Holmgren A, Khanna KK</AU>
<TI>From selenium to selenoproteins: synthesis, identity, and their role in human health</TI>
<SO>Antioxidants &amp; Redox Signaling</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>7</NO>
<PG>775-806</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17508906"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patel-1998" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Patel 1998" TYPE="JOURNAL_ARTICLE">
<AU>Patel T, Roberts LR, Jones BA, Gores GJ</AU>
<TI>Dysregulation of apoptosis as a mechanism of liver disease: An overview</TI>
<SO>Seminars in Liver Disease</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>105-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9606808"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peto-1981" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Peto 1981" TYPE="JOURNAL_ARTICLE">
<AU>Peto R, Doll R, Buckley JD, Sporn MB</AU>
<TI>A dietary carotene materially reduces human cancer rates?</TI>
<SO>Nature</SO>
<YR>1981</YR>
<VL>290</VL>
<NO>5803</NO>
<PG>201-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7010181"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pocock-1991" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Pocock 1991" TYPE="BOOK">
<AU>Pocock SJ</AU>
<SO>Clinical Trials. A Practical Approach</SO>
<YR>1991</YR>
<PB>John Wiley and Sons</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Podmore-1998" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Podmore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J</AU>
<TI>Vitamin C exhibits pro-oxidant properties</TI>
<SO>Nature</SO>
<YR>1998</YR>
<VL>392</VL>
<NO>6676</NO>
<PG>559</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9560150"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poppel-1997" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Poppel 1997" TYPE="JOURNAL_ARTICLE">
<AU>Poppel G, Berg H</AU>
<TI>Vitamins and cancer</TI>
<SO>Cancer Letters</SO>
<YR>1997</YR>
<VL>114</VL>
<NO>1-2</NO>
<PG>195-202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9103291"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Potter-1999" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Potter 1999" TYPE="JOURNAL_ARTICLE">
<AU>Potter JD</AU>
<TI>Colorectal cancer: molecules and populations</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>11</NO>
<PG>916-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10359544"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Radimer-2004" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Radimer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF</AU>
<TI>Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2004</YR>
<VL>160</VL>
<NO>4</NO>
<PG>339-49</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15286019"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rayman-2000" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Rayman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rayman M</AU>
<TI>The importance of selenium to human health</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9225</NO>
<PG>233-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10963212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rayman-2005" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Rayman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rayman MP</AU>
<TI>Selenium in cancer prevention: a review of the evidence and mechanism of action</TI>
<SO>The Proceedings of the Nutrition Society</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>4</NO>
<PG>527-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16313696"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2003" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2003" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2003</YR>
<EN>4.2 for Windows</EN>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salganik-2001" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Salganik 2001" TYPE="JOURNAL_ARTICLE">
<AU>Salganik RI</AU>
<TI>The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>5 Suppl</NO>
<PG>464S-72S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11603657"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sasaki-2006" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Sasaki 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sasaki Y</AU>
<TI>Does oxidative stress participate in the development of hepatocellular carcinoma?</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>41</VL>
<NO>12</NO>
<PG>1135-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17287893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SCF-2003" MODIFIED="2008-05-24 17:01:18 +0100" MODIFIED_BY="[Empty name]" NAME="SCF 2003" TYPE="OTHER">
<AU>European Commission Scientific Committee on Food</AU>
<TI>Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin E</TI>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schrauzer-1977" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Schrauzer 1977" TYPE="JOURNAL_ARTICLE">
<AU>Schrauzer GN, White DA, Schneider CJ</AU>
<TI>Cancer mortality correlation studies. III. Statistical association with dietary selenium intakes</TI>
<SO>Bioinorganic Chemistry</SO>
<YR>1977</YR>
<VL>7</VL>
<NO>1</NO>
<PG>35-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="856292"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="7823387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2007" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 2007" TYPE="JOURNAL_ARTICLE">
<AU>Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M</AU>
<TI>Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress respiration and increasing oxidative stress</TI>
<SO>Cell Metabolism</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>4</NO>
<PG>280-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17908557"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1996" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Schwartz 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz JL</AU>
<TI>The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth</TI>
<SO>Journal of Nutrition</SO>
<YR>1996</YR>
<VL>126</VL>
<NO>4 Suppl</NO>
<PG>1221S-7S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8642460"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Seifried-2003" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Seifried 2003" TYPE="JOURNAL_ARTICLE">
<AU>Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA</AU>
<TI>The antioxidant conundrum in cancer</TI>
<SO>Cancer Research</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>15</NO>
<PG>4295-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12907593"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharma-2004" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sharma N, Trope B, Lipman TO</AU>
<TI>Vitamin supplementation: what the gastroenterologist needs to know</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>10</NO>
<PG>844-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15492599"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharp-1998" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Sharp 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sharp SJ</AU>
<TI>Meta­analysis regression</TI>
<SO>Stata Technical Bulletin</SO>
<YR>1998</YR>
<VL>42</VL>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shimoda-1994" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Shimoda 1994" TYPE="JOURNAL_ARTICLE">
<AU>Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, et al</AU>
<TI>Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis</TI>
<SO>Cancer Research</SO>
<YR>1994</YR>
<VL>54</VL>
<NO>12</NO>
<PG>3171-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8205535"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sies-1985" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sies 1985" TYPE="BOOK_SECTION">
<AU>Sies H</AU>
<TI>Introductory remarks</TI>
<SO>Oxidative Stress</SO>
<YR>1985</YR>
<PG>1-7</PG>
<ED>Sies H</ED>
<PB>Academic Press</PB>
<CY>Orlando</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sihvo-2002" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Sihvo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sihvo EI, Salminen JT, Rantanen TK, Ramo OJ, Ahotupa M, Farkkila M, et al</AU>
<TI>Oxidative stress has a role in malignant transformation in Barrett's oesophagus</TI>
<SO>International Journal of Cancer</SO>
<YR>2002</YR>
<VL>102</VL>
<NO>6</NO>
<PG>551-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12447994"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Slatore-2007" MODIFIED="2008-05-24 16:59:19 +0100" MODIFIED_BY="[Empty name]" NAME="Slatore 2007" TYPE="JOURNAL_ARTICLE">
<AU>Slatore CG, Littman AJ, Au DH, Satia JA, White E</AU>
<TI>Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>5</NO>
<PG>524-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoner-2007" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Stoner 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stoner GD, Wang LS, Chen T</AU>
<TI>Chemoprevention of esophageal squamous cell carcinoma</TI>
<SO>Toxicology and Applied Pharmacology</SO>
<YR>2007</YR>
<VL>224</VL>
<NO>3</NO>
<PG>337-49</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17475300"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stranges-2007" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Stranges 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al</AU>
<TI>Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>147</VL>
<NO>4</NO>
<PG>217-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17620655"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sugiyama-2004" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Sugiyama 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sugiyama T</AU>
<TI>Development of gastric cancer associated with Helicobacter pylori infection</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>Suppl 1</NO>
<PG>S12-S20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15309509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tabor-1999" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Tabor 1999" TYPE="JOURNAL_ARTICLE">
<AU>Tabor E, Di Bisceglie AM</AU>
<TI>Hepatitis B. Hepatocellular carcinoma</TI>
<SO>Clinics in Liver Disease</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>2</NO>
<PG>327-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takachi-2007" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Takachi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Takachi R, Inoue M, Ishihara J, Kurahashi N, Iwasaki M, Sasazuki S, et al</AU>
<TI>Fruit and vegetable intake and risk of total cancer and cardiovascular disease: Japan Public Health Center-Based Prospective Study</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2007</YR>
<VL>167</VL>
<NO>1</NO>
<PG>59-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takeda-2002" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Takeda 2002" TYPE="JOURNAL_ARTICLE">
<AU>Takada M, Ku Y, Habara K, Ajiki T, Suzuki Y, Kuroda Y</AU>
<TI>Inhibitory effect of epigallocatechin-3-gallate on growth and invasion in human biliary tract carcinoma cells</TI>
<SO>World Journal of Surgery</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>6</NO>
<PG>683-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12053219"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tamimi-2002" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Tamimi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tamimi RM, Lagiou P, Adami HO, Trichopoulos D</AU>
<TI>Prospect for chemoprevention of cancer</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2002</YR>
<VL>251</VL>
<PG>286-300</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11952879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tzonou-1996" MODIFIED="2008-05-24 16:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Tzonou 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tzonou A, Lipworth L, Garidou A, Signorello LB, Lagiou P, Hsieh C, et al</AU>
<TI>Diet and risk of esophageal cancer by histologic type in a low-risk population</TI>
<SO>International Journal of Cancer</SO>
<YR>1996</YR>
<VL>68</VL>
<NO>3</NO>
<PG>300-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8903470"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-USPSTF-2003" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="USPSTF 2003" TYPE="JOURNAL_ARTICLE">
<AU>U.S. Preventive Services Task Force</AU>
<TI>Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12834319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vivekananthan-2003" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Vivekananthan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ</AU>
<TI>Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9374</NO>
<PG>2017-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12814711"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Webb-2007" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Webb 2007" TYPE="JOURNAL_ARTICLE">
<AU>Webb GP</AU>
<TI>Nutritional supplements and conventional medicine; what should the physician know?</TI>
<SO>The Proceedings of the Nutrition Society</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>4</NO>
<PG>471-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17961267"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Willcox-2004" MODIFIED="2008-05-24 16:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Willcox 2004" TYPE="JOURNAL_ARTICLE">
<AU>Willcox JK, Ash SL, Catignani GL</AU>
<TI>Antioxidants and prevention of chronic disease</TI>
<SO>Critical Reviews in Food Science and Nutrition</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>4</NO>
<PG>275-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15462130"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williamson-2005" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Williamson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Williamson PR, Gamble C, Altman DG, Hutton JL</AU>
<TI>Outcome selection bias in meta-analysis</TI>
<SO>Statistical Methods in Medical Research</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>5</NO>
<PG>515-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16248351"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Woo-2007" MODIFIED="2008-05-24 16:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Woo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Woo JJ</AU>
<TI>Adverse event monitoring and multivitamin-multimineral dietary supplements</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2007</YR>
<VL>85</VL>
<NO>1</NO>
<PG>323S-4S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17209219"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-World-Bank-2006" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="World Bank 2006" TYPE="OTHER">
<TI>World Bank List of Economies (July 2006)</TI>
<SO>http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS</SO>
<YR>(accessed 31 October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yates-2007" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Yates 2007" TYPE="JOURNAL_ARTICLE">
<AU>Yates MS, Kensler TW</AU>
<TI>Keap1 eye on the target: chemoprevention of liver cancer</TI>
<SO>Acta Pharmacologica Sinica</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>9</NO>
<PG>1331-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17723167"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ziegler-1989" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NAME="Ziegler 1989" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler RG</AU>
<TI>A review of epidemiologic evidence that carotenoids reduce the risk of cancer</TI>
<SO>Journal of Nutrition</SO>
<YR>1989</YR>
<VL>119</VL>
<NO>1</NO>
<PG>116-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2643694"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bjelakovic-2004a" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bjelakovic 2004a" TYPE="OTHER">
<AU>Bjelakovic G, Nikolova D, Simonetti RG, Gluud C</AU>
<TI>Antioxidant supplements for preventing gastrointestinal cancers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004, Issue 4. Art. No.: CD004183. DOI: 10.1002/14651858.CD004183.pub2</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bjelakovic-2004b" MODIFIED="2008-05-24 16:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bjelakovic 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Bjelakovic G, Nikolova D, Simonetti RG, Gluud C</AU>
<TI>Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9441</NO>
<PG>1219-28</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15464182"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-ATBC-2003">
<CHAR_METHODS>
<P>Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC). </P>
<P>Randomised, double-blind, placebo-controlled trial with two-by-two factorial design. </P>
<P>Generation of the allocation sequence: adequate, centrally by computer. Randomisation performed in blocks of eight within each of the study areas. </P>
<P>Allocation concealment: adequate, coded capsule packs maintained centrally. </P>
<P>Blinding: adequate, identical placebo capsules. </P>
<P>Follow-up: adequate, no losses to follow-up. </P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland. Number of participants randomised: 29,133 males. </P>
<P>Inclusion criteria: male smokers (five or more cigarettes daily), aged 50 to 69 years, averaged 57.2 years of age at study entry, who lived in south-western Finland. </P>
<P>Exclusion criteria: men with a prior cancer or with other serious illness, or who used vitamin E, vitamin A, or beta-carotene supplements in excess of predefined doses (&gt; 20 mg, &gt; 20000 IU, or &gt; 6 mg, respectively), or anticoagulants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned in four groups to receive: </P>
<P>group 1: alpha-tocopherol 50 mg (n = 7286); <BR/>group 2: beta-carotene 20 mg (n = 7282); <BR/>group 3: alpha-tocopherol and beta-carotene, (n = 7278); <BR/>group 4: placebo (n = 7287); daily for five to eight years (median 6.1 years). </P>
<P>All participants took a single capsule daily. The four trial intervention groups were well balanced for all baseline characteristics evaluated. The two-by-two factorial design allowed assessment of the two intervention agents independently, with one-half of participants receiving alpha-tocopherol (n = 14,564) and the other half not (n = 14,569); similarly, half of the participants received beta-carotene (n = 14,560) and half did not (n = 14,573). The study was conducted between 1985 and 1993. The active intervention continued through April 30, 1993 and postintervention follow-up until April 30, 2001. Mean follow-up time was 14.1 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure was: incidence of lung cancer.</P>
<P>Secondary outcome measures were: occurrence of other major cancers, overall and cause specific mortality, and occurrence of other diseases.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was assessed by counts of the remaining capsules at each visit, by measurement of serum alpha-tocopherol and beta-carotene levels after three years of supplementation, and by measurements in random serum samples throughout the study. Compliance with treatment was excellent with four out of five active participants taking more than 95% of the scheduled capsules. Dropout rate and compliance were similar between all four groups. All capsules were supplied by Hoffmann-La Roche, Basel, Switzerland. Additional information received through personal communication with the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CARET-2004">
<CHAR_METHODS>
<P>The Beta-Carotene and Retinol Efficacy Trial (CARET). </P>
<P>Randomised, double-blind, placebo-controlled trial with two-by-two factorial design in a pilot phase and then one-by-one. </P>
<P>Generation of the allocation sequence: adequate, permuted block design with random block size chosen uniformly among 8, 10, 12, 14, and 16. </P>
<P>Allocation concealment: adequate, locked central database with the link between study identifier and intervention assignment; all data analyses were performed centrally; the analyses that involved intervention assignment were performed only by the Co-ordinating Center's statisticians using coded intervention assignment unknown to the statisticians; analyses involving the coded intervention assignments were seen only by CARET's Data and Safety Monitoring Board, Co-ordinating Center statisticians, and a single CARET investigator who saw no participants. </P>
<P>Blinding: adequate, identical placebo capsules provided by a sponsor. </P>
<P>Follow-up: adequate. The losses to follow-up were less than 2% at the end of treatment. </P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America. Number of participants randomised: 18314; 12025 males and 6289 females. </P>
<P>Inclusion criteria: smokers, former smokers, and workers exposed to asbestos at high risk of developing lung cancer. A total of 4060 male workers, mean age 57 years, exposed to asbestos and 14254 heavy smokers (44% of whom were women), mean age 58 years, were randomised. The participants agreed to limit their supplemental intake of vitamin A to less than 5500 IU per day and to take no supplemental beta-carotene.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>CARET builds on the experience of two pilot studies performed in Seattle (1985-1988). The first pilot study initiated a phase III trial of the safety and efficacy of the study vitamins in 816 asbestos-exposed participants randomised to a daily combination of 15 mg 13-carotene and 25,000 IU retinol or a placebo medication. Participants were eligible up to age 74 and were not required to have a history of cigarette smoking; otherwise, the eligibility criteria were the same as for the asbestos-exposed population in CARET. </P>
<P>The second pilot study was a phase II trial of the comparative safety of the study vitamins in heavy smokers. The eligibility criteria were identical to those for heavy smokers in CARET. Overall 539 men and 490 women were randomised to one of four intervention groups:</P>
<P>group 1: a daily combination of 30 mg 13-carotene and 25,000 IU retinol; </P>
<P>group 2: 30 mg 13-carotene only; </P>
<P>group 3: 25,000 IU retinol only; </P>
<P>group 4: placebo medication. </P>
<P>All 1845 participants in the two pilot studies continue to be followed for outcomes in CARET, together with approximately 16,000 additional participants.</P>
<P>Participants of CARET trial were randomly assigned to receive: </P>
<P>group 1: combination of 30 mg beta-carotene and 25,000 IU vitamin A (n = 9420); </P>
<P>group 2: placebo, (n = 8894). </P>
<P>Both formulations were given as capsules. Beta-carotene beadlets were combined with retinyl palmitate in a single capsule and dispensed in bottles, which were weighed and their content checked. <BR/>The design projected active intervention until late 1997. </P>
<P>The CARET active intervention was stopped 21 months earlier because of clear evidence of no benefit and substantial evidence of possible harm. </P>
<P>The average duration of follow-up was 10.0 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure was: the occurrence of lung cancer.</P>
<P>Other outcomes reported are: mortality rates and occurrence of other cancers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance was assessed by weighing the returned bottles to estimate the number of capsules remaining (in 85% of the assessments), or by relying on the participants own estimates (in 15% of the assessments).</P>
<P>Compliance with treatment was excellent. Among the active participants, the mean rate of capsule consumption was 93% through five years of follow-up, with no significant differences between the treatment groups. Participants who stopped receiving trial vitamins for any reason other than death were defined as inactive participants and were still followed for outcomes and counted in the analysis. As of December 15, 1995 ascertainment of vital status for more than 98% was complete.</P>
<P>Active agents and placebos were purchased from Hoffmann-La Roche and formulated by Tischon Corporation. </P>
<P>Data were extracted from the primary publication, but additional information was received through personal communication with the authors.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Correa-2000">
<CHAR_METHODS>
<P>Randomised, controlled, partially double-blind, chemoprevention trial with two-by-two-by-two factorial design. </P>
<P>Generation of the allocation sequence: adequate, computer-generated lists. Participants were randomly assigned in a single step, using a permuted block design, to one of eight different treatment regimens. </P>
<P>Allocation concealment: adequate, coded capsules. </P>
<P>Blinding: adequate, using identical placebo capsules. </P>
<P>Follow-up: adequate, the average rate of loss was 4.3% per year over the six-year trial. Two hundred twenty-one participants withdrew from the study before their 72-month evaluation: 102 quitted treatment, 59 were lost to follow-up, 34 dropped out of the study because of pregnancy and other medical conditions, 18 died of causes unrelated to gastric cancer, and eight developed cancer other than gastric cancer. In one participant, the 72-month biopsy specimen was inadequate for histologic evaluation and determination of outcome. A total of 684 participants came to the 36-month biopsy; of those, 92% (631) came for the 72-month biopsy, there was a dropout rate of 2.6% per year for the last three years of the trial. Overall 24 participants from the placebo group, 25 from anti-Helicobacter pylori (anti-HP), 34 from the beta-carotene (BC), 23 from the ascorbic acid (AA), 20 from the anti-HP + BC, 23 from anti-HP + AA, 17 from BC + AA, and 37 from anti-HP + BC + AA were lost to follow-up. </P>
<P>Intention-to-treat analysis: no. </P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Colombia.</P>
<P>Number of participants randomised: 976; 46% males, aged 29 to 69 years, mean age 51.1 years.</P>
<P>Inclusion criteria: preliminary histologic diagnosis of multifocal atrophic gastritis with or without intestinal metaplasia and dysplasia, good health.</P>
<P>Exclusion criteria: normal histology, non-atrophic gastritis, gastric cancer.</P>
<P>Before randomisation, participants were classified into one of three strata: atrophy (without metaplasia), intestinal metaplasia, or dysplasia according to baseline histologic diagnosis.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to a dietary supplement of beta-carotene (30 mg once per day) and/or ascorbic acid (1 g twice a day) or their corresponding placebos, for a six-year period. The prevalence of Helicobacter pylori infection among all gastric biopsy specimens was 97%. Anti-Helicobacter pylori treatment consisting of amoxicillin (500 mg three times per day), metronidazole (375 mg three times per day), and bismuth subsalicylate (262 mg three times per day) was given for 14 days to half of the study participants assigned randomly. This treatment was not blinded or placebo controlled because an appropriate placebo was not available for bismuth subsalicylate.</P>
<P>Participants were divided in eight treatment groups to receive: </P>
<P>group 1: placebo (n = 117); </P>
<P>group 2: anti-Helicobacter pylori treatment, which consisted of amoxicillin, metronidazole, and bismuth subsalicylate (n = 120); </P>
<P>group 3: beta-carotene (n = 117); </P>
<P>group 4: ascorbic acid (n = 130); </P>
<P>group 5: Helicobacter pylori treatment consisting of amoxicillin, metronidazole, and bismuth subsalicylate, and additionally beta-carotene (n = 126); </P>
<P>group 6: Helicobacter pylori treatment consisting of amoxicillin, metronidazole, and bismuth subsalicylate, and additionally ascorbic acid (n = 111); </P>
<P>group 7: beta-carotene and ascorbic acid (n = 121); </P>
<P>group 8: Helicobacter pylori treatment, consisting of amoxicillin, metronidazole, and bismuth subsalicylate, and additionally beta-carotene and ascorbic acid (n = 134). </P>
<P>Gastric biopsy specimens taken at baseline were compared with those taken at 72 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: progression, no change or regression of gastric precancerous lesions (preliminary histologic diagnosis of multifocal atrophic gastritis with or without intestinal metaplasia and dysplasia). For our purposes we extracted data about the occurrence of gastric cancer.</P>
<P>We have also extracted data on overall mortality for all antioxidants as well as for beta-carotene and vitamin C.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was constantly encouraged and monitored by a social worker who interviewed the participants and recorded pill counts every three months. In addition, blood levels of beta-carotene and ascorbic acid were measured every three months in a 20% random sample of the participants. Compliance with treatment among participants who completed the study was high for all intervention modalities (mean compliance for ascorbic acid, 91.8%; for beta-carotene, 92.3%; and for anti-Helicobacter pylori treatment, 99.1%). Active medication and placebos were provided like identical coded tablets by Hoffmann-La Roche Inc. (Nutley, NJ). Additional information received through personal communication with the authors. Data were extracted from the article: Correa, et al. Re: Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute 2001; 93: 559.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HOPE-TOO-2005">
<CHAR_METHODS>
<P>The Heart Outcomes Prevention Evaluation Study (HOPE).</P>
<P>Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.</P>
<P>Generation of the allocation sequence: adequate, by computer.</P>
<P>Allocation concealment: adequate, randomisation is done by a telephone call to a central office. After receipt of appropriate baseline data over the telephone, the patient is randomised.</P>
<P>Blinding: adequate, identical placebo capsules. </P>
<P>Follow-up: adequate. At the end of the initial HOPE trial, vital status was ascertained for 9535 (99.9%) of 9541 randomised patients. At the end of the HOPE-TOO trial, vital status was ascertained for 4724 (99.8%) of 4732 patients who participated in the extension trial.</P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: International, North America, South America, Europe (19 countries)</P>
<P>Number of participants randomised: 9541; 6996 males and 2545 females, 55 years old or older, mean age 66 years.</P>
<P>Inclusion criteria: 55 years or older, had a history of CV disease (coronary artery disease, stroke or peripheral arterial disease) or diabetes in the presence of at least one additional CV risk factor (total cholesterol &gt; 5.2 mmol/l, HDL cholesterol =0.9 mmol/l, hypertension, defined as use of medications to treat high blood pressure, or blood pressure at time of recruitment &gt; 160 mmHg systolic or &gt; 90 mmHg diastolic, known microalbuminuria, or current smoking).</P>
<P>Exclusion criteria: Dipstick-positive proteinuria, diabetic nephropathy, serum creatinine &gt; 200 mmol/l, history of congestive heart failure, or known left ventricular ejection fraction (&lt; 40%), hyperkalemia, uncontrolled hypertension, myocardial infarction, unstable angina or stroke within 1 month before trial enrollment, and use of or intolerance to vitamin E or angionetsin-converting-enzyme (ACE) inhibitors.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomly assigned to receive: </P>
<P>group 1: 400 IU of vitamin E (RRR-a-tocopheryl acetate) daily from natural sources (n = 4761);</P>
<P>group 2: matching placebo (n = 4780); </P>
<P>group 3: an angiotensin-converting&#8211;enzyme inhibitor (ramipril 10 mg) (n = 4645);</P>
<P>group 4: matching placebo (n = 4652), </P>
<P>once a day for a four to six years, mean 4.5 years. </P>
<P>The Heart Outcomes Prevention Evaluation [HOPE] trial was conducted between December 21, 1993, and April 15, 1999. The Heart Outcomes Prevention was extended (HOPE-The Ongoing Outcomes [HOPE-TOO]) between April 16, 1999, and May 26, 2003. Of the initial 267 HOPE centres that had enrolled 9541 patients, 174 centres participated in the HOPE-TOO trial. Of 7030 patients enrolled at these centres, 916 were deceased at the beginning of the extension of the trial, 1382 refused participation, 3994 continued to take the study intervention, and 738 agreed to passive follow-up. The mean follow-up period was 7 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: cancer occurrence, cancer deaths, major cardiovascular events (myocardial infarction, stroke, and cardiovascular death). </P>
<P>The secondary outcome measures were: unstable angina, congestive heart failure, revascularization or amputation, death from any cause, complications of diabetes, and cancer.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was checked by measuring the plasma vitamin E levels in randomly selected patients. The rate of compliance with the assigned regimen was high throughout the study. The percentages of patients who were taking vitamin E in the vitamin E and placebo groups, respectively, were 94.2% and 1.0% at 1 year, 93.3% and 1.7% at 2 years, 91.3% and 2.0% at 3 years, 90.2% and 2.7% at 4 years, and 89.2% and 3.4% at the final visit. There was no significant interaction between the study treatments (ramipril and vitamin E) for the primary, secondary, and other study outcomes. At the end of the initial HOPE trial, vital status was ascertained for 9535 (99.9%) of 9541 randomised patients. Funded by the Medical Research Council of Canada, Natural Source Vitamin E Association, Negma, Hoechst-Marion Roussel, AstraZeneca, King Pharmaceuticals, and the Heart and Stroke Foundation of Ontario.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HPS-2002">
<CHAR_METHODS>
<P>Heart Protection Study. </P>
<P>Randomised, double-blind, placebo-controlled trial with two-by-two factorial design. </P>
<P>Generation of the allocation sequence: adequate, computer generated random numbers. </P>
<P>Allocation concealment: adequate, central telephone randomisation system. </P>
<P>Blinding: adequate, identical placebo capsules. </P>
<P>Follow-up: adequate. 99.7% of the participants were with complete follow-up for average of 5 years in vitamins allocated group and 99.6% in placebo group. Overall, 25 participants allocated to vitamins group and 35 participants to placebo group were lost to follow-up. </P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United Kingdom.</P>
<P>Number of participants randomised: 20536; 15454 males and 5082 females at an age 40 to 80 years.</P>
<P>Inclusion criteria: adults with coronary disease, other occlusive arterial disease, or diabetes, and non-fasting blood total cholesterol concentrations of at least 3.5 mmol/L.</P>
<P>Exclusion criteria: other life-threatening conditions, such as chronic liver disease, severe renal disease, severe heart failure, severe chronic airways disease, or diagnosed cancer (other than non-melanoma skin cancer). In addition, anyone already taking high-dose vitamin E supplements or in whom such supplements were considered indicated, was not to be randomised.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive: </P>
<P>group 1: 600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily (n = 10,269); or </P>
<P>group 2: matching placebo capsules (n = 10,267), daily during the scheduled 5-year treatment period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: major coronary events (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was assessed at each follow-up by reviewing the calendar packed tablets remaining and for those who had stopped, the reasons for doing so were sought. An average of 83% of the participants in each treatment group remained compliant during the scheduled five-year treatment period. To assess the effects of the treatment allocation on blood concentrations of the vitamins being studied, assays were performed in non-fasting samples collected from about 5% of the participants at the initial screening visit and at an average of about three years of follow-up (the approximate mid-point of the study). </P>
<P>Vitamins were provided by Roche.</P>
<P>Data were extracted from the primary publication, but additional information was received through personal communication with the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2000">
<CHAR_METHODS>
<P>Randomised, placebo-controlled trial with parallel group design.</P>
<P>Generation of the allocation sequence: unclear, not described.</P>
<P>Allocation concealment: unclear, not described.</P>
<P>Blinding: adequate, matching placebo.</P>
<P>Follow-up: adequate, no losses to follow-up.</P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China.</P>
<P>Number of participants randomised:<BR/>2065 males, aged 20 to 65 years. </P>
<P>Inclusion criteria:<BR/>males living in Qidong, Jiangsu province (a high risk area for liver cancer), HBsAg positive, AFP negative with normal liver function.</P>
<P>Exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive:</P>
<P>group 1: sodium selenite 0.5 mg (228 µg of selenium) (n = 1112); </P>
<P>group 2: placebo (n = 953); </P>
<P>per day for three years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure was the occurrence of liver cancer.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment: good, between 81.5% in the first year and 79.8% in the third year.</P>
<P>Data were extracted from the primary publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2004">
<CHAR_METHODS>
<P>Randomised double-blind, placebo-controlled trial with parallel group design.</P>
<P>Generation of the allocation sequence: unclear, not reported.</P>
<P>Allocation concealment: unclear, not reported. The whole process was conducted by the double-blind method.</P>
<P>Blinding: adequate, identical looking placebo capsules and placebo tablets.</P>
<P>Follow-up: inadequate.</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China.</P>
<P>Number of participants randomised: 5033, aged 34 to 74 years, 3250 men and 1783 women.</P>
<P>Inclusion criteria: 34 to 74 years old, stomach disorder, or tumours in other family members, or smoking and/or alcohol consumption.</P>
<P>Exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive:</P>
<P>group 1: selenium (sodium selenite) 100 µg and synthetic allitridum 200 mg (n = 2526);</P>
<P>group 2: placebo (n = 2507);</P>
<P>Each participant took orally two soft intestinal dissolving capsules that contained synthetic allitridum every day and one table of sodium selenite which contained selenium every other day for one month of each year during two years and at the same time each participant in the control group was given two placebo capsules which contained corn oil and one starch table of identical appearance to that in intervention group. Participants were treated from 1989 to 1991, and followed during next five years (1192 to 1997), overall 7 years.</P>
<P>Allitridum is an extract of garlic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure was the occurrence of gastric cancer.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was checked by interviews face to face and by measuring thiamine concentration in the urine.</P>
<P>Compliance with treatment was excellent. Mean compliance estimated for the taking of the medication was 93%.</P>
<P>Synthetic allitridum was made from in Dongfeng Pharmaceutical Factory, Lianyuguang, China, and the soft intestinal dissolving capsule of allitridum turned out in the Weihai Branch Factory of Shangdong Xinhua Pharmaceutical Factory, Zibo, China. The tables of sodium seletine came from the Office of Shangdong Endemic Diseases, and were manufactured by Hezhe Pharmaceutical Factory, Hezhe, China.</P>
<P>Authors reported that the major side effects of the drugs were garlic-odour and heartburn, but did not provide numbers.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Munoz-1985">
<CHAR_METHODS>
<P>Randomised, double-blind, placebo-controlled trial with parallel group design.</P>
<P>Generation of the allocation sequence: unclear, not described.</P>
<P>Allocation concealment: adequate, the capsules were packed individually on two and three blister charts, respectively. On the reverse side of the blisters was self-adhesive label with the individual's study number. The participants, barefoot doctors, and field supervisors were unaware of the treatment assignment. The code for the treatment assignment was not opened until the histological evaluation was completed.</P>
<P>Blinding: adequate, identical-looking gelatin capsules.</P>
<P>Follow-up: adequate, 567 persons (93%) attended the final endoscopic examination.</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China, Huixian, Henan Province.</P>
<P>Number of participants randomised:<BR/>610, 50% males, aged 35 to 64 years.</P>
<P>Inclusion criteria:<BR/>inhabitants of Huixian, Henan province of China with high risk of oesophageal cancer.</P>
<P>Exclusion criteria:<BR/>none stated.</P>
<P>In September, 1983 a random population sample was drawn from two production brigades (Meng Zhuang and Dong Xia Feng) in Huixian, Henan province.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive: </P>
<P>group 1: 15 mg (50,000 IU) retinol, 200 mg riboflavine, and 50 mg zinc (as zinc gluconate), (n = 305);</P>
<P>group 2: matching placebo (n = 305).</P>
<P>once a week for 13.5 months.</P>
<P>The final examination was in October/November 1984, 13.5 months after the beginning of the trial and included endoscopy. Two biopsy specimens were taken at random from the middle and lower third of the oesophagus, and additional ones from any macroscopic lesion. Of 567 persons (93%) who attended the final endoscopic examination, histological slides were evaluated from 552 persons (90.5%). In the other 15 the available material was inadequate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were the prevalence of precancerous lesions of the oesophagus, as well as occurrence of oesophageal cancer.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>In the early stages of the trial compliance was assessed by vitamin measurements in blood two months after the start of the trial from a sample of 100 participants stratified by age, sex, production brigade, and treatment. Follow-up forms and remaining capsules were inspected every two months by fields supervisors. Compliance was excellent. The final examination on 567 (93%) participants included oesophagoscopy and at least two biopsies.</P>
<P>All vitamin and placebo preparations were provided by Hoffmann-La Roche, Basel, Switzerland.</P>
<P>Data were extracted from the primary publication.</P>
<P>During the trial one patient died, but authors did not report from which arm and we were unable to obtain this information.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-NIT1-1993">
<CHAR_METHODS>
<P>Nutrition Intervention Trial (NIT); The General Population Trial, in Linxian, China. </P>
<P>Randomised, placebo-controlled trial with one-half replicate of a two-by-two-by-two-by-two factorial design. </P>
<P>Generation of the allocation sequence: adequate, random numbers generated by independent data management centre in USA. The randomisation sequence was known only at data management centre until the intervention ended.</P>
<P>Allocation concealment: adequate, sequentially numbered coded bottles. Pill containers were labelled in the USA at the pill distribution centre. </P>
<P>Blinding: adequate, identical placebo pills.</P>
<P>Follow-up: inadequate, losses to follow-up not reported. </P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China, Henan Province of north central China, Linxian County. Number of participants randomised: 29584; 45% males, aged 40 to 69 years.</P>
<P>Inclusion criteria: residents willing to take part in a multi-year, daily pill-taking regimen. </P>
<P>Exclusion criteria: debilitating disease or prior oesophageal or stomach cancer.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive one of eight vitamin/mineral supplement combinations in the form of individual oral tablets. The eight intervention groups (each with 3677 to 3709 participants) were derived from a one-half replicate of a two-by-two-by-two-by-two factorial design which allowed to asses four factors (ie, nutrient combinations) in a single experiment. The four factors designated by the letters A, B, C, D were: A - retinol (as palmitate) 5000 IU, zinc (as zinc oxide) 22.5 mg; B - riboflavin (vitamin B2) 3.2 mg and niacin (vitamin B3) 40 mg; C - ascorbic acid 120 mg and molybdenum (as molybdenum yeast complex) 30 µg; D - beta carotene 15 mg, selenium (as selenium yeast) 50 µg, and alpha-tocopherol 30 mg. Doses of each nutrient varied from one to two times US Recommended Daily Allowances (RDAs). The eight intervention groups were defined by the following combinations of supplements; AB, AC, AD, BC, BD, CD, ABCD, or placebo and packed in coded bottles containing a one-month supply. Bottles were distributed monthly beginning in March 1986 and continuing through May 1991, average 5.25 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: cancer occurence, cancer mortality, and overall mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with study treatment was assessed by monthly pill counts and biochemical measures. </P>
<P>Compliance was excellent throughout the study. The overall pill disappearance rate was 93% for all participants, with no difference by treatment group (range 92% to 93%) and little change during the trial. <BR/>All vitamin/mineral supplements and placebos were provided by Hoffmann-La Roche, Basel, Switzerland and Lederle Laboratories, Inc.</P>
<P>Data were extracted from the primary publication.</P>
<P>Additional information was received through personal communication with the authors. However, we did not receive information on gastrointestinal cancer occurrence per group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-NIT2-1993">
<CHAR_METHODS>
<P>The Dysplasia Trial. </P>
<P>Randomised, placebo-controlled trial with parallel group design. </P>
<P>Generation of the allocation sequence: adequate, random numbers generated by independent data management centre in USA. </P>
<P>Allocation concealment: adequate, sequentially numbered coded bottles. Pill containers were labelled in the USA at the pill distribution centre. </P>
<P>Blinding: adequate, identical placebo pills. </P>
<P>Follow-up: adequate, the morbidity and mortality follow-up rates were 99%. </P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculation: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China, Henan Province of north central China, Linxian County. Number of participants randomised: 3318; 1461 males and 1857 females at age 40 to 69 years, mean age 54 years. </P>
<P>Inclusion criteria: place of living in one of the three northern Linxian communes (Yaocun, Rencun, or Donggang), provided consent, diagnosis of oesophageal dysplasia on a balloon cytology examination. </P>
<P>Exclusion criteria: taking vitamins of any type regularly, or antitumour B (a traditional Chinese drug consisting of a mixture of six medical herbs), history of malignancy or other debilitating disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive:</P>
<P>group 1: 13 vitamins and 13 minerals (vitamin A (acetate) 10000 IU; vitamin<BR/> E (dl-alpha tocopherol acetate) 60 IU, vitamin C (ascorbic acid) 180 mg, vitamin B1 5 mg, vitamin B2 5.2 mg, vitamin B6 6 mg, vitamin B12 18 µg, vitamin D 800 IU; beta-carotene 15 mg, folic acid 800 µg, niacinamide 40 mg, biotin 90 µg, pantothenic acid 20 mg, calcium 324 mg, phosphorus 250 mg, iodine 300 µg, iron 54 mg, magnesium 200 mg, copper 6 mg, manganese 15 mg, potassium 15.4 mg, chloride 14 mg, chromium 30 µg, molybdenum 30 µg, selenium (sodium selenate) 50 µg, and zinc 45 mg (n = 1657);</P>
<P>group 2: placebo (n = 1661);</P>
<P>for a period of 6 years.</P>
<P>The doses were typically two to three times the US Recommended Daily Allowances (RDAs), but ranged from 0.26 to seven times the RDA depending on the vitamin or mineral. Each participant was given three pills daily, including one capsule beta-carotene or placebos and two tablets of vitamin/mineral supplement, or placebos.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: cancer occurrence, cancer mortality, and overall mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was assessed by counting unused pills for all trial participants and by assessing nutrient levels in blood collected from samples of individuals randomly selected without replacement every three months throughout the trial. Compliance with treatment was excellent. The overall pill disappearance rate was 94% in both groups with slight decline (from 96% in year 1 to 92% in year 6 in both groups) over the duration of the trial.</P>
<P>Data were extracted from the primary publication.</P>
<P>Active medications and placebos were provided: beta-carotene as Solatane by Hoffmann-La Roche, Inc., Nutley, N.Y., and vitamin/mineral supplement as Centrum Lederle Laboratories, Inc., Pearl River, N.Y.</P>
<P>Additional information was received through personal communication with the authors.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-NPCT-1996">
<CHAR_METHODS>
<P>Nutritional Prevention of Cancer Trial (NPCT).</P>
<P>Randomised, double-blind, placebo-controlled trial with parallel group design. </P>
<P>Generation of the allocation sequence: adequate, computer generated random numbers. </P>
<P>Allocation concealment: adequate, treatment group assignment was made centrally. The co-ordinating centre held all treatment information in blinded form. Medications were distributed using sealed pill bottles.</P>
<P>Blinding: adequate, identical placebo tablets.</P>
<P>Follow-up: adequate. At the end of the blinded period of treatment no participants were lost to vital follow-up, and only 7 participants (3 in the selenium group and 4 in the placebo group) declined to provide additional information about the illness.</P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America. Number of participants randomised: 1312; 75% males, aged 18 to 80 years, mean age 63 years. </P>
<P>Inclusion criteria: history of two or more basal cell skin cancers (BCC) or one squamous cell skin cancer (SCC), with one of this occurring within the year prior the randomisation, life expectancy of at least five years and no internal malignancies treated within the previous five years. </P>
<P>Exclusion criteria: history of significant liver or kidney disorders. Recruitment began on September 15, 1983 and continued each year through 1991.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomly assigned to receive: </P>
<P>group 1: 200 µg of selenium supplied in a 0.5 g high-selenium bakers yeast tablet (n = 653); </P>
<P>group 2: placebo (n = 659); </P>
<P>The end of a blinded period of treatment was on February 1, 1996. Mean length of treatment was 4.5 years and follow-up 7.4 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: incidences of basal cell and squamous cell carcinoma of the skin. In 1990 secondary outcome measures were identified, which included: total mortality and cancer mortality, as well as the incidence of the lung, colorectal, and prostate cancers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment: excellent, 79.3% of the participants (80.3% in the placebo group and 78.4% in the selenium group) missed taking a pill less than twice a month.</P>
<P>Trial medications were provided by Nutrition 21 (La Jolla, CA), through 1995 and by Cypress Systems (Fresno, CA) thereafter.</P>
<P>Data about the gastrointestinal cancer occurrence were extracted from the article: Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11(7):630-9.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PHS-1996">
<CHAR_METHODS>
<P>Physicians Health Study (PHS). </P>
<P>Randomised, double-blind, placebo-controlled trial with two-by-two factorial design. </P>
<P>Generation of the allocation sequence: adequate, by computer in blocks. </P>
<P>Allocation concealment: adequate, the shipping department sent out calendar packs (which were identical whether active or placebo) to individual participants depending on this code. All of the calendar packs were in coded boxes, supplied by the drug manufacturer, so that the shippers did not know which drug they were shipping. </P>
<P>Blinding: adequate, identical placebo capsules. </P>
<P>Follow-up: adequate. By December 31, 1995, the scheduled end of the trial, less than 1% of the participants were lost to follow up.</P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.</P>
<P>Number of participants randomised: 22071 US male physicians at age 40 to 84 years, mean age 53 years.</P>
<P>Inclusion criteria: US male physicians willing to take part in this trial. </P>
<P>Exclusion criteria: chronic liver disease or evidence of abnormal liver function, severe renal disease or evidence of impaired renal function, inflammatory muscle disease or evidence of muscle problems (creatine kinase &gt; 750 IU/L); concurrent treatment with cyclosporin, fibrates, or high-dose niacin; child-bearing potential; severe heart failure; some life-threatening condition other than vascular disease or diabetes (eg, severe chronic airways disease or any cancer other than non-melanoma skin cancer); or conditions that might limit long-term compliance (eg, severely disabling stroke, dementia, or psychiatric disorder).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physicians were randomly assigned to one of the four groups to receive:</P>
<P>group 1: active aspirin 325 mg on alternate days plus beta-carotene placebo; </P>
<P>group 2: active beta-carotene 50 mg on alternate days plus aspirin placebo;</P>
<P>group 3: both active agents; or</P>
<P>group 4: both placebos.</P>
<P>The randomised aspirin component of the trial was terminated early, on 25 January 1988. The beta-carotene component continued uninterrupted until its scheduled end in December 1995. </P>
<P>A total of 11036 physicians were assigned at random to receive beta-carotene and 11035 to receive beta-carotene placebo.</P>
<P>Time from randomisation to the end of the trial averaged 12 years, and time of follow-up 12.9 years.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: overall and within subgroups, occurrence of malignant neoplasms (except non melanoma skin cancer), incidence of cardiovascular disease, and overall mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was checked by random serum assessments obtained at unannounced visits to trial participants. Compliance with treatment excellent, the average per cent of pills taken was 97% in both the active and placebo groups. There was 85% compliance with beta-carotene treatment after five years and 78% after 12 years. The use of vitamin A supplements was reported by only 6% of the placebo group even by the end of trial. Active trial packs and matching placebos were provided by: aspirin (Bufferin) by Bristol Meyers; beta-carotene (Lurotin), BASF corporation. Additional information received through personal communication with the authors. Data were extracted from the article: Cook et al. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes and Control 2000; 11: 617-26, with extended follow-up of 12.9 years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Plummer-2007">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled, primary-prevention trial with parallel group design.</P>
<P>Generation of the allocation sequence: adequate, the random allocation sequence to determine treatment group was generated by Hoffmann-La Roche, using random permuted blocks of size eight.</P>
<P>Allocation concealment: adequate, all histologic diagnoses and assays on biologic samples were conducted blind to the treatment allocation. During the trial, the central study database at IARC did not contain data on treatment allocation. The data were added to the database after the trial had been completed.</P>
<P>Blinding: adequate, the placebo was prepared in the form of capsules identical to those containing the vitamins.</P>
<P>Follow-up: adequate, overall 302 participants from active and 278 participants from placebo group dropped-out during the trial. The number of participants who dropped out was slightly higher in the vitamin group than in the placebo group, but the difference was not statistically significant (P = 0.14, for difference of two proportions).</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Venezuela</P>
<P>Number of participants randomised: 1980, aged 35 to 69 years, 52.7% females.</P>
<P>Inclusion criteria: population at high risk for stomach cancer in general good health, and permanent residents of Tachira State.</P>
<P>Exclusion criteria: serious illness, including any type of cancer, those whose mental status made long-term adherence to the treatment regimen unlikely and pregnant women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive:</P>
<P>group 1: vitamin C (750 mg), vitamin E (600 mg), and beta-carotene (18 mg) (n = 990);</P>
<P>group 2: placebo (n = 990);</P>
<P>daily for 3 years.</P>
<P>The treatment was taken in the form of three capsules per day, one with each of the three main meals. Each capsule contained 250 mg vitamin C, 200 mg vitamin E, and 6 mg of beta-carotene, for a daily dose of 750 mg of vitamin C (12.5 times the recommended daily allowance), 600 mg vitamin E (20 times the recommended daily allowance), and 18 mg beta-carotene (considered the maximum dose if carotenoderma is to be avoided).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome of the trial was the progression and regression of precancerous lesions of the stomach, as determined by histologic findings.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance for the intervention group was confirmed by the pill counts and measuring the biochemical markers of supplementation. Excellent compliance was indicated by pill counts when participants returned for their vitamin pills: 91% of all containers were returned with less than 10% of pills. There were clear increases in beta-carotene and vitamin E levels in the treated group beyond the levels observed at baseline. In the placebo group, by contrast, no changes were observed. Participants who did not return for their supply of capsules were contacted first by telephone, then visited at home by social workers who enquired about the reasons for nonattendance, encouraged continuing participation, and provided the next month's supply of capsules.</P>
<P>Both vitamin capsules and placebo were supplied by Hoffman-La Roche.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SIT-2006">
<CHAR_METHODS>
<P>Shandong Intervention Trial</P>
<P>Randomised, double-blind, placebo controlled, primary prevention trial with stratified, factorial design 2x2x2 versus 2x2.</P>
<P>Generation of the allocation sequence: adequate, randomized treatment assignments were generated at Westat in the United States.</P>
<P>Allocation concealment: adequate, pill bottles bearing codes corresponding to assignments were then distributed to the study participants.</P>
<P>Blinding: adequate, using identical placebo capsules.</P>
<P>Follow-up: adequate, overall 15 participants from placebo and 19 participants from active intervention group were lost to follow-up. </P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China (Linqu County, Shandong Province). Number of participants randomised: 3411, 1753 men and 1658 women aged 35 to 64 years.</P>
<P>Inclusion criteria: participants aged 35 to 64 years willing to participate in 42-month study, baseline gastroscopy with biopsies, known Helicobacter pylori status. </P>
<P>Exclusion criteria: illness, bleeding disorders, cancers (except nonmelanoma skin cancer), heart failure, emphysema, renal or liver diseases, other life-threatening illnesses, allergy to penicillin or related antibiotics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were first divided on the basis of whether they showed serologic evidence of Helicobacter pylori infection at baseline (2285) or not (1126). Participants with serologic evidence of Helicobacter pylori at baseline were eligible to receive amoxicillin (1 g twice a day) and omeprazole (20 mg twice a day) in three capsules (two 500 mg amoxicillin and one 20 mg omeprazole) to be taken twice daily (before breakfast and dinner) for 2 weeks. Look-alike placebo capsules containing lactose and starch for amoxicillin and sucrose and starch for omeprazole were given to serologically positive controls and to all seronegative participants. Approximately 3 months after initial treatment for Helicobacter pylori, supplementation with 100 IU alpha-tocopherol, 250 mg vitamin C, and 37.5 µg selenium twice a day began its 39-month course. Participants received this mixture in one capsule, to be taken twice daily before or after breakfast and dinner. From December 1995 to May 1996, this mixture also contained beta-carotene (7.5 mg twice a day). Look-alike placebo capsules contained cellulose, lactose, and magnesium stearate.</P>
<P>In the garlic group, participants took two capsules twice a day before or after breakfast and dinner. Each capsule contains 200 mg Kyolic aged garlic extract and 1 mg steam-distilled garlic oil. To prepare the extract, the manufacturer sliced garlic cloves and soaks them in aqueous ethanol (about 20%) for over 18 months at room temperature. The extract is then filtered, concentrated, and dried. The look-alike placebo capsules contained cellulose, granulated sugar, caramel, and magnesium stearate. Bottles holding placebo capsules contained minute quantities of garlic oil so they would smell like garlic.</P>
<P>HP-seropositive at baseline (2258) entered 2x2x2 factorial of antibiotics, vitamins, and garlic. HP-seronegative at baseline (1126) entered 2x2 factorial trial of vitamins, and garlic.</P>
<P>Participants were randomised in 12 groups: </P>
<P>group 1: amoxicillin and omeprazole, garlic, vitamin and selenium (n = 286);</P>
<P>group 2: amoxicillin and omeprazole, garlic, vitamin and selenium placebo (n = 285);</P>
<P>group 3: amoxicillin and omeprazole, garlic placebo, vitamin and selenium (n = 286);</P>
<P>group 4: amoxicillin and omeprazole, garlic placebo, vitamin and selenium placebo (n = 285);</P>
<P>group 5: amoxicillin and omeprazole placebo, garlic, vitamin and selenium (n = 285);</P>
<P>group 6: amoxicillin and omeprazole placebo, garlic, vitamin and selenium placebo (n = 286);</P>
<P>group 7: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium (n = 286);</P>
<P>group 8: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium placebo (n = 286);</P>
<P>group 9: amoxicillin and omeprazole placebo, garlic; vitamin and selenium (n = 282);</P>
<P>group 10: amoxicillin and omeprazole placebo, garlic, vitamin and selenium placebo (n = 281);</P>
<P>group 11: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium (n = 281);</P>
<P>group 12: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium placebo (n = 282);</P>
<P>daily for 7.3 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: prevalence of dysplasia or gastric cancer, prevalence of severe chronic atrophic gastritis, intestinal metaplasia, dysplasia or gastric cancer, and average severity score. Secondary outcome measures were: rates of transition from baseline to final histopathologic states and the effects of treatments on these rates of transition; evidence of the effectiveness of amoxicillin and omeprazole in eradicating Helicobacter pylori, based on 13C-urea breath tests 3 months following treatment, on annual serology, and on a final pathologic examination of biopsies to look for Helicobacter pylori; and blood pressure at the time of the final examination.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was checked by measuring the plasma vitamin levels in randomly selected participants every 3 months and counting of the pills. Compliance with treatment was good. The average monthly proportion of participants taking all pills was 92.3%. Serum samples obtained from randomly selected participants demonstrate higher levels of vitamins C and E in participants assigned to vitamins 2 and higher levels of S-allylcysteine in those assigned to garlic preparation. (Wakunaga of America, Co., Ltd, Mission Viejo, CA) provided the garlic preparation, Astra (East Asia Region) provided amoxicillin and omeprazole; and Sino-American Shanghai-Squibb Pharmaceuticals, Ltd. provided vitamin and mineral supplement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SUVIMAX-2004">
<CHAR_METHODS>
<P>The SUpplementation en VItamines et Mine´raux AntioXydants (SU.VI.MAX) Study. </P>
<P>Randomised, double-blind, placebo-controlled, primary-prevention trial with parallel group design. </P>
<P>Generation of the allocation sequence: adequate, random treatment allocation was performed by block-sequence generation stratified by sex and age group by computer. </P>
<P>Allocation concealment: adequate, capsule boxes were labelled with the participant's number, using partitioned organisation to ensure total security of the blind study. </P>
<P>Blinding: adequate, identical placebo capsules. </P>
<P>Follow-up: adequate. Losses to follow-up; 5.4 % in the intervention group and 6.2% in the placebo group. Overall, 739 participants in the active and 828 participants in the placebo group were lost to follow-up. </P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculations: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: France. </P>
<P>Number of participants randomised: 13017 French adults, 5141 men and 7876 women, aged from 35 to 60 years, mean age 48.95 years. </P>
<P>Inclusion criteria: lack of disease likely to hinder active participation or threatened 5-year survival; acceptance of possibility to be given placebo and acceptance of the constraints of participation; lack of previous regular supplementation with any of the vitamins and minerals in the supplement provided and absence of extreme beliefs or behaviour regarding diet. </P>
<P>Exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive: group 1: beta-carotene 6 mg; vitamin C 120 mg; vitamin E 30 mg; selenium 100 µg; zinc 20 mg (n = 6481); group 2: placebo (n = 6536). All participants took a single daily capsule. Median follow-up time was 7.5 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: major fatal and nonfatal ischaemic cardiovascular events and cancer of any kind, except for the basal cell carcinoma of the skin. The secondary outcome measure was: all cause mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance for the intervention group was confirmed by measuring the biochemical markers of supplementation after 2 years and after 7 years for beta-carotene, vitamin C and selenium. At the end of follow-up, 74% of participants reported having taken at least two thirds of the capsules. There were no differences between the groups mean percentage of capsules taken, ie, 79% in each group). Sponsors of the trial: Fruit d'Or Recherche, Candia, Lipton, Kellogg's, Centre d'Information sur Canderel, Orangina, EsteÂ e Lauder, Cereal, Grands Moulins de Paris, CERIN, L'OreÂ al, Peugeot, Jet Service, RP Scherer, Sodexho, France Telecom, Santogen, Becton Dickinson, Fould Springer, Boehringer Diagnostic, Seppic Givaudan Lavirotte, Le Grand Canal.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-WACS-2007">
<CHAR_METHODS>
<P>The Women's Antioxidant Cardiovascular Study</P>
<P>Randomised, double-blind, placebo-controlled secondary prevention trial with two-by-two-by-two factorial design.</P>
<P>Generation of the allocation sequence: adequate, centrally by computer.</P>
<P>Allocation concealment: adequate, the randomisation allocation is coded. Shipping department sends out calendar packs (which are identical whether active or placebo) to individual participants depending on this code. All of the calendar packs are in coded boxes, supplied by the drug manufacturer, so that the shippers do not know which drug they are shipping.</P>
<P>Blinding: adequate, identical placebo capsules and tablets. </P>
<P>Follow-up: adequate. Losses to follow-up almost equal in the intervention arms (62 to 78 participants).</P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculations: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.</P>
<P>Number of participants randomised: 8171, women at high risk with either a history of vascular disease or at least 3 cardiovascular risk factors.</P>
<P>Inclusion criteria: women 40 years or older, postmenopausal, or had no intention of becoming pregnant, had a self-reported history of cardiovascular disease (CVD), or had at least 3 cardiac risk factors. The cardiac risk factors determining eligibility were self-reported diagnosis of hypertension, high cholesterol level, or diabetes mellitus; parental history of premature myocardial infarction (MI) (before age 60 years); obesity (body mass index [BMI] &gt;30 [calculated as weight in kilograms divided by height in meters squared]), current cigarette smoking; and inconsistent report of prior CVD.</P>
<P>Exclusion criteria: self-reported history of cancer (excluding nonmelanoma skin cancer) within the past 10 years, any serious non-CVD illness, or were currently using warfarin sodium or other anticoagulants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Women were randomly assigned according to a 2 x 2 x 2 factorial design to take ascorbic acid (500 mg/d), vitamin E (600 IU every other day), and beta carotene (50 mg every other day) yielding eight treatment groups.</P>
<P>A fourth arm was subsequently added to test a combination of folic acid 2.5 mg, vitamin B6 (50 mg, and vitamin B12 1 mg. Surviving members of the original cohort of 8171 women were invited to participate in this arm (referred to hereafter as the folic acid arm). Of 8026 survivors, a total of 5442 were additionally randomised to a folic acid/vitamin B6/vitamin B12 combination or its placebo on April 16, 1998, thus creating a total of 24 distinct treatment groups (16 groups in the folic acid arm, plus 8 groups not in that arm).</P>
<P>group 1: beta-carotene, vitamin C, and vitamin E (n = 1020);</P>
<P>group 2: beta-carotene placebo, vitamin C, and vitamin E (n = 1021);</P>
<P>group 3: beta-carotene, vitamin C, vitamin E placebo (n = 1023);</P>
<P>group 4: beta-carotene placebo, vitamin C, vitamin E placebo (n = 1023);</P>
<P>group 5: beta-carotene, vitamin C placebo, vitamin E (n = 1021);</P>
<P>group 6: beta-carotene placebo, vitamin C placebo, vitamin E (n = 1021);</P>
<P>group 7: beta-carotene, vitamin C placebo, vitamin E placebo (n = 1020);</P>
<P>group 8: beta-carotene placebo, vitamin C placebo, vitamin E placebo (n = 1022);</P>
<P>for a mean duration of 9.4 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome was a combined outcome measure of cardiovascular disease morbidity and mortality, including incident myocardial infarction, stroke, coronary revascularization procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty), and cardiovascular mortality. The individual components of myocardial infarction, stroke, coronary revascularization, and cardiovascular disease death were prespecified secondary outcome measures. Information on transient ischaemic attack and total mortality was also collected and reviewed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance was assessed through self-report and defined as taking at least two-thirds of study pills. Reported compliance was, on average, 76% at 4 years and 68% at 8 years of follow-up for each antioxidant, with no significant difference between active and placebo groups at these times except for ascorbic acid at 8 years (70% versus 67% in the active vs placebo group; P = .01). Mean compliance over follow-up was approximately 73% for all active and placebo agents. In 1999, blood samples were obtained from 30 local participants to evaluate biomarkers for compliance. Blood levels were elevated in each active vs placebo group. </P>
<P>Vitamin C (ascorbic acid), was provided by BASF Corporation (Mount Olive, New Jersey), vitamin E (600 IU of natural vitamin E (d-alpha tocopherol acetate) by Cognis Corporation (La Grange, Illinois), and beta carotene (50 mg of Lurotin, provided by BASF Corporation).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-WHS-2005">
<CHAR_METHODS>
<P>Women's Health Study (WHS). </P>
<P>Randomised, double-blind, placebo-controlled trial with two-by-two-by-two factorial design in the beginning and than two-by-two. </P>
<P>Generation of the allocation sequence: adequate, centrally by computer in batches of blocks of size 16. </P>
<P>Allocation concealment: adequate, the randomisation allocation is coded. Shipping department sends out calendar packs (which are identical whether active or placebo) to individual participants depending on this code. All of the calendar packs are in coded boxes, supplied by the drug manufacturer, so that the shippers do not know which drug they are shipping.</P>
<P>Blinding: adequate, identical placebo capsules. </P>
<P>Follow-up: adequate. Losses to follow-up; 0.01% in beta-carotene group and 0.005% in placebo group. Overall, 132 participants in the active group and 102 participants in the placebo group had unknown vital status.</P>
<P>Intention-to-treat analysis: yes. </P>
<P>Sample size calculations: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America. Number of participants randomised: 39876 females aged 45 years or older, mean age 54.6 years. </P>
<P>Inclusion criteria: female health professionals willing to take part in the trial. Age 45 years or older; no previous history of coronary heart disease, cerebrovascular disease, cancer (except nonmelanoma skin cancer), or other major chronic illnesses; no history of adverse effects from aspirin; no use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) more than once a week, or willingness to forgo their use; no use of anticoagulants or corticosteroids; and no use of individual supplements of vitamin A, E, or beta carotene for more than once a week. </P>
<P>Exclusion criteria: history of cancer (except non-melanoma skin cancer), coronary heart disease, or cerebrovascular disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to one of the eight treatment groups. The active agents were 100 mg of aspirin, given on alternate days; 600 IU of vitamin E, given on alternate days; and 50 mg of beta-carotene, given on alternate days.</P>
<P>group 1: aspirin 100 mg, beta-carotene 50 mg, vitamin E 600 IU;</P>
<P>group 2: aspirin 100 mg, beta-carotene 50 mg, vitamin E placebo;</P>
<P>group 3: aspirin 100 mg, beta-carotene 50 mg placebo, vitamin E 600 IU;</P>
<P>group 4: aspirin 100 mg, beta-carotene placebo, vitamin E placebo;</P>
<P>group 5: aspirin placebo, beta-carotene 50 mg, vitamin E 600 IU;</P>
<P>group 6: aspirin placebo, beta-carotene 50 mg, vitamin E placebo;</P>
<P>group 7: aspirin placebo, beta-carotene placebo, vitamin E 600 IU;</P>
<P>group 8: aspirin placebo, beta-carotene placebo, vitamin E placebo;</P>
<P>A total of 19939 women were assigned at random to receive beta-carotene and 19937 to receive placebo in the beginning of April 1993. A total of 19937 women were assigned at random to receive vitamin E and 19939 to receive placebo. The beta-carotene component of the trial was terminated early, on January 18, 1996. The aspirin and vitamin E components of the trial continued uninterrupted. The time from randomisation to the end of beta-carotene component of the trial averaged 2.1 years. Authors published results of the beta-carotene component of the trial on February 6, 1998, after a median total follow-up of 4.1 years (2.1 years treatment plus 2.0 years follow-up). From that time trials proceeded as two-arm (vitamin E and placebo). Follow-up and validation of reported end points were completed in February 2005. The average duration of follow-up from<BR/>randomisation to the end of the trial was 10.1 years (range, 8.2 to 10.9 years).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were: incidence of invasive cancer (except non-melanoma skin cancer), myocardial infarction, and stroke. The secondary outcome measures were: non-fatal myocardial infarction, non-fatal stroke, death from cardiovascular causes, and death from any cause.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was checked by random serum assessments. Compliance with treatment was excellent. At the time of termination of the beta-carotene component, 87% of the active group have taken at least two thirds of the study capsules, while 9.9% of the women in the placebo group have taken beta-carotene or vitamin A supplements outside the trial.</P>
<P>The active agents were provided as follows: aspirin by Bayer AG, Leverkusen, Germany; vitamin E by Natural Source Vitamin E Association, Washington DC; and beta-carotene by Lurotin, BASF Corporation, Wiandotte, MI.</P>
<P>Data were extracted from the primary publication, but additional information was received through personal communication with the authors.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yu-1991">
<CHAR_METHODS>
<P>Randomised clinical placebo-controlled trial with parallel group design. </P>
<P>Generation of the allocation sequence: unclear, not reported.</P>
<P>Allocation concealment: unclear, not reported.</P>
<P>Blinding: adequate, identical placebo tablets.</P>
<P>Follow-up: inadequate.</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China.</P>
<P>Number of participants randomised:<BR/>2474, aged 18 to 75 years.</P>
<P>Inclusion criteria:<BR/>members of families with high incidences of liver cancer. </P>
<P>Exclusion criteria:<BR/>none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive: </P>
<P>group 1: 200 µg of selenium in the form of selenized yeast tablet (n = 1444); </P>
<P>group 2: identical placebo of yeast tablet (n = 1030); </P>
<P>daily for two years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure was the occurrence of liver cancer.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment is not reported.</P>
<P>Data were extracted from the primary publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yu-1997">
<CHAR_METHODS>
<P>Randomised clinical placebo-controlled trial with parallel group design. </P>
<P>Generation of the allocation sequence: unclear, not reported.</P>
<P>Allocation concealment: unclear, not reported.</P>
<P>Blinding: adequate, identical placebo tablets. </P>
<P>Follow-up: adequate, no losses to follow-up. </P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China.</P>
<P>Number of participants randomised: 226, aged 21 to 63 years. </P>
<P>Inclusion criteria: HBsAg carriers with normal liver function.</P>
<P>Exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive: </P>
<P>group 1: 200 µg of selenium in the form of selenized yeast tablet (n = 113); </P>
<P>group 2: identical placebo of yeast tablet (n = 113); </P>
<P>daily for four years. </P>
<P>Patients were followed-up eight years from 1987 to 1994.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure was the occurrence of liver cancer.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment is not reported.</P>
<P>Data were extracted from the primary publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhu-2003">
<CHAR_METHODS>
<P>Randomised double-blind, placebo-controlled trial with parallel group design.</P>
<P>Generation of the allocation sequence: unclear, not reported.</P>
<P>Allocation concealment: unclear, not reported.</P>
<P>Blinding: adequate. Patients were allocated to four arms (see Interventions). The three arms (group 2 to 4), used in this review, seem to have been adequately placebo controlled.</P>
<P>Follow-up: adequate, 3.7 % of patients were lost to follow up, and the losses were similar between the treatment groups. </P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: China.</P>
<P>Number of participants randomised: 216; 137 males, 79 females, aged 28 to 77 years, mean age 55.6 years.</P>
<P>Inclusion criteria: patients with atrophic gastritis.</P>
<P>Exclusion criteria: history of malignant tumour, gastrointestinal operation, chronic heart, lung, liver, and renal disease, taking vitamin pills in the last three months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were assigned to four treatment groups to receive: </P>
<P>group 1: folate 20 mg per day plus vitamin B12, 1 mg intramuscularly, per month for one year, then folate 20 mg twice a week plus vitamin B12 1 mg per three months for the next year (n = 44); </P>
<P>group 2: natural beta-carotene, 30 mg per day in the first year, then 30 mg twice a week for the next year (n = 61);</P>
<P>group 3: synthetic beta-carotene administered as natural beta-carotene (n = 57); </P>
<P>group 4: placebo (n = 54).</P>
<P>All patients were followed-up from 1994 to 2001, in total seven years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures were the occurrence of gastrointestinal tumors and mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Compliance with treatment was checked by counting the remaining pills at each visit, as well as by measurement of relevant vitamin concentrations in serum randomly at 15 days, 3, 6, 12, and 24 months.</P>
<P>Compliance, as assessed by quarterly pill counting and random blood sampling, was excellent throughout the trial. More than 90% of all patients took pills according to the protocol. After the supplementation, the serum levels of folic acid or relative carotenoids increased several times in the three active treated groups, but not in placebo.</P>
<P>Folate and vitamin B12 were provided by Shanghai Huanghe Pharmacy and Shanghai First Pharmacy, China; natural beta-carotene by Betatene Co. Australia and Henkel Co.; synthetic beta-carotene by Shanghai Sixth Pharmacy and Henkel Co.</P>
<P>Data were extracted from the primary publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ATBC: Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study<BR/>CARET: The Beta-Carotene and Retinol Efficacy Trial<BR/>HOPE: Heart Outcomes Prevention Evaluation Study<BR/>HOPE TOO: Heart Outcomes Prevention Evaluation Study The Ongoing Outcomes<BR/>HPS: Heart Protection Study.<BR/>NIT: Nutrition Intervetion Trial<BR/>NPCT: Nutritional Prevention of Cancer Trial<BR/>PHS: Physicians Health Study<BR/>SIT: Shandong Intervention Trial<BR/>SUVIMAX: The SUpplementation en VItamines et Mine´raux AntioXydants<BR/>WACS: Women Antioxidant Cardiovascular Study<BR/>WHS: Women's Health Study<BR/>BCC: basal cell skin cancers<BR/>SCC: squamous cell skin cancer<BR/>RDA: recommended daily allowance<BR/>HBsAg: hepatitis B surface antigen<BR/>AFP: alpha fetoprotein<BR/>US: United States<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bespalov-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial of the drug karinat was carried out in patients with chronic multifocal atrophic gastritis. Karinat contains beta-carotene 2.5 mg, alpha-tocopherol 5 mg, ascorbic acid 30 mg and garlic powder 150 mg per tablet. Out of 66 patients, 34 received karinat and 32 placebo. This is phase II clinical trial. There were no participants with gastrointestinal cancers at the end of the trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bostick-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>A prospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bukin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial which studied the effects of beta-carotene, vitamin E, and pharmaceutical complex of natural antioxidants on abnormally high ornithine decarboxylase activity in antral gastric mucosa of patients with atrophic gastritis accompanied by intestinal metaplasia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bussey-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>We have been unable to obtain data on gastrointestinal cancers from this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chuang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial to test test whether vitamin C and E supplements to triple therapy can improve the Helicobacter pylori eradication rate and gastric inflammation. Trial is of short follow-up period without data on incidence of gastrointestinal cancers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Stefani-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study in Uruguay with patients already afflicted with cancer of the oral cavity, pharynx, larynx, and oesophagus. Patients were interviewed about their dietary habits. Based on food frequency questionnaire, intake of certain nutrients was calculated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Stefani-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study in Uruguay with patients already afflicted with cancer of the oral cavity, pharynx, larynx, and oesophagus. Patients were interviewed about their dietary habits and based on food frequency questionnaire intake of certain food groups was calculated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Stefani-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study in Uruguay. Intake of antioxidants and other dietary habits were obtained indirectly by face-to-face interviews with patients already having oesophageal cancer and control group of patients by the food frequency questionnaire.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DeCosse-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ascorbic acid, 3 g daily, was given to five patients who had active rectal adenomatous polyp formation long after ileorectal anastomosis for familial polyposis. This is not randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DeCosse-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>We have been unable to obtain data on gastrointestinal cancers from this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ECP_x002d_IM-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>We have been unable to obtain data on gastrointestinal cancers from this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-EUROSCAN-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial in patients with head and neck cancer or with lung cancer, most of whom had a history of smoking. Patients were supplemented with vitamin A and N-acetylcysteine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frank-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational study of the demographic and psychosocial characteristics as well as the health behaviours, health status, and counselling practices of women physicians.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greenberg-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial of beta-carotene in prevention of basal-cell and squamous-cell cancers of the skin. The trial did not provide data about the incidence of gastrointestinal cancers in supplemented and placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishikawa-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial for prevention of colorectal cancer where patients with multiple colorectal tumours were enrolled in two regimens. One was dietary guidance alone, and the other was dietary guidance plus eating wheat bran biscuits.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jacobs-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>A large prospective cohort study that examined the association between colorectal cancer mortality and use of individual vitamin C and E supplements in the American's Cancer Society's Cancer Prevention Study II cohort. Intake of vitamin C and vitamin E was calculated based on self-administrated questionnaire.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jansen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ecological analysis of data from The Seven Countries Study to investigate whether intake of fiber and plant foods contributes to cross cultural diferences in 25-year colorectal-cancer mortality in man.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ji-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>A population-based case control study, which examined the effects of diet on pancreatic cancer among the residents of Shanghai, newly diagnosed with this type of cancer. Information of usual adult dietary intake was obtained by interviewers, using a food frequency questionnaire. Intake of certain group foods was compared with incidence of pancreatic cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kirk-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised, double-blind, placebo-controlled crossover trial, evaluating the efficacy of a combined antioxidant preparation in the management of chronic pancreatitis. Patients with confirmed chronic pancreatitis (N = 36) were randomised to receive treatment with either antioxidants, which contains the antioxidants selenium, beta-carotene, L-methionine, and vitamins C and E, or placebo for 10 weeks. Each group of patients then switched to receive the alternative treatment for a further 10 weeks. Markers of antioxidant status were measured by blood sampling, whereas quality of life and pain were assessed using the SF-36 questionnaire. Nineteen patients completed the full 20 weeks of treatment. This trial did not fulfil our inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krishnaswamy-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study. Serum selenium levels were measured in patients with oral or oesophageal cancer and compared with matched controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-La-Vecchia-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study in Italy concerning intake of lycopene in patients with histologically confirmed cancer of several organs (between them oesophageal and colorectal). Intake of antioxidants was calculated retrospectively based on the interview with patients using a food frequency questionnaire.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lacroix-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational study conducted to determine whether it is possible to increase plasma levels of retinol in cancer patients. Plasma levels of retinol were measured in 46 patients treated with chemotherapy for various malignancies and in 43 control individuals, before and after supplementation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lanza-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>An article describing the rationale, design, recruitment, and baseline participant characteristics of the Polyp Prevention Trial (Schatzkin 1996), a multicenter randomised controlled trial examining the effect of a low-fat, high-fiber, high-vegetable and -fruit dietary pattern on the recurrence of colorectal adenomatous polyps.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lanza-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>A multicenter randomised clinical trial, as a part of Polyp Prevention Trial (Schatzkin 1996), which examined results of dietary changes (implementation of four year high-fiber, high-fruit and -vegetable, low-fat dietary intervention) on the recurrence of adenomatous polyps in large the bowel.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levi-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The association between dietary intake of various micronutrients and colorectal cancer risk was analysed using data from a case-control study conducted between 1992 and 1997 in the Swiss Canton of Vaud. Dietary habits were investigated using a validated food frequency questionnaire.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Limburg-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial of selenomethionine 200 microg daily and/or celecoxib 200 mg twice daily (2 x 2 factorial design) among residents of Linxian, People's Republic of China. Subjects had histologically confirmed mild or moderate esophageal squamous dysplasia at baseline. Esophagogastroduodenoscopy was performed before and after a 10-month intervention. Per-subject change (regression, stable, or progression) in the worst dysplasia grade was defined as the primary end point. Results were compared by agent group (selenomethionine versus placebo; celecoxib versus placebo). Two hundred sixty-seven subjects fulfilled all eligibility criteria, and 238 (89%) completed the trial. Authors did not report incidence of oesophageal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Macrae-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review, discussing the results of several randomised clinical trials concerning the wheat bran fiber and development of adenomatous polyps.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marotta-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this study was to test the effect of antioxidants on enzymatic abnormalities and free radicals-modified DNA adducts associated with pre-malignant changes in HP-negative chronic atrophic gastritis patients. 60 patients with and intestinal metaplasia underwent a GI endoscopy with biopsy samples for histology and for: alpha-tocopherol, malonyldialdehyde, xanthine oxidase, ornithine decarboxylase and 8-hydroxydeoxyguanosine. Patients were randomly allocated into three groups supplemented for 6 months with: vitamin E, 300 mg/day; Multivitamin, 2 tablets/day and a certified fermented papaya preparation 6 g (Immune-Age FPP, Osato Research Institute, Gifu, Japan). Ten dyspeptic patients without histological abnormalities served as control. Histological and biochemical parameters were blindly repeated at 3 and 6 months. There are no results about the incidence of gastric cancer. This is phase II clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marotta-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial to test the effect of antioxidant supplementation on enzymatic abnormalities and free radical-modified DNA adducts associated with premalignant changes in the gastric mucosa of elderly patients with HP-negative atrophic gastritis (CAG). Sixty patients with atrophic gastritis and intestinal metaplasia underwent a nutritional interview and a gastroscopy with multiple biopsy samples in the antrum that were processed for histology and for assaying: alpha-tocopherol, MDA, xanthine oxidase (XO), ornithine decarboxylase (ODC), and 8-OHdG. Patients were randomly allocated into three matched groups and supplemented for 6 months with (1) vitamin E, 300 mg/day; (2) multivitamin, two tablets t.i.d.; and (3) Immun-Age 6 g/day nocte (ORI, Gifu, Japan), a certified fermented papaya preparation with basic science-validated antioxidant/immunomodulant properties. Ten dyspeptic patients served as controls. Histology and biochemistry were blindly repeated at 3 and 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mayne-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study, which examined nutrient intake as a risk factor for oesophageal and gastric cancers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moriwaki-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review concerning current perspectives in prevention of liver cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muto-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial in which 89 patients were studied after surgical resection of primary hepatoma or the percutaneous injection of ethanol. They were randomly assigned to receive either polyprenoic acid (600 mg daily) or placebo for 12 months. The primary outcome measure of the study was appearance of a histologically confirmed recurrence or new hepatoma. The reason for excluding this trial was existence of liver cancer at the time of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Newsome-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational study investigated serum retinol levels in patients with liver disease and hepatocellular carcinoma, assessing its importance as a risk factor for the development of hepatocellular carcinoma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nomura-1987a">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study comparing plasma selenium levels and risk of cancer by specific sites.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pan-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-control study carried out on patients with newly diagnosed hepatocellular carcinoma and controls without hepatocellular carcinoma. Plasma levels of vitamin A, vitamin E, or beta-carotene were compared among the two groups as well as education level, consumption of alcohol, and smoking status.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Podmore-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study involving healthy volunteers whose diets were supplemented with 500 milligrams per day of vitamin C for six weeks. The levels of oxidative damage to peripheral blood lymphocytes in terms of modified DNA bases were assessed. It is not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Qu-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Substudy of the Nutrition Prevention Trial already included in the analyses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rocchi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational study, which compared plasma liposoluble vitamins with tocopherol content in healthy and neoplastic liver tissue in humans.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Russo-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>A cross-sectional observational study among patients with colorectal adenomas, comparing the incidence of adenomas with plasma selenium levels.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sasazuki-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial to examine the effect of vitamin C supplementation on serum pepsinogen level, Helicobacter pylori infection, and cytotoxin-associated gene A status. Subjects aged 40 to 69 years living in one village in Akita prefecture, a high-risk area for gastric cancer in Japan, were recruited through annual health check-up programs. Among 635 participants diagnosed as having chronic gastritis on the basis of serum PG levels, after excluding ineligible cases, 439 subjects were assigned to one of four groups using a 2 x 2 factorial design (0 or 15 mg/day beta-carotene and 50 or 500 mg/day vitamin C). However, based on the results from two beta-carotene trials in the United States, beta-carotene was discontinued (vitamin C supplementation was continued). Finally, 120 subjects in the low-dose group (vitamin C 50 mg), and 124 subjects in the high-dose group (vitamin C 500 mg) completed the 5-year supplementation. Due to modification of protocol primary end point was not incidence of gastric cancer as it was first planned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schatzkin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study describing the dietary intervention programme and participant baseline dietary characteristics of the Polyp Prevention Trial (PPT), a multicenter randomised trial examining the effect of a low-fat, high-fiber high-vegetable and -fruit dietary pattern on the recurrence of colorectal adenomatous polyps, precursors of most colorectal malignancies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simone-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational study with aim to determine whether short-term supplementation of beta-carotene or vitamin E would result in their respective accumulation in normal colonic mucosa and in adenomatous polyps and to determine whether the intake of beta-carotene would interfere with the concentration of vitamin E in these target tissues.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siriwardena-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in patients with predicted severe acute pancreatitis. This trial did not fulfill our inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takshashi-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>The Hiraka Dietary Intervention Study is a community-based randomized cross-over trial designed to develop an effective dietary modification tool and system in an area with high mortality of stomach cancer and stroke. The participants were 550 healthy volunteers and were randomized into two groups with tailored dietary education to decrease sodium intake and to increase vitamin C and carotene intakes either in the first year (intervention group) or in the second year (control group). Dietary changes were assessed using a validated self-administered diet history questionnaire, fasting blood samples, and 48-hour urine samples, which were obtained before and after the one year period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Terry-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A nation-wide, population-based, case-control study in Sweden. Intake of antioxidants in newly diagnosed patients with oesophageal cancer was calculated indirectly by interviews with patients about their dietary habits, by food frequency questionnaires, during the 20 years period prior to interview.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weisburger-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review of the causes of the main human cancers, analysing the mechanisms of the protective effects of fruits and vegetables.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whelan-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>The purpose of this case-control study was to further investigate whether regular vitamin or calcium supplement intake influenced the incidence of recurrent adenomatous polyps in patients with previous neoplasia who were undergoing follow-up colonoscopy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review discussing the problem of vitamin nutrition and gastroesophageal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yu-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational cohort study of 8436 men in Taiwan recruited between 1984 and 1986. Serum retinol levels were compared between patients with hepatocellular carcinoma and matched controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yu-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational study, which examined the association between plasma selenium levels and risk of hepatocellular carcinoma among chronic carriers of hepatitis B and/or C virus in a cohort of 7342 men in Taiwan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zheng-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational prospective cohort study evaluating the association of retinol and antioxidant vitamins intake and the risk of cancers of upper digestive tract in Iowa Women's Health Study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PPT: Polyp Prevention Trial<BR/>t.i.d: ter in die (three times a day).</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-APPOSE-2001">
<CHAR_STUDY_NAME>
<P>The Australian Prostate Cancer Prevention Trial Using Selenium (APPOSE) trial.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Country: Australia. Inclusion criteria: men at risk of prostate cancer. The cohort size will be 2000 participants in each arm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Parallel group design. Participants were randomly assigned to receive either 200 microg selenium or matching placebo daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure is incidence of prostate cancer.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Anthony J. Costello, MD, Level 1, 77 Victoria Parade, Fitzroy, Melbourne 3065, Australia; email: cosurol@mpx.com.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-HGPIN-2006">
<CHAR_STUDY_NAME>
<P>High-grade prostatic intraepithelial neoplasia (HGPIN) trial.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Country: United States of America</P>
<P>Inclusion criteria: men high-grade prostatic intraepithelial neoplasia (HGPIN) must be identified by biopsy; the tissue must then be confirmed by centralized pathology review to show HGPIN and no cancer.</P>
<P>Exclusion criteria: taking finasteride or any other drug known to affect PSA, or selenium supplements in excess of 50 µg/d.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The patient is randomly assigned to 200 µg/d of selenium as L-selenomethionine, or to placebo, with treatment scheduled for 3 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure is incidence of prostate cancer.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>James R. Marshall, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: 716-845-8444; Fax: 716-845-8487. E-mail: james.marshall@roswellpark.org</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-PHS-II-2000">
<CHAR_STUDY_NAME>
<P>Physicians' Health Study II (PHS II).</P>
<P>Randomised double-blind, placebo-controlled trial with two-by-two-by-two-by-two factorial design.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.</P>
<P>Number of participants randomised: <BR/>15,000 US male physicians, aged 55 years and older.</P>
<P>Inclusion criteria: willing and eligible physicians to take part in this trial, including all willing and eligible participants from Physician Health Study I.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physicians' Health Study II utilized a two-by-two-by-two-by-two factorial design to test alternate day beta-carotene, alternate day vitamin E, daily vitamin C, and a daily multivitamin. During the first half of 2003 the beta-carotene component of the ongoing Physicians' Healthy Study II has been terminated. It continues to examine a multivitamin, vitamin C, and vitamin E.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measures are the incidence of total and prostate cancer, cardiovascular and eye diseases.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Charles H. Hennekens MD<BR/>1415 W. Camino Real, Boca Raton, FL 33486, United States of America</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-SELECT-2003">
<CHAR_STUDY_NAME>
<P>The selenium and vitamin E cancer prevention trial, SELECT).</P>
<P>Randomised double-blind, placebo-controlled trial with two-by-two factorial design.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.</P>
<P>Number of participants randomised: <BR/>32,400 males, aged 50 years or older.</P>
<P>Inclusion criteria: age &gt; 55 years for Caucasians and &gt; 50 years for African-Americans, digital rectal examination not suspicious for prostate cancer, total serum prostate specific antigen &lt; 4.0 ng/ml, no prior history of prostate cancer or high-grade prostatic intraepithelial neoplasia, no anticoagulation therapy, except low-dose aspirin, normal blood pressure (systolic blood pressure &lt; 150 mm Hg and diastolic blood pressure &lt; 90 mm Hg), willing to restrict supplementation of selenium and vitamin E during<BR/>participation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Participants were randomly assigned to receive either 200 µg of 1-selenomethionine, 400 mg of racaemic alpha-tocopherol, and an optional multivitamin containing no selenium or vitamin E. The racaemic mix of alpha-tocopherol will include both the d- and l-isomers. Participants will be divided in four group according to two-by-two factorial design: </P>
<P>group 1: placebo (n = 8100); </P>
<P>group 2: vitamin E (n = 8100); </P>
<P>group 3: selenium (n = 8100); </P>
<P>group 4: vitamin E and selenium (n = 8100).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The primary outcome measure is the clinical incidence of prostate cancer as determined by a clinical diagnostic work-up, including yearly digital rectal examination<BR/>and serum prostate specific antigen level.</P>
<P>Secondary outcome measures will include prostate cancer-free<BR/>survival, all cause mortality, and the incidence and mortality<BR/>of other cancers and diseases potentially impacted by the<BR/>chronic use of selenium and vitamin E. Other trial objectives will include periodic quality of life assessments,<BR/>assessment of serum micronutrient levels and prostate cancer<BR/>risk, and studies of the evaluation of biological and<BR/>genetic markers with the risk of prostate cancer.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Eric A. Klein, Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA Tel.: +1-216-444-5591; Fax: +1-216-445-<BR/>3532, e-mail address: kleine@ccf.org.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>APOSE: The Australian Prostate Cancer Prevention Trial <BR/>HGPIN: High-Grade Prostatic Intraepithelial Neoplasia<BR/>PHS II: Physicians' Health Study II<BR/>SELECT: The selenium and vitamin E cancer prevention trial<BR/>PSA: prostate-specific antigen</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-ATBC-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-CARET-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Correa-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-HOPE-TOO-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-HPS-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Munoz-1985">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-NIT1-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-NIT2-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-NPCT-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-PHS-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Plummer-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SIT-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SUVIMAX-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-WACS-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-WHS-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yu-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-05-24 16:59:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Table</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search performed</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>The Cochrane Central Register of Controlled Trials on the Cochrane Library</P>
</TD>
<TD>
<P>October 2007</P>
</TD>
<TD>
<P>Digestive system neoplasms / explode all trees (MeSH),<BR/>antioxidants / explode all trees (MeSH), (#1 and #2).<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>The Controlled Trials Registers of the four Cochrane gastrointestinal groups</P>
</TD>
<TD>
<P>October 2007</P>
</TD>
<TD>
<P>'oesophageal cancer' or 'gastric cancer' or 'stomach cancer' or 'bowel cancer' or 'colorectal cancer' or 'colon cancer' or 'rectal cancer' or 'pancreatic cancer' or 'hepatocellular carcinoma' or 'liver cancer' or 'biliary tract cancer' AND 'antioxidant*' or 'vitamin* and supplement* and random*'.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>October 2007</P>
</TD>
<TD>
<P>#1 explode "Digestive-System-Neoplasms"/ all subheadings<BR/>#2 retinol or beta carotene or ascorbic acid or alpha tocopherol or selenium or vitamin* or antioxidant*<BR/>#3 TG = ANIMAL<BR/>#4 random*<BR/>#5 ((#1 and #2) not #3) and random*<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>October 2007</P>
</TD>
<TD>
<P>#1 explode "digestive-system-tumor"/ all subheadings<BR/>#2 retinol or beta carotene or ascorbic acid or alpha tocopherol or selenium or vitamin* or antioxidant*<BR/>#3 random*<BR/>#4 #1 and #2 and #3<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>LILACS</P>
</TD>
<TD>
<P>October 2007</P>
</TD>
<TD>
<P>#1 antioxidantes and cancer</P>
</TD>
</TR>
<TR>
<TD>
<P>The Web of Science<BR/>(http://portal.isiknowledge.com/portal.cgi?DestApp=WOS&amp;Func=Frame)</P>
</TD>
<TD>
<P>Accessed 01 October 2007</P>
</TD>
<TD>
<P>#1 - &gt; [TS=(retinol or beta-carotene or ascorbic acid or alpha tocopherol or selenium or vitamin* or antioxidant*)<BR/>DocType=All document types; Language=All languages; Database(s)=SCI-EXPANDED, SSCI, A&amp;HCI; Timespan=1945-2003] #2 - ((o)esophageal or gastric or small intestin* or colorectal or pancreatic or liver or biliary tract) and cancer* <BR/>#3 - &gt; TS=(random*) DocType=All document types; Language=All languages; Database(s)=SCI-EXPANDED; Timespan = 1945-2003 #4 - 62 #1 and #2 and #3<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>The Chinese Biomedical Database</P>
</TD>
<TD>
<P>October 2007</P>
</TD>
<TD>
<P>(retinol or beta-carotene or ascorbic acid or alpha tocopherol or selenium or vitamin* or antioxidant*) and<BR/>#1 ((o)esophageal or gastric or small intestin* or colorectal or pancreatic or liver or biliary tract) and cancer* <BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Table</TITLE>
<TABLE COLS="6" ROWS="16">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Experimental antioxidant supplements</P>
</TD>
<TD>
<P>Oesophageal cancer</P>
</TD>
<TD>
<P>Gastric cancer</P>
</TD>
<TD>
<P>Colorectal cancer</P>
</TD>
<TD>
<P>Pancreatic cancer</P>
</TD>
<TD>
<P>Hepatocellular carcinoma</P>
</TD>
</TR>
<TR>
<TD>
<P>Beta-carotene (PHS 1996; Correa 2000; ATBC 2003; Zhu 2003)</P>
</TD>
<TD>
<P>0.75, 0.25 to 2.30</P>
</TD>
<TD>
<P>1.12, 0.79 to 1.59</P>
</TD>
<TD>
<P>1.09, 0.79 to 1.51</P>
</TD>
<TD>
<P>1.02, 0.54 to 1.90</P>
</TD>
<TD>
<P>1.92, 0.96 to 3.85</P>
</TD>
</TR>
<TR>
<TD>
<P>Vitamin E (ATBC 2003; HOPE TOO 2005)</P>
</TD>
<TD>
<P>1.46, 0.72 to 2.96</P>
</TD>
<TD>
<P>1.30, 0.90 to 1.88</P>
</TD>
<TD>
<P>1.10, 0.87 to 1.39</P>
</TD>
<TD>
<P>0.97, 0.67 to 1.39</P>
</TD>
<TD>
<P>1.33, 0.63 to 2.82</P>
</TD>
</TR>
<TR>
<TD>
<P>Selenium (Yu 1991; NPCT 1996; Yu 1997; Li 2000; Li 2004)</P>
</TD>
<TD>
<P>0.40, 0.08 to 2.07</P>
</TD>
<TD>
<P>0.76, 0.44 to 1.31</P>
</TD>
<TD>
<P>0.48, 0.22 to 1.05</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>0.56, 0.42 to 0.76</P>
</TD>
</TR>
<TR>
<TD>
<P>Beta-carotene and vitamin A (CARET 2004)</P>
</TD>
<TD>
<P>1.43, 0.90 to 2.29</P>
</TD>
<TD>
<P>0.89, 0.46 to 1.73</P>
</TD>
<TD>
<P>0.97, 0.76 to 1.25</P>
</TD>
<TD>
<P>1.33, 0.84 to 2.09</P>
</TD>
<TD>
<P>1.35, 0.51 to 3.54</P>
</TD>
</TR>
<TR>
<TD>
<P>Beta-carotene and vitamin C (Correa 2000)</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>2.90, 0.12 to 70.52</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
</TR>
<TR>
<TD>
<P>Beta-carotene and vitamin E (ATBC 2003)</P>
</TD>
<TD>
<P>1.23, 0.59 to 2.56</P>
</TD>
<TD>
<P>1.40, 0.98 to 2.01</P>
</TD>
<TD>
<P>1.20, 0.89 to 1.63</P>
</TD>
<TD>
<P>0.93, 0.65 to 1.35</P>
</TD>
<TD>
<P>1.25, 0.59 to 2.67</P>
</TD>
</TR>
<TR>
<TD>
<P>Beta-carotene, vitamin C, and vitamin E (HPS 2002; Plummer 2007)</P>
</TD>
<TD>
<P>1.19, 0.71 to 2.01</P>
</TD>
<TD>
<P>1.25, 0.78 to 2.00</P>
</TD>
<TD>
<P>0.84, 0.65 to 1.07</P>
</TD>
<TD>
<P>1.00, 0.57 to 1.76</P>
</TD>
<TD>
<P>1.40, 0.44 to 4.41</P>
</TD>
</TR>
<TR>
<TD>
<P>Vitamin A, riboflavin, and zinc (Munoz 1985)</P>
</TD>
<TD>
<P>1.33, 0.30 to 5.91</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
</TR>
<TR>
<TD>
<P>Vitamin C, vitamin E, and selenium (SIT 2006)</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>1.01, 0.60 to 1.68</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
</TR>
<TR>
<TD>
<P>Beta-carotene, vitamin C, vitamin E, and selenium (SUVIMAX 2004)</P>
</TD>
<TD>
<P>1.01, 0.14 to 7.16</P>
</TD>
<TD>
<P>1.01, 0.14 to 7.16</P>
</TD>
<TD>
<P>0.88, 0.49 to 1.58</P>
</TD>
<TD>
<P>0.67, 0.19 to 2.38</P>
</TD>
<TD>
<P>1.01, 0.06 to 16.12</P>
</TD>
</TR>
<TR>
<TD>
<P>26 vitamins/minerals (NIT2 1993)</P>
</TD>
<TD>
<P>0.96, 0.76 to 1.22</P>
</TD>
<TD>
<P>1.19, 0.89 to 1.58</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
<TD>
<P>ND</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>GI = gastrointestinal; ND = No data</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Relative risk, 95% confidence interval (random).</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Table</TITLE>
<TABLE COLS="6" ROWS="22">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Trial</P>
</TD>
<TD>
<P>Design of the trials</P>
</TD>
<TD>
<P>Number of arms</P>
</TD>
<TD>
<P>Antioxidant vitamin supplements plus any additional non-antioxidant interventions in the experimental arm/arms</P>
</TD>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>Analysis reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Munoz 1985</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Vitamin A, vitamin B2, and zinc.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yu 1991</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Selenium.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NIT1 1993</P>
</TD>
<TD>
<P>Half replicate of a 2x2x2x2 factorial trial.</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>A) Vitamin A, vitamin B2, vitamin B3, and zinc. <BR/>B) Vitamin A, vitamin C, zinc, and molybdenum. <BR/>C) Vitamin A, beta-carotene, vitamin E, selenium, and zinc.<BR/>D) Vitamin C, vitamin B2, vitamin B3, and molybdenum.<BR/>E) Beta-carotene, vitamin E, selenium, vitamin B2, and vitamin B3.<BR/>F) Beta-carotene, vitamin C, vitamin E, selenium, and molybdenum. <BR/>G) Vitamin A, beta-carotene, vitamin C, vitamin E, selenium, zinc, vitamin B2, vitamin B3, and molybdenum.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P>Four-way.</P>
</TD>
</TR>
<TR>
<TD>
<P>NIT2 1993</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>13 vitamins (vitamin A, beta-carotene, vitamin E, vitamin C, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin D, folic acid, niacinamide, biotin, pantothenic acid) and 13 minerals (calcium, phosphorus, iodine, iron, magnesium, copper, manganese, potassium, chloride, chromium, molybdenum, selenium, and zinc).</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NPCT 1996</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Selenium.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>PHS 1996</P>
</TD>
<TD>
<P>2x2 factorial trial changed into two-armed trial.</P>
</TD>
<TD>
<P>Initially 4, then changed into 2.</P>
</TD>
<TD>
<P>A) Aspirin.<BR/>B) Beta-carotene.<BR/>C) Beta-carotene and aspirin.<BR/>
</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P>Two-way.</P>
</TD>
</TR>
<TR>
<TD>
<P>Yu 1997</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Selenium.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Correa 2000</P>
</TD>
<TD>
<P>2x2x2 factorial trial.</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>A random half of the patients were treated with anti-Helicobacter pylori treatment medication (which consisted of amoxicillin, metronidazole, and bismuth subsalicylate) before the start of the 2x2 factorial design of beta-carotene and/or vitamin C versus placebo.<BR/>A) Beta-carotene. <BR/>B) Vitamin C. <BR/>C) Beta-carotene plus anti-Helicobacter pylori treatment. <BR/>D) Vitamin C plus anti-Helicobacter pylori treatment. <BR/>E) Beta-carotene and vitamin C. <BR/>F) Beta-carotene and vitamin C plus anti-Helicobacter pylori treatment. <BR/>G) anti-Helicobacter pylori treatment.</P>
</TD>
<TD>
<P>Placebo.<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Eight-way.</P>
</TD>
</TR>
<TR>
<TD>
<P>Li 2000</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Selenium.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>HPS 2002</P>
</TD>
<TD>
<P>2x2 factorial trial.</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>A) Vitamin E, vitamin C, and beta-carotene. <BR/>B) Simvastatin.<BR/>C) Vitamin E, vitamin C, beta-carotene, and simvastatin.</P>
</TD>
<TD>
<P>
<BR/>Placebo.</P>
</TD>
<TD>
<P>Two-way.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>ATBC 2003</P>
</TD>
<TD>
<P>2x2 factorial trial.</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>A) Vitamin E.<BR/>B) Beta-carotene.<BR/>C) Beta carotene and vitamin E.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P>Four-way</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhu 2003</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>3 (A fourth group assessing folate and vitamin B12 was disregarded.)</P>
</TD>
<TD>
<P>A) Beta-carotene (natural).<BR/>B) Beta-carotene (synthetic).</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>CARET 2004</P>
</TD>
<TD>
<P>2x2 factorial trial changed into two-armed trial.</P>
</TD>
<TD>
<P>Initially 4, then changed into 2.</P>
</TD>
<TD>
<P>Vitamin A and beta-carotene.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Li 2004</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Selenium, synthetic allitridum (garlic extract).</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>SUVIMAX 2004</P>
</TD>
<TD>
<P>Parallel.</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Beta-carotene, vitamin C, vitamin E, selenium, and zinc [as gluconate]) .</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>HOPE TOO 2005</P>
</TD>
<TD>
<P>2x2</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>A) Vitamin E. <BR/>B) Ramipril (angiotensin-converting enzyme inhibitor).<BR/>C) Vitamin E plus ramipril.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P>Two-way.</P>
</TD>
</TR>
<TR>
<TD>
<P>WHS 2005</P>
</TD>
<TD>
<P>2x2x2 factorial trial.</P>
</TD>
<TD>
<P>Initially 8, changed into 4.</P>
</TD>
<TD>
<P>A) Beta-carotene (abandoned after 22.8 months).<BR/>B) Vitamin E.<BR/>C) Beta-carotene and vitamin E.<BR/>D) Beta-carotene and aspirin.<BR/>E) Vitamin E and aspirin.<BR/>F) Beta-carotene, vitamin E, and aspirin.<BR/>G) Aspirin.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P>Two-way.</P>
</TD>
</TR>
<TR>
<TD>
<P>SIT 2006</P>
</TD>
<TD>
<P>2x2x2; 2x2</P>
</TD>
<TD>
<P>8 plus 4</P>
</TD>
<TD>
<P>A) Amoxicillin and omeprazole, garlic, vitamin capsule* and selenium.<BR/>B) Amoxicillin and omeprazole, garlic, vitamin placebo<BR/>C) Amoxicillin and omeprazole, vitamin capsule* and selenium.<BR/>D) Amoxicillin and omeprazole and vitamin placebo<BR/>E) Garlic, vitamin capsule*, and selenium.<BR/>F) Garlic and vitamin placebo.<BR/>G) Vitamin capsule* and selenium.<BR/>H) Garlic and selenium placebo.<BR/>I) Garlic.<BR/>J) Vitamin placebo.<BR/>K) Selenium.<BR/>
<BR/>*The vitamin capsule contained vitamin C (250 mg), vitamin E (100 IU), and selenium from yeast (37.5 µg) .</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P>Two-way</P>
</TD>
</TR>
<TR>
<TD>
<P>Plummer 2007</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Beta-carotene, vitamin C, and vitamin E.</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>WACS 2007</P>
</TD>
<TD>
<P>2x2x2</P>
</TD>
<TD>
<P>8<BR/>Another arm testing a combination of folic acid (2.5 mg), vitamin B6 (50 mg), and vitamin B12 (1 mg) was disregarded.</P>
</TD>
<TD>
<P>A) Beta-carotene, vitamin C, and vitamin E.<BR/>B) Beta-carotene placebo, vitamin C, and vitamin E.<BR/>C) Beta-carotene, vitamin C, and vitamin E placebo.<BR/>D) Beta-carotene placebo, vitamin C, and vitamin E placebo.<BR/>E) Beta-carotene, vitamin C placebo, and vitamin E.<BR/>F) Beta-carotene placebo, vitamin C placebo, and vitamin E.<BR/>G) Beta-carotene, vitamin C placebo, and vitamin E placebo.<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Placebo.</P>
</TD>
<TD>
<P>Eight-way</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-23 15:52:00 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-23 15:52:00 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Antioxidants versus placebo</NAME>
<DICH_OUTCOME CHI2="36.97615219940799" CI_END="1.0593874814843498" CI_START="0.8302513863649312" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9378474957049436" ESTIMABLE="YES" EVENTS_1="2057" EVENTS_2="1549" I2="54.024421177409096" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.025054836681143406" LOG_CI_START="-0.08079039053820485" LOG_EFFECT_SIZE="-0.02786777692853074" METHOD="MH" MODIFIED="2008-05-23 15:52:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.003390287596488073" P_Q="0.0" P_Z="0.3020393651122092" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02670078294590629" TOTALS="YES" TOTAL_1="95084" TOTAL_2="78935" WEIGHT="100.0" Z="1.0320699486227207">
<NAME>Occurrence of gastrointestinal cancers in trials with a low or high risk of bias</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.67776753469552" CI_END="1.1340924000127215" CI_START="0.9603493751058559" DF="11.0" EFFECT_SIZE="1.0436114831030356" ESTIMABLE="YES" EVENTS_1="1959" EVENTS_2="1403" I2="19.57751897671164" ID="CMP-001.01.01" LOG_CI_END="0.05464844007793154" LOG_CI_START="-0.017570741879965875" LOG_EFFECT_SIZE="0.018538849098982863" MODIFIED="2008-05-23 15:52:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.25133956118922385" P_Z="0.3142926673692348" STUDIES="12" TAU2="0.003926594946728112" TOTAL_1="89466" TOTAL_2="73973" WEIGHT="84.55612180326116" Z="1.006255556038068">
<NAME>Trials with low risk of bias</NAME>
<DICH_DATA CI_END="1.340999325624364" CI_START="0.990163570256729" EFFECT_SIZE="1.1523058100921326" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="209" LOG_CI_END="0.12742855944914472" LOG_CI_START="-0.004293056117563228" LOG_EFFECT_SIZE="0.06156775166579072" ORDER="551" O_E="0.0" SE="0.07737392901639713" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.005986724891434462" WEIGHT="11.825947667284378"/>
<DICH_DATA CI_END="1.31769754324871" CI_START="0.9145273190467578" EFFECT_SIZE="1.0977569865602048" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="209" LOG_CI_END="0.11981573622747665" LOG_CI_START="-0.038803316612883304" LOG_EFFECT_SIZE="0.04050620980729665" ORDER="552" O_E="0.0" SE="0.09317361681540218" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.008681322870463394" WEIGHT="10.925317986005673"/>
<DICH_DATA CI_END="1.271883604411962" CI_START="0.035939988032653664" EFFECT_SIZE="0.21380243572395127" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.10444736895818481" LOG_CI_START="-1.444422071838991" LOG_EFFECT_SIZE="-0.6699873514404031" MODIFIED="2008-05-23 15:52:00 +0100" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.9098135765516453" STUDY_ID="STD-Correa-2000" TOTAL_1="739" TOTAL_2="237" VAR="0.8277607440776965" WEIGHT="0.4524027645865695"/>
<DICH_DATA CI_END="1.7221002259380627" CI_START="0.8577277809800483" EFFECT_SIZE="1.2153572336638698" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.2360584237176191" LOG_CI_START="-0.06665052331287476" LOG_EFFECT_SIZE="0.08470395020237217" ORDER="554" O_E="0.0" SE="0.17781273391916638" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.031617368343808266" WEIGHT="6.628480987642633"/>
<DICH_DATA CI_END="1.1494160979261696" CI_START="0.7940821334524522" EFFECT_SIZE="0.9553694506659742" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="225" LOG_CI_END="0.06047727526813997" LOG_CI_START="-0.10013457533058383" LOG_EFFECT_SIZE="-0.019828650031221938" ORDER="555" O_E="0.0" SE="0.09434419608317311" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.008900827334580218" WEIGHT="10.857957098368"/>
<DICH_DATA CI_END="1.2536238796830856" CI_START="0.880081008452458" EFFECT_SIZE="1.0503763936092494" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="209" LOG_CI_END="0.09816725620767691" LOG_CI_START="-0.0554773506854328" LOG_EFFECT_SIZE="0.02134495276112205" ORDER="556" O_E="0.0" SE="0.0902516026420828" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.008145351779464408" WEIGHT="11.09336114621899"/>
<DICH_DATA CI_END="0.9364828215969734" CI_START="0.22845861427814007" EFFECT_SIZE="0.4625446656457376" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.028500184710599438" LOG_CI_START="-0.6411924617582907" LOG_EFFECT_SIZE="-0.3348463232344451" ORDER="557" O_E="0.0" SE="0.3598984764134988" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.12952691332475774" WEIGHT="2.4743420423266325"/>
<DICH_DATA CI_END="1.2152535685037456" CI_START="0.8379597303617472" EFFECT_SIZE="1.0091251421823508" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="217" LOG_CI_END="0.08466690502262168" LOG_CI_START="-0.07677685165839208" LOG_EFFECT_SIZE="0.003945026682114812" ORDER="558" O_E="0.0" SE="0.09483286183391172" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.008993271683609791" WEIGHT="10.82983597886594"/>
<DICH_DATA CI_END="28.79116539740041" CI_START="0.3125958909885815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4592592444340635" LOG_CI_START="-0.5050167349947388" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="559" O_E="0.0" SE="1.1538254336393923" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="1.3313131313131314" WEIGHT="0.2846515436988403"/>
<DICH_DATA CI_END="1.6766445283678897" CI_START="0.6042793639185033" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" ORDER="560" O_E="0.0" SE="0.26033977271612496" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.06777679725788362" WEIGHT="4.0915607303290455"/>
<DICH_DATA CI_END="1.3174698521080426" CI_START="0.5254207926640037" EFFECT_SIZE="0.8320012343774109" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.11974068596206247" LOG_CI_START="-0.2794927447197962" LOG_EFFECT_SIZE="-0.07987602937886684" ORDER="561" O_E="0.0" SE="0.234511693419878" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.05499573435065884" WEIGHT="4.731667515949206"/>
<DICH_DATA CI_END="1.3190164139133533" CI_START="0.8808366543562658" EFFECT_SIZE="1.07788589612836" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="180" LOG_CI_END="0.12025019996459278" LOG_CI_START="-0.055104621314410615" LOG_EFFECT_SIZE="0.03257278932509107" ORDER="562" O_E="0.0" SE="0.10300429003965118" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.010609883766572584" WEIGHT="10.360596341985255"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.104281691112649" CI_END="0.8031294041197651" CI_START="0.4302760006957924" DF="5.0" EFFECT_SIZE="0.5878497325387223" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="146" I2="18.090280674962887" ID="CMP-001.01.02" LOG_CI_END="-0.09521447344194398" LOG_CI_START="-0.3662528766830832" LOG_EFFECT_SIZE="-0.23073367506251363" NO="2" P_CHI2="0.2962037947352514" P_Z="8.468318760230983E-4" STUDIES="6" TAU2="0.027804689430433356" TOTAL_1="5618" TOTAL_2="4962" WEIGHT="15.443878196738838" Z="3.3370156238763826">
<NAME>Trials with high risk of bias</NAME>
<DICH_DATA CI_END="0.7747710510865886" CI_START="0.3372958240464894" EFFECT_SIZE="0.5112015650637385" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" LOG_CI_END="-0.11082661483499756" LOG_CI_START="-0.47198903564089956" LOG_EFFECT_SIZE="-0.29140782523794856" ORDER="563" O_E="0.0" SE="0.2121485937642028" STUDY_ID="STD-Li-2000" TOTAL_1="1112" TOTAL_2="953" VAR="0.045007025836128756" WEIGHT="5.390776313265128"/>
<DICH_DATA CI_END="1.1308920527482222" CI_START="0.5190108835327407" EFFECT_SIZE="0.7661235432206803" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" LOG_CI_END="0.053421152110974306" LOG_CI_START="-0.2848235350057731" LOG_EFFECT_SIZE="-0.1157011914473994" ORDER="564" O_E="0.0" SE="0.198686603550582" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.03947636643046615" WEIGHT="5.841302635443457"/>
<DICH_DATA CI_END="5.907317036986026" CI_START="0.3009450426728439" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="565" O_E="0.0" SE="0.7594576724769808" STUDY_ID="STD-Munoz-1985" TOTAL_1="305" TOTAL_2="305" VAR="0.576775956284153" WEIGHT="0.6405561837421107"/>
<DICH_DATA CI_END="1.2464473248619825" CI_START="0.24153464224020815" EFFECT_SIZE="0.5486895376092052" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.09567392984729235" LOG_CI_START="-0.617020571517862" LOG_EFFECT_SIZE="-0.2606733208352848" ORDER="566" O_E="0.0" SE="0.4186402779965706" STUDY_ID="STD-Yu-1991" TOTAL_1="1444" TOTAL_2="1030" VAR="0.17525968236104592" WEIGHT="1.9140417233185725"/>
<DICH_DATA CI_END="1.1081247464231647" CI_START="0.11932898835216686" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04458865356357585" LOG_CI_START="-0.9232540412241012" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="567" O_E="0.0" SE="0.5685155898168872" STUDY_ID="STD-Yu-1997" TOTAL_1="113" TOTAL_2="113" VAR="0.3232099758648431" WEIGHT="1.104740987022387"/>
<DICH_DATA CI_END="0.9138437320595765" CI_START="0.03666667678448441" EFFECT_SIZE="0.18305084745762712" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.03912806258836465" LOG_CI_START="-1.4357284497220244" LOG_EFFECT_SIZE="-0.7374282561551945" ORDER="568" O_E="0.0" SE="0.820369980685724" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="0.673006905210295" WEIGHT="0.5524603539471823"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.14435900873384" CI_END="1.0682115538870285" CI_START="0.8460152062844355" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9506435810108602" ESTIMABLE="YES" EVENTS_1="2057" EVENTS_2="1546" I2="50.21139510731028" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.028657271032710742" LOG_CI_START="-0.0726218308781514" LOG_EFFECT_SIZE="-0.02198227992272029" METHOD="MH" NO="2" P_CHI2="0.008043077373301233" P_Q="0.0" P_Z="0.39487666321275827" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.022942946833060064" TOTALS="SUB" TOTAL_1="94713" TOTAL_2="78815" WEIGHT="200.0" Z="0.8508068522276053">
<NAME>Occurrence of gastrointestinal cancers - generation of the allocation sequence</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.684017061835103" CI_END="1.129131310547284" CI_START="0.9826836063188044" DF="11.0" EFFECT_SIZE="1.0533654770572667" ESTIMABLE="YES" EVENTS_1="1959" EVENTS_2="1400" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.052744450454652606" LOG_CI_START="-0.0075862890326082845" LOG_EFFECT_SIZE="0.022579080711022194" NO="1" P_CHI2="0.47010245852635335" P_Z="0.14236173903554264" STUDIES="12" TAU2="0.0" TOTAL_1="89095" TOTAL_2="73853" WEIGHT="100.0" Z="1.4670526293472974">
<NAME>Adequate</NAME>
<DICH_DATA CI_END="1.340999325624364" CI_START="0.990163570256729" EFFECT_SIZE="1.1523058100921326" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="209" LOG_CI_END="0.12742855944914472" LOG_CI_START="-0.004293056117563228" LOG_EFFECT_SIZE="0.06156775166579072" ORDER="569" O_E="0.0" SE="0.07737392901639713" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.005986724891434462" WEIGHT="14.356838292435913"/>
<DICH_DATA CI_END="1.31769754324871" CI_START="0.9145273190467578" EFFECT_SIZE="1.0977569865602048" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="209" LOG_CI_END="0.11981573622747665" LOG_CI_START="-0.038803316612883304" LOG_EFFECT_SIZE="0.04050620980729665" ORDER="570" O_E="0.0" SE="0.09317361681540218" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.008681322870463394" WEIGHT="13.133540242845452"/>
<DICH_DATA CI_END="33.06931031113999" CI_START="0.07730830538458316" EFFECT_SIZE="1.5989159891598916" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5194251374238459" LOG_CI_START="-1.111773846457678" LOG_EFFECT_SIZE="0.20382564548308382" ORDER="571" O_E="0.0" SE="1.5455793077770363" STUDY_ID="STD-Correa-2000" TOTAL_1="368" TOTAL_2="117" VAR="2.3888153966285426" WEIGHT="0.17221402796338503"/>
<DICH_DATA CI_END="1.7221002259380627" CI_START="0.8577277809800483" EFFECT_SIZE="1.2153572336638698" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.2360584237176191" LOG_CI_START="-0.06665052331287476" LOG_EFFECT_SIZE="0.08470395020237217" ORDER="572" O_E="0.0" SE="0.17781273391916638" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.031617368343808266" WEIGHT="7.612467366719184"/>
<DICH_DATA CI_END="1.1494160979261696" CI_START="0.7940821334524522" EFFECT_SIZE="0.9553694506659742" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="225" LOG_CI_END="0.06047727526813997" LOG_CI_START="-0.10013457533058383" LOG_EFFECT_SIZE="-0.019828650031221938" ORDER="573" O_E="0.0" SE="0.09434419608317311" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.008900827334580218" WEIGHT="13.043008552167526"/>
<DICH_DATA CI_END="1.2536238796830856" CI_START="0.880081008452458" EFFECT_SIZE="1.0503763936092494" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="209" LOG_CI_END="0.09816725620767691" LOG_CI_START="-0.0554773506854328" LOG_EFFECT_SIZE="0.02134495276112205" ORDER="574" O_E="0.0" SE="0.0902516026420828" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.008145351779464408" WEIGHT="13.359966203956143"/>
<DICH_DATA CI_END="0.9364828215969734" CI_START="0.22845861427814007" EFFECT_SIZE="0.4625446656457376" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.028500184710599438" LOG_CI_START="-0.6411924617582907" LOG_EFFECT_SIZE="-0.3348463232344451" ORDER="575" O_E="0.0" SE="0.3598984764134988" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.12952691332475774" WEIGHT="2.724070307219517"/>
<DICH_DATA CI_END="1.2152535685037456" CI_START="0.8379597303617472" EFFECT_SIZE="1.0091251421823508" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="217" LOG_CI_END="0.08466690502262168" LOG_CI_START="-0.07677685165839208" LOG_EFFECT_SIZE="0.003945026682114812" ORDER="576" O_E="0.0" SE="0.09483286183391172" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.008993271683609791" WEIGHT="13.005253536358033"/>
<DICH_DATA CI_END="28.79116539740041" CI_START="0.3125958909885815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4592592444340635" LOG_CI_START="-0.5050167349947388" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="577" O_E="0.0" SE="1.1538254336393923" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="1.3313131313131314" WEIGHT="0.30669134553220584"/>
<DICH_DATA CI_END="1.6766445283678897" CI_START="0.6042793639185033" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" ORDER="578" O_E="0.0" SE="0.26033977271612496" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.06777679725788362" WEIGHT="4.5782604764124954"/>
<DICH_DATA CI_END="1.3174698521080426" CI_START="0.5254207926640037" EFFECT_SIZE="0.8320012343774109" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.11974068596206247" LOG_CI_START="-0.2794927447197962" LOG_EFFECT_SIZE="-0.07987602937886684" ORDER="579" O_E="0.0" SE="0.234511693419878" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.05499573435065884" WEIGHT="5.329043454337872"/>
<DICH_DATA CI_END="1.3190164139133533" CI_START="0.8808366543562658" EFFECT_SIZE="1.07788589612836" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="180" LOG_CI_END="0.12025019996459278" LOG_CI_START="-0.055104621314410615" LOG_EFFECT_SIZE="0.03257278932509107" ORDER="580" O_E="0.0" SE="0.10300429003965118" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.010609883766572584" WEIGHT="12.37864619405228"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.104281691112648" CI_END="0.803129404119765" CI_START="0.43027600069579247" DF="5.0" EFFECT_SIZE="0.5878497325387223" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="146" I2="18.090280674962873" ID="CMP-001.02.02" LOG_CI_END="-0.09521447344194403" LOG_CI_START="-0.36625287668308315" LOG_EFFECT_SIZE="-0.23073367506251363" NO="2" P_CHI2="0.29620379473525127" P_Z="8.468318760230968E-4" STUDIES="6" TAU2="0.027804689430433332" TOTAL_1="5618" TOTAL_2="4962" WEIGHT="100.0" Z="3.337015623876383">
<NAME>Unclear/Inadequate</NAME>
<DICH_DATA CI_END="0.7747710510865886" CI_START="0.3372958240464894" EFFECT_SIZE="0.5112015650637385" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" LOG_CI_END="-0.11082661483499756" LOG_CI_START="-0.47198903564089956" LOG_EFFECT_SIZE="-0.29140782523794856" ORDER="581" O_E="0.0" SE="0.2121485937642028" STUDY_ID="STD-Li-2000" TOTAL_1="1112" TOTAL_2="953" VAR="0.045007025836128756" WEIGHT="35.22769612376507"/>
<DICH_DATA CI_END="1.1308920527482222" CI_START="0.5190108835327407" EFFECT_SIZE="0.7661235432206803" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" LOG_CI_END="0.053421152110974306" LOG_CI_START="-0.2848235350057731" LOG_EFFECT_SIZE="-0.1157011914473994" ORDER="582" O_E="0.0" SE="0.198686603550582" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.03947636643046615" WEIGHT="38.34904396820816"/>
<DICH_DATA CI_END="5.907317036986026" CI_START="0.3009450426728439" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="583" O_E="0.0" SE="0.7594576724769808" STUDY_ID="STD-Munoz-1985" TOTAL_1="305" TOTAL_2="305" VAR="0.576775956284153" WEIGHT="3.9914049338219377"/>
<DICH_DATA CI_END="1.2464473248619825" CI_START="0.24153464224020815" EFFECT_SIZE="0.5486895376092052" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.09567392984729235" LOG_CI_START="-0.617020571517862" LOG_EFFECT_SIZE="-0.2606733208352848" ORDER="584" O_E="0.0" SE="0.4186402779965706" STUDY_ID="STD-Yu-1991" TOTAL_1="1444" TOTAL_2="1030" VAR="0.17525968236104592" WEIGHT="12.077140442289895"/>
<DICH_DATA CI_END="1.1081247464231647" CI_START="0.11932898835216686" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04458865356357585" LOG_CI_START="-0.9232540412241012" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="585" O_E="0.0" SE="0.5685155898168872" STUDY_ID="STD-Yu-1997" TOTAL_1="113" TOTAL_2="113" VAR="0.3232099758648431" WEIGHT="6.915212415806723"/>
<DICH_DATA CI_END="0.9138437320595765" CI_START="0.03666667678448441" EFFECT_SIZE="0.18305084745762712" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.03912806258836465" LOG_CI_START="-1.4357284497220244" LOG_EFFECT_SIZE="-0.7374282561551945" ORDER="586" O_E="0.0" SE="0.820369980685724" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="0.673006905210295" WEIGHT="3.4395021161082235"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.14435900873383" CI_END="1.0682115538870285" CI_START="0.8460152062844355" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9506435810108601" ESTIMABLE="YES" EVENTS_1="2057" EVENTS_2="1546" I2="50.21139510731027" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.028657271032710742" LOG_CI_START="-0.0726218308781514" LOG_EFFECT_SIZE="-0.021982279922720338" METHOD="MH" NO="3" P_CHI2="0.008043077373301233" P_Q="0.0" P_Z="0.39487666321275805" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.022942946833060043" TOTALS="SUB" TOTAL_1="94713" TOTAL_2="78815" WEIGHT="200.0" Z="0.8508068522276057">
<NAME>Occurrence of gastrointestinal cancers - allocation concealment</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.780120072925172" CI_END="1.1296243873065743" CI_START="0.9832611871318472" DF="12.0" EFFECT_SIZE="1.0539050318108116" ESTIMABLE="YES" EVENTS_1="1963" EVENTS_2="1403" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.052934059733176594" LOG_CI_START="-0.007331103670323063" LOG_EFFECT_SIZE="0.02280147803142678" NO="1" P_CHI2="0.5478506355547035" P_Z="0.1380439314189469" STUDIES="13" TAU2="0.0" TOTAL_1="89400" TOTAL_2="74158" WEIGHT="100.00000000000001" Z="1.4831147287085111">
<NAME>Adequate</NAME>
<DICH_DATA CI_END="1.340999325624364" CI_START="0.990163570256729" EFFECT_SIZE="1.1523058100921326" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="209" LOG_CI_END="0.12742855944914472" LOG_CI_START="-0.004293056117563228" LOG_EFFECT_SIZE="0.06156775166579072" ORDER="587" O_E="0.0" SE="0.07737392901639713" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.005986724891434462" WEIGHT="14.258093086001589"/>
<DICH_DATA CI_END="1.31769754324871" CI_START="0.9145273190467578" EFFECT_SIZE="1.0977569865602048" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="209" LOG_CI_END="0.11981573622747665" LOG_CI_START="-0.038803316612883304" LOG_EFFECT_SIZE="0.04050620980729665" ORDER="588" O_E="0.0" SE="0.09317361681540218" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.008681322870463394" WEIGHT="13.043208784339258"/>
<DICH_DATA CI_END="33.06931031113999" CI_START="0.07730830538458316" EFFECT_SIZE="1.5989159891598916" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5194251374238459" LOG_CI_START="-1.111773846457678" LOG_EFFECT_SIZE="0.20382564548308382" ORDER="589" O_E="0.0" SE="1.5455793077770363" STUDY_ID="STD-Correa-2000" TOTAL_1="368" TOTAL_2="117" VAR="2.3888153966285426" WEIGHT="0.17102955340180329"/>
<DICH_DATA CI_END="1.7221002259380627" CI_START="0.8577277809800483" EFFECT_SIZE="1.2153572336638698" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.2360584237176191" LOG_CI_START="-0.06665052331287476" LOG_EFFECT_SIZE="0.08470395020237217" ORDER="590" O_E="0.0" SE="0.17781273391916638" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.031617368343808266" WEIGHT="7.560109413924149"/>
<DICH_DATA CI_END="1.1494160979261696" CI_START="0.7940821334524522" EFFECT_SIZE="0.9553694506659742" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="225" LOG_CI_END="0.06047727526813997" LOG_CI_START="-0.10013457533058383" LOG_EFFECT_SIZE="-0.019828650031221938" ORDER="591" O_E="0.0" SE="0.09434419608317311" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.008900827334580218" WEIGHT="12.953299763521002"/>
<DICH_DATA CI_END="5.907317036986026" CI_START="0.3009450426728439" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="592" O_E="0.0" SE="0.7594576724769808" STUDY_ID="STD-Munoz-1985" TOTAL_1="305" TOTAL_2="305" VAR="0.576775956284153" WEIGHT="0.6877921477067274"/>
<DICH_DATA CI_END="1.2536238796830856" CI_START="0.880081008452458" EFFECT_SIZE="1.0503763936092494" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="209" LOG_CI_END="0.09816725620767691" LOG_CI_START="-0.0554773506854328" LOG_EFFECT_SIZE="0.02134495276112205" ORDER="593" O_E="0.0" SE="0.0902516026420828" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.008145351779464408" WEIGHT="13.26807740546906"/>
<DICH_DATA CI_END="0.9364828215969734" CI_START="0.22845861427814007" EFFECT_SIZE="0.4625446656457376" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.028500184710599438" LOG_CI_START="-0.6411924617582907" LOG_EFFECT_SIZE="-0.3348463232344451" ORDER="594" O_E="0.0" SE="0.3598984764134988" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.12952691332475774" WEIGHT="2.7053343655484494"/>
<DICH_DATA CI_END="1.2152535685037456" CI_START="0.8379597303617472" EFFECT_SIZE="1.0091251421823508" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="217" LOG_CI_END="0.08466690502262168" LOG_CI_START="-0.07677685165839208" LOG_EFFECT_SIZE="0.003945026682114812" ORDER="595" O_E="0.0" SE="0.09483286183391172" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.008993271683609791" WEIGHT="12.91580442374561"/>
<DICH_DATA CI_END="28.79116539740041" CI_START="0.3125958909885815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4592592444340635" LOG_CI_START="-0.5050167349947388" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="596" O_E="0.0" SE="1.1538254336393923" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="1.3313131313131314" WEIGHT="0.30458194653993903"/>
<DICH_DATA CI_END="1.6766445283678897" CI_START="0.6042793639185033" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" ORDER="597" O_E="0.0" SE="0.26033977271612496" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.06777679725788362" WEIGHT="4.546771560354169"/>
<DICH_DATA CI_END="1.3174698521080426" CI_START="0.5254207926640037" EFFECT_SIZE="0.8320012343774109" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.11974068596206247" LOG_CI_START="-0.2794927447197962" LOG_EFFECT_SIZE="-0.07987602937886684" ORDER="598" O_E="0.0" SE="0.234511693419878" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.05499573435065884" WEIGHT="5.292390711911056"/>
<DICH_DATA CI_END="1.3190164139133533" CI_START="0.8808366543562658" EFFECT_SIZE="1.07788589612836" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="180" LOG_CI_END="0.12025019996459278" LOG_CI_START="-0.055104621314410615" LOG_EFFECT_SIZE="0.03257278932509107" ORDER="599" O_E="0.0" SE="0.10300429003965118" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.010609883766572584" WEIGHT="12.29350683753719"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.975148864577312" CI_END="0.778989776042932" CI_START="0.4144858041298798" DF="4.0" EFFECT_SIZE="0.5682254866970591" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="143" I2="19.6003957091676" ID="CMP-001.03.02" LOG_CI_END="-0.10846824224691667" LOG_CI_START="-0.38249033916348973" LOG_EFFECT_SIZE="-0.24547929070520316" NO="2" P_CHI2="0.2898569600724702" P_Z="4.453864074876592E-4" STUDIES="5" TAU2="0.026046556614936964" TOTAL_1="5313" TOTAL_2="4657" WEIGHT="100.0" Z="3.51161876466567">
<NAME>Unclear/Inadequate</NAME>
<DICH_DATA CI_END="0.7747710510865886" CI_START="0.3372958240464894" EFFECT_SIZE="0.5112015650637385" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" LOG_CI_END="-0.11082661483499756" LOG_CI_START="-0.47198903564089956" LOG_EFFECT_SIZE="-0.29140782523794856" ORDER="600" O_E="0.0" SE="0.2121485937642028" STUDY_ID="STD-Li-2000" TOTAL_1="1112" TOTAL_2="953" VAR="0.045007025836128756" WEIGHT="36.69223166892804"/>
<DICH_DATA CI_END="1.1308920527482222" CI_START="0.5190108835327407" EFFECT_SIZE="0.7661235432206803" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" LOG_CI_END="0.053421152110974306" LOG_CI_START="-0.2848235350057731" LOG_EFFECT_SIZE="-0.1157011914473994" ORDER="601" O_E="0.0" SE="0.198686603550582" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.03947636643046615" WEIGHT="39.94334459511091"/>
<DICH_DATA CI_END="1.2464473248619825" CI_START="0.24153464224020815" EFFECT_SIZE="0.5486895376092052" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.09567392984729235" LOG_CI_START="-0.617020571517862" LOG_EFFECT_SIZE="-0.2606733208352848" ORDER="602" O_E="0.0" SE="0.4186402779965706" STUDY_ID="STD-Yu-1991" TOTAL_1="1444" TOTAL_2="1030" VAR="0.17525968236104592" WEIGHT="12.579228384672438"/>
<DICH_DATA CI_END="1.1081247464231647" CI_START="0.11932898835216686" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04458865356357585" LOG_CI_START="-0.9232540412241012" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="603" O_E="0.0" SE="0.5685155898168872" STUDY_ID="STD-Yu-1997" TOTAL_1="113" TOTAL_2="113" VAR="0.3232099758648431" WEIGHT="7.20270139464088"/>
<DICH_DATA CI_END="0.9138437320595765" CI_START="0.03666667678448441" EFFECT_SIZE="0.18305084745762712" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.03912806258836465" LOG_CI_START="-1.4357284497220244" LOG_EFFECT_SIZE="-0.7374282561551945" ORDER="604" O_E="0.0" SE="0.820369980685724" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="0.673006905210295" WEIGHT="3.5824939566477334"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.14435900873384" CI_END="1.0682115538870285" CI_START="0.8460152062844355" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9506435810108601" ESTIMABLE="YES" EVENTS_1="2057" EVENTS_2="1546" I2="50.21139510731028" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.028657271032710742" LOG_CI_START="-0.0726218308781514" LOG_EFFECT_SIZE="-0.021982279922720338" METHOD="MH" NO="4" P_CHI2="0.008043077373301233" P_Q="0.0" P_Z="0.39487666321275783" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.022942946833060064" TOTALS="SUB" TOTAL_1="94713" TOTAL_2="78815" WEIGHT="200.00000000000003" Z="0.850806852227606">
<NAME>Occurrence of gastrointestinal cancers - follow-up</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="29.883964414878808" CI_END="1.098649506638937" CI_START="0.8680477303459812" DF="15.0" EFFECT_SIZE="0.9765655178653715" ESTIMABLE="YES" EVENTS_1="2003" EVENTS_2="1476" I2="49.80585643940966" ID="CMP-001.04.01" LOG_CI_END="0.040859165025482716" LOG_CI_START="-0.06145639411386881" LOG_EFFECT_SIZE="-0.01029861454419305" NO="1" P_CHI2="0.012346867764235547" P_Z="0.6931661954238257" STUDIES="16" TAU2="0.020876427700320676" TOTAL_1="90743" TOTAL_2="75278" WEIGHT="100.00000000000003" Z="0.394561956501403">
<NAME>Adequate</NAME>
<DICH_DATA CI_END="1.340999325624364" CI_START="0.990163570256729" EFFECT_SIZE="1.1523058100921326" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="209" LOG_CI_END="0.12742855944914472" LOG_CI_START="-0.004293056117563228" LOG_EFFECT_SIZE="0.06156775166579072" ORDER="605" O_E="0.0" SE="0.07737392901639713" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.005986724891434462" WEIGHT="13.219725438674907"/>
<DICH_DATA CI_END="1.31769754324871" CI_START="0.9145273190467578" EFFECT_SIZE="1.0977569865602048" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="209" LOG_CI_END="0.11981573622747665" LOG_CI_START="-0.038803316612883304" LOG_EFFECT_SIZE="0.04050620980729665" ORDER="606" O_E="0.0" SE="0.09317361681540218" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.008681322870463394" WEIGHT="12.09331696238994"/>
<DICH_DATA CI_END="33.06931031113999" CI_START="0.07730830538458316" EFFECT_SIZE="1.5989159891598916" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5194251374238459" LOG_CI_START="-1.111773846457678" LOG_EFFECT_SIZE="0.20382564548308382" ORDER="607" O_E="0.0" SE="1.5455793077770363" STUDY_ID="STD-Correa-2000" TOTAL_1="368" TOTAL_2="117" VAR="2.3888153966285426" WEIGHT="0.15857406205959015"/>
<DICH_DATA CI_END="1.7221002259380627" CI_START="0.8577277809800483" EFFECT_SIZE="1.2153572336638698" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.2360584237176191" LOG_CI_START="-0.06665052331287476" LOG_EFFECT_SIZE="0.08470395020237217" ORDER="608" O_E="0.0" SE="0.17781273391916638" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.031617368343808266" WEIGHT="7.009532771008565"/>
<DICH_DATA CI_END="1.1494160979261696" CI_START="0.7940821334524522" EFFECT_SIZE="0.9553694506659742" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="225" LOG_CI_END="0.06047727526813997" LOG_CI_START="-0.10013457533058383" LOG_EFFECT_SIZE="-0.019828650031221938" ORDER="609" O_E="0.0" SE="0.09434419608317311" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.008900827334580218" WEIGHT="12.009955704856534"/>
<DICH_DATA CI_END="0.7747710510865886" CI_START="0.3372958240464894" EFFECT_SIZE="0.5112015650637385" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" LOG_CI_END="-0.11082661483499756" LOG_CI_START="-0.47198903564089956" LOG_EFFECT_SIZE="-0.29140782523794856" ORDER="610" O_E="0.0" SE="0.2121485937642028" STUDY_ID="STD-Li-2000" TOTAL_1="1112" TOTAL_2="953" VAR="0.045007025836128756" WEIGHT="5.628292436418137"/>
<DICH_DATA CI_END="5.907317036986026" CI_START="0.3009450426728439" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="611" O_E="0.0" SE="0.7594576724769808" STUDY_ID="STD-Munoz-1985" TOTAL_1="305" TOTAL_2="305" VAR="0.576775956284153" WEIGHT="0.6377026224135333"/>
<DICH_DATA CI_END="1.2536238796830856" CI_START="0.880081008452458" EFFECT_SIZE="1.0503763936092494" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="209" LOG_CI_END="0.09816725620767691" LOG_CI_START="-0.0554773506854328" LOG_EFFECT_SIZE="0.02134495276112205" ORDER="612" O_E="0.0" SE="0.0902516026420828" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.008145351779464408" WEIGHT="12.301809178928204"/>
<DICH_DATA CI_END="0.9364828215969734" CI_START="0.22845861427814007" EFFECT_SIZE="0.4625446656457376" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.028500184710599438" LOG_CI_START="-0.6411924617582907" LOG_EFFECT_SIZE="-0.3348463232344451" ORDER="613" O_E="0.0" SE="0.3598984764134988" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.12952691332475774" WEIGHT="2.5083142126119737"/>
<DICH_DATA CI_END="1.2152535685037456" CI_START="0.8379597303617472" EFFECT_SIZE="1.0091251421823508" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="217" LOG_CI_END="0.08466690502262168" LOG_CI_START="-0.07677685165839208" LOG_EFFECT_SIZE="0.003945026682114812" ORDER="614" O_E="0.0" SE="0.09483286183391172" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.008993271683609791" WEIGHT="11.975191021103196"/>
<DICH_DATA CI_END="28.79116539740041" CI_START="0.3125958909885815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4592592444340635" LOG_CI_START="-0.5050167349947388" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="615" O_E="0.0" SE="1.1538254336393923" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="1.3313131313131314" WEIGHT="0.28240029592655075"/>
<DICH_DATA CI_END="1.6766445283678897" CI_START="0.6042793639185033" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" ORDER="616" O_E="0.0" SE="0.26033977271612496" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.06777679725788362" WEIGHT="4.215645900030627"/>
<DICH_DATA CI_END="1.3174698521080426" CI_START="0.5254207926640037" EFFECT_SIZE="0.8320012343774109" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.11974068596206247" LOG_CI_START="-0.2794927447197962" LOG_EFFECT_SIZE="-0.07987602937886684" ORDER="617" O_E="0.0" SE="0.234511693419878" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.05499573435065884" WEIGHT="4.9069641854384525"/>
<DICH_DATA CI_END="1.3190164139133533" CI_START="0.8808366543562658" EFFECT_SIZE="1.07788589612836" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="180" LOG_CI_END="0.12025019996459278" LOG_CI_START="-0.055104621314410615" LOG_EFFECT_SIZE="0.03257278932509107" ORDER="618" O_E="0.0" SE="0.10300429003965118" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.010609883766572584" WEIGHT="11.3982132176056"/>
<DICH_DATA CI_END="1.1081247464231647" CI_START="0.11932898835216686" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04458865356357585" LOG_CI_START="-0.9232540412241012" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="619" O_E="0.0" SE="0.5685155898168872" STUDY_ID="STD-Yu-1997" TOTAL_1="113" TOTAL_2="113" VAR="0.3232099758648431" WEIGHT="1.1048363083231338"/>
<DICH_DATA CI_END="0.9138437320595765" CI_START="0.03666667678448441" EFFECT_SIZE="0.18305084745762712" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.03912806258836465" LOG_CI_START="-1.4357284497220244" LOG_EFFECT_SIZE="-0.7374282561551945" ORDER="620" O_E="0.0" SE="0.820369980685724" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="0.673006905210295" WEIGHT="0.549525682211065"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5189141042145974" CI_END="1.024320128556456" CI_START="0.5068267336767361" DF="1.0" EFFECT_SIZE="0.720522605471614" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="70" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.010435706969813814" LOG_CI_START="-0.29514048537881493" LOG_EFFECT_SIZE="-0.14235238920450058" NO="2" P_CHI2="0.47130532846654316" P_Z="0.06783597545026931" STUDIES="2" TAU2="0.0" TOTAL_1="3970" TOTAL_2="3537" WEIGHT="100.0" Z="1.8260948525448932">
<NAME>Unclear/Inadequate</NAME>
<DICH_DATA CI_END="1.1308920527482222" CI_START="0.5190108835327407" EFFECT_SIZE="0.7661235432206803" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" LOG_CI_END="0.053421152110974306" LOG_CI_START="-0.2848235350057731" LOG_EFFECT_SIZE="-0.1157011914473994" ORDER="621" O_E="0.0" SE="0.198686603550582" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.03947636643046615" WEIGHT="76.04986261904124"/>
<DICH_DATA CI_END="1.2464473248619825" CI_START="0.24153464224020815" EFFECT_SIZE="0.5486895376092052" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.09567392984729235" LOG_CI_START="-0.617020571517862" LOG_EFFECT_SIZE="-0.2606733208352848" ORDER="622" O_E="0.0" SE="0.4186402779965706" STUDY_ID="STD-Yu-1991" TOTAL_1="1444" TOTAL_2="1030" VAR="0.17525968236104592" WEIGHT="23.95013738095877"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.51392718524324" CI_END="1.0799742303511093" CI_START="0.8594711171143872" CI_STUDY="95" CI_TOTAL="95" DF="18.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9634348230236534" ESTIMABLE="YES" EVENTS_1="1794" EVENTS_2="1727" I2="50.70374131853303" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.03341339275561977" LOG_CI_START="-0.06576871337903291" LOG_EFFECT_SIZE="-0.016177660311706605" METHOD="MH" NO="5" P_CHI2="0.006059492800611133" P_Q="0.0" P_Z="0.5225743956800001" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02300261829018196" TOTALS="SUB" TOTAL_1="70015" TOTAL_2="68904" WEIGHT="1100.0" Z="0.6393820982591495">
<NAME>Occurrence of all gastrointestinal cancers - different antioxidants</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.224698964865958" CI_END="1.3540481309603822" CI_START="0.8039482823323162" DF="3.0" EFFECT_SIZE="1.0433526101375712" ESTIMABLE="YES" EVENTS_1="465" EVENTS_2="431" I2="51.804898245957155" ID="CMP-001.05.01" LOG_CI_END="0.1316341020440955" LOG_CI_START="-0.0947718883412506" LOG_EFFECT_SIZE="0.018431106851422494" NO="1" P_CHI2="0.10117553992215678" P_Z="0.749642446090195" STUDIES="4" TAU2="0.027728932836987612" TOTAL_1="18553" TOTAL_2="18493" WEIGHT="100.0" Z="0.3191108641826429">
<NAME>Beta-carotene</NAME>
<DICH_DATA CI_END="1.3957626278825133" CI_START="0.9698500646796545" EFFECT_SIZE="1.1634777500791753" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="209" LOG_CI_END="0.14481156573248666" LOG_CI_START="-0.01329540090423428" LOG_EFFECT_SIZE="0.06575808241412617" ORDER="623" O_E="0.0" SE="0.09287281484451704" STUDY_ID="STD-ATBC-2003" TOTAL_1="7282" TOTAL_2="7287" VAR="0.008625359737143944" WEIGHT="48.88118832228412"/>
<DICH_DATA CI_END="72.89590292084497" CI_START="0.12346372895295321" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86270311969148" LOG_CI_START="-0.9084606102521554" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="624" O_E="0.0" SE="1.6277952924505874" STUDY_ID="STD-Correa-2000" TOTAL_1="117" TOTAL_2="117" VAR="2.6497175141242937" WEIGHT="0.5784418396288084"/>
<DICH_DATA CI_END="1.2152535685037456" CI_START="0.8379597303617472" EFFECT_SIZE="1.0091251421823508" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="217" LOG_CI_END="0.08466690502262168" LOG_CI_START="-0.07677685165839208" LOG_EFFECT_SIZE="0.003945026682114812" ORDER="625" O_E="0.0" SE="0.09483286183391172" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.008993271683609791" WEIGHT="48.319116970121506"/>
<DICH_DATA CI_END="0.9138437320595765" CI_START="0.03666667678448441" EFFECT_SIZE="0.18305084745762712" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.03912806258836465" LOG_CI_START="-1.4357284497220244" LOG_EFFECT_SIZE="-0.7374282561551945" ORDER="626" O_E="0.0" SE="0.820369980685724" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="0.673006905210295" WEIGHT="2.2212528679655663"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin C</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="627" O_E="0.0" SE="0.0" STUDY_ID="STD-Correa-2000" TOTAL_1="130" TOTAL_2="117" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3400726381409944" CI_START="0.9277055083897393" DF="0.0" EFFECT_SIZE="1.1149855461151819" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="209" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.1271283397743712" LOG_CI_START="-0.0325898647066495" LOG_EFFECT_SIZE="0.04726923753386084" NO="3" P_CHI2="1.0" P_Z="0.246000678596622" STUDIES="1" TAU2="0.0" TOTAL_1="7286" TOTAL_2="7287" WEIGHT="100.0" Z="1.160118265091633">
<NAME>Vitamin E</NAME>
<DICH_DATA CI_END="1.3400726381409944" CI_START="0.9277055083897393" EFFECT_SIZE="1.1149855461151819" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="209" LOG_CI_END="0.1271283397743712" LOG_CI_START="-0.0325898647066495" LOG_EFFECT_SIZE="0.04726923753386084" ORDER="628" O_E="0.0" SE="0.09381926393001463" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="0.008802054284369745" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.396101875427626" CI_END="0.7494842630420355" CI_START="0.45928189671362235" DF="4.0" EFFECT_SIZE="0.586706531314385" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="162" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="-0.12523748162258272" LOG_CI_START="-0.33792067261457265" LOG_EFFECT_SIZE="-0.23157907711857775" NO="4" P_CHI2="0.4938513146284017" P_Z="1.9706115916947886E-5" STUDIES="5" TAU2="0.0" TOTAL_1="5848" TOTAL_2="5262" WEIGHT="100.0" Z="4.2681948545950705">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="0.7747710510865886" CI_START="0.3372958240464894" EFFECT_SIZE="0.5112015650637385" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" LOG_CI_END="-0.11082661483499756" LOG_CI_START="-0.47198903564089956" LOG_EFFECT_SIZE="-0.29140782523794856" ORDER="629" O_E="0.0" SE="0.2121485937642028" STUDY_ID="STD-Li-2000" TOTAL_1="1112" TOTAL_2="953" VAR="0.045007025836128756" WEIGHT="32.53231783049598"/>
<DICH_DATA CI_END="1.1308920527482222" CI_START="0.5190108835327407" EFFECT_SIZE="0.7661235432206803" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" LOG_CI_END="0.053421152110974306" LOG_CI_START="-0.2848235350057731" LOG_EFFECT_SIZE="-0.1157011914473994" ORDER="630" O_E="0.0" SE="0.198686603550582" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.03947636643046615" WEIGHT="35.412088851131266"/>
<DICH_DATA CI_END="0.9364828215969734" CI_START="0.22845861427814007" EFFECT_SIZE="0.4625446656457376" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.028500184710599438" LOG_CI_START="-0.6411924617582907" LOG_EFFECT_SIZE="-0.3348463232344451" ORDER="631" O_E="0.0" SE="0.3598984764134988" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.12952691332475774" WEIGHT="14.505462219877142"/>
<DICH_DATA CI_END="1.2464473248619825" CI_START="0.24153464224020815" EFFECT_SIZE="0.5486895376092052" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.09567392984729235" LOG_CI_START="-0.617020571517862" LOG_EFFECT_SIZE="-0.2606733208352848" ORDER="632" O_E="0.0" SE="0.4186402779965706" STUDY_ID="STD-Yu-1991" TOTAL_1="1444" TOTAL_2="1030" VAR="0.17525968236104592" WEIGHT="11.15951621154741"/>
<DICH_DATA CI_END="1.1081247464231647" CI_START="0.11932898835216686" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04458865356357585" LOG_CI_START="-0.9232540412241012" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="633" O_E="0.0" SE="0.5685155898168872" STUDY_ID="STD-Yu-1997" TOTAL_1="113" TOTAL_2="113" VAR="0.3232099758648431" WEIGHT="6.390614886948216"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.31769754324871" CI_START="0.9145273190467578" DF="0.0" EFFECT_SIZE="1.0977569865602048" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="209" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="0.11981573622747665" LOG_CI_START="-0.038803316612883304" LOG_EFFECT_SIZE="0.04050620980729665" NO="5" P_CHI2="1.0" P_Z="0.3168153835795421" STUDIES="1" TAU2="0.0" TOTAL_1="9420" TOTAL_2="8894" WEIGHT="100.0" Z="1.0010236595275386">
<NAME>Vitamin A and beta-carotene</NAME>
<DICH_DATA CI_END="1.31769754324871" CI_START="0.9145273190467578" EFFECT_SIZE="1.0977569865602048" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="209" LOG_CI_END="0.11981573622747665" LOG_CI_START="-0.038803316612883304" LOG_EFFECT_SIZE="0.04050620980729665" ORDER="634" O_E="0.0" SE="0.09317361681540218" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.008681322870463394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.5176680113517" CI_START="0.1193957645169942" DF="0.0" EFFECT_SIZE="2.9016393442622954" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.05.06" LOG_CI_END="1.8482979419348913" LOG_CI_START="-0.9230110792328121" LOG_EFFECT_SIZE="0.46264343135103964" NO="6" P_CHI2="1.0" P_Z="0.5128577867427606" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="117" WEIGHT="100.00000000000001" Z="0.6543943358218474">
<NAME>Beta-carotene and vitamin C</NAME>
<DICH_DATA CI_END="70.5176680113517" CI_START="0.1193957645169942" EFFECT_SIZE="2.901639344262295" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8482979419348913" LOG_CI_START="-0.9230110792328121" LOG_EFFECT_SIZE="0.4626434313510396" ORDER="635" O_E="0.0" SE="1.627880637234808" STUDY_ID="STD-Correa-2000" TOTAL_1="121" TOTAL_2="117" VAR="2.649995369084005" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.413020160592601" CI_START="0.9828850293725345" DF="0.0" EFFECT_SIZE="1.1784890165156576" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="209" I2="0.0" ID="CMP-001.05.07" LOG_CI_END="0.15014835828992923" LOG_CI_START="-0.007497279756126264" LOG_EFFECT_SIZE="0.07132553926690147" NO="7" P_CHI2="1.0" P_Z="0.07613913189791972" STUDIES="1" TAU2="0.0" TOTAL_1="7278" TOTAL_2="7287" WEIGHT="100.0" Z="1.7735408333998266">
<NAME>Beta carotene and vitamin E</NAME>
<DICH_DATA CI_END="1.413020160592601" CI_START="0.9828850293725345" EFFECT_SIZE="1.1784890165156576" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="209" LOG_CI_END="0.15014835828992923" LOG_CI_START="-0.007497279756126264" LOG_EFFECT_SIZE="0.07132553926690147" ORDER="636" O_E="0.0" SE="0.09260182814674676" STUDY_ID="STD-ATBC-2003" TOTAL_1="7278" TOTAL_2="7287" VAR="0.00857509857611962" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.907317036986026" CI_START="0.3009450426728439" DF="0.0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.05.08" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" NO="8" P_CHI2="1.0" P_Z="0.7048368711510071" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="305" WEIGHT="100.0" Z="0.37879934969055234">
<NAME>Vitamin A, riboflavin, and zinc</NAME>
<DICH_DATA CI_END="5.907317036986026" CI_START="0.3009450426728439" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="637" O_E="0.0" SE="0.7594576724769808" STUDY_ID="STD-Munoz-1985" TOTAL_1="305" TOTAL_2="305" VAR="0.576775956284153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9773493580741227" CI_END="1.1574722253420167" CI_START="0.8006320217456451" DF="1.0" EFFECT_SIZE="0.9626574301848034" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="226" I2="0.0" ID="CMP-001.05.09" LOG_CI_END="0.06351057850172123" LOG_CI_START="-0.09656704402191517" LOG_EFFECT_SIZE="-0.016528232760096965" NO="9" P_CHI2="0.32285429990849346" P_Z="0.685670176219788" STUDIES="2" TAU2="0.0" TOTAL_1="11259" TOTAL_2="11257" WEIGHT="100.00000000000001" Z="0.40473790686267586">
<NAME>Beta-carotene, vitamin C, and vitamin E</NAME>
<DICH_DATA CI_END="1.1494160979261696" CI_START="0.7940821334524522" EFFECT_SIZE="0.9553694506659742" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="225" LOG_CI_END="0.06047727526813997" LOG_CI_START="-0.10013457533058383" LOG_EFFECT_SIZE="-0.019828650031221938" ORDER="638" O_E="0.0" SE="0.09434419608317311" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.008900827334580218" WEIGHT="97.69852807300704"/>
<DICH_DATA CI_END="28.79116539740041" CI_START="0.3125958909885815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4592592444340635" LOG_CI_START="-0.5050167349947388" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="639" O_E="0.0" SE="1.1538254336393923" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="1.3313131313131314" WEIGHT="2.301471926992981"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6766445283678897" CI_START="0.6042793639185033" DF="0.0" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" ID="CMP-001.05.10" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" NO="10" P_CHI2="1.0" P_Z="0.9799648290496709" STUDIES="1" TAU2="0.0" TOTAL_1="1677" TOTAL_2="1688" WEIGHT="100.00000000000001" Z="0.02511300238332238">
<NAME>Vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="1.6766445283678897" CI_START="0.6042793639185033" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" ORDER="640" O_E="0.0" SE="0.26033977271612496" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.06777679725788362" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3174698521080426" CI_START="0.5254207926640037" DF="0.0" EFFECT_SIZE="0.8320012343774109" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" I2="0.0" ID="CMP-001.05.11" LOG_CI_END="0.11974068596206247" LOG_CI_START="-0.2794927447197962" LOG_EFFECT_SIZE="-0.07987602937886684" NO="11" P_CHI2="1.0" P_Z="0.43287953231624254" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="0.7842737044503533">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="1.3174698521080426" CI_START="0.5254207926640037" EFFECT_SIZE="0.8320012343774109" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.11974068596206247" LOG_CI_START="-0.2794927447197962" LOG_EFFECT_SIZE="-0.07987602937886684" ORDER="641" O_E="0.0" SE="0.234511693419878" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.05499573435065884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2536238796830856" CI_START="0.880081008452458" DF="0.0" EFFECT_SIZE="1.0503763936092494" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="209" I2="0.0" ID="CMP-001.05.12" LOG_CI_END="0.09816725620767691" LOG_CI_START="-0.0554773506854328" LOG_EFFECT_SIZE="0.02134495276112205" NO="12" P_CHI2="1.0" P_Z="0.5860473527670135" STUDIES="1" TAU2="0.0" TOTAL_1="1657" TOTAL_2="1661" WEIGHT="100.0" Z="0.5445728230814217">
<NAME>Combination of antioxidants (13 vitamins and 13 minerals)</NAME>
<DICH_DATA CI_END="1.2536238796830856" CI_START="0.880081008452458" EFFECT_SIZE="1.0503763936092494" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="209" LOG_CI_END="0.09816725620767691" LOG_CI_START="-0.0554773506854328" LOG_EFFECT_SIZE="0.02134495276112205" ORDER="642" O_E="0.0" SE="0.0902516026420828" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.008145351779464408" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="58.015486345651745" CI_END="1.1025979954075575" CI_START="0.9306084504560734" CI_STUDY="95" CI_TOTAL="95" DF="47.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0129595312657855" ESTIMABLE="YES" EVENTS_1="2054" EVENTS_2="1543" I2="18.987148155618893" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.042417198569308985" LOG_CI_START="-0.031233008142984155" LOG_EFFECT_SIZE="0.005592095213162424" METHOD="MH" NO="6" P_CHI2="0.13020236594061674" P_Q="0.0" P_Z="0.7659845451216792" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01401003262705951" TOTALS="SUB" TOTAL_1="440024" TOTAL_2="363926" WEIGHT="700.0" Z="0.29763134973218597">
<NAME>Occurrence of different gastrointestinal cancers - all antioxidants</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.508138244904436" CI_END="1.275876239788126" CI_START="0.8866990509989877" DF="8.0" EFFECT_SIZE="1.0636344536598503" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="210" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.10580854978967909" LOG_CI_START="-0.05222375634424276" LOG_EFFECT_SIZE="0.02679239672271817" NO="1" P_CHI2="0.7021382188264653" P_Z="0.5063225889804903" STUDIES="9" TAU2="0.0" TOTAL_1="70686" TOTAL_2="55602" WEIGHT="99.99999999999999" Z="0.6645746546473356">
<NAME>Occurrence of oesophageal cancer</NAME>
<DICH_DATA CI_END="2.2275232003842045" CI_START="0.6528906597286148" EFFECT_SIZE="1.2059556757441954" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="13" LOG_CI_END="0.3478222360518379" LOG_CI_START="-0.18515954437966536" LOG_EFFECT_SIZE="0.08133134583608626" ORDER="643" O_E="0.0" SE="0.31307613612782814" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.09801666701273039" WEIGHT="11.782048898332842"/>
<DICH_DATA CI_END="2.287216218849148" CI_START="0.8972109800564477" EFFECT_SIZE="1.4325206823339922" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="29" LOG_CI_END="0.3593072219807972" LOG_CI_START="-0.047105420166257544" LOG_EFFECT_SIZE="0.1561009009072698" ORDER="644" O_E="0.0" SE="0.23872879777220407" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.05699143888576191" WEIGHT="18.589812646861873"/>
<DICH_DATA CI_END="2.006102772625904" CI_START="0.7083604903465844" EFFECT_SIZE="1.192075477351551" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.30235317815648916" LOG_CI_START="-0.14974567010050938" LOG_EFFECT_SIZE="0.0763037540279899" ORDER="645" O_E="0.0" SE="0.2655651013915526" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.0705248230771056" WEIGHT="15.613725747565425"/>
<DICH_DATA CI_END="5.907317036986026" CI_START="0.3009450426728439" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="646" O_E="0.0" SE="0.7594576724769808" STUDY_ID="STD-Munoz-1985" TOTAL_1="305" TOTAL_2="305" VAR="0.576775956284153" WEIGHT="2.234149214519059"/>
<DICH_DATA CI_END="1.222010357505382" CI_START="0.7592934347142659" EFFECT_SIZE="0.9632572042848522" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="128" LOG_CI_END="0.08707488691174876" LOG_CI_START="-0.1195903552645741" LOG_EFFECT_SIZE="-0.016257734176412682" ORDER="647" O_E="0.0" SE="0.1213961862638197" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.014737034039400007" WEIGHT="45.914390792951465"/>
<DICH_DATA CI_END="2.073222534579518" CI_START="0.07859927291478755" EFFECT_SIZE="0.4036753445635528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3166459206914899" LOG_CI_START="-1.1045814713976934" LOG_EFFECT_SIZE="-0.3939677753531017" ORDER="648" O_E="0.0" SE="0.8348360053022391" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.6969511557490001" WEIGHT="1.8565064797555355"/>
<DICH_DATA CI_END="7.1571607212389345" CI_START="0.14210170024938246" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8547407698426231" LOG_CI_START="-0.8474007257002072" LOG_EFFECT_SIZE="0.003670022071208049" ORDER="649" O_E="0.0" SE="0.99984634021815" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.9996927040476286" WEIGHT="1.3020622371057355"/>
<DICH_DATA CI_END="5.957201887541498" CI_START="0.2984848437790006" EFFECT_SIZE="1.3334670879938473" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7750423184402113" LOG_CI_START="-0.5250777162272691" LOG_EFFECT_SIZE="0.12498230110647102" ORDER="650" O_E="0.0" SE="0.7636969440616432" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.5832330223690926" WEIGHT="2.2099948120507733"/>
<DICH_DATA CI_END="3.72181364115683" CI_START="0.00637726293635082" EFFECT_SIZE="0.15406162464985995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5707546233236332" LOG_CI_START="-2.1953656765595317" LOG_EFFECT_SIZE="-0.8123055266179493" ORDER="651" O_E="0.0" SE="1.6248327566676857" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="2.6400814871403107" WEIGHT="0.49730917085728066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.377764081559869" CI_END="1.3313868713800823" CI_START="0.9743117120315261" DF="11.0" EFFECT_SIZE="1.13894065781788" ESTIMABLE="YES" EVENTS_1="443" EVENTS_2="271" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.12430427011955991" LOG_CI_START="-0.011302076840420578" LOG_EFFECT_SIZE="0.056501096639569676" NO="2" P_CHI2="0.587066421494149" P_Z="0.10241462523008875" STUDIES="12" TAU2="0.0" TOTAL_1="86325" TOTAL_2="70975" WEIGHT="99.99999999999997" Z="1.633258575031959">
<NAME>Occurrence of gastric cancer</NAME>
<DICH_DATA CI_END="1.8080941836622688" CI_START="0.9747624153713175" EFFECT_SIZE="1.3275775885745675" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="50" LOG_CI_END="0.25722104913683325" LOG_CI_START="-0.011101224575046356" LOG_EFFECT_SIZE="0.12305991228089345" ORDER="652" O_E="0.0" SE="0.15761383179503416" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.02484211997311332" WEIGHT="22.45091484615641"/>
<DICH_DATA CI_END="1.7291138542482694" CI_START="0.4598558192790922" EFFECT_SIZE="0.8917079499882048" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.2378235905230974" LOG_CI_START="-0.33737831333308477" LOG_EFFECT_SIZE="-0.04977736140499367" ORDER="653" O_E="0.0" SE="0.3378764456204661" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.11416049250511978" WEIGHT="6.8055145183871755"/>
<DICH_DATA CI_END="33.06931031113999" CI_START="0.07730830538458316" EFFECT_SIZE="1.5989159891598916" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5194251374238459" LOG_CI_START="-1.111773846457678" LOG_EFFECT_SIZE="0.20382564548308382" ORDER="654" O_E="0.0" SE="1.5455793077770363" STUDY_ID="STD-Correa-2000" TOTAL_1="368" TOTAL_2="117" VAR="2.3888153966285426" WEIGHT="0.363016954538634"/>
<DICH_DATA CI_END="1.946183108935407" CI_START="0.7396216401898896" EFFECT_SIZE="1.1997662868828514" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" LOG_CI_END="0.2891836989637308" LOG_CI_START="-0.13099039053941078" LOG_EFFECT_SIZE="0.07909665421216004" ORDER="655" O_E="0.0" SE="0.24681234006943253" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.06091633121054921" WEIGHT="11.6416482121948"/>
<DICH_DATA CI_END="1.3062118480409983" CI_START="0.44324262615186216" EFFECT_SIZE="0.7608999736078121" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.11601361872613934" LOG_CI_START="-0.3533584806524692" LOG_EFFECT_SIZE="-0.11867243096316495" ORDER="656" O_E="0.0" SE="0.2757114946043584" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.07601682825696915" WEIGHT="9.688956840781065"/>
<DICH_DATA CI_END="1.584195361598077" CI_START="0.8909594509301666" EFFECT_SIZE="1.1880462236527414" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="81" LOG_CI_END="0.19980873737489688" LOG_CI_START="-0.05014206098894418" LOG_EFFECT_SIZE="0.07483333819297637" ORDER="657" O_E="0.0" SE="0.14682233623532673" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.021556798417599336" WEIGHT="24.524714291276307"/>
<DICH_DATA CI_END="1.7557964632575103" CI_START="0.5164978563242095" EFFECT_SIZE="0.9522946547230708" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.2444741698802098" LOG_CI_START="-0.28693147663903396" LOG_EFFECT_SIZE="-0.021228653379412068" ORDER="658" O_E="0.0" SE="0.3121503072657782" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.09743781432611973" WEIGHT="7.8266776206345705"/>
<DICH_DATA CI_END="28.79116539740041" CI_START="0.3125958909885815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4592592444340635" LOG_CI_START="-0.5050167349947388" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="659" O_E="0.0" SE="1.1538254336393923" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="1.3313131313131314" WEIGHT="0.6483693977747736"/>
<DICH_DATA CI_END="1.6766445283678897" CI_START="0.6042793639185033" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" ORDER="660" O_E="0.0" SE="0.26033977271612496" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.06777679725788362" WEIGHT="10.665120176970424"/>
<DICH_DATA CI_END="7.1571607212389345" CI_START="0.14210170024938246" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8547407698426231" LOG_CI_START="-0.8474007257002072" LOG_EFFECT_SIZE="0.003670022071208049" ORDER="661" O_E="0.0" SE="0.99984634021815" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.9996927040476286" WEIGHT="0.8604755004190914"/>
<DICH_DATA CI_END="6.071229795642176" CI_START="0.8969413137466412" EFFECT_SIZE="2.3335674039892327" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7832766712011726" LOG_CI_START="-0.04723597161564186" LOG_EFFECT_SIZE="0.36802034979276543" ORDER="662" O_E="0.0" SE="0.48784723749448183" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.23799492713099737" WEIGHT="3.4613063586279966"/>
<DICH_DATA CI_END="1.7732471045306726" CI_START="0.05248941439649679" EFFECT_SIZE="0.3050847457627119" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.24876925937782043" LOG_CI_START="-1.2799282724554966" LOG_EFFECT_SIZE="-0.5155795065388381" ORDER="663" O_E="0.0" SE="0.8979644973737149" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="0.8063402385436284" WEIGHT="1.0632852822387435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.78801629266278" CI_START="0.44716673151135455" DF="0.0" EFFECT_SIZE="4.000401263981542" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="1.553737626385914" LOG_CI_START="-0.34953051473364705" LOG_EFFECT_SIZE="0.6021035558261334" NO="3" P_CHI2="1.0" P_Z="0.21494625453063976" STUDIES="1" TAU2="0.0" TOTAL_1="19937" TOTAL_2="19939" WEIGHT="100.0" Z="1.2400788505696854">
<NAME>Occurrence of small intestine cancer</NAME>
<DICH_DATA CI_END="35.78801629266278" CI_START="0.44716673151135455" EFFECT_SIZE="4.000401263981542" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.553737626385914" LOG_CI_START="-0.34953051473364705" LOG_EFFECT_SIZE="0.6021035558261334" ORDER="664" O_E="0.0" SE="1.117989127422874" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="1.2498996890357592" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.96518444033357" CI_END="1.0860451748864772" CI_START="0.861080265288569" DF="8.0" EFFECT_SIZE="0.9670429500837169" ESTIMABLE="YES" EVENTS_1="907" EVENTS_2="755" I2="19.72050243625785" ID="CMP-001.06.04" LOG_CI_END="0.03584789044239909" LOG_CI_START="-0.06495636405483604" LOG_EFFECT_SIZE="-0.014554236806218462" NO="4" P_CHI2="0.26747810217323265" P_Z="0.5714183851855794" STUDIES="9" TAU2="0.0059954041878517925" TOTAL_1="84521" TOTAL_2="69451" WEIGHT="99.99999999999996" Z="0.5659638098595898">
<NAME>Occurrence of colorectal cancer</NAME>
<DICH_DATA CI_END="1.5208833658146783" CI_START="0.9133284615644445" EFFECT_SIZE="1.1785864689187953" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="75" LOG_CI_END="0.18209590996009295" LOG_CI_START="-0.03937300845546616" LOG_EFFECT_SIZE="0.0713614507523134" ORDER="665" O_E="0.0" SE="0.13009193896612628" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.016923912583966326" WEIGHT="15.276920882042127"/>
<DICH_DATA CI_END="1.2470679431410818" CI_START="0.7620782172006979" EFFECT_SIZE="0.9748657932439198" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="123" LOG_CI_END="0.09589011548930976" LOG_CI_START="-0.11800045181611492" LOG_EFFECT_SIZE="-0.011055168163402584" ORDER="666" O_E="0.0" SE="0.12564037801059033" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.01578550458664403" WEIGHT="15.860611277749378"/>
<DICH_DATA CI_END="1.7221002259380627" CI_START="0.8577277809800483" EFFECT_SIZE="1.2153572336638698" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.2360584237176191" LOG_CI_START="-0.06665052331287476" LOG_EFFECT_SIZE="0.08470395020237217" ORDER="667" O_E="0.0" SE="0.17781273391916638" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.031617368343808266" WEIGHT="10.357272680510512"/>
<DICH_DATA CI_END="1.0664246403425315" CI_START="0.6546607403896186" EFFECT_SIZE="0.8355515212219857" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="140" LOG_CI_END="0.027930171140578157" LOG_CI_START="-0.18398370267566055" LOG_EFFECT_SIZE="-0.0780267657675412" ORDER="668" O_E="0.0" SE="0.12447925847025193" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.015495085789303788" WEIGHT="16.016727229814514"/>
<DICH_DATA CI_END="1.0487674833114506" CI_START="0.21789289538699824" EFFECT_SIZE="0.47803659224631256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="0.02067921373415826" LOG_CI_START="-0.6617569301232945" LOG_EFFECT_SIZE="-0.3205388581945681" ORDER="669" O_E="0.0" SE="0.40086636901526135" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.1606938458074797" WEIGHT="2.7050082562153284"/>
<DICH_DATA CI_END="1.1904531728107008" CI_START="0.7835766424266841" EFFECT_SIZE="0.9658215674322054" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="176" LOG_CI_END="0.07571231684304874" LOG_CI_START="-0.10591851833374848" LOG_EFFECT_SIZE="-0.015103100745349887" ORDER="670" O_E="0.0" SE="0.10669085166998511" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.011382937830066766" WEIGHT="18.6104825489467"/>
<DICH_DATA CI_END="1.583379855661148" CI_START="0.49178019497621983" EFFECT_SIZE="0.8824255516124055" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1995851153852671" LOG_CI_START="-0.30822896519822446" LOG_EFFECT_SIZE="-0.05432192490647867" ORDER="671" O_E="0.0" SE="0.2982925046549826" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.08897841833334282" WEIGHT="4.588625512388438"/>
<DICH_DATA CI_END="1.169604626940712" CI_START="0.7260581430086572" EFFECT_SIZE="0.9215210054528908" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="140" LOG_CI_END="0.06803907768051289" LOG_CI_START="-0.139028599442149" LOG_EFFECT_SIZE="-0.03549476088081801" ORDER="672" O_E="0.0" SE="0.12163257854338434" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.014794484163112562" WEIGHT="16.40629617225544"/>
<DICH_DATA CI_END="3.72181364115683" CI_START="0.00637726293635082" EFFECT_SIZE="0.15406162464985995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5707546233236332" LOG_CI_START="-2.1953656765595317" LOG_EFFECT_SIZE="-0.8123055266179493" ORDER="673" O_E="0.0" SE="1.6248327566676857" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="2.6400814871403107" WEIGHT="0.17805544007754814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.286086305724982" CI_END="1.4987836079681507" CI_START="0.8977215671826281" DF="5.0" EFFECT_SIZE="1.159952744474016" ESTIMABLE="YES" EVENTS_1="292" EVENTS_2="159" I2="31.376053066084445" ID="CMP-001.06.05" LOG_CI_END="0.17573893461664367" LOG_CI_START="-0.046858341045927274" LOG_EFFECT_SIZE="0.06444029678535822" NO="5" P_CHI2="0.20021838761769883" P_Z="0.25646303614632815" STUDIES="6" TAU2="0.03111927630758606" TOTAL_1="78989" TOTAL_2="63958" WEIGHT="100.0" Z="1.1347907154428067">
<NAME>Occurrence of pancreatic cancer</NAME>
<DICH_DATA CI_END="1.19590172330468" CI_START="0.6587998175751058" EFFECT_SIZE="0.8876146895758755" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="59" LOG_CI_END="0.07769549170912471" LOG_CI_START="-0.18124652976053449" LOG_EFFECT_SIZE="-0.05177551902570487" ORDER="674" O_E="0.0" SE="0.1521038251949564" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.023135573638937854" WEIGHT="36.087236994587485"/>
<DICH_DATA CI_END="2.0870766187254506" CI_START="0.8446545440260289" EFFECT_SIZE="1.3277269108280254" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" LOG_CI_END="0.31953839275442614" LOG_CI_START="-0.0733208772034738" LOG_EFFECT_SIZE="0.12310875777547614" ORDER="675" O_E="0.0" SE="0.23076747985802018" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.05325362976002175" WEIGHT="19.92877356149039"/>
<DICH_DATA CI_END="1.7593360082609828" CI_START="0.5681748747119498" EFFECT_SIZE="0.9998052390690427" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.24534879147439184" LOG_CI_START="-0.24551797514532142" LOG_EFFECT_SIZE="-8.459183546481616E-5" ORDER="676" O_E="0.0" SE="0.28833756854210213" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.08313855343277143" WEIGHT="13.79826872419036"/>
<DICH_DATA CI_END="2.5613721011950057" CI_START="0.8207003545280093" EFFECT_SIZE="1.4498686118158752" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="20" LOG_CI_END="0.408472674820195" LOG_CI_START="-0.08581537896919325" LOG_EFFECT_SIZE="0.16132864792550086" ORDER="677" O_E="0.0" SE="0.2903472495612138" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.08430152532776178" WEIGHT="13.63504276114406"/>
<DICH_DATA CI_END="2.3813561225099487" CI_START="0.18981615798801132" EFFECT_SIZE="0.672324229799928" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3768243473056877" LOG_CI_START="-0.721666821274634" LOG_EFFECT_SIZE="-0.17242123698447315" ORDER="678" O_E="0.0" SE="0.6452591500430623" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.4163593707142952" WEIGHT="3.114724899635708"/>
<DICH_DATA CI_END="3.2550317772524826" CI_START="1.0327965197888263" EFFECT_SIZE="1.83351724599154" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" LOG_CI_END="0.5125552327254207" LOG_CI_START="0.014014765820084308" LOG_EFFECT_SIZE="0.2632849992727525" ORDER="679" O_E="0.0" SE="0.2928451380753062" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.08575827489434516" WEIGHT="13.435953058951998"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.007755128476875" CI_END="1.1363105557299789" CI_START="0.5614630098420176" DF="8.0" EFFECT_SIZE="0.7987467337870056" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="138" I2="38.49822724225322" ID="CMP-001.06.06" LOG_CI_END="0.05549704106488194" LOG_CI_START="-0.2506788505346115" LOG_EFFECT_SIZE="-0.09759090473486479" NO="6" P_CHI2="0.11158316723199169" P_Z="0.2115031224879914" STUDIES="9" TAU2="0.10020136459099517" TOTAL_1="73148" TOTAL_2="57526" WEIGHT="100.00000000000001" Z="1.249442975407218">
<NAME>Occurrence of hepatocellular carcinoma</NAME>
<DICH_DATA CI_END="2.8041398509999294" CI_START="0.8034873404969682" EFFECT_SIZE="1.501029936830541" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="12" LOG_CI_END="0.4477996694240701" LOG_CI_START="-0.09502096145897161" LOG_EFFECT_SIZE="0.17638935398254926" ORDER="680" O_E="0.0" SE="0.31885552558615704" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="0.10166884619682445" WEIGHT="16.107614568663355"/>
<DICH_DATA CI_END="3.541898058523906" CI_START="0.513641738529163" EFFECT_SIZE="1.348801941158629" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5492360573459654" LOG_CI_START="-0.289339692734402" LOG_EFFECT_SIZE="0.1299481823057816" ORDER="681" O_E="0.0" SE="0.4925835466141174" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.24263855039494236" WEIGHT="7.260163963852856"/>
<DICH_DATA CI_END="4.408739481248463" CI_START="0.4443983637114798" EFFECT_SIZE="1.3997273346966599" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6443144364994874" LOG_CI_START="-0.35222754881394097" LOG_EFFECT_SIZE="0.14604344384277324" ORDER="682" O_E="0.0" SE="0.5853736951354929" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.3426623629565809" WEIGHT="5.224151958217035"/>
<DICH_DATA CI_END="0.7747710510865886" CI_START="0.3372958240464894" EFFECT_SIZE="0.5112015650637385" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" LOG_CI_END="-0.11082661483499756" LOG_CI_START="-0.47198903564089956" LOG_EFFECT_SIZE="-0.29140782523794856" ORDER="683" O_E="0.0" SE="0.2121485937642028" STUDY_ID="STD-Li-2000" TOTAL_1="1112" TOTAL_2="953" VAR="0.045007025836128756" WEIGHT="31.57241045811308"/>
<DICH_DATA CI_END="1.3616780317635189" CI_START="0.43760130218527393" EFFECT_SIZE="0.7719275094572007" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.134074430955321" LOG_CI_START="-0.3589213943276479" LOG_EFFECT_SIZE="-0.11242348168616345" ORDER="684" O_E="0.0" SE="0.2895881881399089" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.08386131871015526" WEIGHT="19.038367902065815"/>
<DICH_DATA CI_END="16.11975014572564" CI_START="0.06309308135993856" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.207358306006691" LOG_CI_START="-1.200018261864275" LOG_EFFECT_SIZE="0.003670022071208049" ORDER="685" O_E="0.0" SE="1.4141049126736065" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="1.9996927040476284" WEIGHT="0.9253157181020668"/>
<DICH_DATA CI_END="3.4540067543366284" CI_START="0.2895769212953282" EFFECT_SIZE="1.0001003159953854" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5383231824984517" LOG_CI_START="-0.5382360535021096" LOG_EFFECT_SIZE="4.3564498171045436E-5" ORDER="686" O_E="0.0" SE="0.6323762242808938" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.3998996890357593" WEIGHT="4.501732373776268"/>
<DICH_DATA CI_END="1.2464473248619825" CI_START="0.24153464224020815" EFFECT_SIZE="0.5486895376092052" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.09567392984729235" LOG_CI_START="-0.617020571517862" LOG_EFFECT_SIZE="-0.2606733208352848" ORDER="687" O_E="0.0" SE="0.4186402779965706" STUDY_ID="STD-Yu-1991" TOTAL_1="1444" TOTAL_2="1030" VAR="0.17525968236104592" WEIGHT="9.844738203084074"/>
<DICH_DATA CI_END="1.1081247464231647" CI_START="0.11932898835216686" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04458865356357585" LOG_CI_START="-0.9232540412241012" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="688" O_E="0.0" SE="0.5685155898168872" STUDY_ID="STD-Yu-1997" TOTAL_1="113" TOTAL_2="113" VAR="0.3232099758648431" WEIGHT="5.525504854125457"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5916646870643536" CI_END="1.7841537604387603" CI_START="0.20850406759212575" DF="1.0" EFFECT_SIZE="0.6099207458852901" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-001.06.07" LOG_CI_END="0.2514322796547528" LOG_CI_START="-0.68088546819342" LOG_EFFECT_SIZE="-0.2147265942693336" NO="7" P_CHI2="0.44177626644574863" P_Z="0.3666227694149161" STUDIES="2" TAU2="0.0" TOTAL_1="26418" TOTAL_2="26475" WEIGHT="100.0" Z="0.9028175045732902">
<NAME>Occurrence of biliary tract cancer</NAME>
<DICH_DATA CI_END="4.200401482099619" CI_START="0.009685189105156838" EFFECT_SIZE="0.20169700709657512" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6232908030472546" LOG_CI_START="-2.0138918951798384" LOG_EFFECT_SIZE="-0.695300546066292" ORDER="689" O_E="0.0" SE="1.5490941712034871" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="2.3996927512566186" WEIGHT="12.877486845074543"/>
<DICH_DATA CI_END="2.250376589059288" CI_START="0.22676491237446933" EFFECT_SIZE="0.7143573685681325" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3522552011624535" LOG_CI_START="-0.6444241435225875" LOG_EFFECT_SIZE="-0.14608447118006695" ORDER="690" O_E="0.0" SE="0.5854543807103181" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.3427568318929021" WEIGHT="87.12251315492546"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.314077407989333" CI_END="1.2769801749773575" CI_START="0.8997054583363053" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0718703436584012" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="233" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.10618415492608489" LOG_CI_START="-0.04589964473349576" LOG_EFFECT_SIZE="0.030142255096294607" METHOD="MH" NO="7" P_CHI2="0.7081190162841337" P_Q="0.0" P_Z="0.43721170685989785" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50749" TOTAL_2="50237" WEIGHT="900.0" Z="0.7769102893772236">
<NAME>Occurrence of oesophageal cancer</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1478458316991367" CI_END="2.3016358530865046" CI_START="0.24627004572500066" DF="1.0" EFFECT_SIZE="0.7528771259521134" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="12.880286499824022" ID="CMP-001.07.01" LOG_CI_END="0.3620366140353599" LOG_CI_START="-0.6085884089788518" LOG_EFFECT_SIZE="-0.1232758974717459" NO="1" P_CHI2="0.2840005916757733" P_Z="0.6185847107841302" STUDIES="2" TAU2="0.20698884678943175" TOTAL_1="7400" TOTAL_2="7341" WEIGHT="100.00000000000001" Z="0.4978571816666149">
<NAME>Beta-carotene</NAME>
<DICH_DATA CI_END="2.0230065957339645" CI_START="0.421769021997465" EFFECT_SIZE="0.923710730357256" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.30599729873036735" LOG_CI_START="-0.37492532139505524" LOG_EFFECT_SIZE="-0.03446401133234393" ORDER="691" O_E="0.0" SE="0.39997731768300354" STUDY_ID="STD-ATBC-2003" TOTAL_1="7282" TOTAL_2="7287" VAR="0.15998185466089032" WEIGHT="94.28649158493756"/>
<DICH_DATA CI_END="3.72181364115683" CI_START="0.00637726293635082" EFFECT_SIZE="0.15406162464985995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5707546233236332" LOG_CI_START="-2.1953656765595317" LOG_EFFECT_SIZE="-0.8123055266179493" ORDER="692" O_E="0.0" SE="1.6248327566676857" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="2.6400814871403107" WEIGHT="5.713508415062445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9574953409742255" CI_START="0.7224630386152446" DF="0.0" EFFECT_SIZE="1.4617390569902236" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.47092406914416796" LOG_CI_START="-0.14118436661439182" LOG_EFFECT_SIZE="0.16486985126488807" NO="2" P_CHI2="1.0" P_Z="0.2910492707196036" STUDIES="1" TAU2="0.0" TOTAL_1="7286" TOTAL_2="7287" WEIGHT="100.0" Z="1.0558226344820876">
<NAME>Vitamin E</NAME>
<DICH_DATA CI_END="2.9574953409742255" CI_START="0.7224630386152446" EFFECT_SIZE="1.4617390569902236" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.47092406914416796" LOG_CI_START="-0.14118436661439182" LOG_EFFECT_SIZE="0.16486985126488807" ORDER="693" O_E="0.0" SE="0.359555525150202" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="0.12928017566603756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.073222534579518" CI_START="0.07859927291478755" DF="0.0" EFFECT_SIZE="0.4036753445635528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.3166459206914899" LOG_CI_START="-1.1045814713976934" LOG_EFFECT_SIZE="-0.3939677753531017" NO="3" P_CHI2="1.0" P_Z="0.27720753907519324" STUDIES="1" TAU2="0.0" TOTAL_1="653" TOTAL_2="659" WEIGHT="100.0" Z="1.0866138030542438">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="2.073222534579518" CI_START="0.07859927291478755" EFFECT_SIZE="0.4036753445635528" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3166459206914899" LOG_CI_START="-1.1045814713976934" LOG_EFFECT_SIZE="-0.3939677753531017" ORDER="694" O_E="0.0" SE="0.8348360053022391" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.6969511557490001" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.287216218849148" CI_START="0.8972109800564477" DF="0.0" EFFECT_SIZE="1.4325206823339922" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="29" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.3593072219807972" LOG_CI_START="-0.047105420166257544" LOG_EFFECT_SIZE="0.1561009009072698" NO="4" P_CHI2="1.0" P_Z="0.1321639390167623" STUDIES="1" TAU2="0.0" TOTAL_1="9420" TOTAL_2="8894" WEIGHT="100.00000000000001" Z="1.5056231622922802">
<NAME>Vitamin A and beta-carotene</NAME>
<DICH_DATA CI_END="2.287216218849148" CI_START="0.8972109800564477" EFFECT_SIZE="1.4325206823339922" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="29" LOG_CI_END="0.3593072219807972" LOG_CI_START="-0.047105420166257544" LOG_EFFECT_SIZE="0.1561009009072698" ORDER="695" O_E="0.0" SE="0.23872879777220407" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.05699143888576191" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.55996313697477" CI_START="0.5931888589203882" DF="0.0" EFFECT_SIZE="1.2322912042615257" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-001.07.05" LOG_CI_END="0.40823371159165056" LOG_CI_START="-0.22680701434432182" LOG_EFFECT_SIZE="0.09071334862366437" NO="5" P_CHI2="1.0" P_Z="0.5755149009392186" STUDIES="1" TAU2="0.0" TOTAL_1="7278" TOTAL_2="7287" WEIGHT="100.0" Z="0.55994801264867">
<NAME>Beta-carotene and vitamin E</NAME>
<DICH_DATA CI_END="2.55996313697477" CI_START="0.5931888589203882" EFFECT_SIZE="1.2322912042615257" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.40823371159165056" LOG_CI_START="-0.22680701434432182" LOG_EFFECT_SIZE="0.09071334862366437" ORDER="696" O_E="0.0" SE="0.3730260659170814" STUDY_ID="STD-ATBC-2003" TOTAL_1="7278" TOTAL_2="7287" VAR="0.13914844585357475" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.907317036986026" CI_START="0.3009450426728439" DF="0.0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.07.06" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" NO="6" P_CHI2="1.0" P_Z="0.7048368711510071" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="305" WEIGHT="100.0" Z="0.37879934969055234">
<NAME>Vitamin A, riboflavin, and zinc</NAME>
<DICH_DATA CI_END="5.907317036986026" CI_START="0.3009450426728439" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7713902794270686" LOG_CI_START="-0.5215128062104688" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="697" O_E="0.0" SE="0.7594576724769808" STUDY_ID="STD-Munoz-1985" TOTAL_1="305" TOTAL_2="305" VAR="0.576775956284153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.006102772625904" CI_START="0.7083604903465844" DF="0.0" EFFECT_SIZE="1.192075477351551" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="0.0" ID="CMP-001.07.07" LOG_CI_END="0.30235317815648916" LOG_CI_START="-0.14974567010050938" LOG_EFFECT_SIZE="0.0763037540279899" NO="7" P_CHI2="1.0" P_Z="0.5082324021933471" STUDIES="1" TAU2="0.0" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="0.6615925271946242">
<NAME>Beta-carotene, vitamin C, and vitamin E</NAME>
<DICH_DATA CI_END="2.006102772625904" CI_START="0.7083604903465844" EFFECT_SIZE="1.192075477351551" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" LOG_CI_END="0.30235317815648916" LOG_CI_START="-0.14974567010050938" LOG_EFFECT_SIZE="0.0763037540279899" ORDER="698" O_E="0.0" SE="0.2655651013915526" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.0705248230771056" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.157160721238936" CI_START="0.14210170024938243" DF="0.0" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.07.08" LOG_CI_END="0.8547407698426233" LOG_CI_START="-0.8474007257002073" LOG_EFFECT_SIZE="0.003670022071208049" NO="8" P_CHI2="1.0" P_Z="0.9932564901761318" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="0.008451836819524704">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="7.1571607212389345" CI_START="0.14210170024938246" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8547407698426231" LOG_CI_START="-0.8474007257002072" LOG_EFFECT_SIZE="0.003670022071208049" ORDER="699" O_E="0.0" SE="0.99984634021815" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.9996927040476286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.222010357505382" CI_START="0.7592934347142659" DF="0.0" EFFECT_SIZE="0.9632572042848522" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="128" I2="0.0" ID="CMP-001.07.09" LOG_CI_END="0.08707488691174876" LOG_CI_START="-0.1195903552645741" LOG_EFFECT_SIZE="-0.016257734176412682" NO="9" P_CHI2="1.0" P_Z="0.757801594561556" STUDIES="1" TAU2="0.0" TOTAL_1="1657" TOTAL_2="1661" WEIGHT="100.0" Z="0.30836896539001535">
<NAME>Combination of antioxidants</NAME>
<DICH_DATA CI_END="1.222010357505382" CI_START="0.7592934347142659" EFFECT_SIZE="0.9632572042848522" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="128" LOG_CI_END="0.08707488691174876" LOG_CI_START="-0.1195903552645741" LOG_EFFECT_SIZE="-0.016257734176412682" ORDER="700" O_E="0.0" SE="0.1213961862638197" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.014737034039400007" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.952915479273459" CI_END="1.3388384568611098" CI_START="1.014486498171624" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1654327684249006" ESTIMABLE="YES" EVENTS_1="429" EVENTS_2="365" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.12672817856077703" LOG_CI_START="0.006246271370764808" LOG_EFFECT_SIZE="0.0664872249657709" METHOD="MH" NO="8" P_CHI2="0.7764902792259136" P_Q="0.0" P_Z="0.03052664826398347" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66388" TOTAL_2="65844" WEIGHT="1000.0" Z="2.1631889700983438">
<NAME>Occurrence of gastric cancer</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.223950072457468" CI_END="1.5934988560807104" CI_START="0.7922757512968697" DF="3.0" EFFECT_SIZE="1.1236060267691907" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="74" I2="6.946449771995418" ID="CMP-001.08.01" LOG_CI_END="0.20235175604444647" LOG_CI_START="-0.10112363605766232" LOG_EFFECT_SIZE="0.0506140599933921" NO="1" P_CHI2="0.3583684538504116" P_Z="0.5132592318744628" STUDIES="4" TAU2="0.012736580108779422" TOTAL_1="18553" TOTAL_2="18493" WEIGHT="100.00000000000001" Z="0.6537711938437513">
<NAME>Beta-carotene</NAME>
<DICH_DATA CI_END="1.8516058451565183" CI_START="0.8860690886552636" EFFECT_SIZE="1.2808788794287285" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="50" LOG_CI_END="0.26754854309544307" LOG_CI_START="-0.052532413945970226" LOG_EFFECT_SIZE="0.10750806457473641" ORDER="701" O_E="0.0" SE="0.18801713859241684" STUDY_ID="STD-ATBC-2003" TOTAL_1="7282" TOTAL_2="7287" VAR="0.03535044440448008" WEIGHT="70.42343419079052"/>
<DICH_DATA CI_END="72.89590292084497" CI_START="0.12346372895295321" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86270311969148" LOG_CI_START="-0.9084606102521554" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="702" O_E="0.0" SE="1.6277952924505874" STUDY_ID="STD-Correa-2000" TOTAL_1="117" TOTAL_2="117" VAR="2.6497175141242937" WEIGHT="0.9395340000825928"/>
<DICH_DATA CI_END="1.7557964632575103" CI_START="0.5164978563242095" EFFECT_SIZE="0.9522946547230708" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.2444741698802098" LOG_CI_START="-0.28693147663903396" LOG_EFFECT_SIZE="-0.021228653379412068" ORDER="703" O_E="0.0" SE="0.3121503072657782" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.09743781432611973" WEIGHT="25.5496258034059"/>
<DICH_DATA CI_END="1.7732471045306726" CI_START="0.05248941439649679" EFFECT_SIZE="0.3050847457627119" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.24876925937782043" LOG_CI_START="-1.2799282724554966" LOG_EFFECT_SIZE="-0.5155795065388381" ORDER="704" O_E="0.0" SE="0.8979644973737149" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="0.8063402385436284" WEIGHT="3.0874060057209998"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin C</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="705" O_E="0.0" SE="0.0" STUDY_ID="STD-Correa-2000" TOTAL_1="130" TOTAL_2="117" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8771480872776374" CI_START="0.9005490545304912" DF="0.0" EFFECT_SIZE="1.3001784243755148" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="50" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.2734985352482093" LOG_CI_START="-0.045492625396743876" LOG_EFFECT_SIZE="0.1140029549257327" NO="3" P_CHI2="1.0" P_Z="0.16123586459537734" STUDIES="1" TAU2="0.0" TOTAL_1="7286" TOTAL_2="7287" WEIGHT="100.0" Z="1.4009271312334364">
<NAME>Vitamin E</NAME>
<DICH_DATA CI_END="1.8771480872776374" CI_START="0.9005490545304912" EFFECT_SIZE="1.3001784243755148" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="50" LOG_CI_END="0.2734985352482093" LOG_CI_START="-0.045492625396743876" LOG_EFFECT_SIZE="0.1140029549257327" ORDER="706" O_E="0.0" SE="0.187376986794557" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="0.03511013518020759" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3062118480409983" CI_START="0.44324262615186216" DF="0.0" EFFECT_SIZE="0.7608999736078121" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.11601361872613934" LOG_CI_START="-0.3533584806524692" LOG_EFFECT_SIZE="-0.11867243096316495" NO="4" P_CHI2="1.0" P_Z="0.32164436637885774" STUDIES="1" TAU2="0.0" TOTAL_1="2526" TOTAL_2="2507" WEIGHT="100.0" Z="0.9910844336659336">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="1.3062118480409983" CI_START="0.44324262615186216" EFFECT_SIZE="0.7608999736078121" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.11601361872613934" LOG_CI_START="-0.3533584806524692" LOG_EFFECT_SIZE="-0.11867243096316495" ORDER="707" O_E="0.0" SE="0.2757114946043584" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.07601682825696915" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7291138542482694" CI_START="0.4598558192790922" DF="0.0" EFFECT_SIZE="0.8917079499882048" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="0.2378235905230974" LOG_CI_START="-0.33737831333308477" LOG_EFFECT_SIZE="-0.04977736140499367" NO="5" P_CHI2="1.0" P_Z="0.7344391832801327" STUDIES="1" TAU2="0.0" TOTAL_1="9420" TOTAL_2="8894" WEIGHT="100.0" Z="0.3392264001393678">
<NAME>Vitamin A and beta-carotene</NAME>
<DICH_DATA CI_END="1.7291138542482694" CI_START="0.4598558192790922" EFFECT_SIZE="0.8917079499882048" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.2378235905230974" LOG_CI_START="-0.33737831333308477" LOG_EFFECT_SIZE="-0.04977736140499367" ORDER="708" O_E="0.0" SE="0.3378764456204661" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.11416049250511978" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.5176680113517" CI_START="0.1193957645169942" DF="0.0" EFFECT_SIZE="2.9016393442622954" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.06" LOG_CI_END="1.8482979419348913" LOG_CI_START="-0.9230110792328121" LOG_EFFECT_SIZE="0.46264343135103964" NO="6" P_CHI2="1.0" P_Z="0.5128577867427606" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="117" WEIGHT="100.0" Z="0.6543943358218474">
<NAME>Beta-carotene and vitamin C</NAME>
<DICH_DATA CI_END="70.5176680113517" CI_START="0.1193957645169942" EFFECT_SIZE="2.901639344262295" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8482979419348913" LOG_CI_START="-0.9230110792328121" LOG_EFFECT_SIZE="0.4626434313510396" ORDER="709" O_E="0.0" SE="1.627880637234808" STUDY_ID="STD-Correa-2000" TOTAL_1="121" TOTAL_2="117" VAR="2.649995369084005" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.012074897769571" CI_START="0.9765294944834119" DF="0.0" EFFECT_SIZE="1.4017312448474857" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="50" I2="0.0" ID="CMP-001.08.07" LOG_CI_END="0.3036441429259456" LOG_CI_START="-0.010314635020316758" LOG_EFFECT_SIZE="0.14666475395281445" NO="7" P_CHI2="1.0" P_Z="0.06707356867037706" STUDIES="1" TAU2="0.0" TOTAL_1="7278" TOTAL_2="7287" WEIGHT="100.0" Z="1.8311807520039878">
<NAME>Beta-carotene and vitamin E</NAME>
<DICH_DATA CI_END="2.012074897769571" CI_START="0.9765294944834119" EFFECT_SIZE="1.4017312448474857" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="50" LOG_CI_END="0.3036441429259456" LOG_CI_START="-0.010314635020316758" LOG_EFFECT_SIZE="0.14666475395281445" ORDER="710" O_E="0.0" SE="0.1844209402866499" STUDY_ID="STD-ATBC-2003" TOTAL_1="7278" TOTAL_2="7287" VAR="0.034011083216212094" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6041906629926834" CI_END="2.004248369674148" CI_START="0.7781664806638816" DF="1.0" EFFECT_SIZE="1.248855035704967" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" I2="0.0" ID="CMP-001.08.08" LOG_CI_END="0.30195153899922045" LOG_CI_START="-0.10892748026092457" LOG_EFFECT_SIZE="0.09651202936914798" NO="8" P_CHI2="0.4369837225808698" P_Z="0.3571767226839927" STUDIES="2" TAU2="0.0" TOTAL_1="11259" TOTAL_2="11257" WEIGHT="99.99999999999999" Z="0.9207581442294899">
<NAME>Beta-carotene, vitamin C, and vitamin E</NAME>
<DICH_DATA CI_END="1.946183108935407" CI_START="0.7396216401898896" EFFECT_SIZE="1.1997662868828514" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" LOG_CI_END="0.2891836989637308" LOG_CI_START="-0.13099039053941078" LOG_EFFECT_SIZE="0.07909665421216004" ORDER="711" O_E="0.0" SE="0.24681234006943253" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.06091633121054921" WEIGHT="95.62454804683368"/>
<DICH_DATA CI_END="28.79116539740041" CI_START="0.3125958909885815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4592592444340635" LOG_CI_START="-0.5050167349947388" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="712" O_E="0.0" SE="1.1538254336393923" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="1.3313131313131314" WEIGHT="4.375451953166309"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6766445283678897" CI_START="0.6042793639185033" DF="0.0" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" ID="CMP-001.08.09" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" NO="9" P_CHI2="1.0" P_Z="0.9799648290496709" STUDIES="1" TAU2="0.0" TOTAL_1="1677" TOTAL_2="1688" WEIGHT="100.0" Z="0.02511300238332238">
<NAME>Vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="1.6766445283678897" CI_START="0.6042793639185033" EFFECT_SIZE="1.0065593321407276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.22444099597972092" LOG_CI_START="-0.21876223661261987" LOG_EFFECT_SIZE="0.002839379683550552" ORDER="713" O_E="0.0" SE="0.26033977271612496" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.06777679725788362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.157160721238936" CI_START="0.14210170024938243" DF="0.0" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.08.10" LOG_CI_END="0.8547407698426233" LOG_CI_START="-0.8474007257002073" LOG_EFFECT_SIZE="0.003670022071208049" NO="10" P_CHI2="1.0" P_Z="0.9932564901761318" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="0.008451836819524704">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="7.1571607212389345" CI_START="0.14210170024938246" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8547407698426231" LOG_CI_START="-0.8474007257002072" LOG_EFFECT_SIZE="0.003670022071208049" ORDER="714" O_E="0.0" SE="0.99984634021815" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.9996927040476286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.584195361598077" CI_START="0.8909594509301666" DF="0.0" EFFECT_SIZE="1.1880462236527414" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="81" I2="0.0" ID="CMP-001.08.11" LOG_CI_END="0.19980873737489688" LOG_CI_START="-0.05014206098894418" LOG_EFFECT_SIZE="0.07483333819297637" NO="11" P_CHI2="1.0" P_Z="0.24055684342099914" STUDIES="1" TAU2="0.0" TOTAL_1="1657" TOTAL_2="1661" WEIGHT="99.99999999999999" Z="1.173596153012787">
<NAME>Combination of antioxidants</NAME>
<DICH_DATA CI_END="1.584195361598077" CI_START="0.8909594509301666" EFFECT_SIZE="1.1880462236527414" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="81" LOG_CI_END="0.19980873737489688" LOG_CI_START="-0.05014206098894418" LOG_EFFECT_SIZE="0.07483333819297637" ORDER="715" O_E="0.0" SE="0.14682233623532673" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.021556798417599336" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.041988063837131" CI_END="1.1492639010495598" CI_START="0.8898658287355328" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0112816985110022" ESTIMABLE="YES" EVENTS_1="778" EVENTS_2="765" I2="30.99211595695881" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.0604197655114095" LOG_CI_START="-0.050675470020752365" LOG_EFFECT_SIZE="0.0048721477453285275" METHOD="MH" NO="9" P_CHI2="0.16071559042358485" P_Q="0.0" P_Z="0.8635076742918653" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.012213394073124998" TOTALS="SUB" TOTAL_1="64584" TOTAL_2="64086" WEIGHT="700.0" Z="0.171910776595591">
<NAME>Occurrence of colorectal cancer</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.257590655933022" CI_END="1.5056119154856016" CI_START="0.7874230127866371" DF="2.0" EFFECT_SIZE="1.088831240633337" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="252" I2="53.02507540942276" ID="CMP-001.09.01" LOG_CI_END="0.1777130431243407" LOG_CI_START="-0.10379189691154495" LOG_EFFECT_SIZE="0.0369605731063978" NO="1" P_CHI2="0.11898060241254405" P_Z="0.606782061608458" STUDIES="3" TAU2="0.038599351231014746" TOTAL_1="18436" TOTAL_2="18376" WEIGHT="100.0" Z="0.5146722620730195">
<NAME>Beta-carotene</NAME>
<DICH_DATA CI_END="1.7799621721245245" CI_START="0.9802419388623054" EFFECT_SIZE="1.3209063444108762" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="75" LOG_CI_END="0.25041077275150686" LOG_CI_START="-0.008666720486071052" LOG_EFFECT_SIZE="0.1208720261327179" ORDER="716" O_E="0.0" SE="0.15218340198202795" STUDY_ID="STD-ATBC-2003" TOTAL_1="7282" TOTAL_2="7287" VAR="0.023159787838823512" WEIGHT="39.8020490842605"/>
<DICH_DATA CI_END="1.1904531728107008" CI_START="0.7835766424266841" EFFECT_SIZE="0.9658215674322054" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="176" LOG_CI_END="0.07571231684304874" LOG_CI_START="-0.10591851833374848" LOG_EFFECT_SIZE="-0.015103100745349887" ORDER="717" O_E="0.0" SE="0.10669085166998511" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.011382937830066766" WEIGHT="59.66711811404072"/>
<DICH_DATA CI_END="3.72181364115683" CI_START="0.00637726293635082" EFFECT_SIZE="0.15406162464985995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5707546233236332" LOG_CI_START="-2.1953656765595317" LOG_EFFECT_SIZE="-0.8123055266179493" ORDER="718" O_E="0.0" SE="1.6248327566676857" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="2.6400814871403107" WEIGHT="0.530832801698776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5705763955984401" CI_END="1.3914857071536872" CI_START="0.8703022349100535" DF="1.0" EFFECT_SIZE="1.1004604130913798" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="132" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.14347874977450745" LOG_CI_START="-0.060329901221029124" LOG_EFFECT_SIZE="0.04157442427673915" NO="2" P_CHI2="0.4500300832589822" P_Z="0.4239330650260258" STUDIES="2" TAU2="0.0" TOTAL_1="12047" TOTAL_2="12067" WEIGHT="100.0" Z="0.7996164427993878">
<NAME>Vitamin E</NAME>
<DICH_DATA CI_END="1.3919863195681448" CI_START="0.7378853636432848" EFFECT_SIZE="1.013472412846555" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="75" LOG_CI_END="0.1436349670523735" LOG_CI_START="-0.13201110403639904" LOG_EFFECT_SIZE="0.00581193150798722" ORDER="719" O_E="0.0" SE="0.16191586662760277" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="0.026216747865767644" WEIGHT="53.28261676693938"/>
<DICH_DATA CI_END="1.7221002259380627" CI_START="0.8577277809800483" EFFECT_SIZE="1.2153572336638698" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.2360584237176191" LOG_CI_START="-0.06665052331287476" LOG_EFFECT_SIZE="0.08470395020237217" ORDER="720" O_E="0.0" SE="0.17781273391916638" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.031617368343808266" WEIGHT="46.717383233060616"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0487674833114506" CI_START="0.21789289538699824" DF="0.0" EFFECT_SIZE="0.47803659224631256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.02067921373415826" LOG_CI_START="-0.6617569301232945" LOG_EFFECT_SIZE="-0.3205388581945681" NO="3" P_CHI2="1.0" P_Z="0.06559487265006317" STUDIES="1" TAU2="0.0" TOTAL_1="653" TOTAL_2="659" WEIGHT="100.0" Z="1.8411821336302872">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="1.0487674833114506" CI_START="0.21789289538699824" EFFECT_SIZE="0.47803659224631256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="0.02067921373415826" LOG_CI_START="-0.6617569301232945" LOG_EFFECT_SIZE="-0.3205388581945681" ORDER="721" O_E="0.0" SE="0.40086636901526135" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.1606938458074797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2470679431410818" CI_START="0.7620782172006979" DF="0.0" EFFECT_SIZE="0.9748657932439198" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="123" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="0.09589011548930976" LOG_CI_START="-0.11800045181611492" LOG_EFFECT_SIZE="-0.011055168163402584" NO="4" P_CHI2="1.0" P_Z="0.8394431805775265" STUDIES="1" TAU2="0.0" TOTAL_1="9420" TOTAL_2="8894" WEIGHT="100.0" Z="0.202605769074075">
<NAME>Vitamin A and beta-carotene</NAME>
<DICH_DATA CI_END="1.2470679431410818" CI_START="0.7620782172006979" EFFECT_SIZE="0.9748657932439198" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="123" LOG_CI_END="0.09589011548930976" LOG_CI_START="-0.11800045181611492" LOG_EFFECT_SIZE="-0.011055168163402584" ORDER="722" O_E="0.0" SE="0.12564037801059033" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.01578550458664403" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6294882618964253" CI_START="0.8858999808460266" DF="0.0" EFFECT_SIZE="1.2014839241549877" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="75" I2="0.0" ID="CMP-001.09.05" LOG_CI_END="0.21205123634950815" LOG_CI_START="-0.05261530770510565" LOG_EFFECT_SIZE="0.07971796432220123" NO="5" P_CHI2="1.0" P_Z="0.23772661301308362" STUDIES="1" TAU2="0.0" TOTAL_1="7278" TOTAL_2="7287" WEIGHT="100.0" Z="1.180688247171297">
<NAME>Beta-carotene and vitamin E</NAME>
<DICH_DATA CI_END="1.6294882618964253" CI_START="0.8858999808460266" EFFECT_SIZE="1.2014839241549877" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="75" LOG_CI_END="0.21205123634950815" LOG_CI_START="-0.05261530770510565" LOG_EFFECT_SIZE="0.07971796432220123" ORDER="723" O_E="0.0" SE="0.15546643809820257" STUDY_ID="STD-ATBC-2003" TOTAL_1="7278" TOTAL_2="7287" VAR="0.024169813374942253" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0664246403425315" CI_START="0.6546607403896186" DF="0.0" EFFECT_SIZE="0.8355515212219857" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="140" I2="0.0" ID="CMP-001.09.06" LOG_CI_END="0.027930171140578157" LOG_CI_START="-0.18398370267566055" LOG_EFFECT_SIZE="-0.0780267657675412" NO="6" P_CHI2="1.0" P_Z="0.14893065511293335" STUDIES="1" TAU2="0.0" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="1.44331891046583">
<NAME>Beta-carotene, vitamin C, and vitamin E</NAME>
<DICH_DATA CI_END="1.0664246403425315" CI_START="0.6546607403896186" EFFECT_SIZE="0.8355515212219857" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="140" LOG_CI_END="0.027930171140578157" LOG_CI_START="-0.18398370267566055" LOG_EFFECT_SIZE="-0.0780267657675412" ORDER="724" O_E="0.0" SE="0.12447925847025193" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.015495085789303788" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.164491098472958E-31" CI_END="1.583379855661148" CI_START="0.49178019497621983" DF="0.0" EFFECT_SIZE="0.8824255516124055" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" I2="100.0" ID="CMP-001.09.07" LOG_CI_END="0.1995851153852671" LOG_CI_START="-0.30822896519822446" LOG_EFFECT_SIZE="-0.05432192490647867" NO="7" P_CHI2="0.0" P_Z="0.6749802216086044" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="0.4193228209239566">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="1.583379855661148" CI_START="0.49178019497621983" EFFECT_SIZE="0.8824255516124055" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1995851153852671" LOG_CI_START="-0.30822896519822446" LOG_EFFECT_SIZE="-0.05432192490647867" ORDER="725" O_E="0.0" SE="0.2982925046549826" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.08897841833334282" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.561869495112783" CI_END="1.1779730777559185" CI_START="0.8338118095295435" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9910640057739701" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="259" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.07113536488601085" LOG_CI_START="-0.07893195812169795" LOG_EFFECT_SIZE="-0.003898296617843579" METHOD="MH" NO="10" P_CHI2="0.47401096450748403" P_Q="0.0" P_Z="0.9188932713866096" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="59052" TOTAL_2="58593" WEIGHT="600.0" Z="0.10182791055232213">
<NAME>Occurrence of pancreatic cancer</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3422694531679893" CI_END="1.8969952235708352" CI_START="0.5434908812125759" DF="1.0" EFFECT_SIZE="1.0153815074712365" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="79" I2="70.08021004853022" ID="CMP-001.10.01" LOG_CI_END="0.2780662373834222" LOG_CI_START="-0.26480773818722214" LOG_EFFECT_SIZE="0.006629249598099998" NO="1" P_CHI2="0.06752149657090423" P_Z="0.961821604734072" STUDIES="2" TAU2="0.1442818594979039" TOTAL_1="18318" TOTAL_2="18322" WEIGHT="99.99999999999997" Z="0.047867796363400446">
<NAME>Beta-carotene</NAME>
<DICH_DATA CI_END="1.1234012926799053" CI_START="0.518540013727787" EFFECT_SIZE="0.7632355611002751" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="59" LOG_CI_END="0.05053491927612732" LOG_CI_START="-0.28521772515599236" LOG_EFFECT_SIZE="-0.11734140293993248" ORDER="726" O_E="0.0" SE="0.19722276534182148" STUDY_ID="STD-ATBC-2003" TOTAL_1="7282" TOTAL_2="7287" VAR="0.038896819169075184" WEIGHT="68.4274822620901"/>
<DICH_DATA CI_END="2.5613721011950057" CI_START="0.8207003545280093" EFFECT_SIZE="1.4498686118158752" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="20" LOG_CI_END="0.408472674820195" LOG_CI_START="-0.08581537896919325" LOG_EFFECT_SIZE="0.16132864792550086" ORDER="727" O_E="0.0" SE="0.2903472495612138" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.08430152532776178" WEIGHT="31.572517737909884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.388480713076325" CI_START="0.6723958770676592" DF="0.0" EFFECT_SIZE="0.9662342919087918" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="59" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.14253985148800472" LOG_CI_START="-0.1723749581895185" LOG_EFFECT_SIZE="-0.014917553350756917" NO="2" P_CHI2="1.0" P_Z="0.852689854180518" STUDIES="1" TAU2="0.0" TOTAL_1="7286" TOTAL_2="7287" WEIGHT="100.0" Z="0.1856874710648147">
<NAME>Vitamin E</NAME>
<DICH_DATA CI_END="1.388480713076325" CI_START="0.6723958770676592" EFFECT_SIZE="0.9662342919087918" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="59" LOG_CI_END="0.14253985148800472" LOG_CI_START="-0.1723749581895185" LOG_EFFECT_SIZE="-0.014917553350756917" ORDER="728" O_E="0.0" SE="0.18498251805802593" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="0.03421853198708789" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0870766187254506" CI_START="0.8446545440260289" DF="0.0" EFFECT_SIZE="1.3277269108280254" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.31953839275442614" LOG_CI_START="-0.0733208772034738" LOG_EFFECT_SIZE="0.12310875777547614" NO="3" P_CHI2="1.0" P_Z="0.21930724749609776" STUDIES="1" TAU2="0.0" TOTAL_1="9420" TOTAL_2="8894" WEIGHT="100.0" Z="1.2283723453808582">
<NAME>Vitamin A and beta-carotene</NAME>
<DICH_DATA CI_END="2.0870766187254506" CI_START="0.8446545440260289" EFFECT_SIZE="1.3277269108280254" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" LOG_CI_END="0.31953839275442614" LOG_CI_START="-0.0733208772034738" LOG_EFFECT_SIZE="0.12310875777547614" ORDER="729" O_E="0.0" SE="0.23076747985802018" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.05325362976002175" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3457533502814703" CI_START="0.647335348139216" DF="0.0" EFFECT_SIZE="0.9333561557701175" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="59" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="0.12896546967438288" LOG_CI_START="-0.18887067742103084" LOG_EFFECT_SIZE="-0.029952603873323946" NO="4" P_CHI2="1.0" P_Z="0.7118216805364024" STUDIES="1" TAU2="0.0" TOTAL_1="7278" TOTAL_2="7287" WEIGHT="100.0" Z="0.3694106247599739">
<NAME>Beta-carotene and vitamin E</NAME>
<DICH_DATA CI_END="1.3457533502814703" CI_START="0.647335348139216" EFFECT_SIZE="0.9333561557701175" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="59" LOG_CI_END="0.12896546967438288" LOG_CI_START="-0.18887067742103084" LOG_EFFECT_SIZE="-0.029952603873323946" ORDER="730" O_E="0.0" SE="0.18669852611814822" STUDY_ID="STD-ATBC-2003" TOTAL_1="7278" TOTAL_2="7287" VAR="0.03485633965468887" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7593360082609828" CI_START="0.5681748747119498" DF="0.0" EFFECT_SIZE="0.9998052390690427" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="0.24534879147439184" LOG_CI_START="-0.24551797514532142" LOG_EFFECT_SIZE="-8.459183546481616E-5" NO="5" P_CHI2="1.0" P_Z="0.9994610072374103" STUDIES="1" TAU2="0.0" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="6.755273005704409E-4">
<NAME>Beta-carotene, vitamin C, and vitamin E</NAME>
<DICH_DATA CI_END="1.7593360082609828" CI_START="0.5681748747119498" EFFECT_SIZE="0.9998052390690427" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.24534879147439184" LOG_CI_START="-0.24551797514532142" LOG_EFFECT_SIZE="-8.459183546481616E-5" ORDER="731" O_E="0.0" SE="0.28833756854210213" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.08313855343277143" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.381356122509948" CI_START="0.18981615798801135" DF="0.0" EFFECT_SIZE="0.672324229799928" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-001.10.06" LOG_CI_END="0.37682434730568765" LOG_CI_START="-0.721666821274634" LOG_EFFECT_SIZE="-0.17242123698447315" NO="6" P_CHI2="1.0" P_Z="0.5383703177142436" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="0.6152792563569943">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="2.3813561225099487" CI_START="0.18981615798801132" EFFECT_SIZE="0.672324229799928" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3768243473056877" LOG_CI_START="-0.721666821274634" LOG_EFFECT_SIZE="-0.17242123698447315" ORDER="732" O_E="0.0" SE="0.6452591500430623" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.4163593707142952" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.371920933694447" CI_END="1.3001587130689933" CI_START="0.6304949570208644" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9053968808852488" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="157" I2="51.01219936400972" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.1139963707705243" LOG_CI_START="-0.20031838275746539" LOG_EFFECT_SIZE="-0.04316100599347052" METHOD="MH" NO="11" P_CHI2="0.031095749592816357" P_Q="0.0" P_Z="0.5903866381555123" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1561806487188276" TOTALS="SUB" TOTAL_1="53211" TOTAL_2="52161" WEIGHT="700.0" Z="0.5382758291439005">
<NAME>Occurrence of hepatocellular carcinoma</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8515406065499644" CI_START="0.9551132915411503" DF="0.0" EFFECT_SIZE="1.9179826970612468" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.5856344809607203" LOG_CI_START="-0.01994511116704809" LOG_EFFECT_SIZE="0.28284468489683606" NO="1" P_CHI2="1.0" P_Z="0.06712160493986996" STUDIES="1" TAU2="0.0" TOTAL_1="7282" TOTAL_2="7287" WEIGHT="100.0" Z="1.8308589087969664">
<NAME>Beta-carotene</NAME>
<DICH_DATA CI_END="3.8515406065499644" CI_START="0.9551132915411503" EFFECT_SIZE="1.9179826970612468" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5856344809607203" LOG_CI_START="-0.01994511116704809" LOG_EFFECT_SIZE="0.28284468489683606" ORDER="733" O_E="0.0" SE="0.3557204500831779" STUDY_ID="STD-ATBC-2003" TOTAL_1="7282" TOTAL_2="7287" VAR="0.12653703860737864" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8167626270479054" CI_START="0.6313154656635915" DF="0.0" EFFECT_SIZE="1.3335163326928356" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.44975024985872586" LOG_CI_START="-0.19975357140433403" LOG_EFFECT_SIZE="0.12499833922719587" NO="2" P_CHI2="1.0" P_Z="0.45061018374684714" STUDIES="1" TAU2="0.0" TOTAL_1="7286" TOTAL_2="7287" WEIGHT="100.0" Z="0.7543981574617965">
<NAME>Vitamin E</NAME>
<DICH_DATA CI_END="2.8167626270479054" CI_START="0.6313154656635915" EFFECT_SIZE="1.3335163326928356" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.44975024985872586" LOG_CI_START="-0.19975357140433403" LOG_EFFECT_SIZE="0.12499833922719587" ORDER="734" O_E="0.0" SE="0.381521759705689" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="0.14555885312892552" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9895300512740084" CI_END="0.761398197028061" CI_START="0.41862534663023676" DF="3.0" EFFECT_SIZE="0.5645711506573015" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="108" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="-0.11838815591893452" LOG_CI_START="-0.3781744798473308" LOG_EFFECT_SIZE="-0.2482813178831326" NO="3" P_CHI2="0.5745826552501514" P_Z="1.7944165481107032E-4" STUDIES="4" TAU2="0.0" TOTAL_1="5195" TOTAL_2="4603" WEIGHT="99.99999999999997" Z="3.746328395787347">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="0.7747710510865886" CI_START="0.3372958240464894" EFFECT_SIZE="0.5112015650637385" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" LOG_CI_END="-0.11082661483499756" LOG_CI_START="-0.47198903564089956" LOG_EFFECT_SIZE="-0.29140782523794856" ORDER="735" O_E="0.0" SE="0.2121485937642028" STUDY_ID="STD-Li-2000" TOTAL_1="1112" TOTAL_2="953" VAR="0.045007025836128756" WEIGHT="34.906213914818345"/>
<DICH_DATA CI_END="1.3616780317635189" CI_START="0.43760130218527393" EFFECT_SIZE="0.7719275094572007" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.134074430955321" LOG_CI_START="-0.3589213943276479" LOG_EFFECT_SIZE="-0.11242348168616345" ORDER="736" O_E="0.0" SE="0.2895881881399089" STUDY_ID="STD-Li-2004" TOTAL_1="2526" TOTAL_2="2507" VAR="0.08386131871015526" WEIGHT="29.256134167946485"/>
<DICH_DATA CI_END="1.2464473248619825" CI_START="0.24153464224020815" EFFECT_SIZE="0.5486895376092052" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.09567392984729235" LOG_CI_START="-0.617020571517862" LOG_EFFECT_SIZE="-0.2606733208352848" ORDER="737" O_E="0.0" SE="0.4186402779965706" STUDY_ID="STD-Yu-1991" TOTAL_1="1444" TOTAL_2="1030" VAR="0.17525968236104592" WEIGHT="21.188429248062054"/>
<DICH_DATA CI_END="1.1081247464231647" CI_START="0.11932898835216686" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.04458865356357585" LOG_CI_START="-0.9232540412241012" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="738" O_E="0.0" SE="0.5685155898168872" STUDY_ID="STD-Yu-1997" TOTAL_1="113" TOTAL_2="113" VAR="0.3232099758648431" WEIGHT="14.649222669173101"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.541898058523906" CI_START="0.513641738529163" DF="0.0" EFFECT_SIZE="1.348801941158629" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="0.5492360573459654" LOG_CI_START="-0.289339692734402" LOG_EFFECT_SIZE="0.1299481823057816" NO="4" P_CHI2="1.0" P_Z="0.5435565313651125" STUDIES="1" TAU2="0.0" TOTAL_1="9420" TOTAL_2="8894" WEIGHT="100.0" Z="0.6074436499060885">
<NAME>Vitamin A and beta-carotene</NAME>
<DICH_DATA CI_END="3.541898058523906" CI_START="0.513641738529163" EFFECT_SIZE="1.348801941158629" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5492360573459654" LOG_CI_START="-0.289339692734402" LOG_EFFECT_SIZE="0.1299481823057816" ORDER="739" O_E="0.0" SE="0.4925835466141174" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="0.24263855039494236" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6718602692529316" CI_START="0.5862457678652069" DF="0.0" EFFECT_SIZE="1.251545754328112" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-001.11.05" LOG_CI_END="0.426813742022376" LOG_CI_START="-0.23192027945711033" LOG_EFFECT_SIZE="0.09744673128263279" NO="5" P_CHI2="1.0" P_Z="0.5619981234779059" STUDIES="1" TAU2="0.0" TOTAL_1="7278" TOTAL_2="7287" WEIGHT="100.0" Z="0.5798761791478553">
<NAME>Beta-carotene and vitamin E</NAME>
<DICH_DATA CI_END="2.6718602692529316" CI_START="0.5862457678652069" EFFECT_SIZE="1.251545754328112" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.426813742022376" LOG_CI_START="-0.23192027945711033" LOG_EFFECT_SIZE="0.09744673128263279" ORDER="740" O_E="0.0" SE="0.3869436250030459" STUDY_ID="STD-ATBC-2003" TOTAL_1="7278" TOTAL_2="7287" VAR="0.14972536893049782" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.408739481248463" CI_START="0.4443983637114798" DF="0.0" EFFECT_SIZE="1.3997273346966599" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.11.06" LOG_CI_END="0.6443144364994874" LOG_CI_START="-0.35222754881394097" LOG_EFFECT_SIZE="0.14604344384277324" NO="6" P_CHI2="1.0" P_Z="0.5656523064270722" STUDIES="1" TAU2="0.0" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="0.5744662930985421">
<NAME>Beta-carotene, vitamin C, and vitamin E</NAME>
<DICH_DATA CI_END="4.408739481248463" CI_START="0.4443983637114798" EFFECT_SIZE="1.3997273346966599" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6443144364994874" LOG_CI_START="-0.35222754881394097" LOG_EFFECT_SIZE="0.14604344384277324" ORDER="741" O_E="0.0" SE="0.5853736951354929" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.3426623629565809" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.119750145725646" CI_START="0.06309308135993853" DF="0.0" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.11.07" LOG_CI_END="1.2073583060066913" LOG_CI_START="-1.2000182618642752" LOG_EFFECT_SIZE="0.003670022071208049" NO="7" P_CHI2="1.0" P_Z="0.995231956483735" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="0.005975891913242562">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="16.11975014572564" CI_START="0.06309308135993856" EFFECT_SIZE="1.008486344699892" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.207358306006691" LOG_CI_START="-1.200018261864275" LOG_EFFECT_SIZE="0.003670022071208049" ORDER="742" O_E="0.0" SE="1.4141049126736065" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="1.9996927040476284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.200401482099619" CI_START="0.009685189105156838" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20169700709657512" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.6232908030472546" LOG_CI_START="-2.0138918951798384" LOG_EFFECT_SIZE="-0.695300546066292" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.3013700314954175" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="1.0334999009640968">
<NAME>Occurrence of biliary tract cancer</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.200401482099619" CI_START="0.009685189105156838" DF="0.0" EFFECT_SIZE="0.20169700709657512" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.6232908030472546" LOG_CI_START="-2.0138918951798384" LOG_EFFECT_SIZE="-0.695300546066292" NO="1" P_CHI2="1.0" P_Z="0.3013700314954175" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="1.0334999009640968">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="4.200401482099619" CI_START="0.009685189105156838" EFFECT_SIZE="0.20169700709657512" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6232908030472546" LOG_CI_START="-2.0138918951798384" LOG_EFFECT_SIZE="-0.695300546066292" ORDER="743" O_E="0.0" SE="1.5490941712034871" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="2.3996927512566186" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.8193501326547" CI_END="1.0672286096450332" CI_START="0.9728475493229923" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0189458952567378" ESTIMABLE="YES" EVENTS_1="17114" EVENTS_2="8799" I2="54.891418646980775" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.028257459042886415" LOG_CI_START="-0.011955210785231754" LOG_EFFECT_SIZE="0.008151124128827332" METHOD="MH" NO="13" P_CHI2="0.006943187438671505" P_Q="0.0" P_Z="0.42686312664841397" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0030511334272691603" TOTALS="YES" TOTAL_1="122501" TOTAL_2="78693" WEIGHT="100.0" Z="0.7945709545923288">
<NAME>Mortality in trials with a low or high risk of bias</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="25.80075134445475" CI_END="1.0767227825153727" CI_START="0.9796252718922515" DF="12.0" EFFECT_SIZE="1.027027189793047" ESTIMABLE="YES" EVENTS_1="15267" EVENTS_2="8519" I2="53.48972655953637" ID="CMP-001.13.01" LOG_CI_END="0.03210390244273408" LOG_CI_START="-0.00894001968678727" LOG_EFFECT_SIZE="0.011581941377973368" NO="1" P_CHI2="0.01145240944451642" P_Z="0.26866539797150857" STUDIES="13" TAU2="0.002837585177700185" TOTAL_1="96615" TOTAL_2="74995" WEIGHT="91.86049871572706" Z="1.1061412649720763">
<NAME>Trials with low risk of bias</NAME>
<DICH_DATA CI_END="1.0910444663267969" CI_START="1.0168881455583128" EFFECT_SIZE="1.0533139057682261" ESTIMABLE="YES" EVENTS_1="8226" EVENTS_2="2605" LOG_CI_END="0.037842450942903" LOG_CI_START="0.007273184546734144" LOG_EFFECT_SIZE="0.022557817744818593" ORDER="744" O_E="0.0" SE="0.01795653840141872" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="3.224372713616251E-4" WEIGHT="16.53907452741839"/>
<DICH_DATA CI_END="1.2342153394857684" CI_START="1.091467612428485" EFFECT_SIZE="1.1606489864774552" ESTIMABLE="YES" EVENTS_1="1855" EVENTS_2="1509" LOG_CI_END="0.09139093975510218" LOG_CI_START="0.038010853235924395" LOG_EFFECT_SIZE="0.06470089649551332" ORDER="745" O_E="0.0" SE="0.03135572705705482" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="9.831816192765195E-4" WEIGHT="13.830287561687511"/>
<DICH_DATA CI_END="11.077070418664412" CI_START="0.5942413553681141" EFFECT_SIZE="2.5656292286874156" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.0444249165983799" LOG_CI_START="-0.22603712738393641" LOG_EFFECT_SIZE="0.4091938946072218" ORDER="746" O_E="0.0" SE="0.7462756935237562" STUDY_ID="STD-Correa-2000" TOTAL_1="739" TOTAL_2="237" VAR="0.5569274107443632" WEIGHT="0.09963906258356249"/>
<DICH_DATA CI_END="1.095145501831898" CI_START="0.915832672581855" EFFECT_SIZE="1.0014839149026329" ESTIMABLE="YES" EVENTS_1="799" EVENTS_2="801" LOG_CI_END="0.03947182369187845" LOG_CI_START="-0.03818386695715462" LOG_EFFECT_SIZE="6.439783673619335E-4" ORDER="747" O_E="0.0" SE="0.045615337089110294" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.0020807589777531612" WEIGHT="10.872351328637569"/>
<DICH_DATA CI_END="1.1144811312125353" CI_START="0.9720535501435152" EFFECT_SIZE="1.0408339637824593" ESTIMABLE="YES" EVENTS_1="1446" EVENTS_2="1389" LOG_CI_END="0.04707272003057203" LOG_CI_START="-0.01230980925970866" LOG_EFFECT_SIZE="0.01738145538543168" ORDER="748" O_E="0.0" SE="0.03488159165337159" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.0012167254362725624" WEIGHT="13.073472903428412"/>
<DICH_DATA CI_END="1.1590959236008698" CI_START="0.766198384784343" EFFECT_SIZE="0.9423892107155635" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="167" LOG_CI_END="0.06411937847153251" LOG_CI_START="-0.11565876788411612" LOG_EFFECT_SIZE="-0.02576969470629179" ORDER="749" O_E="0.0" SE="0.10560257308548482" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.011151903442275162" WEIGHT="3.9284371166995067"/>
<DICH_DATA CI_END="1.0650899739037616" CI_START="0.6702336995249387" EFFECT_SIZE="0.8449018839702268" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="129" LOG_CI_END="0.027386296525392328" LOG_CI_START="-0.17377373951211905" LOG_EFFECT_SIZE="-0.07319372149336334" ORDER="750" O_E="0.0" SE="0.11816240092667193" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.01396235299275556" WEIGHT="3.2795004992332673"/>
<DICH_DATA CI_END="1.100801796707442" CI_START="0.9290237799215413" EFFECT_SIZE="1.0112719941348973" ESTIMABLE="YES" EVENTS_1="979" EVENTS_2="968" LOG_CI_END="0.04170912973908401" LOG_CI_START="-0.03197316936854376" LOG_EFFECT_SIZE="0.004867980185270133" ORDER="751" O_E="0.0" SE="0.04328134722908345" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.00187327501796449" WEIGHT="11.330444626739755"/>
<DICH_DATA CI_END="3.1183076919528787" CI_START="0.6784777797260468" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.49391896599210416" LOG_CI_START="-0.16846437099670467" LOG_EFFECT_SIZE="0.16272729749769974" ORDER="752" O_E="0.0" SE="0.38908725099762503" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="0.15138888888888888" WEIGHT="0.3612777074970155"/>
<DICH_DATA CI_END="1.0849516828261208" CI_START="0.6155358027224427" EFFECT_SIZE="0.8172065864904916" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="101" LOG_CI_END="0.03541039777050457" LOG_CI_START="-0.21074668120125536" LOG_EFFECT_SIZE="-0.08766814171537538" ORDER="753" O_E="0.0" SE="0.14459388668520437" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.02090739206673372" WEIGHT="2.3288468742425676"/>
<DICH_DATA CI_END="1.0531785477820348" CI_START="0.5807818997097306" EFFECT_SIZE="0.7820914509917529" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="98" LOG_CI_END="0.0225020043698727" LOG_CI_START="-0.23598692705086366" LOG_EFFECT_SIZE="-0.10674246134049548" ORDER="754" O_E="0.0" SE="0.15183767785738722" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.023054680417123698" WEIGHT="2.1372916217340445"/>
<DICH_DATA CI_END="1.1977966630716208" CI_START="0.8418234866915439" EFFECT_SIZE="1.0041580369914131" ESTIMABLE="YES" EVENTS_1="871" EVENTS_2="124" LOG_CI_END="0.07838309885371654" LOG_CI_START="-0.07477896169770953" LOG_EFFECT_SIZE="0.0018020685780034925" ORDER="755" O_E="0.0" SE="0.08996815253233495" STUDY_ID="STD-WACS-2007" TOTAL_1="7149" TOTAL_2="1022" VAR="0.008094268470081488" WEIGHT="5.006166464166051"/>
<DICH_DATA CI_END="1.1534623340496328" CI_START="0.9273586162004079" EFFECT_SIZE="1.0342500828830328" ESTIMABLE="YES" EVENTS_1="636" EVENTS_2="615" LOG_CI_END="0.062003417338705916" LOG_CI_START="-0.03275228859636949" LOG_EFFECT_SIZE="0.014625564371168208" ORDER="756" O_E="0.0" SE="0.055659970714572383" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.0030980323399470554" WEIGHT="9.073708421659404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0634293405763928" CI_START="0.8350510176240367" DF="0.0" EFFECT_SIZE="0.9423469387755102" ESTIMABLE="YES" EVENTS_1="1847" EVENTS_2="280" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="0.026708638557279743" LOG_CI_START="-0.07828699038974907" LOG_EFFECT_SIZE="-0.025789175916234627" NO="2" P_CHI2="1.0" P_Z="0.33563873224438534" STUDIES="1" TAU2="0.0" TOTAL_1="25886" TOTAL_2="3698" WEIGHT="8.139501284272942" Z="0.9628182905078541">
<NAME>Trials with high risk of bias</NAME>
<DICH_DATA CI_END="1.0634293405763928" CI_START="0.8350510176240367" EFFECT_SIZE="0.9423469387755102" ESTIMABLE="YES" EVENTS_1="1847" EVENTS_2="280" LOG_CI_END="0.026708638557279743" LOG_CI_START="-0.07828699038974907" LOG_EFFECT_SIZE="-0.025789175916234627" ORDER="757" O_E="0.0" SE="0.06167495218023023" STUDY_ID="STD-NIT1-1993" TOTAL_1="25886" TOTAL_2="3698" VAR="0.0038037997264336854" WEIGHT="8.139501284272942"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.11523204223643" CI_END="1.0986119946580484" CI_START="1.013456246223157" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0551754300408445" ESTIMABLE="YES" EVENTS_1="14844" EVENTS_2="8024" I2="43.32363806657993" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.04084433634323697" LOG_CI_START="0.005805003710798616" LOG_EFFECT_SIZE="0.02332467002701783" METHOD="MH" NO="14" P_CHI2="0.07881097270251525" P_Q="0.0" P_Z="0.009070575261331407" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0013461032284248099" TOTALS="YES" TOTAL_1="86147" TOTAL_2="64451" WEIGHT="100.0" Z="2.609382643430471">
<NAME>Mortality after excluding selenium trials</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.11523204223643" CI_END="1.0986119946580484" CI_START="1.013456246223157" DF="8.0" EFFECT_SIZE="1.0551754300408445" ESTIMABLE="YES" EVENTS_1="14844" EVENTS_2="8024" I2="43.32363806657993" ID="CMP-001.14.01" LOG_CI_END="0.04084433634323697" LOG_CI_START="0.005805003710798616" LOG_EFFECT_SIZE="0.02332467002701783" NO="1" P_CHI2="0.07881097270251525" P_Z="0.009070575261331407" STUDIES="9" TAU2="0.0013461032284248099" TOTAL_1="86147" TOTAL_2="64451" WEIGHT="100.0" Z="2.609382643430471">
<NAME>Trials with low risk of bias</NAME>
<DICH_DATA CI_END="1.0910444663267969" CI_START="1.0168881455583128" EFFECT_SIZE="1.0533139057682261" ESTIMABLE="YES" EVENTS_1="8226" EVENTS_2="2605" LOG_CI_END="0.037842450942903" LOG_CI_START="0.007273184546734144" LOG_EFFECT_SIZE="0.022557817744818593" ORDER="758" O_E="0.0" SE="0.01795653840141872" STUDY_ID="STD-ATBC-2003" TOTAL_1="21846" TOTAL_2="7287" VAR="3.224372713616251E-4" WEIGHT="25.389263520902023"/>
<DICH_DATA CI_END="1.2342153394857684" CI_START="1.091467612428485" EFFECT_SIZE="1.1606489864774552" ESTIMABLE="YES" EVENTS_1="1855" EVENTS_2="1509" LOG_CI_END="0.09139093975510218" LOG_CI_START="0.038010853235924395" LOG_EFFECT_SIZE="0.06470089649551332" ORDER="759" O_E="0.0" SE="0.03135572705705482" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="9.831816192765195E-4" WEIGHT="18.18713348270032"/>
<DICH_DATA CI_END="11.077070418664412" CI_START="0.5942413553681141" EFFECT_SIZE="2.5656292286874156" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.0444249165983799" LOG_CI_START="-0.22603712738393641" LOG_EFFECT_SIZE="0.4091938946072218" ORDER="760" O_E="0.0" SE="0.7462756935237562" STUDY_ID="STD-Correa-2000" TOTAL_1="739" TOTAL_2="237" VAR="0.5569274107443632" WEIGHT="0.0758821856743866"/>
<DICH_DATA CI_END="1.095145501831898" CI_START="0.915832672581855" EFFECT_SIZE="1.0014839149026329" ESTIMABLE="YES" EVENTS_1="799" EVENTS_2="801" LOG_CI_END="0.03947182369187845" LOG_CI_START="-0.03818386695715462" LOG_EFFECT_SIZE="6.439783673619335E-4" ORDER="761" O_E="0.0" SE="0.045615337089110294" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.0020807589777531612" WEIGHT="12.362041977644456"/>
<DICH_DATA CI_END="1.1144811312125353" CI_START="0.9720535501435152" EFFECT_SIZE="1.0408339637824593" ESTIMABLE="YES" EVENTS_1="1446" EVENTS_2="1389" LOG_CI_END="0.04707272003057203" LOG_CI_START="-0.01230980925970866" LOG_EFFECT_SIZE="0.01738145538543168" ORDER="762" O_E="0.0" SE="0.03488159165337159" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.0012167254362725624" WEIGHT="16.529787975263552"/>
<DICH_DATA CI_END="1.100801796707442" CI_START="0.9290237799215413" EFFECT_SIZE="1.0112719941348973" ESTIMABLE="YES" EVENTS_1="979" EVENTS_2="968" LOG_CI_END="0.04170912973908401" LOG_CI_START="-0.03197316936854376" LOG_EFFECT_SIZE="0.004867980185270133" ORDER="763" O_E="0.0" SE="0.04328134722908345" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.00187327501796449" WEIGHT="13.158756505821486"/>
<DICH_DATA CI_END="3.1183076919528787" CI_START="0.6784777797260468" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.49391896599210416" LOG_CI_START="-0.16846437099670467" LOG_EFFECT_SIZE="0.16272729749769974" ORDER="764" O_E="0.0" SE="0.38908725099762503" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="0.15138888888888888" WEIGHT="0.2773628613660248"/>
<DICH_DATA CI_END="1.1977966630716208" CI_START="0.8418234866915439" EFFECT_SIZE="1.0041580369914131" ESTIMABLE="YES" EVENTS_1="871" EVENTS_2="124" LOG_CI_END="0.07838309885371654" LOG_CI_START="-0.07477896169770953" LOG_EFFECT_SIZE="0.0018020685780034925" ORDER="765" O_E="0.0" SE="0.08996815253233495" STUDY_ID="STD-WACS-2007" TOTAL_1="7149" TOTAL_2="1022" VAR="0.008094268470081488" WEIGHT="4.487430770451364"/>
<DICH_DATA CI_END="1.1534623340496328" CI_START="0.9273586162004079" EFFECT_SIZE="1.0342500828830328" ESTIMABLE="YES" EVENTS_1="636" EVENTS_2="615" LOG_CI_END="0.062003417338705916" LOG_CI_START="-0.03275228859636949" LOG_EFFECT_SIZE="0.014625564371168208" ORDER="766" O_E="0.0" SE="0.055659970714572383" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.0030980323399470554" WEIGHT="9.532340720176387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trials with high risk of bias</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.590965853672124" CI_END="1.066392515216604" CI_START="0.9950137854821286" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.030085070940979" ESTIMABLE="YES" EVENTS_1="16842" EVENTS_2="13770" I2="45.07236345936553" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.02791708819543641" LOG_CI_START="-0.0021709022519174766" LOG_EFFECT_SIZE="0.012873092971759491" METHOD="MH" NO="15" P_CHI2="0.015636933844030976" P_Q="0.0" P_Z="0.09351624632353883" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0018390622842475292" TOTALS="SUB" TOTAL_1="105628" TOTAL_2="76868" WEIGHT="1100.0" Z="1.6771341800597501">
<NAME>Mortality - different antioxidants</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9095711636983883" CI_END="1.1135894688903833" CI_START="0.9913657982302349" DF="3.0" EFFECT_SIZE="1.0507019143064784" ESTIMABLE="YES" EVENTS_1="3903" EVENTS_2="3699" I2="23.265241265948703" ID="CMP-001.15.01" LOG_CI_END="0.046725115204327386" LOG_CI_START="-0.003766068178598413" LOG_EFFECT_SIZE="0.02147952351286451" NO="1" P_CHI2="0.27139589079404536" P_Z="0.0953987480395708" STUDIES="4" TAU2="9.351959934902286E-4" TOTAL_1="19581" TOTAL_2="19581" WEIGHT="100.0" Z="1.6675819289484914">
<NAME>Beta-carotene</NAME>
<DICH_DATA CI_END="1.1193425241126314" CI_START="1.0283941629021747" EFFECT_SIZE="1.0729050834466285" ESTIMABLE="YES" EVENTS_1="2793" EVENTS_2="2605" LOG_CI_END="0.0489630030338386" LOG_CI_START="0.012159602950820893" LOG_EFFECT_SIZE="0.030561302992329755" ORDER="767" O_E="0.0" SE="0.021618499388533205" STUDY_ID="STD-ATBC-2003" TOTAL_1="7282" TOTAL_2="7287" VAR="4.673595158120105E-4" WEIGHT="56.52980665213447"/>
<DICH_DATA CI_END="16.264887288596622" CI_START="0.7164224316689987" EFFECT_SIZE="3.4135802469135803" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.211251058081436" LOG_CI_START="-0.1448308245573013" LOG_EFFECT_SIZE="0.5332101167620673" ORDER="768" O_E="0.0" SE="0.7965692105755745" STUDY_ID="STD-Correa-2000" TOTAL_1="243" TOTAL_2="237" VAR="0.6345225072369939" WEIGHT="0.20488600295854548"/>
<DICH_DATA CI_END="1.100801796707442" CI_START="0.9290237799215413" EFFECT_SIZE="1.0112719941348973" ESTIMABLE="YES" EVENTS_1="979" EVENTS_2="968" LOG_CI_END="0.04170912973908401" LOG_CI_START="-0.03197316936854376" LOG_EFFECT_SIZE="0.004867980185270133" ORDER="769" O_E="0.0" SE="0.04328134722908345" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.00187327501796449" WEIGHT="35.12115624244194"/>
<DICH_DATA CI_END="1.2652504085778769" CI_START="0.7934598609859163" EFFECT_SIZE="1.0019607843137255" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="124" LOG_CI_END="0.10217648622432551" LOG_CI_START="-0.10047503815077279" LOG_EFFECT_SIZE="8.507240367763628E-4" ORDER="770" O_E="0.0" SE="0.11903850855915687" STUDY_ID="STD-WACS-2007" TOTAL_1="1020" TOTAL_2="1022" VAR="0.014170166519988463" WEIGHT="8.144151102465043"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2127400094073911" CI_END="1.229986817166727" CI_START="0.7710507184346872" DF="1.0" EFFECT_SIZE="0.973849176742271" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="126" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.08990045675449765" LOG_CI_START="-0.11291705384027714" LOG_EFFECT_SIZE="-0.011508298542889775" NO="2" P_CHI2="0.6446282512364869" P_Z="0.8239829887021161" STUDIES="2" TAU2="0.0" TOTAL_1="1264" TOTAL_2="1259" WEIGHT="100.00000000000001" Z="0.2224250815548647">
<NAME>Vitamin C</NAME>
<DICH_DATA CI_END="8.748793097863292" CI_START="0.24871213697918745" EFFECT_SIZE="1.4751037344398341" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.941948145926313" LOG_CI_START="-0.6043030209444795" LOG_EFFECT_SIZE="0.16882256249091676" ORDER="771" O_E="0.0" SE="0.9082755894866227" STUDY_ID="STD-Correa-2000" TOTAL_1="241" TOTAL_2="237" VAR="0.8249645464572719" WEIGHT="1.931113723876007"/>
<DICH_DATA CI_END="1.223565885475962" CI_START="0.7639101599080549" EFFECT_SIZE="0.9667959511872103" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="124" LOG_CI_END="0.08762735981633404" LOG_CI_START="-0.11695771387248695" LOG_EFFECT_SIZE="-0.014665177028076475" ORDER="772" O_E="0.0" SE="0.12017428499726103" STUDY_ID="STD-WACS-2007" TOTAL_1="1023" TOTAL_2="1022" VAR="0.014441858774602918" WEIGHT="98.068886276124"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40965156081102305" CI_END="1.0593081175197685" CI_START="0.9811675734470165" DF="2.0" EFFECT_SIZE="1.0194894679198987" ESTIMABLE="YES" EVENTS_1="3590" EVENTS_2="3530" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.02502230031120716" LOG_CI_START="-0.008256813202845163" LOG_EFFECT_SIZE="0.008382743554180968" NO="3" P_CHI2="0.8147893423739917" P_Z="0.32344727125836326" STUDIES="3" TAU2="0.0" TOTAL_1="13068" TOTAL_2="13089" WEIGHT="99.99999999999999" Z="0.9873986247195217">
<NAME>Vitamin E</NAME>
<DICH_DATA CI_END="1.0706514420030986" CI_START="0.9822078929006257" EFFECT_SIZE="1.025476619373099" ESTIMABLE="YES" EVENTS_1="2671" EVENTS_2="2605" LOG_CI_END="0.029648106263331336" LOG_CI_START="-0.007796580253880353" LOG_EFFECT_SIZE="0.010925763004725492" ORDER="773" O_E="0.0" SE="0.02199519421439778" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="4.837885685290775E-4" WEIGHT="57.627554950573284"/>
<DICH_DATA CI_END="1.095145501831898" CI_START="0.915832672581855" EFFECT_SIZE="1.0014839149026329" ESTIMABLE="YES" EVENTS_1="799" EVENTS_2="801" LOG_CI_END="0.03947182369187845" LOG_CI_START="-0.03818386695715462" LOG_EFFECT_SIZE="6.439783673619335E-4" ORDER="774" O_E="0.0" SE="0.045615337089110294" STUDY_ID="STD-HOPE-TOO-2005" TOTAL_1="4761" TOTAL_2="4780" VAR="0.0020807589777531612" WEIGHT="34.14957116999952"/>
<DICH_DATA CI_END="1.2259435408762758" CI_START="0.7654185080369772" EFFECT_SIZE="0.9686897728349815" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="124" LOG_CI_END="0.08847046981494723" LOG_CI_START="-0.11610104062060042" LOG_EFFECT_SIZE="-0.01381528540282658" ORDER="775" O_E="0.0" SE="0.12016631787514911" STUDY_ID="STD-WACS-2007" TOTAL_1="1021" TOTAL_2="1022" VAR="0.01443994395167138" WEIGHT="8.222873879427187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0650899739037616" CI_START="0.6702336995249387" DF="0.0" EFFECT_SIZE="0.8449018839702268" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="129" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="0.027386296525392328" LOG_CI_START="-0.17377373951211905" LOG_EFFECT_SIZE="-0.07319372149336334" NO="4" P_CHI2="1.0" P_Z="0.15378240054441042" STUDIES="1" TAU2="0.0" TOTAL_1="653" TOTAL_2="659" WEIGHT="100.0" Z="1.426297795996579">
<NAME>Selenium</NAME>
<DICH_DATA CI_END="1.0650899739037616" CI_START="0.6702336995249387" EFFECT_SIZE="0.8449018839702268" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="129" LOG_CI_END="0.027386296525392328" LOG_CI_START="-0.17377373951211905" LOG_EFFECT_SIZE="-0.07319372149336334" ORDER="776" O_E="0.0" SE="0.11816240092667193" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.01396235299275556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2342153394857684" CI_START="1.091467612428485" DF="0.0" EFFECT_SIZE="1.1606489864774552" ESTIMABLE="YES" EVENTS_1="1855" EVENTS_2="1509" I2="0.0" ID="CMP-001.15.05" LOG_CI_END="0.09139093975510218" LOG_CI_START="0.038010853235924395" LOG_EFFECT_SIZE="0.06470089649551332" NO="5" P_CHI2="1.0" P_Z="2.0214955310730964E-6" STUDIES="1" TAU2="0.0" TOTAL_1="9420" TOTAL_2="8894" WEIGHT="100.0" Z="4.751263445521042">
<NAME>Vitamin A and beta-carotene</NAME>
<DICH_DATA CI_END="1.2342153394857684" CI_START="1.091467612428485" EFFECT_SIZE="1.1606489864774552" ESTIMABLE="YES" EVENTS_1="1855" EVENTS_2="1509" LOG_CI_END="0.09139093975510218" LOG_CI_START="0.038010853235924395" LOG_EFFECT_SIZE="0.06470089649551332" ORDER="777" O_E="0.0" SE="0.03135572705705482" STUDY_ID="STD-CARET-2004" TOTAL_1="9420" TOTAL_2="8894" VAR="9.831816192765195E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.67968293423382" CI_START="0.5683067431269193" DF="0.0" EFFECT_SIZE="2.788235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-001.15.06" LOG_CI_END="1.136076031484358" LOG_CI_START="-0.24541719089273578" LOG_EFFECT_SIZE="0.44532942029581113" NO="6" P_CHI2="1.0" P_Z="0.20637251111428778" STUDIES="1" TAU2="0.0" TOTAL_1="255" TOTAL_2="237" WEIGHT="100.0" Z="1.2636031952933344">
<NAME>Beta-carotene and vitamin C</NAME>
<DICH_DATA CI_END="13.67968293423382" CI_START="0.5683067431269193" EFFECT_SIZE="2.788235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.136076031484358" LOG_CI_START="-0.24541719089273578" LOG_EFFECT_SIZE="0.44532942029581113" ORDER="778" O_E="0.0" SE="0.8114959573260456" STUDY_ID="STD-Correa-2000" TOTAL_1="255" TOTAL_2="237" VAR="0.6585256887565153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1077246709730104" CI_START="1.0173572900468133" DF="0.0" EFFECT_SIZE="1.0615798459744326" ESTIMABLE="YES" EVENTS_1="2762" EVENTS_2="2605" I2="0.0" ID="CMP-001.15.07" LOG_CI_END="0.044431828320063434" LOG_CI_START="0.007473501443227749" LOG_EFFECT_SIZE="0.02595266488164562" NO="7" P_CHI2="1.0" P_Z="0.005911877871231356" STUDIES="1" TAU2="0.0" TOTAL_1="7278" TOTAL_2="7287" WEIGHT="100.0" Z="2.7526293947437486">
<NAME>Beta-carotene and vitamin E</NAME>
<DICH_DATA CI_END="1.1077246709730104" CI_START="1.0173572900468133" EFFECT_SIZE="1.0615798459744326" ESTIMABLE="YES" EVENTS_1="2762" EVENTS_2="2605" LOG_CI_END="0.044431828320063434" LOG_CI_START="0.007473501443227749" LOG_EFFECT_SIZE="0.02595266488164562" ORDER="779" O_E="0.0" SE="0.021709504154121838" STUDY_ID="STD-ATBC-2003" TOTAL_1="7278" TOTAL_2="7287" VAR="4.713025706178333E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8937397800830963" CI_END="1.106510103043493" CI_START="0.9744980824659919" DF="2.0" EFFECT_SIZE="1.0384083848106826" ESTIMABLE="YES" EVENTS_1="2333" EVENTS_2="1524" I2="0.0" ID="CMP-001.15.08" LOG_CI_END="0.043955383627947625" LOG_CI_START="-0.01121901111306875" LOG_EFFECT_SIZE="0.016368186257439396" NO="8" P_CHI2="0.6396271512569307" P_Z="0.24487151348050074" STUDIES="3" TAU2="0.0" TOTAL_1="18408" TOTAL_2="12279" WEIGHT="100.00000000000001" Z="1.1628965105067413">
<NAME>Beta-carotene, vitamin C, and vitamin E</NAME>
<DICH_DATA CI_END="1.1144811312125353" CI_START="0.9720535501435152" EFFECT_SIZE="1.0408339637824593" ESTIMABLE="YES" EVENTS_1="1446" EVENTS_2="1389" LOG_CI_END="0.04707272003057203" LOG_CI_START="-0.01230980925970866" LOG_EFFECT_SIZE="0.01738145538543168" ORDER="780" O_E="0.0" SE="0.03488159165337159" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.0012167254362725624" WEIGHT="75.32545458605581"/>
<DICH_DATA CI_END="3.1183076919528787" CI_START="0.6784777797260468" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.49391896599210416" LOG_CI_START="-0.16846437099670467" LOG_EFFECT_SIZE="0.16272729749769974" ORDER="781" O_E="0.0" SE="0.38908725099762503" STUDY_ID="STD-Plummer-2007" TOTAL_1="990" TOTAL_2="990" VAR="0.15138888888888888" WEIGHT="1.502197199690924"/>
<DICH_DATA CI_END="1.1977966630716208" CI_START="0.8418234866915439" EFFECT_SIZE="1.0041580369914131" ESTIMABLE="YES" EVENTS_1="871" EVENTS_2="124" LOG_CI_END="0.07838309885371654" LOG_CI_START="-0.07477896169770953" LOG_EFFECT_SIZE="0.0018020685780034925" ORDER="782" O_E="0.0" SE="0.08996815253233495" STUDY_ID="STD-WACS-2007" TOTAL_1="7149" TOTAL_2="1022" VAR="0.008094268470081488" WEIGHT="23.172348214253276"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0849516828261208" CI_START="0.6155358027224427" DF="0.0" EFFECT_SIZE="0.8172065864904916" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="101" I2="0.0" ID="CMP-001.15.09" LOG_CI_END="0.03541039777050457" LOG_CI_START="-0.21074668120125536" LOG_EFFECT_SIZE="-0.08766814171537538" NO="9" P_CHI2="1.0" P_Z="0.16269306515540327" STUDIES="1" TAU2="0.0" TOTAL_1="1677" TOTAL_2="1688" WEIGHT="100.00000000000001" Z="1.396071167820462">
<NAME>Vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="1.0849516828261208" CI_START="0.6155358027224427" EFFECT_SIZE="0.8172065864904916" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="101" LOG_CI_END="0.03541039777050457" LOG_CI_START="-0.21074668120125536" LOG_EFFECT_SIZE="-0.08766814171537538" ORDER="783" O_E="0.0" SE="0.14459388668520437" STUDY_ID="STD-SIT-2006" TOTAL_1="1677" TOTAL_2="1688" VAR="0.02090739206673372" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0531785477820348" CI_START="0.5807818997097307" DF="0.0" EFFECT_SIZE="0.7820914509917529" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="98" I2="0.0" ID="CMP-001.15.10" LOG_CI_END="0.0225020043698727" LOG_CI_START="-0.23598692705086355" LOG_EFFECT_SIZE="-0.10674246134049548" NO="10" P_CHI2="1.0" P_Z="0.10550622537439702" STUDIES="1" TAU2="0.0" TOTAL_1="6481" TOTAL_2="6536" WEIGHT="100.0" Z="1.6187260220283999">
<NAME>Beta-carotene, vitamin C, vitamin E, and selenium</NAME>
<DICH_DATA CI_END="1.0531785477820348" CI_START="0.5807818997097306" EFFECT_SIZE="0.7820914509917529" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="98" LOG_CI_END="0.0225020043698727" LOG_CI_START="-0.23598692705086366" LOG_EFFECT_SIZE="-0.10674246134049548" ORDER="784" O_E="0.0" SE="0.15183767785738722" STUDY_ID="STD-SUVIMAX-2004" TOTAL_1="6481" TOTAL_2="6536" VAR="0.023054680417123698" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3454164028275543E-7" CI_END="1.0460406308933288" CI_START="0.8489517419994942" DF="1.0" EFFECT_SIZE="0.9423576899453526" ESTIMABLE="YES" EVENTS_1="2004" EVENTS_2="447" I2="0.0" ID="CMP-001.15.11" LOG_CI_END="0.019548553967258853" LOG_CI_START="-0.07111699618595531" LOG_EFFECT_SIZE="-0.02578422110934823" NO="11" P_CHI2="0.9997073366150557" P_Z="0.26494402970946906" STUDIES="2" TAU2="0.0" TOTAL_1="27543" TOTAL_2="5359" WEIGHT="100.00000000000001" Z="1.1147816267223833">
<NAME>Combination of antioxidants</NAME>
<DICH_DATA CI_END="1.0634293405763928" CI_START="0.8350510176240367" EFFECT_SIZE="0.9423469387755102" ESTIMABLE="YES" EVENTS_1="1847" EVENTS_2="280" LOG_CI_END="0.026708638557279743" LOG_CI_START="-0.07828699038974907" LOG_EFFECT_SIZE="-0.025789175916234627" ORDER="785" O_E="0.0" SE="0.06167495218023023" STUDY_ID="STD-NIT1-1993" TOTAL_1="25886" TOTAL_2="3698" VAR="0.0038037997264336854" WEIGHT="69.7171075623137"/>
<DICH_DATA CI_END="1.1590959236008698" CI_START="0.766198384784343" EFFECT_SIZE="0.9423892107155635" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="167" LOG_CI_END="0.06411937847153251" LOG_CI_START="-0.11565876788411612" LOG_EFFECT_SIZE="-0.02576969470629179" ORDER="786" O_E="0.0" SE="0.10560257308548482" STUDY_ID="STD-NIT2-1993" TOTAL_1="1657" TOTAL_2="1661" VAR="0.011151903442275162" WEIGHT="30.28289243768631"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3050.3795462310864" CI_END="5.082783042833384" CI_START="1.3999686920078105" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.667533903858568" ESTIMABLE="YES" EVENTS_1="13169" EVENTS_2="7384" I2="99.8033031657515" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.7061015723603488" LOG_CI_START="0.14611832350660786" LOG_EFFECT_SIZE="0.42610994793347834" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.002856207928139993" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6669107034186018" TOTALS="SUB" TOTAL_1="75333" TOTAL_2="75294" WEIGHT="400.0" Z="2.9828040503475357">
<NAME>Adverse effects - beta-carotene</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1455.7437870347164" CI_END="4.669432458221337" CI_START="0.7358568743265145" DF="3.0" EFFECT_SIZE="1.85365422168902" ESTIMABLE="YES" EVENTS_1="8828" EVENTS_2="4499" I2="99.79391977992839" ID="CMP-001.16.01" LOG_CI_END="0.6692640978592124" LOG_CI_START="-0.13320664861741693" LOG_EFFECT_SIZE="0.2680287246208977" NO="1" P_CHI2="0.0" P_Z="0.19044188683485178" STUDIES="4" TAU2="0.7172280873728915" TOTAL_1="45653" TOTAL_2="45599" WEIGHT="99.99999999999999" Z="1.3092730155851555">
<NAME>Transient yellowing of the skin</NAME>
<DICH_DATA CI_END="5.1750006745513835" CI_START="4.5590549153278275" EFFECT_SIZE="4.8572741596638656" ESTIMABLE="YES" EVENTS_1="4950" EVENTS_2="1020" LOG_CI_END="0.7139104107384093" LOG_CI_START="0.6588748234544759" LOG_EFFECT_SIZE="0.6863926170964427" ORDER="787" O_E="0.0" SE="0.03232817640113328" STUDY_ID="STD-ATBC-2003" TOTAL_1="14560" TOTAL_2="14573" VAR="0.0010451109894227908" WEIGHT="31.056443442477796"/>
<DICH_DATA CI_END="1.2109929582826264" CI_START="1.0669738522686205" EFFECT_SIZE="1.1367048085448512" ESTIMABLE="YES" EVENTS_1="1745" EVENTS_2="1535" LOG_CI_END="0.08314161780210275" LOG_CI_START="0.028153776542936087" LOG_EFFECT_SIZE="0.05564769717251944" ORDER="788" O_E="0.0" SE="0.03230013014983861" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.001043298407696513" WEIGHT="31.05652771825385"/>
<DICH_DATA CI_END="1.1618296078917432" CI_START="1.0340577871088201" EFFECT_SIZE="1.096083460934451" ESTIMABLE="YES" EVENTS_1="2131" EVENTS_2="1944" LOG_CI_END="0.06514243977677461" LOG_CI_START="0.014544809474775707" LOG_EFFECT_SIZE="0.039843624625775155" ORDER="789" O_E="0.0" SE="0.02972129850170359" STUDY_ID="STD-WHS-2005" TOTAL_1="19939" TOTAL_2="19937" VAR="8.83355584627368E-4" WEIGHT="31.063966042466248"/>
<DICH_DATA CI_END="47.33011550963781" CI_START="0.11283241938438254" EFFECT_SIZE="2.310924369747899" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.675137564369475" LOG_CI_START="-0.9475660994940114" LOG_EFFECT_SIZE="0.3637857324377318" ORDER="790" O_E="0.0" SE="1.5405891147459285" STUDY_ID="STD-Zhu-2003" TOTAL_1="118" TOTAL_2="54" VAR="2.373414820473644" WEIGHT="6.823062796802093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="39.31977735159152" CI_START="21.595190346071238" DF="0.0" EFFECT_SIZE="29.139630681818183" ESTIMABLE="YES" EVENTS_1="1281" EVENTS_2="44" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="1.5946110499726878" LOG_CI_START="1.3343570363938932" LOG_EFFECT_SIZE="1.4644840431832904" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14560" TOTAL_2="14573" WEIGHT="100.0" Z="22.0579574631907">
<NAME>Persistent yellowing of the skin</NAME>
<DICH_DATA CI_END="39.31977735159152" CI_START="21.595190346071238" EFFECT_SIZE="29.139630681818183" ESTIMABLE="YES" EVENTS_1="1281" EVENTS_2="44" LOG_CI_END="1.5946110499726878" LOG_CI_START="1.3343570363938932" LOG_EFFECT_SIZE="1.4644840431832904" ORDER="791" O_E="0.0" SE="0.15287449585432814" STUDY_ID="STD-ATBC-2003" TOTAL_1="14560" TOTAL_2="14573" VAR="0.023370611482714992" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7367226661979616" CI_START="1.7968528780192734" DF="0.0" EFFECT_SIZE="2.2175409802523123" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="124" I2="0.0" ID="CMP-001.16.03" LOG_CI_END="0.4372307891373928" LOG_CI_START="0.2545125195797145" LOG_EFFECT_SIZE="0.3458716543585536" NO="3" P_CHI2="1.0" P_Z="1.1701191989865377E-13" STUDIES="1" TAU2="0.0" TOTAL_1="11036" TOTAL_2="11035" WEIGHT="100.00000000000001" Z="7.420122656120727">
<NAME>Belching</NAME>
<DICH_DATA CI_END="2.7367226661979616" CI_START="1.7968528780192734" EFFECT_SIZE="2.2175409802523123" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="124" LOG_CI_END="0.4372307891373928" LOG_CI_START="0.2545125195797145" LOG_EFFECT_SIZE="0.3458716543585536" ORDER="792" O_E="0.0" SE="0.10732961600820161" STUDY_ID="STD-PHS-1996" TOTAL_1="11036" TOTAL_2="11035" VAR="0.011519646472468007" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0572426134337212" CI_START="0.9952547779773114" DF="0.0" EFFECT_SIZE="1.0257805625479217" ESTIMABLE="YES" EVENTS_1="2785" EVENTS_2="2717" I2="0.0" ID="CMP-001.16.04" LOG_CI_END="0.024174659573318276" LOG_CI_START="-0.002065728796162756" LOG_EFFECT_SIZE="0.011054465388577774" NO="4" P_CHI2="1.0" P_Z="0.09866212969290097" STUDIES="1" TAU2="0.0" TOTAL_1="4084" TOTAL_2="4087" WEIGHT="100.0" Z="1.6513744937674872">
<NAME>Gastrointestinal upset</NAME>
<DICH_DATA CI_END="1.0572426134337212" CI_START="0.9952547779773114" EFFECT_SIZE="1.0257805625479217" ESTIMABLE="YES" EVENTS_1="2785" EVENTS_2="2717" LOG_CI_END="0.024174659573318276" LOG_CI_START="-0.002065728796162756" LOG_EFFECT_SIZE="0.011054465388577774" ORDER="793" O_E="0.0" SE="0.01541373402025047" STUDY_ID="STD-WACS-2007" TOTAL_1="4084" TOTAL_2="4087" VAR="2.375831964470267E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4908600104908065" CI_END="1.2312357658988358" CI_START="0.821516748950498" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.005724019596225" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="186" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.09034122273220731" LOG_CI_START="-0.08538357781306054" LOG_EFFECT_SIZE="0.0024788224595733563" METHOD="MH" NO="17" P_CHI2="0.7823680521265706" P_Q="0.0" P_Z="0.9559029801496335" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37492" TOTAL_2="37493" WEIGHT="100.0" Z="0.055295584115131725">
<NAME>Adverse effects - vitamin E</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4908600104908065" CI_END="1.2312357658988358" CI_START="0.821516748950498" DF="2.0" EFFECT_SIZE="1.005724019596225" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="186" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.09034122273220731" LOG_CI_START="-0.08538357781306054" LOG_EFFECT_SIZE="0.0024788224595733563" NO="1" P_CHI2="0.7823680521265706" P_Z="0.9559029801496335" STUDIES="3" TAU2="0.0" TOTAL_1="37492" TOTAL_2="37493" WEIGHT="100.0" Z="0.055295584115131725">
<NAME>Haemorrhagic stroke</NAME>
<DICH_DATA CI_END="1.4511432743859964" CI_START="0.8075077797794248" EFFECT_SIZE="1.0825014935977135" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="85" LOG_CI_END="0.1617102933498094" LOG_CI_START="-0.09285328484949261" LOG_EFFECT_SIZE="0.03442850425015841" ORDER="794" O_E="0.0" SE="0.1495319059443049" STUDY_ID="STD-ATBC-2003" TOTAL_1="7286" TOTAL_2="7287" VAR="0.022359790895336448" WEIGHT="47.65117173431408"/>
<DICH_DATA CI_END="1.4117304724498199" CI_START="0.6556433191140283" EFFECT_SIZE="0.9620767394815317" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="53" LOG_CI_END="0.14975178913713205" LOG_CI_START="-0.18333235981376694" LOG_EFFECT_SIZE="-0.01679028533831748" ORDER="795" O_E="0.0" SE="0.19565527788688677" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.03828098776499488" WEIGHT="27.832882537877534"/>
<DICH_DATA CI_END="1.379450499366474" CI_START="0.6092617119810269" EFFECT_SIZE="0.91675862299577" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" LOG_CI_END="0.13970612073567962" LOG_CI_START="-0.21519611351813706" LOG_EFFECT_SIZE="-0.0377449963912287" ORDER="796" O_E="0.0" SE="0.20847132919508468" STUDY_ID="STD-WHS-2005" TOTAL_1="19937" TOTAL_2="19939" VAR="0.04346029509636536" WEIGHT="24.515945727808372"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.951010538556247" CI_START="0.7765263982853098" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.513782542113323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.4699707604415565" LOG_CI_START="-0.10984377569232223" LOG_EFFECT_SIZE="0.18006349237461716" METHOD="MH" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.2234719571340158" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="653" TOTAL_2="659" WEIGHT="100.0" Z="1.217347748257432">
<NAME>Adverse effects - selenium</NAME>
<GROUP_LABEL_1>Antioxidants</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antioxidants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.951010538556247" CI_START="0.7765263982853098" DF="0.0" EFFECT_SIZE="1.513782542113323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.4699707604415565" LOG_CI_START="-0.10984377569232223" LOG_EFFECT_SIZE="0.18006349237461716" NO="1" P_CHI2="1.0" P_Z="0.2234719571340158" STUDIES="1" TAU2="0.0" TOTAL_1="653" TOTAL_2="659" WEIGHT="100.0" Z="1.217347748257432">
<NAME>Gastrointestinal upset</NAME>
<DICH_DATA CI_END="2.951010538556247" CI_START="0.7765263982853098" EFFECT_SIZE="1.513782542113323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4699707604415565" LOG_CI_START="-0.10984377569232223" LOG_EFFECT_SIZE="0.18006349237461716" ORDER="797" O_E="0.0" SE="0.3405859286532831" STUDY_ID="STD-NPCT-1996" TOTAL_1="653" TOTAL_2="659" VAR="0.11599877479661923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="FIgure 1.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Recommended dietary allowance, tolerable upper intake level, experimental doses, and regimen used in antioxidant supplements</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Table 05.</P>
<P>Bias risk of the trials</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA50AAAIiCAIAAADEpTsJAABihklEQVR42u2d68GjIBBFv36sx36s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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot - occurrence of gastrointestinal cancers</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-05-24 16:59:17 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot - overall mortality</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>